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The tetrahydroisoquinoline (THIQ) core has displayed a rich history as a biologically 
active natural product and is an interesting scaffold to use in drug discovery. Its 
structural skeleton is present in a number of structurally diverse natural products 
exhibiting a wide range of biological, pharmaceutical and estrogen receptor (ER) 
activities.1-5 Estrogen is a steroid hormone which influences the functioning of many 
target tissues. However, the normal existence of estradiol in women affected with 
breast cancer may worsen the infection; and a deficiency may increase the risk of 
various hormone related diseases. Estradiol is the natural ligand responsible for 
modulating the expression and/or repression of specific estrogen gene 
transcriptions.6,7 In this project, we therefore considered the synthesis of four small 
sets of THIQ-based compounds with the potential ability to bind the ER with affinities 
competing with that of estradiol. The THIQ compounds generated included structures 
with or without linker groups, and a lactam core without a linker group. 
 
The compounds were structurally designed by making use of Schrodinger and 
Acclerys Discovery Studio software, to accommodate the receptors binding pocket 
and improve the potency and selectivity toward the ERβ. With the successful synthesis 
of the THIQ compounds generated, which included structures with or without linker 
groups, and a lactam core without a linker group, further biochemical studies were 
explored. During the synthesis of these final compounds, it was found that once 
demethylated, the final compounds showed some degree of decomposition and 
sedimentation upon preparation for bioevaluations. Whole cell testing however, only 
revealed that only one compound showed potential activity, with the rest showing quite 
poor activity. In terms of the cell proliferation, this compound (65%) compared well to 










Die tetrahidroisokinolien (THIQ) kern het ‘n ryk geskiedenis as dit kom by natuurlike 
aktiewe tetrahidroisokinoliene en is ‘n struktuur wat dikwels gebruik word gedurende 
die ondekking van nuwe medisinale middels. Die struktuur kom in baie verskillinde 
natuurlike produkte voor en het biologiese, farmaseutiese en estrogeen reseptor (ER) 
aktiewiteite.1-5 Baie organe word beïnvloed deur die funksionering van die steroïde 
hormoon estrogeen. In vrouens wat aan borskanker ly kan estrogeen 'n nadelige 
uitwerking hê, hoewel te min estrogeen tot ander hormoonverwante siektes kan ly. 
Estradiool is die natuurlikethe bindingsmiddel wat verantwoordelik is vir die modulering 
van en/of die onderdrukking van spesifieke estrogeen gene transkripsies.6,7 In hierdie 
projek stel ons die sintese van vier stelsels voor wat die THIQ kern bevat. Die 
molekules het die potensiaal om in die binding met die ER, met estradiol te kompeteer. 
Die molekules wat gesintiseer is, het die volgende algemene strukture wat op 
trifluorometielsulfoniel THIQ – gebaseerd is: THIQ met bindings groepe, geen bindings 
groep en die laktam kern sonder die bindings groep. 
 
Die molekules was ontwerp deur gebruik te maak van die Schrodinger en Acclerys 
Discovery Studio sagteware, om sodoende interaksies met die ERβ, en dus 
selektiwiteit, te verbeter. Met die suksesvole sintese van die molekules, dws 
trifluorometielsulfoniel THIQ – gebaseerd, met bindings groepe, geen bindings groep 
en die laktam kern sonder die bindings groep, is verder biochemiese toetse gedoen. 
Gedeurende die sintese van hierdie finale molekules is dit bevind dat die 
demetieleerde weergawes degradasie en sedementasie ondergaan gedurende 
voorbereiding vir bio-evaluasie. Biochemiese en heel sel toetse het gewys dat van die 
molekules potensieel aktief is, terwyl die meeste minder aktief was. Een van die 
molekules het ‘n sel groei persentasie waarde van 65.0% getoon, teenoor die wel 
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This Chapter, briefly introduces a few important concepts, aimed toward generating a link 
between our dependence on hormones, their function and the modes of action they assume 
when transmitting valuable genetic information throughout the body. These concepts 
provide an understanding to the varied complexities associated with hormones, which allow 
them to function optimally, as well as effects caused when the malfunctioning of one system 
occurs. The focus then converges towards the estrogen hormone, fostering the general 
understanding of its versatility and association to the development of breast cancer (further 
elaborated in Chapter 2). In this chapter, further discussions on the introduction of cancer, 
the evolutionary development of cancer therapeutics and the current need for further 
development, especially in third world countries, will briefly be discussed. 
 
1.1 The significant and multifaceted role of hormones 
Hormones are critical biological messengers which function at a cellular level conveying 
specific chemical information, thereby controlling vital processes in the body such as 
metabolic homeostasis, growth, development and reproduction, which are listed in Table 
1.1.8 
 
Table 1.1. Transcriptional activity mediated by major glands within the endocrine system.8 
Gland Hormone Physiological effects 
Pituitary Antidiuretic hormone 
Regulates the retention of water in kidneys 
and blood pressure 
 Corticotropin (ACTH) 
Regulates the production and secretion of 
hormones from the adrenal glands 
 Growth hormone (GH) 
Regulates growth and development, as well 
as promotes protein production 
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 Luteinizing hormone (LH) 
Regulates the physiological function of the 
reproductive gland in males and females 
 Oxytocin Aids in childbirth and lactation processes 
 Prolactin 





Regulates the production and secretion of 
hormones from the thyroid glands 
Parathyroid Parathyroid hormone 
Regulates the functioning and excretion of 
calcium and phosphorous ions 
Thyroid Thyroid hormone Regulates metabolic processes 
Adrenal Aldosterone 
Regulates the salt and water content of the 
kidneys 
Maintains the blood sugar level, blood 
pressure and muscle strength 
 Cortisol 
Induces anti−inflammatory functions 









Stimulates the functioning of blood vessels, 
heart, lungs and nervous system 
Pancreas Glucagon Increases blood−sugar level 
 Insulin 
Decreases blood−sugar level 
Regulates the metabolism of sugar, proteins 
and lipids 
Gonads Ovaries: Estrogen 
Regulates the development of female sex 
characteristics and the reproductive system 
 Progesterone Prepares the body for impregnation 
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 Testes: Testosterone 
Regulates the development of male sex 
characteristics and the reproductive system 
 
In mammals, these hormones are secreted by the endocrine system, which is composed of 
the pineal, pituitary, parathyroid (thymus), thyroid, adrenal, pancreas and the gonads 
(ovaries in females and testes in males), to mention a few of the major glands responsible 
for the secretion of hormones. Hormones can be classified into three major categories viz., 
steroid hormones (composed of the adrenal cortical and sex hormones), peptide hormones 
(which include insulin and glucagon) and amino acid derivatives (such as thyroidal 
hormones).7,8 The hormones secreted by these glands are directly translocated into the 
blood stream, where the hormone receptor is responsible to either express or repress the 
modulation of particular physiological effect. Hormone receptors are classed into two 
groups, described as steroidal and nuclear receptors, which are designated by their 
agonistic and/or antagonistic mediation of gene expression. Steroid receptors regulate gene 
transcription with the aid of a binding site (agonistically) for a specific steroid hormone, 
whereas nuclear receptors are ligand activated (antagonistically) when expressing their 
gene transcriptions. 
 
The importance of these hormones is reflected by their synergistic and independent ability 
to effect important physiological functions within the body, shown in Table 1.1. It can thus 
be expected, that a cascade of adverse physiological events would occur if one system 
(gland) malfunctions. However, it is important to note, that the optimal functioning of 
hormones is not only dependent on the endocrine system, but can significantly be influenced 
by lifestyle decisions.9,10 The exponential growth in the world’s population has generated the 
need for food to be grown at faster rates, resulting in the incorporation of synthetic chemicals 
such as hormones in milk, antibiotics in meat and pesticides in agricultural produce.11 
Research contributions by Key et al.,12 suggests that exposure to high concentrations, as 
well as long term exposure to low concentrations, of these synthetic chemicals may result 
in a number of adverse physiological side effects within the body.12 In addition to chemical 
stimuli, the evolution of technology, coupled with busier lifestyles and the exposure to 
numerous radiation sources, has further influenced healthy living (which include exercise 
and enough rest), usually required to assist in the regeneration of new or damaged cells.10 
Regular exercise is essential not only for maintaining a healthy body, but also for reducing 
the production of cholesterol. Interestingly, estrogen is a side product generated from 
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processes, in which cholesterol is produced. Work reported by Tsuchiya and co−workers, 
have suggested that estrogen concentrations were found to be lower in women that 
exercise.13 
 
1.2 Established link between hormones and the development of carcinomas 
The development of carcinoma cells can be attributed to a number of diverse and complex 
processes within the body, with the major argument being related to the unregulated cell 
growth that occurs at an alarming rate (normally controlled by certain members of the 
endocrine system). Since certain hormones are responsible for the regulation of growth and 
cell differentiation (described in Table 1.1), a link has been confirmed between hormones 
and the development of certain cancers.14 The term tumour (associated with carcinomas), 
often refers to growths caused by cancerous cells. However, not all tumours are necessarily 
malignant since numerous benign tumours are known to exist. It should be noted that unlike 
malignant tumours, the latter do not invade the surrounding cellular environments. 
 
1.3 Estrogen’s distinct contribution toward breast carcinoma development 
For the purpose of this dissertation, the main focus is on the hormone estrogen and its 




Figure 1.1. Three essential estrogenic hormones secreted by the female body. 
 
The estrogens (Figure 1.1), namely estrone (E1), 17β−estradiol (E2) and estriol (E3) are the 
natural (or endogenous) ligands for the estrogen receptor subtypes (ERα and ERβ).15 E2 is 
the most important estrogen, which is responsible for modulating the expression and/or 
repression of specific gene transcriptions.6,7 An insightful review by Gustafsson and 
co−workers,16 has revealed the intricate distribution and functioning of both ERα and ERβ 
subtypes within the body. Both ER−subtypes contain overlapping distributions, with ERα 
being responsible for reproductive functions and is dominantly expressed in the uterus and 
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mammary glands. ERβ on the other hand, is more generally expressed within skeletal tissue, 
the central nervous and cardiovascular system, as well as the uterus and liver.6,7 Both 
ER−subtypes display similar binding affinities toward the hormone E2 (for which further 
elaboration will be reported in Chapter 2), which can be explained by the modes of binding 
adopted by estrogen and its receptors. Unlike other hormones, reports by Gustafsson,16 
Korach17 and co−workers suggest that estrogens do not follow the classical protein−protein 
binding mode, when mediating their transcriptional effects. This feature confirms that the 
ER’s mechanisms, which influence gene transcriptions, are more complex than initially 
thought. Since E2 and its receptors are important mediators involved in the proliferation and 
differentiation within reproductive tissues, it appears to hold one of the keys in understanding 
the development of breast cancer.14,18-20 
 
1.3.1 Estradiol metabolism pathways and the unfavourable resulting DNA adducts 
It has been postulated that a number of mechanistic routes are responsible for the 
development of carcinogenesis in breast tissue. A number of reports indicated that the ERα 
was associated with playing a key role in the development and progression of breast 
cancer.11,14 It is considered that the complex hormonal binding mode mechanisms are 
responsible for the development of this malignancy.21 Due to key contributions by the E2 
ligand in modulating ER−subtypes to exert specific transcriptional effects in multiple tissues, 
it can be postulated that this ligand may stimulate desirable effects in some tissues and 
undesirable effects in others. It is important to note that E2 and ER do not function 
independently but involve many cellular processes which could have a domino effect. If one 
receptor is repressed or expressed more dominantly than the other, adverse effects might 
well be expected. Scheme 1.1 is an illustration of the two pathways, in which the metabolism 
of E2 can initiate the development and progression of estrogen positive breast cancer.18 The 
metabolism of estrogen, results in the formation of genotoxic mutagenic metabolites via., 
the protein cytochrome P450 (in Scheme 1.1).13,19 The second receptor ERβ, has likewise 
been detected in breast cancers, which may additionally contribute to hormonal sensitivity 
and resistance experienced by many patients undergoing hormonal therapeutic treatment.22 
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Scheme 1.1. Two pathways in which estrogen could initiate carcinogenesis. a) Metabolism: 16−α− 
hydroxyestrone 1.1 and 2−hydroxyestrone, 2−hydroxyestradiol, 4−hydroxyestrone, 4−hydroxyestradiol 1.2. b) 
Altered gene expression.18 (Source: Modified from Yagar, J. D.; Davidson, N. E. N. Engl. J. Med. 2006, 354, 
270) 
 
Unlike other hormones (in Table 1.1), the ERs are able to mediate gene transcription in the 
absence of their natural ligand (E2), leading to an important question as to whether it could 
be considered as a versatile mechanism for gene transcription.6,7 This dynamic feature has 
allowed scientists to take advantage of this unique property to further develop synthetic 
ligands with improved and selective estrogenic activity. Both ER−subtypes differ on the 
basis of their gene transcription responses due to their agonistic and antagonistic binding, 
which can be explained by the inherent differences presented on the binding domains of the 
individual receptor.23-25 
 
The metabolism of E2 includes its oxidation by the cytochrome (CYP) P450 protein, which 
is a heme−containing superfamily of monooxygenases, and is responsible for the oxidative 
metabolism of many biological agents.13,18 It is composed of three families namely CYP1, 
CYP2 and CYP3, which catalyse the oxidative metabolism of both exo− and endogenous 
ligands of ER.13 The enzymes CYP1A1, CYP1A2 and CYP3A4 modulate catalytic activity 
toward generating the 2−hydroxylation species, rather than the 4−hydroxylation species of 
E2. In contrast, the CYP1B1 and CYP3A5 enzymes, exhibited specific catalytic activity 
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toward generating the 4−hydroxylation of the estrogen metabolite.13 CYP1A1 is not 
expressed in the liver, therefore the 2−hydroxylation metabolite in the liver is mainly 
catalyzed by the enzymes CYP1A2 and CYP3A,13 which are usually associated breast, 
uterine, placenta, brain and pituitary tissues.13 
 
The E2 metabolites, contribute to the initiation of carcinogenesis by the resulting harmful 
adducts (1.1 and 1.2) formed during metabolism, as illustrated in Scheme 1.1. Additional 
metabolic reactions generate radicals from the oxidized estradiol and estrone metabolites, 
which are both catalyzed by the P450 enzyme. These radicals and their unique 
corresponding quinones (for example the 3,4−quinones) can form unstable adducts with the 
adenine and guanine residues within the DNA sequence, thus mutating and depuriating the 
nucleic base and thereby damaging the DNA sequence. The presence of these unstable 
adducts and damaged DNA sequences in human breast cancer tissue, further support the 
claim that estrogen metabolites are essential in understanding the development of breast 
cancer.13,18,19 
 
1.4 The diverse source and characteristics of mammary gland carcinomas 
Breast cancer is a term broadly used for the description of a number of mammary gland 
tumours. The most common breast cancer originates from cells that line the ducts and 
lobules in mammary glands, while others originate within other tissues and metastasize. 
Despite this, benign breast tumours do exist and are known as fibro adenomas. Unlike many 
other malignancies, breast cancers are developed sporadically but can also be inherited 
from shared familial genetic traits.26 
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Figure 1.2. Anatomical description of mammary glands and their associated lymph nodes.26 
(Source:www.cancer.ca/en/cancer−information/cancer−type/breast/breast−cancer/the−breast/ ?region=on) 
 
The lymphatic system is of paramount importance, as it is involved with the immune 
responses within the body. The lymphatic system is composed of lymph nodes (a collection 
of immune system cells), which are connected to lymphatic vessels that further consist of 
small veins responsible for carrying lymph fluid away from the breast (as shown in Figure 
1.2). Lymph fluid is a composition of waste products and immune system cells. 
Unfortunately, breast cancer cells can enter lymphatic vessels and grow within these lymph 
nodes. As illustrated in Figure 1.2, lymph nodes within the breast are connected to axillary 
nodes (found under the arm), internal mammary nodes (found in the chest), supra− and 
infra−clavicular nodes (found above and below the clavicle). Once cancer cells metastasize 
to lymph nodes, it can further permeate other cells and tissues within the body. The most 
common breast cancers are developed in epithelial cells (cells lining organs and tissues) 
and are known as adenocarcinomas. Cancers which develop within the cells of muscles, 
lipids or connective tissues are known as sarcomas. 
 
Ductal carcinoma in situ (DCIS), also known as intra ductal carcinoma, is considered to be 
a non−invasive or pre−invasive breast cancer. Non−invasive cancers are not able to 
metastasize but do contain the ability to become invasive (hence its pre−invasive breast 
cancer category). Invasive ductal carcinoma (IDC) originates within the milk ducts, which 
easily move through the cell wall and grows into the adipose tissue of the breast. Once the 
growth is present within the adipose tissue, it is able to metastasize, thereby infiltrating other 
tissues and organs.27 Like IDC, invasive lobular carcinoma (ILC) develops within the lobules 
and has the ability to metastasize infecting healthy tissues and organs.28 More rare forms of 
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breast cancer include the inflammatory breast cancer (IBC), which affects 1 – 3% of women, 
where lymph vessels blocked by cancerous cells result in swelling of the affected breast. 
The growth initiated within the ducts, is spread outward to the areola, with mastectomy often 
employed as a treatment. Phyllode tumors are rare and benign, and even more rarely have 
the ability to become malignant. This type of tumor often develops within the stroma caused 
by complications experienced during radiation therapy, which leads to the development of 
cancer within the cells that line blood vessels and/or lymph vessels, and is known as 
angiosarcoma.26 
 
1.5 The evolutionary development in therapeutic strategies toward alleviating 
carcinomas 
It has been reported by Sudhakar and co−workers, that this ancient and non−communicable 
disease (cancer) has been recorded throughout time, with the first symptoms of this dreaded 
disease being reported by the Egyptians in 3000 B.C.29 The first diagnosis was recorded in 
the 1700s, with chimney sweepers being the unfortunate victims during this time.29 With the 
passing of time, the collective research by many scientists, with the development of 
technology, has clarified the understanding of this disease.29 In earlier days, the lack of 
proper instrumentation and knowledge prevented any comprehensive study of the disease. 
This resulted in many theories being established, primarily believing that cancer resulted 
from an imbalance of fluids in the body, which later gave rise to the humoral theory. A second 
theory included the belief that lymph nodes played a role in the development of cancer, thus 
a lymph theory arose. These theories later fell in abeyance with new ones taking their place 
viz., blastema, chronic irritation, trauma and finally the parasite theory (where it was believed 
that cancer was contagious).29 As time progressed, the evolution of scientific discoveries 
made the studying and treatment of cancer possible. Today science might not have all the 
answers, but the developed theories have been able to explain a good deal about cancer, 
as our current inputs will hopefully impact future decades. 
 
1.5.1 Surgical techniques used for the removal of carcinomas 
Since 50 A.D., the Greeks and Romans utilized cautery and surgical techniques for the 
elimination of small tumours. With the passing of time (after 1590 A.D.), autopsies presented 
scientists with the unique opportunity to further study and gain an improved understanding 
of internal tumours. Shortly thereafter, with the discovery of the microscope during 1600 
A.D., scientists were afforded the opportunity to study cancer at the cellular level. The 1840 
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– 1900’s era led to the discovery of anaesthesia, which granted surgeons novel therapeutic 
opportunities to surgically remove small tumours, as implemented by Bilroth, Handley and 
Halsted. With increased knowledge, it was later discovered that primary tumours had the 
ability to spread via the bloodstream, by a process now known as metastasis, originally 
identified by Paget.29 This was key in understanding the limitations surgery offered as a 
treatment, but this area of medicine soon evolved with the use of more sophisticated 
applications for treating tumours. 
 
1.5.2 Eradication of carcinomas with radiation 
The late 1800’s (1895) brought with it the discovery and development of x−rays, which 
played a vital role in the diagnosis and treatment of cancer, as founded by Roentgen.29 
However, it was later realized that this form of radiation not only alleviated cancer, but in 
certain instances it had also unfortunately promoted its growth. This was an important 
realization, which led to the understanding that only very specific forms of radiation can be 
implemented in such a treatment regime. Today, radiation therapy has progressed to the 
use of a conformal proton beam, where X−rays are exchanged for a beam of protons. The 
inclusion of stereotactic surgery includes the use of a gamma knife and is commonly utilized 
on brain tumours, with its outstanding merit being that no harm is caused to healthy cells. 
Lastly, intra−operative radiation therapy, which includes the surgical removal of tumours in 
conjunction with radiation to adjacent cells, has also been utilized.29 
 
1.5.3 A chemical approach toward treating carcinomas 
Later, chemotherapy was identified as a therapeutic treatment in targeting a broad range of 
cancerous cell lines. However, the major problems associated with chemotherapeutic 
agents include the lack of selectivity, metastasis of the initial tumour, heterogeneity of the 
disease and multidrug resistance.30 During the initial stages of chemotherapy, cytotoxic 
nitrogen mustard agents (see for example the structures of representative steroidal nitrogen 
mustard agents depicted in Figure 1.3) were developed to avoid these unfavourable 
effects.30 
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Figure 1.3. N−Substituted steroidal−based mustard agents tested. N−mustard agents refer to the N−haloalkyl 
substituents which have substituted the hydroxyl group at C17 (1.5 – 1.8) on various cholesterol−based 
compounds.30 (Source: Reported in Bansal, R.; Acharya, P. C. Chem. Rev. 2014, 114, 6986) 
 
The structural characteristics for these mustard agents (1.3 – 1.8) were adopted from the 
structural skeleton of molecules such as cholesterol, ergosterol and stigmasterol in Figure 
1.3. These compounds generated by Bansal and co−workers were extensively utilized as 
chemotherapeutics, based on animal studies.30 The steroidal−type moiety was included for 
the enhancement of binding with the DNA adducts within the tumour’s tissue. Thus, leading 
to DNA damaging effects with reduced toxicity. These compounds showed a delay in cell 
division and the induction of apoptosis suggesting that the mustard agents (1.5 – 1.8) 
presented a certain binding mode. Upon testing, compound 1.3 showed less toxicity upon 
comparison to compounds 1.4 – 1.8 but the antitumor activity was found to be reduced.30 
Compounds 1.4 and 1.5 showed a 100% increase in the lifespan of mice with Gardner 
ascites tumours.30 An interesting report by Jones et al., in the review by Bansal and 
Stellenbosch University  https://scholar.sun.ac.za




co−workers, showed that the treatment of 7,12−dimethylbenz[a]anthracene 
(DMBA)−induced mammary gland tumours when treated with compounds 1.6 and 1.7 
proved ineffective toward proliferation, with compound 1.8 showing a moderate regression.30 
This was later replaced by the use of a combination of drugs and therapeutics, monoclonal 
antibody therapy, hematopoietic stem cell transplantation and with agents to overcome 
multidrug resistance, and adjuvant therapy (co−administration of chemotherapy 
implemented after surgical treatment).29,30 
 
1.5.4 The manipulation of hormones for promoting cellular health 
The late 1800s (1878) brought forth new knowledge about a ground−breaking link between 
the ovaries (where certain hormones are produced) and mammary glands, was established 
by Thomas Beatson.29 This concept proved to be validated later when hormones were 
connected to the growth of cancer cells.11,21 Since then, hormone replacement therapy 
(HRT) has proven to be effective in the treatment of breast cancer, but like alternate cancer 
treatments, it is not without risk. HRT was primarily employed for the enhancement of 
hormone levels in women (especially undergoing menopause), by treatment with estrogen 
on its own or co−administered with progesterone. The use of estrogen improved skeletal 
and cardiovascular related ailments, but it was soon realized that its implementation was 
responsible for an increased incidence of both breast and uterine cancers.1 The adverse 
effects associated with HRT, resulted in the use of estrogen receptors being targeted for 
pharmacological interest. Since the connection between breast cancer and estrogen has 
emerged, attempts have been made to antagonize estrogen’s biological effects as a 
therapeutic strategy for women with breast cancer. This led to a more modern approach, 
where synthetic estrogenic ligands have been developed to behave agonistically in some 
tissues and antagonistically in others. These compounds are known as selective estrogen 
receptor modulators (SERMs) and display tissue selective behaviour by mimicking estrogen 
quite effectively.31,32 The development of these compounds were aimed toward reducing 
adverse effects (such as the increased incidence of certain cancers), associated with HRT.1 
Further elaboration on SERMs will be reported in Chapter 2. 
 
1.5.5 Immunotherapy treatment targeting gene specific tumours 
Immunotherapy treatment includes the use of biological agents (for example antibodies), 
intended to mimic signals within the body for controlling tumour growth. In the 1900s 
scientists developed two therapeutic monoclonal antibodies viz., rituximab and trastuzumab, 
targeting specific cancer cell lines.29 Rituximab was approved by the Food and Drug 
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Administration (FDA) in 1998 in the treatment of lymphoma and in 1999 trastuzumab was 
soon approved for the treatment of breast cancer cell lines.33 Rituximab is an antibody 
responsible for targeting the CD20−cells present in healthy B lymphocytes, as well as induce 
apoptosis directly. Whereas the antibody trastuzumab’s action is mediated by binding to the 
human epidermal growth factor receptor (HER2) by blocking the transduction signal.34 Apart 
from this, reports by Dillman revealed a large number of side effects associated with these 
agents due to antigen−antibody interactions within certain cells.33 These effects included 
ailments such as, nausea, fever and abdominal pain, which are but a few associated with 
both rituximab and trastuzumab.33 The application of these agents as therapeutics for 
malignant cancers were soon abandoned and the search for improved therapeutic agents 
continued. 
 
1.6 Carcinomas: An overall understanding, therapeutic challenges and the way 
forward 
With the enhancements in therapeutic strategies over time and gained understanding it has 
been noticed, that the normal existence of estrogen within women who have breast cancer 
and are undergoing hormonal therapy, can cause them to experience a number of adverse 
hormonal side effects such as osteoporosis, cardiovascular disease and obesity, as well as 
problems associated with the central nervous and immune system.15 As described by Marino 
and co−workers these adverse effects, associated with current hormonal treatment and 
antiestrogenic drugs, have had a diminished efficiency and thus as a consequence, the 
search for novel drugs, which can selectively bind to a specific ER continues.15 Despite the 
excellent progress made by science in this area, there are still quite a number of drawbacks 
which include; the lack of selectivity, metastatic spreading and the heterogeneity of the 
disease as well as resistance.30 In spite of this, a number of preventative measures have 
been put in place, where treatment such as surgical applications, radiation, chemotherapy 
and HRT (used singularly or in combination with additional forms of treatment), have 
increased the life span of sufferers, with the inclusion of a better quality of life.35 However, 
despite the valuable information provided, the development of cancers are still not 
completely understood. 
 
1.7 Feasibility for this research study 
Research efforts and evidence reported by Jemal and co−workers, do indicate that cancer 
is not just a global health epidemic, but increasing in Africa with 715 000 new cancer cases 
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and 542 000 cancer deaths recorded during 2008, which is further expected to double within 
the following 20 years.10,36 
 
 
Figure 1.4. A demonstration of the gender related cancers prevalent during 2008.10 (Source: Figure taken from 
Jemal, A. et al., Cancer 2012, 118, 4372) 
 
The cancers frequented by women in Africa are generally associated with reproductive 
organs demonstrated in Figure 1.4 and by the statistics reported in the graph Figure 1.5. 
The graph in Figure 1.5, provides the cancer statistics associated with 2008. However, the 
predicted increase of these values for 2028 presents an irksome view and future challenges 
posed to the scientific community. Despite many newly reported cases and the predicted 
increase, as a preventative measure early detection has been put in place. 
 
 
Figure 1.5. Common cancers experienced by African women.10 (Source: Taken from Jemal, A. et al., Cancer 
2012, 118, 4372) 
 











Estimated new cancer cases for 2008
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Apart from what is reported in the graph, reports by Jemal and co−workers imply that breast 
cancer is the most prevalent cancer experienced by women in Southern Africa.10 The 
advancements in technology and therapeutic strategies have led to a better quality of life, 
as well as a prolonged lifespan for women burdened with breast cancer. There is thus an 
urgent need to focus on some economically effective treatments, as well as screening 
techniques to improve on current preventative strategies for breast cancer in Africa. These 
findings highlight the importance of further exploration into this research topic.11,37 




Part 1: Estrogen modulation 
 
In part one of this chapter, a detailed focus will address both estrogen receptors, their 
distribution and overlapping functions of the receptors in the body. Furthermore, the 
individual characteristics of both ERs will be explored. These characteristics would provide 
some understanding toward their binding domains by providing an explanation for the affinity 
at which endo− and exogenous ligands bind with ER. Lastly, and most importantly, the 
transcriptase machinery and the varied modes of binding, will be discussed to provide some 
explanation for the complexities associated with ERs including its ability to effectively 
express gene transcription, even in the absence of its endogenous ligand. 
4  
2.1 The distribution and physiological importance presented by the ER isoforms 
E2 is the principle ligand responsible for the elucidation of a number of physiological 
responses in tissues and biological systems of the body viz., the ERs.38,39 These ERs exist 
as two main subtypes, namely the alpha and beta (ERα and ERβ) species, and are from the 
class of biochemical entities known as nuclear receptors.40 
 
Figure 2.1. The ERα and ERβ distribution within target tissues.16 (Source: Figure taken from Gustafsson, J. 
Å. J. Endocrinol. 1999, 163, 379) 
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These two ER−subtypes are expressed throughout the body, with ERα being more 
dominantly expressed than ERβ, and for which E2 is the endogenous ligand.39 Both 
ER−subtypes possess overlapping distributions as illustrated in Figure 2.1, but instigate 
distinct functions within their designated tissues.16 Apart from the diverse expression of 
these receptors, reports by Ascenzi15 and Gustafsson16,41-44 and co−authors, have further 
substantiated the importance of their role in maintaining the healthy functioning of the body. 
As previously mentioned, ERα is mainly implicated in reproductive processes and is thus 
generally expressed in mammary glands and the uterus.15 The more generally distributed 
ERβ, is expressed within the central nervous system (CNS), skeletal tissues, the 
cardiovascular system, the gastrointestinal tract, liver and the urogenital tract, in Figure 
2.1.45 The necessary requirement of E2 within these tissues was realised after a 
comprehensive screening process, in which the treatment of a number of breast cancer 
patients with antiestrogens interestingly, revealed many patients experiencing many 
adverse effects.46 Reports by Howell,32 Rahman,47 Martinkovich48 and co−workers, suggest 
that the alleviation of these effects could be improved by compounds, which would include 
both an agonistic, as well as an antagonistic, mode of binding for modulating gene 
transcription. These many observations thus leading up to the development of SERMs, to 
further improve on therapeutic agents with limitted side effects.32 
 
In the CNS, the hypothalamus is responsible for regulating target functions of the endocrinal 
system. Here, E2 contributes to the maintenance of mental health by regulating hormones 
such as serotonin and dopamine (usually associated with alleviating stress and depression), 
as well as choline (involved in memory and delaying the development of Alzheimer’s), aiding 
in the healthy functioning of the CNS.15,42 The optimal functioning of the cardiovascular 
system can also be attributed to contributions from the E2 ligand, where regulating low 
density lipoprotein (LDL) and high density lipoprotein (HDL), as well as reduce the 
development of venous thrombosis, which could eventually lead to additional secondary 
ailments for example, a stroke and coronary heart disease. However, more commonly 
associated with the reproductive tissue, E2 has also proved essential in facilitating the 
proliferation and differentiation in premalignant cells (during adolescence), as well as 
malignant breast epithelial cells.16,42,49,50 
 
In addition, the metabolism and homeostasis of skeletal tissue also relies on both 
ER−subtypes.43 E2 is but one of the molecules responsible for the development and growth 
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of bone during early developmental stages and adolescence. In addition to regulation of 
bone mass density in pre− and postmenopausal women, E2 is also a key element hindering 
the progression of ailments such as osteoporosis and osteopenia.15,43 Apart from regulating 
bone mass density, a number of essential metabolic processes in the liver, where enzymes 
in addition to ERs are responsible for regulatory functions, which include processes such as 
aiding in blood clotting and the removal of damaged blood cells by preventing their 
circulation through the body.16,42,49,50 Despite E2’s physiological importance, the over− or 
under−expression of E2 may result in a cascade of adverse events viz., mental illness and 
venous thrombosis (already mentioned), which are often experienced by women affected 
with breast cancer and are undergoing a combination of treatments with hormone therapy 
being one of the components.16 The normal existence of E2 can worsen the associated 
symptoms, but a deficiency would further increase the risk of hormone−related ailments in 
breast cancer patients.51 
 
2.2 The structural architecture of estradiol and its binding sites 
The active site in which the E2 ligand binds, consists of two hydrophobic pockets reported 
by Anstead,52 Marino15 and co−workers and Maalouf et al.23 This entails the A− and D−rings 
of the E2 molecule, which interact with a water molecule and/or amino acid residues 
respectively, within the binding site. In addition to this, the E2 ligand consists of a phenolic 
ring, ring−A, two six membered aliphatic fused ring systems referred to as the B− and 
C−rings, and a D−ring comprised of a five membered aliphatic ring containing a hydroxyl 
functional group.24,52 Contributions by Anstead and co−workers, have reported that the 
A−ring of E2 is non−polar and not very tolerant of polar substituents.52 However, despite its 
hydrophobic nature, it can interact with water molecules via hydrogen bonding with the 
hydroxyl groups present on both the A− and D−rings of E2. These hydroxyl functional groups 
provide the primary hydrogen donor sources, required for anchoring the ligand to residues 
as illustrated in Figure 2.2 (amino acid residues are listed in Figure 2.3). Once the ligand is 
anchored to the glutamic acid residue (Glu353/305), it is able to undergo conformational 
changes within the binding site and further undergo proton bond donor/acceptor interactions 
with other key residues within the proximity, for example the arginine (Arg394/346) and 
histidine (His524/475) in Figure 2.2.24,53 
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Figure 2.2. Binding mode of a) ERα and b) ERβ in the ligand binding domain.54 (Source: Figures taken from 
Zeng, J. Li, W.; Zhoa, Y.; Liu, G.; Tang, Y.; Jiang, H. J. Phys. Chem. B 2008, 112, 2719) 
 
Regardless of the number of residues as illustrated in Figure 2.2, it is important to note that 
a significant number of residues are present within the receptor’s active site. However, the 
aim of Figure 2.2 is to illustrate a few important target residues, which play a role in providing 
certain residue interactions. From Figure 2.2, one may appreciate that both ER−subtypes 
possess a certain degree of similarity within their binding site, with a variation of two 
important residues highlighted in Figure 2.2. The ERα (shown in frame a, of Figure 2.2) 
contains the residues Leu384/Met421, and ERβ (shown in frame b, of Figure 2.2) contains 
the residues Met336/Ile373.54 In Figure 2.3 below, a structural depiction of a few important 




Figure 2.3. There are three and one letter codes used in the identification of amino acid residues, these 
describe the residues within the ER binding cavity.55 (Source: Taken and edited from Patrick, G. L. An 
introduction to medicinal chemistry; 5th ed.; Oxford University Press, 2013) 
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Apart from the A−ring, the E2 ligand contains two fused cyclohexyl B− and C−rings, which 
contribute a certain degree of conformational freedom to the molecule, thus allowing E2 to 
adopt a range of structural orientations enhancing complexation of the ligand with the ER. 
The limited conformational freedom within this region is essential for initiating binding with a 
specific ER subtype. The newly formed E2−ER bound complex is forced to undergo 
allosteric conformational changes dictating how the E2−ER complex fits into a particular 
binding cavity which affects the recruitment of transcriptional proteins (cofactors) by either 
enhancing or repressing a particular transcriptional effect.44,54 
 
The D−ring’s terminal C17 hydroxyl motif serves as a proton donor/acceptor depending on 
the positioning of the ligand to His524/475 and is situated in the second hydrophobic binding 
cavity of the receptor, where its polar character undergoes hydrogen bonding interactions 
with the His residues (His524/475 as illustrated in Scheme 2.1). Additionally, the D−ring also 
contributes a certain degree of flexibility, further allowing for the accommodation of 
conformational changes to enhance the proton donor/acceptor required interactions, which 
are also dependent on the orientation of the His−residue within the cavity.24,52 
 
 
Scheme 2.1. Proposed mode of proton bond interactions induced by the His−residue. 
 
An interesting structural feature of the His−residue derived from its mesoionic ability, in 
which six π−electrons (four attributed to the two double bonds and two from the lone pair on 
the nitrogen of the diazine ring system), are involved. This affords it the abiltiy to form both 
bond interactions, as well as partake in π−stacking interactions, and the side chain 
additionally allowing ligand coordination with metalloproteins and catalytic sites of varied 
enzymes. Depending on the orientation of the His−residue, it thus behaves either as a proton 
source (for enzymes of interest) or a proton acceptor as illustrated in Scheme 2.1. 
Understanding the structural architecture of the E2 ligand and the ER residues is vital in 
understanding its function, as well as assisting in the structural design for the development 
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of novel compounds with the potential of mimicking important biological processes by 
promoting specific target residue interactions. 
 
2.3 The ERs and their associated binding domains 
As with most nuclear receptors, both ERα and ERβ contain six structurally conserved 
domains (A – F), which are distinct regions serving functions common to the physiology of 




Figure 2.4. The six distinct binding domain regions which define nuclear receptors.16,53,56 (Source: Modified 
from Levin, E. R. J. Appl. Physiol. 2001, 91, 1860) A/B: Amino−terminal or transcriptional activation function 
(AF−1) responsible for the recruitment of coregulatory proteins. C: DNA binding domain where dimerization 
occurs. D: hinge region. E: Ligand binding domain, responsible for secondary dimerization and the recruitment 
of coregulatory proteins. F: Carboxyl−terminal or transcriptional function (AF−2). 
 
The difference within these regions enable the binding of endo− or exogenous ligands and 
affect the affinity, to which specific ER subtype binding occurs. As illustrated in Figure 2.4, 
each ER is encoded on different chromosomes with ERα consisting of a 595 sequence of 
amino acid residues, while a significantly smaller number of residues (530) are observed for 
the ERβ subtype.16,17,22 A certain degree of homology is displayed between these two 
receptors in the C−domain, which roughly shows a 97% similarity in Figure 2.4.23 It is 
important to note that these similarities play a crucial role in the congruent binding affinities 
and efficacies displayed toward both ERα and ERβ.16 
 
2.3.1 The amino terminal domain 
The A/B domain harbours the activation function (AF)−1. This region contributes to the 
transcriptional activity and is also known as the amino terminal. Reports by Heldring et al.,42 
suggest that the amino/N−terminal domain is not conserved (as illustrated in Figure 2.4) and 
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is illustrated by the variation of residues within this domain and thus represents the most 
varied domain (18%).7 AF−1 is known to function by encoding ligand independent activation, 
achieved by the recruiting of protein−protein interactions with the transcriptional activation 
for targeted gene expression.15,43 The activation function of this domain can be attributed to 
the negative charges and hydrophobic residues provided within this region.15 Within the 
ERα, this domain binds antagonistically to E2 and is responsible for stimulating gene 
expression viz., a variety of estrogen response elements (ERE), which vary depending on 
the cell line.7,15,43,57 However, the same conditions are inconsequential for the ERβ subtype, 
which binds purely agonistically to E2 within this domain.43 
 
2.3.2 The DNA binding domain 
The C−domain or DNA binding domain (DBD) contains approximately 70 residues, with 97% 
being almost identical for both receptor subtypes (in Figure 2.4).23 The DBD is the most 
central and conserved binding domain, consisting of two zinc finger motifs, which are 
tetrahedrally coordinated, with two groups of the four sulfur atoms on the eight cysteine 
residues present (see Figure 2.5).15,44 Interestingly, the nucleophilic motif on the cysteine 
residue not only allows co−ordination of the zinc, but also enables its participation in a 
number of enzymatic and binding interactions.58 Of importance is that in this domain, 
dimerization of the bound receptor and ligand does occur. Dimerization is essential as it is 
a prerequisite for the recruitment of specific ERE and is thus responsible for initiating the 
gene transcription processes (Figure 2.5). The DBD domain in both ER−subtypes are 
homologized, enhancing their ability to bind with similar affinities and specifications to 
various ERE.23,43 
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Figure 2.5. Demonstration of the DBD complexed with ERE.25 (Source: The diagram was taken and modified 
from Ruff, M.; Gangloff, M.; Wurtz, J. M.; Moras, D. Breast Cancer Res. 2000, 2, 353) 
 
This domain can further be divided into two subdomains known as the proximal box 
(responsible for DNA recognition) and distal box (responsible for DNA dependent 
dimerization in the DBD), also known as the P−box and D−box respectively.15,44 The P−box 
for both ER−subtypes are identical, thus enabling both receptors to bind with similar affinities 
to EREs, where the role of the D−box provides the topography suited for accommodating 
the head to head dimerization undergone by the ligand and the ER bound complex.15 
 
2.3.3 The D− and E/F−domain 
The D−domain, also known as the hinge region, and is the most variable region within the 
receptor subtypes. The carboxyl/COOH−terminal is linked to the E/F−domain or ligand 
binding domain (LBD) by way of the hinge region.44 The LBD is the second most conserved 
domain, which harbours an activation function (AF−2) governed by the E2−ER complex. 
This region mediates binding of the ligand, as well as the homo− and heterodimerization 
required for nuclear translocation processes and the transactivation of specified gene 
expression.43 Regardless of the shared homology in the E/F−domain, with both 
ER−subtypes being able to bind with similar affinities during ERE activation.23 However, 
variation of the two residues in Figure 2.6 enables both ER−subtypes to bind with different 
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affinities by recruiting EREs, providing selectivity and explaining the versatility associated 
with the ER−subtypes and their binding affinities. This domain is also involved with the 
recruitment of chaperone proteins that are responsible for the stabilization of folded proteins 
during protein−protein translocation. These chaperone proteins [also known as heat−shock 
proteins (Hsp)] are additionally responsible for the inhibition of the synthesis of ligands 
crucial for cell growth, thus enabling the ER−subtypes to modulate transcriptions in the 
absence of its endogenous ligand.15 
 
Figure 2.6. The two distinguishing residues within the ER binding cavity.6 M = Met, L = Leu and I = Ile are the 
different residues present within the ERα and ERβ, which present the factor of selectivity within the LBD.6 
(Source: Figure taken from Wen Ng, H.; Perkins, R.; Tong, W.; Hong, H. Int. J. Environ. Res. Public Health 
2014, 11, 8709) 
 
A key element to the AF−2 conformational orientation is the short helical region (helix 12) 
located at the carboxyl terminal of the LBD, shown in Figure 2.7.42 The helical elements 
consist of a three layered antiparallel α−helices which comprises the AF−2 region.15 
 
 
Figure 2.7. Illustration of the helix12’s conformational orientations permitting different ER modes of binding.42 
(Source: Figure taken from Heldring, N. et al., Physiol. Rev. 2007, 87, 905) 
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The helices (helix 4 – helix 11) assemble to form a shallow hydrophobic binding cavity for 
leucine−rich motifs (LXXLL, where L refers to leucine and X, to the additional residues 
attached to the DNA sequence) of nuclear receptor coactivators.44 As illustrated in Figure 
2.7, in cases where helix 12 is not stabilized (the agonist conformation, frame A), the helix 
is re−orientated to bind along and occlude the AF−2 groove, thus blocking the recruitment 
site. In contrast, receptor antagonists interfere with the orientation of the helix 12, which 
results in an ER conformation unable to complete the recruitment of coactivators. The 
removal of the helix 12 greatly enhances the ER’s ability to interact with traditional nuclear 
receptor corepressors (illustrated in frame E).42 Of importance is that the ligand binding site 
for both ER−subtypes is quite generous in size, further allowing a number of exogenous 
ligands to bind with the receptor.42 
 
2.4 Estradiol instrumentation and its mechanism of action 
With the general understanding of the receptor’s binding domains previously introduced, this 
section further elaborates on the overall biochemical machinery (EREs), which permit the 
gene transcription for ERs.43,59 Scheme 2.2 provides the general layout of the major 
instrumentation required for orchestrating the physiological transcriptions modulated by E2. 
 
ER tripartite pharmacology 
 
Scheme 2.2. The three components (ligands, receptors, and effectors), which together orchestrate 
transcriptional responses to the estrogens in target tissues.60 (Source: Modified from Katzenellenbogen, B. S.; 
Katzenellenbogen, J. A. Breast Cancer Res. 2000, 2, 335) 
 
The overall mechanistic process is initiated by the E2 (ligand), which binds to the ERα and/or 
ERβ (receptors). The resultant E2−ER bound complex further undergoes dimerization, 
which is essential for phosphorylation of the receptor’s protein chain, and gives rise to either 
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occurs within the DBD domain.7 Dimerization is vital, as it further allows the E2−ER 
dimerized complex to recruit specific DNA sequences known as ERE (or coregulatory 
proteins) to either express or repress transcriptional information.46 The homo/heterodimer 
status is important and plays a distinct and sometimes opposite role in the regulation of gene 
transcription.58 The recruitment of coregulatory proteins regulate gene transcription, which 
consists of coactivators that enhances estrogenic gene transcription, and corepressors 
responsible for repressing ER’s gene transcription.44 These coregulatory proteins enforce 
gene transcription by altering the chromatin structure with enzymatic processes 
implemented by the recruitment of DNA polymerase. This either masks or reveals active 
sites on the AF−2 domain, thus enhancing/reducing the structural topography required for 
the efficient binding of coregulatory proteins.42 These coregulatory proteins are further 
discussed in the section below and as illustrated in Scheme 2.3. 
 
2.4.1 Effector machinery responsible for the orchestration of ER modulation 
With previous attention focused on the E2 ligand and its receptors, attention is now shifted 
toward the effector machinery and their contribution to enhancing and repressing estrogenic 
transcription. The coregulatory proteins are the major transcriptional mediators, responsible 
for fostering cooperation between cofactors (coactivators and corepressors with a few 
illustrated in Scheme 2.3) mediated by specific DNA sequences (LXXLL), known as the 
nuclear receptor box (NR box), or LCD/LXD. The NR box is the primary docking site within 
the AF−2 domain.15,43,61 During which, coactivators serve as a bridge between the receptor 
and basal transcription machinery required for the enhancement of gene transcription. 
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Scheme 2.3. A summary of the major ER coregulators.62 (Source: Scheme taken from Perissi, V. and 
Rosenveld, M. G. Nat. Rev. Mol. Cell Biol. 2005, 6, 542) 
 
Scheme 2.3 presents a summarized description of the coregulatory components, with the 
green shaded components representing the coactivator family, while the red shaded 
component represents the corepressor family and lastly, the centre components are the 
basal transcription machinery. It is important to note that despite the opposing functions 
these coregulators offer, they can be found within similar protein complexes.42 The 
coactivator family consists of p160/steroid receptor coactivators (SRC), which can further 
be expanded into three subgroups.43,44 These subgroups include the SRC−1 and the nuclear 
receptor coactivator (NCoA−1). The SRC−2 coactivator includes the transcriptional 
intermediary factor−2 (TIF2), glutamate receptor interacting protein−1 (GRIP1), and 
NCoA−2. The third subgroup SRC−3, is composed of the co−integrator associated protein 
(p/CIP), the activator of thyroid and retinoic acid receptor (ACTR), amplified in breast 
cancer−1 (AIB1), receptor−associated coactivator−3 (RAC3), and TRAM1 summarized in 
Scheme 2.3.15,43,44 
 
The SRC coactivators contain two separate activation domains (AD)−1 and AD−2. AD−1 is 
responsible for the recruitment of the co−integrator CBP/p300, usually involved in multiple 
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signalling pathways, which include acetyl transferase, associated with the RNA polymerase 
II.44 The AD−2 domain recruits secondary protein modifying enzymes, known as the 
coactivator associated arginine methyl transferase (CARM1) that incorporates the use of 
histone acetyl transferase (HAT) enzymes. These HAT enzymes further consist of the SRC, 
CBP/p300 and/or p/CAF/GCNS, which function by recruiting chromatin modifying enzymatic 
activities to the ligand activated nuclear receptor, regulating target gene transcription.43,63 
The RNA processing unit, aided by PGC1 and SRA promotes the RNA transcription of 
coactivator complexes by acting as a protein binding scaffold.15 Mediators such as 
TRAP/SMCC/DRIP/ARC complexes, form a bridge directly linking the ER to the basal 
transcription machinery promoting gene transcription.43 
 
Recent work by Gustafsson and co−workers, suggest that both the agonist and 
antagonistically bound ERs are able to recruit a variety of corepressor proteins,42 which in 
turn decrease the rate of gene transcription by stimulating specific transcriptional effects.60 
Coactivators function by way of histone acetylation, thus altering the chromatin structure. 
Conversely, the corepressor functions by repressing gene transcription by blocking off the 
AF−2 domain, and inhibiting the recruitment of coactivators.62 Baniahmad and co−workers,64 
further support these findings, suggesting that the histone deacetylase offers a platform 
enhancing protein−protein interactions, by bridging the DNA bound transcriptional silencers 
with chromatin modifying enzymes (also known as silencing factors).64 The transcriptional 
silencing factors are comprised of nuclear receptor corepressors (NCoR) and the silencing 
mediator of retinoid and thyroid (SMRT) that function by recruiting protein complex histone 
deacetylase (HDAC).65 Work by Nilsson et al.43 further reports that repressors function by 
antagonizing the AF−2 proteins of SRC−1 by the recruiting of ligand dependent 
corepressors such as RIP140 or ICoR, which block the recruitment of HAT enzymes.43 The 
repression of gene transcription can also be obtained by employing ATP−dependent 
chromatin remodelling complexes (such as SWI/SNF, NURD/Mi2, Sin3 and CtBP 
complexes in Scheme 2.3), which compete for the AF−2 domain on the SRC−1 
coactivator.15,43,62 Despite the use of coregulators in gene transcription, reports by 
Gustafsson has established that many more complex processes further contribute to the 
recognition of coregulators, critical for the functioning of estrogenic gene transcription.42 
 
2.4.2 All pathways lead to gene transcription 
The multifaceted role exhibited by the E2 ligand and its receptors, can be associated with 
its ability to bind in both an agonistic and antagonistic binding mode. The agonistic mode of 
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binding adopted by the ER follows a direct binding path and is ligand dependent, whereas 
the antagonistic mode of binding follows a more indirect path, which is ligand independent. 
In the absence of its endogenous ligand, the receptor recruits cofactors able to enhance the 
transcription of gene expression.66 Once the ligand and receptor binds, the bound complex 
(ligand−ER) undergoes a number of structural conformational changes, allowing for the 
recruitment of coregulatory proteins, modulating either the expression or repression of gene 
transcription via a number of secondary routes. The structural conformations adopted by the 
bound complex, suggests that the binding site is quite flexible and accommodating to these 
conformations.6 Apart from endogenous ligands such as E1, E2 and E3, the ER has proved 




Figure 2.8. Xenoestrogens composed of synthetic and natural chemical compounds compatible with ER 
binding.6 (Source: Taken from the work reported by Wen Ng, et al.; Int. J. Environ. Res. Public Health 2014, 
11, 8709) 
 
These compounds range from industrial by−products, to plastics, phytoestrogens, pesticides 
and pharmaceuticals, further substantiating that the ER does not bind according to the 
conventional lock and key binding models hypothesized by Fischer.6 However, its mode of 
binding has been better supported by Koshlands theory, where the transcriptional processes 
are catalyzed by the receptor recruiting certain cofactors.6,55 The ability of ER to bind with 
numerous endo− and exogenous ligands accommodates its unconventional transcription 
methods. This can be attributed to a number of complex procedures briefly as illustrated by 
Scheme 2.4, which further illustrates the ligand dependent and independent binding modes. 
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2.4.2.1 ERs general binding modes 
The ligand dependent ER mode of binding includes a process where the E2−ER bound 
complex undergoes dimerization. The activated homo/heterodimer undergoes translocation 
from the plasma membrane into the nucleus, where it directly binds with the response 
element machinery. This triggers transcription factors that recruit coregulators, further 
altering the chromatin structure and thus facilitating the recruitment of RNA polymerase II 
transcriptional machinery in Scheme 2.4 (in addition to Table 2.1), which either decreases 
or enhances gene transcription.17,46 
 
 
Scheme 2.4. General signalling transcriptional pathways followed by estrogen.7,67 (Source: Diagram taken 
from the Compston, J. E. Physiol. Rev. 2001, 81, 419) 
 







Dependent ERE / 
Coactivators and 
corepressors42,43 
Dependent AP1 Jun/Fos7,17,43,68 
Coactivators: CBP and 
GRIP69 
Dependent SP1 
GF, EGF and 
IGF−142,68 
Coactivators 
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PKA) tyrosine kinase 
Phosphorylation viz., kinase 
cascades (MAPK and 
P13K−Akt)18 
CREB−binding protein: CBP; glucocorticoid receptor interacting protein: GRIP; growth 
factors: GF; epidermal growth factor: EGF; insulin−like growth factor−1: IGF−1; nuclear 
factor−kB: NFkB. 
 
The multiple binding modes adopted by estrogen receptors create many challenges in the 
design and development of molecules required to selectively modulate their target 
transcriptions. Thus, a few antiestrogens have been developed as an initial strategy to block 
the estrogen receptor’s transcription. However, a number of hormonal related ailments were 
soon realized and antiestrogens were soon replaced by SERMs with the aim of selectively 
allowing gene transcription in certain tissues by the design of molecules, which could behave 
agonistically and/or antagonistically in specific tissues. However, despite many scaffold 
designs, challenges were still encountered and will be discussed in the second part to this 
literature overview. 
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Literature review 
Part 2: Evaluation of past and present SERMs 
 
This subsection to the literature review discusses the development and relevance of the 
designed SERM molecules. A brief overview elaborates on the victories and challenges 
associated with exploration of varied scaffolds during the search for an ideal SERM. The 
metabolic pathways undergone by SERM molecules, their metabolites and their relation to 
the adverse effects experienced by the patients undergoing therapeutic treatment with them 
will also be reviewed briefly. In concluding the literature review, a description into the 
motivation behind the structural design, scaffold use, the aryl groups incorporated, and 
general research objectives targeted by this research will be presented. 
 
2.5 Synthetic ligands and selectively mediating estrogenic gene transcription 
As previously discussed, E2’s vital role in the development and maintenance of the body, 
specifically sustaining overall health by its tissue specific gene transcription has been 
established.7 Since both E2 and ER have been implicated in tumour growth, the need to 
selectively orchestrate gene transcription has emerged.13,19,21 Primarily, women suffering 
from breast cancer have been treated by forms of hormonal therapy, but once it was realized 
that hormones (estrogen) encouraged tumour growth, antiestrogens were introduced. The 
implementation of antiestrogens was aimed toward locking the receptor/s in an inactive state 
thus, preventing any gene transcription. However it was soon realized that a cascade of 
negative health effects were experienced by the women undergoing this therapeutic 
strategy.48 These adverse effects included ailments such as: the deterioration in skeletal 
health, the central nervous system, the reproductive system, as well as the development of 
cardiovascular diseases.16,42 In addressing these issues, the need of estrogen was 
substantiated leading to the realization of the need for synthetic estrogenic ligands. These 
ligands would need to selectively modulate gene transcription targeted at specific tissues. 
This class of synthetic ligands are known as selective estrogen receptor modulators 
(SERMs). The term describes their behaviour as estrogenic agonists in some tissues (such 
as skeletal, liver and the cardiovascular systems) and as antagonists in other tissues (such 
as mammary glands, uterus and the brain).70 Current SERMs include a range of structurally 
diverse compounds, in which the steroidal skeleton of estrogen is absent. 
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2.6 The general SERM binding interaction mechanism 
The unique pharmacology presented by SERMs allow for the agonistic and antagonistic 
behaviour within target estrogenic tissues. Apart from the classic ligand dependent 
transactivation mechanism for gene transcription, estrogens can mediate their transcription 
independently by many complex mechanisms previously summarized in Table 2.1. It was 
initially thought that SERMs occupied the LBD, blocking E2 access by locking the ER in an 
inactive state, and thus being unfavourable for the recruitment of coactivator proteins.23,42 
However, contributions by Howell and co−workers reported that SERMs were able to bind 
with a lower affinity to the receptors in comparison to the endogenous ligand, and dissociate 
heat shock proteins (Hsp90).32 These Hsp90 are chaperone proteins, which assist in the 
folding of the dimerized ligand−ER complex, and the stabilization of proteins required for 
promoting tumour growth.66 
 
 
Scheme 2.5. Binding modes interaction by the SERM−ER bound complex.71 (Source: Diagram taken from the 
Schiff, R.; Massarweh, S.; Shou, J.; Osborne, C. K. Clin. Cancer Res. 2003, 9, 447) 
 
The SERM−ER complex undergoes homodimerization followed by its translocation into the 
nucleus, which triggers activation of AF−1 in the A/B−domains of the receptor, but not the 
E/F−domains (AF−2), generating a partial agonist.32 The transcription of estrogen 
responsive genes is therefore restricted by the inactive AF−2 domain. Inhibiting the 
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recruitment of coactivators, the AF−1 domain is thus available for activation.71 It can 
therefore be established that the SERM pharmacology is not only dependent on the ligand 
and receptor interaction, but includes the recruitment of coregulatory proteins illustrated in 
Scheme 2.5. 
 
2.7 The gradual development of the SERM generations 
As with numerous scientific developments, a prototype is initially established, to which 
further modifications are made to accomplish the ideal interaction. Likewise, since the 
development of the tamoxifen drug (the first generated SERM), new libraries of SERMs have 
been developed for enhancing the pharmacological profiles and reducing the adverse 
effects associated with previous generations of similar molecules. The developed 
generations of SERMs are arranged as 1st, 2nd, 3rd and 4th in the order of progression, in the 
establishment of more effective SERMs. The varied SERM generations are not designated 
according to their structural features, with each generation bearing slight structural variations 
from its predecessor, but possess distinct biological effects on targeted tissues.48 It has been 
confirmed that exogenous ligand bound complexes adopt conformations required for the 
recruitment of coregulatory proteins that either enhance or retard a specified gene 
transcription.42 
 
2.8 First generation SERMS: Triphenylethylene analogues 
The intended aim of the 1st generation of SERMs was for them to behave as antiestrogens. 
However, observing patients undergoing treatment with these SERMs proved otherwise.72 
Displayed in Table 2.2, it was clear that the 1st generation of SERMs were good therapeutics 
for breast cancer treatment. However, apart from mimicking E2 in mammary glands, 
tamoxifen behaved agonistically in other tissues.22,32,48,73 The recognition of the 
tamoxifen−ER complex in specific tissues suggested that instead of it being an antiestrogen, 
it behaved as a SERM and it was soon reclassified as a SERM.72 
 
Table 2.2. Adverse effects observed in breast cancer patients undergoing hormonal mediated treatments.46 
Side Effects Estrogen Tamoxifen Toremifene Raloxifene 
Hot flashes _ + + + 
Uterine bleeding + + + / 
Endometrial cancer + + ? / 
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Bone loss (in postmenopausal 
 women) 
+ + / + 
Breast cancer + _ _ − 
Serum lipids pattern + + + + 
Venous thrombosis + + + + 
+: refers to an increase in the mentioned side−effect. 
−: refers a decrease in the mentioned side−effect. 
?: refers to inconclusive results. 
/: refers to no observed change in the mentioned side−effect. 
 
2.8.1 Victories and challenges associated with tamoxifen 
The 1st generation SERMs are the only class in which structural consistency was retained, 
as it was in this family of compounds where the triphenylethylene scaffold was used. This 
triphenylethylene skeleton was modified from the Stilbestrol (diphenylethylene) skeleton. 
During 1939 work reported by Lewis74 suggested that similar estrogenic behaviour was 
observed when Stilbestrol was administered to a number of girls and women.74,75 It was 
initially developed for the treatment of endometrial irregularities in women and girls however, 
a vast number of side effects, where endometrial carcinomas in addition to cervical and 
vaginal abnormalities were experienced and was thus short lived.75-77 The first 
triphenylethylene molecule generated from the 1st generation SERM series, tamoxifen has 
been employed in clinical treatments for metastatic breast cancer since the early 
1970’s.32,48,70,72 Clinical drug trials have since indicated that tamoxifen had potential chemo 
preventative applications, particularly as a therapeutic agent in ER positive breast cancer 
cell lines.72 Tamoxifen not only showed promising results by reducing breast cancer in 16 – 
49% of patients, but also that the incidence of ER positive breast cancer was reduced 
between 31 – 69%.48,72 With these results, it was understood that tamoxifen’s mechanism 
of action involved blocking cancer cells in the G1 (growth) phase, where growth of these 
cells were inhibited.48 Furthermore, it was observed that the bone mineral density in 
postmenopausal women was maintained, as well as producing decreased LDL cholesterol 
levels. Tamoxifen proved to be an estrogenic agonist in uterine cells and induced growth of 
endometrial cells, while displaying partial agonistic effects in skeletal maintenance and the 
cardiovascular system in postmenopausal women.73 
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Figure 2.9. Evolutionary development of the triphenylethylene analogue. 
 
Despite the successes obtained, tamoxifen has been associated with an increased risk in 
endometrial cancer,72 as well as having additional side effects listed in Table 2.2,70,72 which 
in themselves increase the risk of secondary health effects.48,70,72 It was later found that the 
long term use of tamoxifen resulted in resistance toward the drug, acquired by either the 
continual use or prior to use (the treatment was thus considered to be ineffective).22 
Structural modifications to tamoxifen’s triphenylethylene structure was explored with the 
objective being to limit the genotoxic effects associated with tamoxifen (which would further 
be elaborated on in later sections of the chapter).70 
 
2.8.2 The structural modification of tamoxifen to toremifene 
The second triphenylethylene analogue, toremifene, was designed and targeted toward 
generating a molecule with reduced side effects compared to its predecessor tamoxifen. 
This triphenylethylene analogue included the introduction of a chloride atom on the ethylene 
chain, in Figure 2.9. Since the 1st generation SERMs possess a general scaffold, similar 
pharmacological profiles could be expected for the triphenylethylene analogues.48,70,72 As 
expected, toremifene displayed similar binding affinities toward ERα but also caused 
adverse effects.32,48 However, an increased rate of venous thromboembolism was observed, 
and despite a shared structural profile the toremifene analogue was less prone to the 
formation of genotoxic DNA adducts, previously observed for tamoxifen.48,70 
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2.8.3 The triphenylethylene analogue: Droloxifene 
Droloxifene was the third developed triphenylethylene analogue, targeted toward a more 
potent tamoxifen derivative with less side effects. 
 
 
Figure 2.10. Derivatization of tamoxifen, providing the droloxifene analogue. 
 
Shown in Figure 2.10, the new compound included a hydroxyl group on one of the phenyl 
rings. This significant change resulted in a molecule, which displayed an ER binding affinity 
10 – 60 times greater, in addition to the absence of the genotoxic DNA adduct formation.48,70 
The greater affinity observed toward ERα allowed droloxifene to be administered to patients 
with shorter dosing periods, and the compound displayed full ERα antagonistic behaviour in 
mammary glands with full ERα agonistic behaviour in skeletal tissue. An additional feature 
observed, was its inhibition of the insulin−like growth factor (IGF)−1,42,68 thus preventing the 
stimulation of E2 oncogene c−myc expression.48,68 Unfortunately, during phase III trials, 
droloxifen was found to be inferior upon comparison to tamoxifen.32 Additional side effects 
included hot flashes, nausea, fatigue, headaches, back pain and dyspnea, which brought 
an end to further developments on droloxifene, thus paving the way for structural 
improvements in developing a more effective triphenylethylene analogue.48 
 
2.8.4 The triphenylethylene analogue: Idoxifene 
The structural modifications used to generate idoxifene, involved substitution of the hydroxyl 
motif by an iodine atom with the replacement of the dimethyl group on the side chain by a 
pyrrolidino−group (Figure 2.11).48 
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Figure 2.11. Derivatization of tamoxifen, providing the idoxifene analogue. 
 
Idoxifene possessed an antiestrogenic ability comparable to tamoxifen but without the 
formation of hepatocarcinogenic effects previously observed in rat cell models with 
tamoxifen.70 This analogue proved to be metabolically more stable and the associated 
slower metabolism resulted in a longer half−life when compared to tamoxifen. The idoxifene 
analogue presented an overall reduction in tumour size with good efficacy toward breast 
cancer cell lines. In addition, limited agonistic activity was observed in endometrium cells, 
thus lowering the potential risk of uterine cancer development post−treatment. 
Unfortunately, phase I and II drug trials showed no real significant advantages upon 
comparison of idoxifene with tamoxifen. These results led to the termination of further 
synthesis of the triphenylethylene−based analogues.32,46,47,52 
 
2.9 Second generation SERMs: Benzothiophene analogues 
The development of 2nd generation SERMs was steered toward increasing potency, and the 
elimination of side effects associated with the 1st generation. Diverting from the 
triphenylethylene skeleton, a benzothiophene skeleton was adopted as the scaffold for the 
2nd generation SERM analogues (in Figure 2.12).78 Raloxifene was the first 2nd generation 
SERM developed for the treatment of breast cancer cell lines, but showed no therapeutic 
value when used by patients who developed resistance toward tamoxifen.48 Unlike 
tamoxifen, it however proved to be effective in terms of preventing the development of 
endometrial cancer and possessed less thromboembolic effects.48 Raloxifene showed ER 
agonistic effects in skeletal tissues and the cardiovascular system,73 with antagonistic 
behaviour observed in the uterus and mammary glands.72,79 Despite its failure as a breast 
cancer therapeutic, this drug also proved to be an effective pre−treatment for breast cancer 
and a treatment for osteoporosis in postmenopausal women.48 
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Figure 2.12. Evolutionary design of the benzothiophene analogues. 
 
Studies of tamoxifen and raloxifene (STAR),32 demonstrated that raloxifene showed a 78% 
effectivity upon comparison to tamoxifen.47 However, side effects such as hot flashes, an 
increased risk in blood clot formation and potential drug resistance associated with 
tamoxifen, were also experienced with raloxifene.48,70 Not much literature has been 
published on the additional analogues (Y110, Y134, Y108, 118676 and 118675) in Figure 
2.12. However, studies by Ning and co−workers established that Y134 showed a 2−fold 
improvement in mammary gland efficacy when compared to raloxifene, but no significant 
improvements were observed for the Y110, Y108, 118676 and 118675 analogues, and 
further investigation into these compounds was soon abandoned.79 Regardless of minor 
improvements, no significant pharmacological value was observed and no further 
investigations into 2nd generation SERMs were pursued. 
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2.10 Third generation SERMs 
Unlike the 1st and 2nd generation SERMs, the 3rd generation differs significantly with a few 
fairly diverse range of structural features. The only common feature was that all 3rd 
generation SERM analogues contained three phenyl rings (Figure 2.13). 
 
 
Figure 2.13. Evolution in the design of the 3rd generation SERM analogues. 
 
The major driving force for the development of 3rd generation SERMs, was to establish a 
pharmaceutical containing the auspicious qualities of raloxifene, while decreasing adverse 
effects such as reduce LDL cholesterol serum levels and hot flashes. The most advanced 
3rd generation SERMs included the molecules lasofoxifene and bazedoxifene, which were 
able to complete registration trials.22 
 
2.10.1 Redemption of the benzothiophene scaffold with the development of 
arzoxifene 
The benzothiophene skeleton was recruited as the scaffold for the arzoxifene (LY353381) 
molecule. The arzoxifene structure resembled that of the earlier developed raloxifene but 
included derivations where the carbonyl linker was replaced with an ether linkage and a 
masked hydroxyl motif (as illustrated in Figure 2.14). Since raloxifene failed as a therapeutic 
towards metastatic breast cancer, the arzoxifene analogue was introduced, providing further 
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evidence supporting the claim that the benzothiophene core was a viable candidate for 
therapeutic agents treating metastatic breast cancer.32,48 
 
 
Figure 2.14. Comparison between the 2nd generation raloxifene and the 3rd generation arzoxifene. 
 
Thankfully, the structural modifications significantly improved the pharmacological profile of 
arzoxifene when compared to raloxifene.32 These structural derivations provided a molecule 
with greater bioavailability, increased antiestrogenic activity and an increased binding affinity 
toward the ERα subtype (unlike raloxifene).32 In addition, arzoxifene demonstrated its ability 
to inhibit estrogenic agonistic effects in the uterus and endometrial cell growth, suggesting 
its application as a therapeutic for endometrial cancer.32,48 As observed with the 
triphenylethylene analogues, structural similarities resulted in a similar side−effect profile, 
which was observed for arzoxifene (experienced for raloxifene). The major side effects 
observed during these trials included hot flashes, nausea, cutaneous infection, neuromotor 
toxicity and weight gain.22,48,80 Additional side effects reported by Maximov and co−workers, 
further included cholecystitis, increased pulmonary complications and chronic obstructive 
pulmonary disease.22 Arzoxifene met its primary objective, by reducing vertebral fractures 
and breast cancer in postmenopausal women, but improvements on the non−vertebral 
fractures, cardiovascular and cognitive functioning were not obtained. Despite its valuable 
contribution in the treatment of breast cancer, when compared to tamoxifen, it was 
considered inferior and further developments on the arzoxifene analogue were 
discontinued.22,32,48 
 
2.10.2 Redemption of the triphenylethylene analogue with the development of 
ospemifene 
With the development of each SERM generation, exploring past structural features has 
commonly been revisited, with ospemifene again making use of the triphenylethylene 
skeleton (previously used in 1st generation SERMs in Figure 2.15). Upon reviewing 
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tamoxifen metabolites, an interesting metabolite displayed weak antiestrogen activity, thus 
inspiring the ospemifene structural design.22 Ospemifene was found to bind with both 
ER−subtypes, but a greater affinity was exhibited toward the ERα. Its estrogenic effects 
were observed in skeletal tissue, displaying the ability to prevent bone loss and increase 
skeletal strength in the neck, lumbar and femoral vertebrae.22 
 
 
Figure 2.15. Triphenylethylene−based analogues 3rd generation SERMs. 
 
Additionally, ospemifene showed weak antagonistic activity in the uterus and preserved 
endometrium activity. No genotoxicity was experienced, and the drug was well accepted, 
with headaches being the more commonly experienced side effect (with neutral effects on 
hot flashes).22 In subsequent studies, ospemifene has displayed a similar breast chemo 
preventative profile to toremifene and raloxifene.22,72 
 
2.10.3 The naphthalene analogue: Lasofoxifene 
As mentioned, the 3rd generation of SERMs were developed to improve on the 1st and 2nd 
generations by reducing side effects associated with their applications. Lasofoxifene (shown 
in Figure 2.13) was developed using the tetrahydronaphthalene skeleton, which showed an 
affinity toward both ER−subtypes. This 3rd generation SERM behaved agonistically in 
skeletal tissue and antagonistically in the breast and uterine tissues.48,72 Lasofoxifene was 
found to behave similarly to raloxifene, with pharmacological outcomes that included the 
maintenance of femoral bone mineral density, the inhibition of osteoclast oogenesis, with 
reduction in bone turn−over, thus preventing bone loss during preclinical studies.22,72,81 A 
decrease in bone turn−over markers, coronary heart disease, serum lipid levels and 
endometrium hypertrophy were revealed during osteoporosis prevention and lipid lowering 
(OPAL) and postmenopausal evaluation with the reduction of risk with lasofoxifene (PEARL) 
studies.48,72,82 
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2.10.4 The indole analogue: Bazedoxifene 
Bazedoxifene (in Figure 2.13) is an indole−based analogue developed as a preventative 
measure and a treatment for osteoporosis in postmenopausal women or used collectively 
with estrogens in treating menopausal symptoms. The drug demonstrated improved 
vasomotor activity during phase III clinical drug trials when compared to the 1st and 2nd 
generation SERMs.72 Like lasofoxifene, it has shown a great affinity toward both 
ER−subtypes with greater affinity been shown toward the ERα.22 Bazedoxifene was found 
to be the second most active compound clinically utilized in the 3rd generation series of 
compounds.22 
 
2.11 Fourth generation SERMs: Benzopyrans 
The 4th generation SERMs were structurally based on the benzopyran skeleton also 
resembling the isoflavone structure of the phytoestrogen (see for instance the structure of 
genistein Figure 2.16).83 EM−652 in Figure 2.16, has proved to be the more potent SERM 
inhibiting both ER−subtypes.70 Binding of EM−652 with ER is significantly greater than that 
observed for E2, tamoxifen and raloxifene.32 The pro−drug EM−800, being potent by 
inhibiting E2−induced proliferation in breast cancer cells, prevented cardiovascular disease, 
bone loss, as well as the proliferation of estrogen−stimulated tumour xenographs in animal 
models.32 Additionally, it inhibited breast and endometrial cancer cell lines.70 
 
 
Figure 2.16. Phytoestrogen−like SERM analogues. 
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In summary, the ongoing development of SERMs has resulted in a better understanding of 
the biochemistry and biology of ERs. The significant improvements obtained in the field of 
ER targeted therapeutics, seen by the development of each new SERM generation. 
 
2.12 The metabolic pathways undergone by SERMs 
Briefly introduced in Chapter 1 section 1.3.1, was the metabolism of E2 and the potential 
contribution its metabolites exerted toward the development of carcinogenic cells.13,18,84 
Some of these metabolic processes are also shared by SERMs.70,84 The metabolic 
substrates produced by estrogens and SERMs, not only alter the intensity of their action, 
but also the profile of their physiological effects in target tissues. This further contributes to 
the degree of toxicity associated with certain SERM compounds.13,84 There are at least four 
classes of electrophilic metabolites originating from the metabolic pathways undergone by 
the varied SERM molecules. The electrophilic metabolic substrates include carbocations, 
quinone methides, diquinone methides and o−quinones.70,84 The degree and concentration 
of these metabolites are dependent on the structure and reactivity of the SERM, as well as 
the class of CYP enzyme involved.70,84 
 
2.12.1 Metabolic pathways followed by the triphenylethylene analogues 
The metabolism commonly observed in the triphenylethylene compounds includes a 
mechanism which involves the aromatic hydroxylation of tamoxifen at the 4−position by 
P450 (CYP2D6), giving the metabolite, N−desmethyl−4−hydroxytamoxifen, which is able to 




Scheme 2.6. The quinone methide biotransformation of the triphenylethylene analogue. 
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2.12.1.1 The quinone methide biotransformation 
The p−quinone methide has a transient existence and rapidly reacts by a non−enzymatic 
1,6−Michael addition reaction in biological systems, generating benzylic adducts. However, 
in the case of tamoxifen, the quinone methide’s extended conjugation between the two 
phenyl rings and vinyl motif presents an unusually stable quinone methide, reported to form 
stable adducts with the exocyclic amine of deoxy guanosine in vitro, by way of a 1,8−Michael 
type addition (refer to the numbering in Scheme 2.6).84 
 
The toremifene analogue contains a β−chloro−substituent, which forms less DNA adducts 
than its predecessor. Reports by Dowers,70 Bolton84 and co−workers, suggests that the 
presence of the electron withdrawing chloride group, in addition to the steric hindrance at 
the β−position, could deactivate the benzylic group, thus decreasing the potential formation 
of the quinone methide metabolite. Reducing the formation of the quinone methide 
metabolite explains toremifene’s inability to form the hepatocarcinogenic effects seen during 
rat model studies. Furthermore, Dowers and co−workers, suggest that lower concentrations 
of the quinone methide adducts were detected for the toremifene analogue.70 Upon 
comparison to tamoxifen and droloxifene, the toremifene’s adduct concentration was 
considered insignificant, with no DNA adducts reported for the idoxifene analogue.70 It was 
however understood that the DNA adducts detected in women treated with tamoxifen were 
as a result of the carbocation biotransformation (discussed below).84 
 
2.12.1.2 The carbocation biotransformation 
Formation of the carbocation metabolite is predominantly mediated by a specific CYP class 
(3A, 2D6, 2C9, 1A1, 1A2 and 1B), followed by O−sulfonation shown in Scheme 2.7.70 The 
α−hydroxytamoxifen further reacts with the exocyclic amino group of the guanine in DNA 
forming two cis and trans epimers of the α−(N2−deoxyguanosyl)−tamoxifen. 
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Scheme 2.7. The carbocation biotransformation of tamoxifen. 
 
2.12.1.3 The o−quinone biotransformation 
Both droloxifene and the metabolite 3,4−dihydroxytamoxifen undergo oxidation by the CYP 
enzyme to form the corresponding o−quinone (Scheme 2.8). 
 
 
Scheme 2.8. The o−quinone biotransformation of droloxifene. 
 
The intended catechol readily undergoes oxidization providing the o−quinone by a number 
of oxidative enzymes, metal ions, and in some cases molecular oxygen. The possibility that 
alkylation/oxidation of the cellular macromolecules provided by tamoxifen o−quinone could 
contribute to the toxic effects of tamoxifen has been muted.70 
 
2.12.2 Metabolic pathways followed by the benzothiophene analogues 
The benzothiophene and benzopyran analogues have both demonstrated bioactivation to 
an electrophilic diquinone methide, potentially capable of reacting with cellular nucleophiles. 
Interestingly, this feature showed no known toxicities associated with the formation of the 
diquinone methide metabolite, since the drug’s approval in 1997.70,84 
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2.12.2.1 The diquinone methide biotransformation 
It has been established that raloxifene undergoes bioactivation when forming electrophilic 
diquinone methide metabolites, with the minor o−quinone catalyzed by microsomes present 
within the rat and human liver (Scheme 2.9).70,84 
 
 
Scheme 2.9. The diquinone methide and o−quinone biotransformation adopted by raloxifene. 
 
The diquinone methide metabolite is highly reactive, suggesting its ability to contribute 
toward the compound’s cytotoxicity by in vivo alkylation of proteins.70 Considering its 
transient nature, this reactive intermediate may result in a number of indiscriminate reactions 
with solvent molecules, glutathione (GSH) or non−critical proteins. Raloxifene and its 
diquinone methide metabolite has proven its ability to inhibit the inactivation mechanisms 
mediated by the enzymes CYP3A4 and CYP3A5.84 
 
Scheme 2.10. The demethylation and diquinone methide biotransformation undergone by arzoxifene. 
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In addition, diquinone methide formation has also been observed as the major metabolite 
for the arzoxifene SERM and desmethylarzoxifene (DMA) metabolite. Reports by Bolton and 
co−workers, suggests that the formation of this diquinone methide metabolite can effectively 
be eliminated, while maintaining effective ER binding, by substitution of the 4ˈ−hydroxyl 
group with a fluorine atom (i.e., 4ˈF−desmethylarzoxifene).84 This important observation 
proposes that the metabolism process could be manipulated by the introduction of certain 
heteroatoms onto the scaffold. The advantage would include maintaining the molecule’s 
efficacy, whilst reducing the formation of its toxic metabolites. Arzoxifene is also 
demethylated by the oxidation with P450 providing the DMA metabolite (in Scheme 2.10), 
which is an inactive metabolite, that results in a more potent ligand for both ER−subtypes 
when compared to arzoxifene and raloxifene.84 It is however unclear to quantify the amount 
of DMA formed from arzoxifene, since the DMA plasma concentration varies between 
women. As observed for the raloxifene SERM, DMA can undergo oxidization, providing the 
diquinone methide (a process mediated by microsomes present within the human or rat 
liver).84 
 
2.12.2.2 O−quinone methide biotransformation of Raloxifene 
Raloxifene is known to undergo oxidation forming the highly active o−quinone by way of 




Scheme 2.11. The o−quinone methide metabolite formed from raloxifene’s biotransformation. 
 
The o−quinone metabolite can be trapped by the formation of a mono− and/or di−glutathione 
(GSH) conjugate (Scheme 2.11).70,85 Having a half−life of 67 minutes, the o−quinone is quite 
stable, suggesting that the metabolite can be considered as being toxic.85 Fortunately, this 
metabolic pathway is a minor one, and is associated with insignificant concentrations and 
thus unable to cause toxicity.70,85 
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2.12.3 Metabolic pathway followed by benzopyran analogues 
Acolbifene (EM−652), as well as EM−800, are metabolized producing the respective 
quinone methide and diquinone methide metabolites, Scheme 2.12. These intermediates 
are good for Michael−type reactions with nucleophiles. 
 
 
Scheme 2.12. Metabolic pathways under taken by the benzopyran analogue. 
 
2.12.3.1 The quinone methide biotransformation 
The quinone methide metabolite results from the oxidation of the C17 methyl group of 
EM−652 (Scheme 2.12) and has a half−life of 32 seconds under physiological conditions. 
This is a considerably shorter half−life than that observed for the 4−hydroxytamoxifen 
quinone methide (which is 3 hours). This suggests that the acolbifene and EM−800 quinone 
methide metabolite forms a stable electrophilic intermediate. The quinone methide 
metabolite readily undergoes reactions with GSH and deoxy nucleosides, resulting in the 
formation of stable DNA adducts, which eventually lead to DNA damage.70 
 
2.12.3.2 The diquinone methide biotransformation 
Oxidation involving both phenolic substituents on the benzopyran scaffolds, easily provides 
the diquinone methide metabolites (Scheme 2.12). As described by Dowers and 
co−workers, the classical protocol for the quinone methide formation, which undergoes 
reactions with the GSH resulting in the formation of five mono−GSH and di−GSH 
conjugates.70 Formation of the acolbifene and EM−800 quinone methide metabolites thus 
present a major toxic pathway, relative to the diquinone methide.13,70 Additional information 
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gained from studies focused on SERMs and in particular, their oxidized metabolites, which 
has broadened our understanding of the varied tissue specific biochemical responses. In 
certain cases, the metabolite results in the formation of radicals providing a substrate, which 
forms stable DNA adducts and results in oxidative DNA damage.13,70 In addition, the 
formation of unstable adducts can result in the mutation and depuriation of the nucleic base, 
damaging the DNA sequence contributing to the toxicity associated with a few of the SERM 
molecules.70 
 
2.13 Drug discovery and its development rooted from natural products 
Newman and Cragg,86 in addition to Harvey and co−workers,87 have highlighted that natural 
products derived from medicinal plants, have extensively been used as a guide in the 
synthesis of novel compounds making valuable contributions in terms of physiological and 
pharmacological applications. The isolation and characterization of these natural products 
has allowed chemists to identify biologically active compounds and extrapolate their 
contributions to pharmacokinetic activities. A broad class of chemical compounds such as 
alkaloids, saponins, tannins, flavonoids, steroids and terpenes are but a few general 
functionalized compound classes that have been isolated from medicinal plants.88 
Comprehensive investigative screening processes on medicinal plant species over time, has 
resulted in establishing general pharmacological profiles associated with identification of the 
class of bioactive chemical compounds present within them.89 The identification of these 
bioactive compounds, in combination with technology (such as current computational 
software) has allowed studies of these bioactive compounds, to further understand and 
predict their biochemical reactivity. This has additionally led to the derivatizing of bioactive 
natural products geared toward enhancing the positive biological effects, while diminishing 
any adverse effects associated with these compounds. 
 
2.14 The tetrahydroisoquinoline alkaloids: Natural and synthetic substrates 
Interestingly, the alkaloid class of compounds has been identified as comprising biologically 
active compounds and has contributed to a broad range of pharmacological activities. 
Alkaloids are nitrogen−containing organic compounds, many of which have been 
medicinally employed as hormone, allelopathic, psychotropic, circulatory and respiratory 
therapeutic agents.90 A specific THIQ alkaloid identified and isolated from the Animalia 
kingdom, namely from Ecteinascidia turbinata91 as reported by Wright and co−workers, has 
demonstrated interesting antitumor and antibiotic pharmacological properties.92,93 In terms 
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of structure, the THIQ core can be described as a phenyl−piperidine fused ring system as 
depicted in Figure 2.18. 
 
 
Figure 2.18. Tetrahydroisoquinoline core structure. 
 
This privileged THIQ core has since gained a rich history and a broad spectrum of biological 
applications.5,39,40,51,91,93-100 Interesting work, initially driven by the Novartis company and 
co−workers,1 found that the THIQ scaffold could be utilized as a structural motif which 
exhibited estrogenic modulator activity. At the time, this was quite advantageous since 
SERM research was striving towards generating new scaffolds able to address the 
challenges associated with the earlier developed SERM generations (refer to sections 2.7 – 
2.11).46 This concept was further explored by a number of groups, and valuable input by 
Renaud,4,39 Chesworth1 and co−workers additionally provided new libraries of THIQ−based 
compounds 2.1 – 2.4 (Figure 2.19). It should be noted that analogue libraries (2.1 and 2.2), 
designed and developed by Renaud and co−workers, contain structural similarities to a 
well−known SERM namely lasofoxifene.4,39 Furthermore, THIQ−analogues 2.3 and 2.4, 
designed by Chesworth and co−workers, were inspired by the tetrahydronaphthalene 
skeleton of the lasofoxifene SERM.1 
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Figure 2.19. List of THIQ analogues generated by the independent research contributions by Renaud and 
Chesworth.1,4,39 
 
A few of the analogues listed in Figure 2.19 demonstrated improved ERα/β selectivity with 
a modest improvement observed upon comparison to lasofoxifene.1,39 Further exploration 
into the earlier developed SERMs by Lin and co−workers,51 focussed on generating 
antiestrogenic compounds by also employing the THIQ scaffold illustrated in Figure 2.20. 
 
 
Figure 2.20. Antiestrogen compounds generated by Lin and co−workers.51 
 
Upon comparison of compound 2.5 and its analogues in Figure 2.20 to tamoxifen, the 
compound 2.5 and its analogues where n = 0, R = m−PhOH, proved to be pure antiestrogens 
with an improved ER binding affinity being observed.51 Interestingly, the proliferation of ER 
positive breast cancer cell lines were selectively inhibited, but no inhibition was observed in 
the ER negative breast cancer cell lines.51 Apart from generating an antiestrogen, preventing 
adverse effects such as increased venous thrombosis, endometrial cancer and uterine 
bleeding, all previously associated with the 1st generation tamoxifen, illustrate why the 
diversion from antiestrogens to SERMs is essential.46 
 
These intriguing results linked to the incorporation of the THIQ scaffold attracted the 
attention of a number of scientific groups, including Brunsveld, ourselves and co−workers40 
who focussed their design and synthesis on small THIQ frameworks as potential ER 
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modulators. It was found that the THIQ molecules 2.6 and 2.7 showed moderate selectivity 
toward the ERβ subtype and that this interaction was substituent dependent (Figure 2.21). 
 
 
Figure 2.21. General scaffold employed by the research of Brunsveld and co−workers.40 
 
The trifluoromethyl carbamide moiety on the THIQ’s N−phenyl ring, viz., 2.7 (in Figure 2.21), 
revealed no selectivity or improved binding toward the ER−subtypes when compared to 
compound 2.6; however, upon the incorporation of a trifluoromethyl sulfonamide moiety viz., 
2.6, an improved 5−fold binding affinity was observed toward the ERβ subtype.40 
Furthermore, work by Ouellet and co−workers focussed on generating a nonsteroidal 
sulfamoylated THIQ−based compound 2.9, which showed the mitogenic inhibition of E2 in 
both MCF7 and T−47D cancer cell lines (Figure 2.22).94 Similarly, Scott and co−workers 
employed the THIQ skeleton (which showed some structural equivalence to the compounds 
generated by Chesworth and Renaud), targeting and successfully generating compounds 
2.10 and 2.11 to selectively downregulate ER antagonistically (Figure 2.22).101 Apart from 
this, Zhou and co−workers took a different approach, where the THIQ scaffold included the 
incorporation of furoxan−based nitric−oxide releasing derivatives 2.8 (Figure 2.22), which 
were synthesized and evaluated for their application in anticancer and multidrug resistant 
(MDR) reversal properties.102 The analogues 2.8 (in Figure 2.22) were compared to the 
therapeutic agent Adriamycin and performed reasonably well with a lower cytotoxicity, in 
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Figure 2.22. Compounds where THIQ designed scaffolds (reported by Zou,102 Ouellet,94 and Scott101 and 
co−workers) were adopted as potential cancer therapeutic agents. 
 
As previously mentioned in section 2.1, ERs are broadly distributed throughout the body 
with numerous overlapping functions and control vital pharmacological processes in the 
body.16 Bearing this in mind, it is clear that small molecules containing the THIQ skeleton 
can potentially aid in targeting therapeutic ailments such as Parkinson’s disease, HIV/AIDs, 
antibacterials, antiinflammatories and antivirals.99,102-104 Conversely, reports by Surh,91 Abe3 
and co−workers, suggest that the oxidized metabolites formed by THIQ analogues (namely 
tetrahydropapaverolines) have also demonstrated neurotoxic activity, as well as contribute 
to the development of potential Parkinson’s disease therapeutics.3,91 
 
With its accomplishments, the THIQ scaffold has gained much attention as is evident from 
the literature sources provided since 1990 to date, and structures based on this motif have 
established its ability to behave as a SERM. Selectivity toward a specific ER subtype is 
essential for the inihition of the estrogen positive breast cancer cell lines, which can be 
accomplished by the manipulation of the size, as well as the introduction of functional groups 
that may induce selectivity as reported by Brunsveld and co−workers.40 In addition to the 
pharmacological properties described above, the estrogenic modulation activity presented 
by the THIQ scaffold has drawn our interest in the incorporation of its structural design and 
its relevance for this study. 
 
2.15 Major research objectives of this project 
The THIQ skeleton has proved its ability to underpin a treasure trove of structurally diverse 
natural products and synthetic drugs, which exhibit a series of biological and pharmaceutical 
activity. This has been demonstrated by its affinity for estrogenic modulation, further 
enhancing its applications.1-3,5,51,95,96,105-107 Molecules with the ability to induce or inhibit 
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estrogenic responses add value as biochemical tools and candidates for drug discovery, 
especially when treating estrogen related ailments.108 
 
 
Scheme 2.13. Lasofoxifene and THIQ scaffold. 
 
With this in mind, the THIQ skeleton was selected as the most appropriate scaffold for 
developing a library of small THIQ−based molecules all designed according to rationalizing 
the structural profile of the previously mentioned compounds viz., 2.1 – 2.11 in combination 
with molecular modeling (by making use of Schrodinger and Acclerys Discovery Studio 
software). Since ERα has a slighly larger binding site, larger ligands can more easily be 
accommodated by the α−receptor and conversely smaller ligands could be better 
accommodated by the β−receptor. The use of computational chemistry has further 
facillitated an enhanced understanding of the drug−ER interaction process and recognition 
sites, which could potentially enhance the desired drug interaction.55 Structurally, most 
non−steroid estrogen receptor modulators, including agonists and antagonists contain three 
major components viz., a) a core scaffold that mimics the A−phenolic moiety, b) B−rings of 
estrogen and a second aromatic C−ring directly connected to the B−ring of the core scaffold, 
and c) an antiestrogenic side chain that is substituted onto the B−ring of the core scaffold 
allowing torsional freedom (which can interrupt the localization of the helix 12, refer to 
Scheme 2.13). Chesworth and co−workers1 revealed that the tetrahydronaphthalene 
skeleton of the well−known SERM lasofoxifene is structurally similar to that of the THIQ 
skeleton. Their findings suggested an improved activity provided by the N−atom on the ring 
(of the THIQ scaffold in Scheme 2.13) upon comparison to lasofoxifene and supports the 
incorporation of this scaffold.1,39,109 
 
The major objective of the project is to design and synthesize three small libraries of 
potentially active compounds based on small THIQ molecules and determine their 
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estrogenic structure−activity relationship. With this in mind, it was decided to employ the 
THIQ skeleton as the chemical core scaffold since it accommodates the requirements for 
non−steroid estrogen receptors as previously described. Furthermore, the presence of the 
N−atom on the THIQ skeleton would allow for the incorporation of relevant substituents (able 
to undergo hydrogen bond interactions). Heterocyclic structures belong to one of the most 
important classes of compounds in medicinal chemistry and have the ability to partake in a 
broad range of reactions providing valuable starting materials for broadening synthetic 
libraries.110,111 Heterocyclic systems form an essential component in our body’s functioning 
and their biological importance is displayed by the functioning of various vitamins, enzymes, 
co−enzymes, nucleic acids and neurotransmitter’s in the body.112 In an attempt to take 
advantage of these heteroaryl systems, the thiazole ring structure was introduced onto our 
scaffold. Additionally, the incorporation of haloaryls would be expected to afford π−stacking 
interactions with one of the target residues, His475.55 Literature discussed in section 2.12 
(refering to SERM metabolic pathways), has shown that halogenated aromatic groups have 
less tendency of forming metabolites, which could further result in less toxic DNA adducts. 
 
Three small libraries were designed to establish three important interactions required for 
mimicking key interactions with the ER. 
a) Size and selectivity. Since ERα possesses a slightly larger binding cavity than the 
ERβ subtype, it is able to accommodate larger ligands. We aim to explore the 
limitations presented by steric bulk, by introducing R–groups onto the 4−position of 
the THIQ ring. 
b) Flexibility. This is a vital requirement for estrogenic ligand receptor interactions. 
Allosteric conformations need a certain degree of torsional freedom to generate a 
topographical surface suitable for recruiting of coregulators responsible for enhancing 
or repressing estrogenic gene transcription. 
c) Amino acid residues. A number of residues reside within the binding cavity of these 
receptors. However, only a few recognized key residues are targeted in the design of 
our small molecule. The aim is targeted toward key interactions with these residues, 
by including electron donor/acceptor functional groups onto our structural design. 
These functional groups could potentially generate distinguishable properties such 
as improving receptor specificity or enhancing (as well as diminishing) targeted 
interactions within a specific binding cavity. 
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Figure 2.23. The general use of the THIQ scaffold, for further investigations into the work by Brunsveld.40 
 
In order to achieve and evaluate the three requirements vide supra, for the successful 
selectivity toward the ERβ investigation into the structure−activity relationship, the proposed 
libraries of compounds were decided upon as illustrated in Figure 2.23 – 2.25 (compounds 
2.12 – 2.17). The first library (Library 1), was designed based on the work reported by 
Brunsveld.40 The general scaffold 2.12 (R = H), showed selectivity toward the ERβ with a 
5−fold improved binding affinity. The aim of this library was to determine how increasing the 
molecule’s steric bulk on the lower rim would either enhance or repress the activity, as well 
as determine size limitations, which could be accommodated by the receptor. 
 
 
Figure 2.24. The THIQ analogues designed with the incorporation of a 2−atom spacer and various aryl groups. 
 
The second library (Library 2) incorporates three varied linker groups aimed at facilitating 
the torsional freedom required for the conformational changes upon binding with the 
receptor (illustrated in Figure 2.24). By varying the linker groups, the urea, thiourea and 
sulfonyl urea motifs (compounds 2.13 – 2.15) it is believed that this could also potentially 
facilitate proton donor/acceptor properties and thus influence their effects on the residues 
within the binding site. 
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Figure 2.25. The THIQ scaffold without the 2−atom bridge maintaining the aryl groups. 
 
The third library (Library 3) consists of an architecture similar to that of Library 2 but 
excluding linker groups and with the general structure displayed by compound 2.16 and 2.17 
(in Figure 2.25). The aim here would be to determine the degree of torsional freedom 
required to support the conformations needed for binding interactions with the desired 
receptors. Additionally, the absence of the linker groups would allow one to determine 
whether their presence affects the selectivity toward the receptors or binding affinity. 




Synthesis of THIQ analogues 
 
This chapter includes the synthetic routes considered for the synthesis of 
6−methoxy−1,2,3,4−tetrahydroisoquinoline hydrochloride and its derivatives. The THIQ 
hydrochloride salt is a valuable substrate which plays a major role in several synthetic 
protocols and will be seen throughout this dissertation. This chapter further describes the 
methods employed for the synthesis of Library 1, which was generated to establish the effect 




Many tetrahydroisoquinoline (THIQ)−based derivatives have been established as 
pharmaceuticals,1-3,40,95,96,105-107 including compounds with antitumor, antibiotic, 
antimicrobial and cytotoxic applications, with their estrogenic activity being of interest in this 
thesis.113-115 The link which has been established between estrogen and mammary tumors 
and the development of THIQ−based SERMs further enhanced our interest into the THIQ 
core (see introductory section 2.15). The major aim of this series of compounds was directed 
toward mammary gland malignancies being the initial target cells. In 2004, Chesworth and 
co−workers illustrated structural similarities between the tetrahydronaphthalene ring system 
in lasofoxifene 3.1 and the THIQ core (Figure 3.1).1 Lasofoxifene 3.1 is an estrogen 
modulator developed for the treatment of estrogen positive breast cancer, with the aim being 
to alleviate or significantly reduce side effects initially associated with the 1st and 2nd 
generation SERMs.22,83 According to the work by Renaud, Chesworth and co−workers, 
lasofoxifene−based THIQ analogues 3.2 – 3.9 have in fact displayed an improved 
antagonistic/agonistic estrogenic modulation.39 
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Figure 3.1. Compounds presenting ER binding capabilities and their inhibition of MCF7 cell proliferation.39 
 
Chesworth’s work further suggested that the substitution on the N−atom of the THIQ scaffold 
(3.2 – 3.9) was responsible for the enhanced bioactivity. Previous studies on THIQ 
analogues, where substituted C1 and C3 derivatives showed selectivity toward both ERs, 
with a greater selectivity shown toward ERα binding (which is not further elaborated in this 
dissertation).1,39,51,100 Selectivity being challenging for the different ERs is associated with 
the shared homology between the DNA binding domains. Each binding domain contains 
amino acid residues within proximity of the ligand bound receptor, which plays a key role in 
establishing selectivity for a specific ERα/β isoform. Amino acid residues Leu384 and 
Met421 present within the ERα binding site are replaced by Ile373 and Met336 respectively, 
in the ERβ’s binding site.54 Apart from this feature, a slightly larger binding site is associated 
with the ERα binding site, which thus accommodates bulkier synthetic ligands, a common 
feature associated with the earlier developed SERMs. These minor variations within the 
binding site have been shown to be sufficient for distinguishing varied binding affinities and 
gene transcription with the ERs.6,54,58 
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Reports from several research groups such as Brunsveld,40 Renaud,4,39 Chesworth1 and 
co−workers, to mention but a few, have described the estrogenic activity associated with the 
THIQ scaffold, which has enabled further study of the substrate as a potential drug for the 
treatment of breast cancer.40 Since the functionalization of positions C1 and C3 adjacent to 
N2 on the ring has previously been explored, we intend to focus our attention on substituting 
the 4−position and studying this effect of the activity of these analogues. 
 
 
Figure 3.2. Proposed interaction between methionine residue 421 and the sulfonamide in the ERα binding site 
responsible for giving rise to ERβ selectivity.40 
 
Work previously investigated by Brunsveld and co−workers, and in collaboration with our 
group, included the design and identification of small THIQ molecules as novel agonistic ER 
ligands that showed selectivity toward the ERβ subtype.40 The trifluoromethylsulfonamide 
THIQ analogue designed in this study led to a 5−fold increased selectivity for the ERβ. This 
selectivity was associated with the repulsion experienced between the fluorine−atoms on 
the trifluoromethylsulfonamide moiety with the Met421 residue positioned in the same region 
within the ERα’s binding site, as confirmed by the crystal structure depicted in Figure 3.2.40 
 
As described in sections 2.10 and 2.11, the 3rd and 4th generation SERMs demonstrated 
greater selectivity toward the ERβ subtype.48,58,70,72 Freedman’s contribution towards 
understanding the estrogenic modes of binding proposed that, when looking at binding of 
the receptors with their endogenous ligand (E2), structural modifications projecting above 
the plane of the molecule promoted a greater ERα affinity, whereas modifications resulting 
in groups projecting below the plane of the molecule introduced a greater affinity toward 
ERβ binding.58 This was specifically demonstrated by the two SERMs lasofoxifene and 
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acolbifene (EM−652) (in Figure 3.3). These findings have been further confirmed by a 
computational analysis implemented by Zheng and co−workers.54 Zheng’s investigation 
confirmed that modifications to the lower region of the THIQ (synthetic ligand) enhanced 
interaction with the Ile373 residue situated in the binding pocket of the ERβ, which is absent 
in the ERα binding pocket.54 Thus, a further objective of this study was to determine the (i) 
pharmacological relevance, (ii) effect of size, and (iii) how the selectivity would be affected 
by adding steric bulk onto the C4−position of the THIQ scaffold (in Figure 3.3). 
 
Figure 3.3. Structural enhancements on the THIQ scaffold to be investigated in this project. 
 
Further expanding Brunsveld’s work, the intention was to investigate any enhanced 
structure−activity relationship upon sterically bulking up alkyl groups attached at 
C4−position of the THIQ scaffold. 
 
3.2 Background chemistry on tetrahydroisoquinoline syntheses 
The THIQ core may be synthesized by, amongst other methods, any of the three well 
documented protocols, viz. (a) Bischler−Napieralski, (b) Pictet−Spengler condensation or 
(c) Pomeranz−Fritsch reactions, as shown in Schemes 3.1 – 3.4. 
 
For the Bischler−Napieralski reaction, a procedure described by Wang and co−workers 
included the treatment of phenoxy amide 3.10 with dehydrating agents such as P2O5 or 
POCl3 under acidic conditions, affords the 3,4−dihydro−isoquinoline 3.15.116 In terms of the 
proposed mechanism, it is accepted that the nucleophilic attack of the amide oxygen on the 
dehydrating agent forms the imidoyl chloride 3.11 as a highly reactive intermediate, which 
transforms itself into the nitrilium salt 3.12. An intramolecular electrophilic aromatic 
substitution para to the OR’−group of the phenolic moiety in 3.13 forms the bicyclic 
intermediate 3.14, which rapidly aromatizes to give the 3,4−dihydro−isoquinoline 3.15 in 
Scheme 3.1.117 The presence of electron−donating groups on the phenyl ethyl amides is 
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known to increase the electron density on the aryl nucleus and consequently influences the 




Scheme 3.1. The accepted mechanism for the Bischler−Napieralski reaction.117 
 
In much the same way as the Bischler−Napieralski reaction, it is clear that electron−donating 
groups on the aryl ring are also an essential pre−requisite to drive the electrophilic aromatic 
substitution in the Pictet−Spengler reaction, as shown in Scheme 3.2. The Pictet−Spengler 
method employs a typical phenolic ethyl amine viz., 3.16, which when treated with an 
aldehyde or ketone under acidic conditions forms an enamine 3.17, which upon protonation 
produces the enaminium salt 3.18. An intramolecular cyclization then follows generating the 
THIQ analogue 3.20 by an electrophilic substitution onto the aryl ring again para to the 
alkoxy substituent by way of 3.19 (Scheme 3.2).117,118 
 
 
Scheme 3.2. The Pictet−Spengler reaction.118 
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In the Pomeranz−Fritsch cyclization, the reaction is initiated by condensation between the 
aryl aldehyde 3.21 with a 2−aminoacetal 3.22 to afford the aldimine 3.23. Subjecting 3.23 to 
strong acidic conditions results in the protonation of the ethoxy (OEt) group of the acetal 
3.24, followed by the loss of EtOH to generate the intermediate 3.25, which under the acidic 
conditions forms the unsaturated compound 3.27. Further transformation of compound 3.27 
provides the isoquinoline 3.29 and upon further hydrogenation substituted variants of the 
analogue 3.20 would then be accessible.117 
 
 
Scheme 3.3. The accepted mechanism for the Pomeranz−Fritsch cyclization.117 
 
Regarding the latter protocol, there is a well−known variation of the Pomeranz−Fritsch 
cyclization known as the Schlitter−Mϋller condensation reaction. In this case, the 
isoquinoline analogue 3.33, having a single substituent at C1, may be produced by 
condensation of the aryl amine 3.30 with an aldehyde acetal viz. 3.31, under acidic 
conditions as shown in Scheme 3.4.117 
 
 
Scheme 3.4. The Schlitter−Mϋller condensation.117 
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3.3 Synthesis of the 2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol 
Considering the above synthetic options for constructing the THIQ scaffold, it appeared that 
the Bischler−Napieralski reaction is used mainly for the introduction of substituents onto the 
C1−position viz., 3.15, the Pictet−Spengler reaction is used for producing the general THIQ 
scaffold viz., 3.20, while the Pomeranz−Fritsch reaction introduces substituents onto the C1 
and C3 positions viz., 3.29 (in Figure 3.4). However, when implementing the Pictet−Spengler 
conditions on substrate 3.16, activation of the C5− and C9−position by the methoxy 
electron−donating group, could result in two possible products, 3.20 (being the preferred 
and major product), as well as 3.20a. Since 3.20 was a valuable intermediate, as will be 
seen in the following chapters, it was consequently decided that a modified Pictet−Spengler 
protocol, a method described by Zhong and co−workers, would be implemented to create a 
library of compounds containing the general structure 3.20.119 
 
 
Figure 3.4. General structures from the a) Bischler−Napieralski 3.15, b) Pictet−Spengler 
3.20 and c) Pomeranz−Fritsch 3.29 reaction protocols. 
 
The THIQ scaffold was thus synthesized starting from 2−(3−methoxyphenylethyl)amine 3.35 
(refer to Scheme 3.5) where the amine heteroatom would present the desired opportunity 
for derivatization of the N−atom to generate a library of THIQ analogues based on the 
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Figure 3.5. THIQ scaffold modified by the substitution of trifluoromethyl group. 
 
3.3.1 Synthesis of the 6−methoxy−1,2,3,4−tetrahydroisoquinoline hydrochloride salt 
For the synthesis of 2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol 3.34, 
the employment of a modified Pictet−Spengler protocol was considered to be viable, which 




Scheme 3.5. Reagents and conditions described by Zhong and co−workers:119 (i) 37% CH2O, 1 N HCl, 60 ̊C, 
4 h; (ii) HCl, IPA, RT, 18 h. 
 
We used a procedure reported by Zhong and co−workers, in the first two steps for the 
preparation of the desired THIQ scaffold which was closely followed in this work.119 This 
method included starting from commercially available 2−(3−methoxyphenyl)ethylamine 3.35 
and formaldehyde, which would result in the formylation of the terminal amine under acidic 
conditions to form a Schiff−base−type intermediate. However, under these conditions the 
dimeric intermediate 3.36 was produced (Scheme 3.5). The aminal dimer 3.36, being polar, 
simply precipitated out of the aqueous solution as a white solid, which was filtered and 
allowed to air dry. The structure of 3.36 was confirmed by 1H−NMR spectroscopy, in which 
the protons of the methylene bridge (C9) appeared as a singlet at ẟ 3.26, integrating for 
2−protons. Relative to these methylene protons there was a doubling of all proton 
integrations for the aromatic signals, as well as the methoxy groups, which supported the 
assigned dimeric structure of intermediate 3.36, and corresponded well to the reported 
literature values.119 It is believed that initially the Pictet−Spengler product 3.20 is formed as 
illustrated in Scheme 3.2, but that in the presence of excess formaldehyde, a Mannich−type 
reaction proceeds through an intermediate imine forming the dimer 3.36 (Scheme 3.6). 
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Scheme 3.6. The abbreviated mechanism for the formation of dimer 3.36. 
 
With the aminal dimer 3.36 in hand, it was suspended in isopropyl alcohol (IPA) and upon 
treatment with a strong acid (HCl) under stirring for 18 hours at room temperature, it cleaved 
to give the THIQ hydrochloride salt 3.37. This compound was isolated by trituration with 
methyl tertiary butyl ether (MTBE) and continuous stirring for a further 4 hours, resulting in 
the formation of a dense white mixture. The reaction mixture was then cooled to 0 ̊C and 
filtered using vacuum filtration, whilst washing with a 1:1 ratio of IPA/MTBE. An important 
factor to note was that the use of diethyl ether or petroleum ether as solvent, resulted in no 
precipitation. No further purification was required and the product 3.37 was isolated in good 
yields of 70 – 90% as a white amorphous solid. The structural integrity of compound 3.37 
was confirmed by 1H−NMR spectroscopy. The absence of the methylene bridge, originally 
at ẟ 3.26, was supplemented by a new signal viz., a broad downfield 2−proton singlet at ẟ 
9.47 [for the protonated NH (HCl) functionality]. Compound 3.37 was a valuable intermediate 
in a number of synthetic strategies employed in this project and represents an essential 
scaffold, upon which a number of derivatives were synthesized to produce the library of 
compounds needed for the study. Maintaining the masked hydroxyl as a methyl ether 
throughout all synthetic procedures was essential, mainly to avoid possible side reactions 
with the phenolic hydroxyl group. 
 
3.3.2 Synthesis of the trifluoromethyl sulfonamide 3.34 
Introduction of the trifluoromethyl sulfonyl moiety was performed onto the basic THIQ 
scaffold by following a protocol described by the Brunsveld and van Otterlo groups. The 
THIQ scaffold formed an essential synthetic component for generating the molecule (3.34) 
previously shown to display moderate selectivity for one specific receptor (ERβ) isoform.40 
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Scheme 3.7. Reagents and conditions: (i) Et3N, Tf2O, CH2Cl2, 5 h; (ii) BBr3, CH2Cl2, −60 ̊C, overnight. 
 
According to a procedure described by Bailey and co−workers,120 treatment of 3.37 with 
triflic anhydride was performed under basic conditions (triethylamine) with stirring at room 
temperature for 3 hours. This was followed by concentration under reduced pressure, which 
afforded a brown residue which was purified by column chromatography to obtain product 
3.38 as an orange oil in an 86% yield. The successful production of product 3.38, was 
confirmed by 1H− and 13C−NMR spectroscopy. The most vital variation observed between 
the 1H−NMR spectra of 3.37 and 3.38 was the absence of the amine (NH) signal at ẟ 9.47 
from the former, indicating the successful replacement of NH by the triflate group forming 
the trifluorosulfonamide. 
 
3.3.4 Demethylation of the aryl methyl ether 
As mentioned before, the hydroxyl motif was masked as the methyl ether throughout the 
previous synthetic procedures. Despite the amine presenting a more nucleophilic nucleus 
to that of the hydroxyl motif, the potential of side reactions occurring at the hydroxyl group 
was still a possibility and it was considered wise that in order to avoid this, the hydroxyl motif 
be retained in the masked form. The phenolic group makes a valuable contribution toward 
binding in small molecule−large biomolecule systems, presenting an anchoring/binding site 
for a number of residues.24,53 Thus, the final requirement in the synthesis of reference 
compound 3.34 entailed the demethylation of the aryl methyl ether 3.38. Aryl methyl ethers 
are usually cleaved under fairly harsh conditions such as Lewis acids and strong acids,119 
for long periods of time and at high temperatures. The introduction of functional groups onto 
the scaffold generates a number of additional reactive sites, which could enhance the 
compound’s sensitivity toward harsh conditions, and which could potentially cleave or 
hydrolyse these functional groups under these conditions. 
 
The general reaction procedure described by Brunsveld and co−workers,40 as illustrated in 
Scheme 3.8, was employed to establish the best practice as a demethylation technique 
(using aqueous HBr), but unfortunately the yields associated with this method were not 
reproducible, since it relies on the precipitation of the product.40 Monitoring the progress of 
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the reaction was also rather problematic since it involved proceeding from one salt to 
another, in which the Rf values remained in the region of almost zero and the spots thus 
remaining on the baseline. Yields for the reactions attempted ranged from 40 – 70%. Product 
formation for compound 3.39 was confirmed by use of 1H−NMR spectroscopy, where the 
methoxy signal previously observed at δ 3.71 for compound 3.37 was absent. This method 
required patience in waiting for the product to crystalize from the mother liquor without the 
assurance of complete crystallization. 
 
 
Scheme 3.8. Reagents and conditions described by Brunsveld, L.et al for demethylation: (i) 47% HBr stirred 
at 105 ̊C for 18 h. 
 
Despite the above−mentioned challenges associated with Scheme 3.8, the introduction of 
additional functionalities on the N−atom of the THIQ nucleus, viz., compound 3.38 
necessitated that a milder approach be considered. To this end, a procedure described by 
McOmie and co−workers was utilized,121 where the aryl methyl ether 3.38 was dissolved in 
CH2Cl2 and cooled to −40 C̊, to which three equivalences (per methyl ether) of boron 
tribromide (BBr3) in CH2Cl2 was slowly added (refer to Scheme 3.9). A temperature of −40 ̊C 
was maintained for 1 hour, followed by stirring at room temperature for 4 hours, which gave 
complete conversion to afford the 6−hydroxyl THIQ analogue 3.34. The reaction conditions 
employed were found to be efficient and clean, providing product 3.34 in a moderate yield 
of 60% as a thick brown oil after purification by column chromatography. The proposed 
mechanism for the demethylation is given in Scheme 3.9. 
 
 
Scheme 3.9. A proposed mechanism for the aryl methyl ether demethylation. 
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Methyl bromide, being a gas and one of the side products, was easily liberated from the 
reaction mixture upon reaching room temperature and a water work−up generated HBr in 
situ, affording the acid required for protonation of the alkoxy ion generated. Excess boron 
species was hydrolysed in water giving boronic acid and HBr, which was readily abstracted 
into the aqueous layer, affording 3.34 upon further extraction with EtOAc. The impurities 
easily dissolved into the water layer, which meant that no further purification was required 
unless for the removal of unreacted material. 1H−NMR spectroscopy confirmed the absence 
of the methyl ether signal previously found at ẟ 3.74, thus confirming the successful 
demethylation. In addition, the 13C−NMR spectrum in certain cases clearly demonstrated 
coupling interaction between the C−atom of the triflic motif and the adjacent F−atoms 
providing a quartet signal at δ 121.97 and δ 118.75 (J = 241.5 Hz, CF3) to further 
substantiate the presence of the N−sulfonation (SO2CF3). 
 
3.4 The synthesis of the C4 analogues 3.49 
With the successful synthesis of reference compound 3.34, synthesis of its C4 alkylated 
derivatives were explored. The C4 analogues were generated to provide an understanding 
of the limitations steric bulk would present in the binding pocket. It was considered that the 
introduction of a R−group at the C4−position of the reference compound 3.34, by way of an 
alkylative approach in the presence of the amine or trifluorosulfonamide functionality was 
not possible for the following reasons: (i) amines (3.37) are excellent nucleophiles for 
substitution reactions involving halogenated alkanes and (ii) upon protection of the nitrogen 
giving the sulfonamide compound 3.38, the more reactive positions are the α−carbons 
adjacent to the N−atom with C1 being the more preferred position (being adjacent to the aryl 
ring), followed possibly by the C3−position (Scheme 3.10). 
 
Stellenbosch University  https://scholar.sun.ac.za





Scheme 3.10. Preferred positions for C−alkylation on the general THIQ scaffold. 
 
A known suitable strategy for alkylating the C4−position required a different protocol 
described by Melvin and co−workers,122 involving the use of 
2−(3−methoxyphenyl)acetonitrile 3.46 as the initial substrate. The selective α−alkylation, 
controlled by reaction conditions, may then effectively be employed to synthesize either the 
di− or monoalkylated derivatives 3.47 and 3.48 respectively, as illustrated in Scheme 3.11. 
It is thus important to realize that we deemed it necessary to introduce the alkylations very 
early in the synthetic sequence. The advantage being control, but with the disadvantage that 
it would not allow for a divergent functionalization strategy later. 
 
 
Scheme 3.11. Chemoselective alkylation of 2−(3−methoxyphenyl)acetonitrile with haloalkyls (3.42) under 
alkaline conditions. 
 
The above reasoning was that after alkylation, reduction of the nitrile 3.47 would give the 
corresponding amines and thus act as starting materials for the Pictet−Spengler protocol 
previously illustrated in Scheme 3.2, to afford a library of THIQ analogues 3.49 (in Figure 
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3.6). A reference compound 3.34 (where, R = H) already in hand would be used for the 
purpose of comparing its biochemical effect to that of the various 3.49a – d analogues. 
 
 
Figure 3.6. Target 4−alkylated 2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin− 6−ol analogues. 
 
3.4.1 Synthetic protocol for alkylation of 2−(3−methoxyphenyl)acetonitrile 
To this end, commercially available 2−(3−methoxyphenyl)acetonitrile 3.46 was treated with 
60% NaH at 0 ̊C under anhydrous conditions in DMF, by employing a modified protocol 
described by Melvin and co−workers.122 The suspension was allowed to warm to room 
temperature and then treated with the desired haloalkanes under the conditions illustrated 
in Table 3.1. Upon treatment with the dihalogenated alkanes 1,2−dibromoethane and 
1,3−dibromopropane it was found that 1 equivalent of halogenated species afforded low 
yields (40%) of the desired products. However, the addition of an excess of the halogenated 
species resulted in even lower yields and in some cases no product at all. This was 
confirmed by a multiple number of spots on the TLC. Once isolated it was confirmed that 
the monoalkylated species was formed. It was subsequently found that by modifying the 
stoichiometric ratio of dibrominated alkane to 1.10 – 1.20 equivalents, much improved yields 
ranging between 81 – 86% were obtained. The products were isolated after work−up and 
readily purified by column chromatography. Compound 3.47a was isolated as an oil and its 
structural integrity confirmed by 1H−NMR spectroscopy. The presence of two 2−proton 
multiplets at ẟ 1.40 and ẟ 1.71 supported the cyclopropyl formation. The presence of the 
cyclobutyl moiety of 3.47d, resulted in a more complex 1H−NMR spectrum comprising a 
number of multiplets between ẟ 2.07 – 2.89 integrating for 6−protons, which to an extent 
could be explained by the conformational lability of the cyclobutyl ring. Apart from the 
spirocyclic compounds 3.47a and 3.47d, the dialkylation only required a slight variation in 
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Table 3.1. Diverse alkylation of 2−(3−methoxyphenyl)acetonitrile. 
 
Entry Substrate Haloalkane Product Yield (%) 
1 3.46 b 
3.47a 
86 
2 3.46 a 
3.47b 
Quantitative 
3 3.46 a 
3.47c 
77 
4 3.46 b 
3.47d 
81 
Reaction conditions described by Melvin and co−workers122 for alkylation of 3.46: (i) DMF at 
RT, aNaH (8.0 equiv), haloalkane (4.0 equiv); bNaH (8.0 equiv), haloalkane (1.1 equiv). 
 
Upon treatment of 3.46 in the NaH/DMF suspension with 2 equivalents of the 
monohaloalkanes viz., iodomethane (MeI) and bromoethane (EtBr), multiple products were 
formed, as illustrated by their reaction TLC profiles. The multiple spots no doubt represented 
the monoalkylated product, dialkylated product and/or unreacted starting material. The 
reaction conditions were thus optimized, and it was determined that a large excess of 
haloalkane was required to give the dialkylated species. The products 3.47b and 3.47c were 
isolated and purified by column chromatography in good yields, as shown in Table 3.1. Once 
again, assignment of the structures for these compounds was confirmed by 1H− and 
13C−NMR spectroscopy. For example, compound 3.47b was isolated in a quantitative yield 
as a colourless oil. An intense 6−proton singlet at ẟ 1.67 indicated the presence of the two 
equivalent methyl groups. Compound 3.47c was also isolated as an oil in 77% yield and 
was identified by a 6−proton triplet at ẟ 0.88 and a 4−proton multiplet centred at ẟ 1.92, 
indicative of the diethyl alkyl side chains. 
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3.4.2 Reduction of nitriles 3.46a – d to amines 3.47a – d 
Having the various alkylated nitriles 3.47a – d in hand, reduction of the nitrile functionality 
was next investigated as shown (in Scheme 3.12). 
 
 
Scheme 3.12. Reagents and conditions for the reduction of nitriles: (i) AlH2Cl, THF under reflux for 5 h.123 
 
Reduction of the nitrile group was naturally necessary for the all−important Pictet−Spengler 
ring closing condensation, being an essential element in the synthetic strategy of this THIQ 
protocol formation. The nitrile analogues 3.47a – d were efficiently reduced to their 
corresponding amines (in Scheme 3.12) by following a procedure described by Nystrom,123 
Davis124 and co−workers. Treatment of 3.47c – d with monochloroalane (AlH2Cl), prepared 
in situ from a 1:1 mixture of LiAlH4/AlCl3 in THF at 0 ̊C resulting in a grey suspension. The 
suspension was warmed to room temperature and stirred for 15 minutes, after which it was 
once again cooled to 0 ̊C, to which a mixture of 3.47a – d in THF was slowly added. Upon 
consumption of 3.47a – d (confirmed by TLC monitoring), the products were isolated in good 
yields after column chromatographic purification. The structures of products 3.50a – d, in 
which all had an additional methylene group and an amine functional group, were confirmed 
by 1H− and 13C−NMR spectroscopy. Thus, a 2−proton singlet found at ẟ 2.77 – 2.86 
confirmed the presence of the new methylene group, while the absence of the nitrile motif 
with the carbon signal previously found at ẟ 120.2 in the 13C−NMR spectrum, further 
supported the successful reactions. 
 
3.4.3 Synthesis of the THIQ salts 3.52a – d 
Amines 3.50a – d were treated under similar Pictet−Spengler conditions as previously 
described for compound 3.35 (in Scheme 3.13). Thus amines 3.50a – d were treated with 
37% formaldehyde in the presence of 1 N HCl at 60 ̊C for 4 hours. The reaction mixtures 
were cooled to 0 ̊C and basified with NaOH. It was found that under these small−scale 
reaction conditions no precipitant was formed and thus an EtOAc extraction was required 
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for the isolation of product. Increasing the scale of the reaction still did not afford a solid 
precipitate, but instead gave a sticky gum−like residue after filtration. Unlike for the 
compound 3.36, the yields were not very good giving products ranging in yields of between 
40 – 60%. In addition, purification of the intermediates was not effective, and it was decided 
to use the crude material in the next reaction step. 
 
Scheme 3.13. Reagents and conditions for generating the THIQ salts: (i) 37% CH2O, 1 N HCl, 60 ̊C, 4 h; (ii) 
HCl, IPA, RT, 18 h. 
 
However, it should be noted that the 1H−NMR spectra of all crude intermediates showed the 
presence of the key signal for the methylene bridge protons for compounds 3.51a – d. The 
gum−like residues 3.51a – d were next suspended in IPA, to which the HCl was added and 
stirred overnight at room temperature. Formation of the hydrochloride salts 3.52a – d then 
proceeded, followed by MTBE addition (in Scheme 3.13). The reaction mixtures were cooled 
to 0 ̊C for 3 hours to enhance precipitation and the products 3.52a – d were isolated in good 
to quantitative yields by filtration. The 1H−NMR spectra of these compounds confirmed 
product formation by the presence of a broad 2−proton downfield singlet at ẟ 9.78 – 9.62 for 
the protonated amine (NH2Cl). An intense 2−proton singlet in the region of ẟ 4.25 – 4.11 
was also illustrative of the aryl α−methylene group. 
 
3.4.4 Synthesis of the trifluoromethyl sulfonamide analogues 
To allow for the biochemical comparison of the THIQ scaffolds containing sterically 
demanding groups on the C4−position it was now necessary to convert them into their 
respective trifluorosulfonamide to allow for comparison with compound 3.34 designed and 
tested in the Brunsveld and van Otterlo study.40 To this end, a similar synthetic pathway 
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employed for the synthesis of compound 3.38 was followed in the synthesis of compounds 
3.53a – d as illustrated in Scheme 3.14. 
 
 
Scheme 3.14. Reagents and conditions for the synthesis of trifluorosulfonamide: (i) Et3N, Tf2O in CH2Cl2, RT, 
5 h.102 
 
A general procedure described by Bailey and co−workers120 was followed, where 
hydrochloride salts 3.52a – d and Et3N dissolved in anhydrous CH2Cl2, were combined. The 
reaction mixture was then cooled to −40 ̊C, to which triflic anhydride was slowly added over 
a 15−minute period. The progress of the reaction was monitored using TLC, which indicated 
consumption of starting materials 3.52a – d, between 4 – 6 hours depending on the 
substrate. After a work−up, brown coloured residues were obtained, which were further 
purified by column chromatography to give the products 3.53a – d as thick oil−like 
substances in good yields ranging between 69 – 86%. 1H− and 13C−NMR spectroscopy 
were employed for confirmation of the structures of compounds 3.53a – d. The 1H−NMR 
spectra were very useful in this regard, since the absence of the amine (N−H) signal 
previously noted at ẟ 9.73 – 9.62 for compounds 3.53a – d was absent. Additionally, positive 
electron spray time of flight mass spectrometry (ESI+ TOF MS) was employed to confirm the 
successful N−sulfonation of the precursors 3.52a – d to give sulfonamides 3.53a – d. 
Compound 3.53a did not appear very stable with multiple spots being observed after column 
chromatography. These multiple spots were isolated in trace amounts and further 
spectroscopy to confirm their structure was not attempted. The expected structure was 
further confirmed by a reasonably good 1H−NMR spectrum, but it should be noted that the 
calculated monoisotopic mass of 3.53a was (C13H14F3NO3S) 322.0680, while the 
experimental monoisotopic mass was found to be 290.2690. The calculated monoisotopic 
mass for 3.53c (C15H20F3NO3S) was 350.1038; with the experimental monoisotopic mass 
being 350.1046 and thus corresponded well. Finally, compound 3.53d, had a calculated 
monoisotopic mass of (C14H16F3NO3S) 336.0837 and was found to correspond well with the 
experimental monoisotopic mass of 336.1977. 
Stellenbosch University  https://scholar.sun.ac.za





3.4.5 Demethylation of aryl methyl ethers 3.53a – d 
The final step in the synthesis of the first target library was the demethylation of sulfonamides 
3.53a – d. With the sulfonamides in hand, and using the established protocol described by 
McOmie and co−workers,121 the aryl methyl ethers 3.53a – d were dissolved in CH2Cl2 and 
cooled to −40 ̊C as illustrated in Scheme 3.15. A solution of BBr3 in CH2Cl2 was then slowly 
added to the cooled solution of the sulfonamides, which resulted in orange coloured 
solutions. The reaction mixtures were stirred at room temperature overnight to afford the 




Scheme 3.15. Reagents and conditions for demethylation: (i) BBr3, CH2Cl2, −60 ̊C, overnight.40 
 
The phenolic products 3.49b – d had their structures confirmed by 1H−NMR spectroscopy, 
in which it was noted that the intense 3−proton methoxy singlet, previously present in the ẟ 
3.00 – 4.00 aliphatic region, was absent. Product was obtained for compound 3.49a but 
found to be unstable and soon decomposed. Decomposition of compound 3.49a was 
confirmed by a second 1H−NMR spectrum which showed no product after another round of 
column chromatography. It is proposed that the strain introduced by the cyclopropyl group 
resulted in an unstable THIQ scaffold which readily decomposed on silica gel during 
purification. For compounds 3.49b a broad singlet at ẟ 4.89 was indicative of the phenol 
hydroxyl group, which was also observed for compound 3.49d at ẟ 4.99. However, no broad 
singlet was observed for compound 3.49c, and product structure was further confirmed by 
the use of mass spectrometry. The calculated monoisotopic mass (C14H18F3NO3S) 336.0881 
for 3.49c corresponded exactly with the experimental monoisotopic mass obtained at 
336.0881. 
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3.5 Summary and concluding remarks 
Synthesis of the general THIQ scaffold 3.37 was successful by following a procedure 
described by Zhong and co−workers.119 This procedure included the synthesis of the aminal 
dimer 3.36 obtained in quantitative yield, which was later cleaved under strong acidic 
conditions to provide the THIQ hydrochloride salt 3.37. Under general Pictet−Spengler 
conditions, multiple products such as 3.20 and 3.20a were obtained, but implementation of 
the method described by Zhong resulted in quantitative yields. Since the compound 3.37 
was required in large quantities, the modified protocol seemed viable and was thus 
employed. The THIQ analogues 3.53a – d were efficiently synthesized by alkylating the 
2−(3−methoxyphenyl) acetonitrile 3.46 with a few selected haloalkanes under alkaline 
conditions. The nitrile group in compounds 3.46a – d were readily reduced by use of 
monochloroalane providing product in excellent yields, which produced the amines required 
for cyclization under the conditions described by Zhong and co−workers.119 Demethylation 
of the products 3.53a – d were successfully accomplished upon treatment with BBr3. In our 
hands, the highly strained spirocyclopropyl analogue 3.53a however, proved problematic 
with multiple spots being observed on the TLC after purification and thus a lower yield of 
product was isolated which soon decomposed. As for the rest of the THIQ compounds 3.53b 
– d, the products were obtained in acceptable yields that could be utilized in further 
biochemical testing. 
 




Investigation of linker group effects on the THIQ analogues 
 
The literature reviewed in Chapter 2, section 2.14, introduced a few research objectives for 
the design of compounds able to meet certain criteria, which would potentially allow a small 
library of synthetic compounds to mimic the E2 ligand. In chapter 3 the first objective was 
met, where investigations into the effect of steric hindrance at the C4−position was evaluated 
by bulking up the lower rim of the THIQ scaffold using various alkyl groups. The second 
objective required a library of compounds to investigate and determine the degree of 
flexibility required for potentially determining its structural effect on allosteric conformations 
and/or binding with ER. Chapter 4 would thus include the design and synthesis of these 
compounds described for Library 2 to meet or determine the criteria associated with 
flexibility. This included the structural extension of the THIQ core by the incorporation of 
varied amide−type derivatives onto the amine group of the THIQ scaffold. Additionally, the 
amide−type derivatives (and their terminal functional groups) would also provide a moiety 
allowing for the easy substitution by a number of phenyl groups onto the molecule. Variation 
of the amide derivatives would be essential in determining the structure−activity 
relationships they also presented toward generating selectivity for certain residue 
interactions. In addition to linker groups, the phenyl groups incorporated onto the amide 
functional group are geared toward further enhancing potential target interactions with the 
His475 residue. 
6  
4.1 Initial motivation for the design of the second library 
Efforts by Brunsveld and co−workers have provided evidence that the 
2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol analogues illustrated in 
Figure 4.1, showed modest selectivity toward the ERβ nuclear receptor,40 meeting one of 
the desired objectives, that of selectivity. Selectivity toward the β−receptor is essential since 
reports by Kang et al.,21 Yagar et al.18 and Russo et al.19 have indicated that activation of 
the α−receptor played a significant role in the proliferation of cancer within reproductive 
tissues.13,18,19,21,46 Despite the minor advancement in selectivity generated by the small 
THIQ molecules generated by Brunsveld and co−workers,40 their second objective, which 
required extension of the THIQ analogue toward the His475 residue, was not achieved. 
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Further extrapolation of Brunsveld’s work, led to the THIQ scaffold being used as a starting 
point, followed by functionalization of the amine being employed to influence the selectivity 
toward the ER−subtypes.40 Brunsveld reported that the incorporation of the trifluoromethyl 
sulfonamide moiety on compound 4.1 enhanced both the activity as well as selectivity, and 
showed that incorporation of the trifluoromethyl carboamide moiety on compound 4.2 
resulted in no comparative improvement.40 
 
 
Figure 4.1. Compound scaffolds reported by Brunsveld and co−workers.40 
 
These findings continued to stimulate our interest to design and synthesize a new small 
library of THIQ analogues to primarily maintain key hydrogen bond interactions observed for 
the natural ligand (E2, in Figure 4.2), as well as to provide a certain degree of flexibility 
required during the allosteric conformational changes, which occur in the nuclear receptor. 
 
 
Figure 4.2. Estradiol’s general binding properties are illustrated within the receptors binding cavity taken from 
the PDB website. Frame a) Shows that the residues (Glu353 and His524) interact with E2 as proton acceptors 
(a base), and in frame b) the Arg394 and His524 behave as proton donors (acids) and Glu353 as a base with 
E2. 
 
For the purpose of comparison, four different linker groups were considered, which would 
potentially provide the conformational adaptations usually facilitated by the C− and D−rings 
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of E2, as well as accommodate electrostatic requirements, such as the protic and/or van der 
Waals interactions, required for mediating valuable protein interactions with target residues 
within the receptors active binding site. The intended design included the THIQ skeleton 
illustrated in Figure 4.3, where the Ar−substituents would consist of heteroaryls, viz., 
thiazoles and substituted aromatic rings. In theory, the THIQ amine group should provide an 
easy point for functionalization, where a two−atom linker group viz., peptidyl, carboamide, 
thiocarbamide and sulfonamide (in Figure 4.3) would be incorporated. 
 
 
Figure 4.3. Structural design of the THIQ analogues containing the diverse linker groups. 
 
Since the biological world does not function independently, as clearly demonstrated by the 
versatility associated with the binding ability of the ER,6 small changes brought about on a 
synthetic ligand could significantly influence the residue’s response within the active site to 
the newly introduced functionalities such as those proposed in Figure 4.3. The western 
section of the molecule would be comprised of the 6−hydroxy−THIQ moiety, essential for 
mimicking the A− and B−rings of E2.1,39,40 On the other hand, the heteroatoms on the linker 
groups would serve as hydrogen bond donors/acceptors, as well as participate in dipole 
interactions with target residues present within the receptor’s binding cavity.125-127 
Introduction of the linker group (X) in Figure 4.3, could also potentially enhance or reduce 
certain interactions within the receptor binding cavity, hopefully providing selectivity toward 
a specific receptor subtype observed in the work of Brunsveld, et al.40 The possibility of 
conformational flexibility provided by the linker groups would be a requirement to further 
accommodate allosteric configurations experienced by the ligand upon binding within the 
receptor and promote target protein interactions with desired neighbouring residues.127 
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Figure 4.4. A generic structure designed with Acclerys Discovery studio software displaying the intended 
interaction of the western and eastern section of the synthetic ligand within the receptors active site. 
 
Computational docking studies using Schrodinger and Acclerys Discovery Studio software 
were employed for the design and prediction of the physiological behaviour that the THIQ 
analogues would present within the receptors binding pocket as illustrated in Figure 4.4.  
 
Interestingly, recent work reported by Redda and co−workers,98 described compounds with 
similar structural architectures (as shown in Figure 4.5). These compounds included the 
incorporation of a two spaced hydrazine linker group (compounds 4.4 – 4.7 shown in Figure 
4.5) which displayed effective anti−breast cancer properties.2,98 The following compounds, 
4.4 – 4.7, with IC50 values at the ƞg/mL scale had an improved anti-proliferative activity 
against the human ER+ (MCF7) breast cancer, ER− (MDA−MB−231) breast cancer and 
Ishikawa (endometrial cancer) cell lines, upon comparison to the well−known drug tamoxifen 
4.3, initially developed as a treatment for breast cancer.2 
 
Figure 4.5. Compounds 4.4 – 4.7 with an improved structure−activity relationship relative to compound 4.3.98 
The values in brackets represent the IC50 values reported by Redda and co–workers. 
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The hydrazine (N−NHC=O) structural linker group used in Redda’s compounds (Figure 4.5), 
adopt a planar conformation rendering restrictive conformations for the ligand within the 
binding site (Figure 4.6), yet still managing favourable inhibition.2 Despite this, the excellent 
results obtained by compounds 4.4 – 4.7 were surprising, since these structures also lack 
the phenolic functional group considered as being essential for providing favourable 
interactions with in the ER binding site described in Figure 4.6.52 
 
 
Figure 4.6. Frame a) refers to the structural design Redda’s compounds contain; frame b) relates to the 
structural design we aim to generate.98 
 
The valuable information obtained from Redda and co−workers concerning maintained 
activity, prompted our further exploration in generating the proposed library of compounds 
containing amide derivatized linker groups.98 The main objective of these amide linked 
compounds, would be targeted toward enhancing our compound’s ability to extend within 
the hydrophobic cavity, while at the same time potentially showing preferential selectivity 
toward the ERβ subtype. 
 
4.2 The synthesis of 1,2,3,4−tetrahydroisoquinolin−6−ol peptidyl–linked analogues 
The initial library generated and presented within this chapter included the introduction of a 
peptidyl linker group. Unpublished work generated by previous group members, namely 
Thomas Xhurdebise and Hassam Mohammad, forms the foundation of this synthetic 
strategy. The idea was to generate a library of small molecules that included the THIQ core 
designs 4.8 and 4.9 as illustrated in Figure.4.7. These compounds were generated to 
contain acyl chains forming the derivatized analogues of 4.8 and 4.9, in order to extend 
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these compounds toward the His475 residue, by mimicking the 5−membered ring of E2. It 
was later determined with the use of computational docking studies, that this ultimately 
ineffective binding was due to the increased torsional freedom provided by the acyl chain, 
thus limiting the molecules ability to interact with desired residues, as well as successfully 
dock within the binding cavity. The valuable results obtained from analogues the 4.8 and 4.9 





Figure 4.7. Compounds structurally designed to extend toward the His475 residue. 
 
Our new structural modifications to compounds 4.8 and 4.9 included maintaining the peptidyl 
moiety from the initial library in Figure 4.7 but exchanged the terminal alcohol and heteroaryl 
amine groups as demonstrated in Scheme 4.1. 
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Scheme 4.1. Reagents and conditions: (i) DIPEA, chloroacetyl chloride, CH2Cl2; (ii) amines (a and b), K2CO3, 
EtOH under reflux; (iii) amines (c and d), K2CO3, EtOH under reflux. 
 
In generating analogues of compounds 4.13, the general THIQ scaffold 4.10 was employed 
for optimization of reaction conditions so as to not lose the valuable 6−methoxy− 
1,2,3,4−tetrahydroisoquinoline hydrochloride salt (utilized in the previous chapter). The 
initial step required the synthesis of the carbamoyl chloride 4.11 in Scheme 4.1. The THIQ 
substrate 4.10 was treated with chloroacetyl chloride under basic conditions using Hϋnig’s 
base and readily afforded the chloroacetamide 4.11 in quantitative yield. Upon use of 1H− 
and 13C−NMR spectroscopy, characterization of compound 4.11 provided an interesting 
spectrum, as amide rotamers were observed for compound 4.11. Not surprisingly, the 
rotamers resulted from the two conformations attributed to the two main conformations taken 
on by the amide moiety (see Scheme 4.2). The 13C−NMR spectrum also showed that the 
carbon atoms experienced different chemical environments, resulting in a doubling of the 
resonating signals. In this regard, signals in the 13C−NMR spectrum were split, providing two 
signals at δ 28.08 and δ 29.20 representing the C4 signal. The resonance signals observed 
at δ 40.44 and δ 41.19 were indicative of the methylene signal for C10, while the signals at 
δ 43.73, δ 44.67 and δ 47.64 were representative of the C3 and C1. The four aryl carbons 
(C5 – C8) were represented by doubling up of signals giving a total of eight signals at δ 
125.91 (C7ˈ) and δ 126.52 (C7), δ 127.06 (C8ˈ) and δ 128.25 (C8), δ 128.76 (C6ˈ) and δ 
131.82 (C6), with δ 132.42 (C5ˈ) and δ 133.56 for (C5) in the aromatic region. Only one 
quaternary carbon was observed at δ 134.51 (C4ˈ and C8ˈ) for the carbonyl motif, clearly 
evident by the chemical shift observed at δ 165.48. 
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Scheme 4.2. Tautomeric conformations adopted by compound 4.11. 
 
With chloroacetamide 4.11 in hand, it was then treated under Schotten−Baumann conditions 
and reacted with primary amines (a and b) with the aim of achieving our first desired 
products 4.13. However, coupling of 4.11 with primary amines (a and b) instead provided 
compound 4.12. Work reported by Lippa and co−workers,128 provided an explanation for this 
challenge described in Scheme 4.3. This could further be explained by the nucleophilic 
competition between the amine and the ethanol solvent, the latter which proved a more 
effective nucleophile under the reaction conditions in Scheme 4.3. Another issue might have 
been that the initial amines chosen were not nucleophilic due to conjugation of the amine 
lone pairs. 
 
Surprisingly, upon reacting the chloroacetamide 4.11 with other secondary amines (c and 
d) product formation was achieved within acceptable to good yield under similar conditions. 
One may therefore conclude that failure to synthesise the desired product from amines (a 
and b) was due to the weaker nucleophilic character of the heteroaryl amines compared to 
the ethanol group. The explanation for failing to obtain product when using amines (a and 
b) was explained mechanistically in a report by Lippa and co−workers,128 who postulated 
the formation of very electrophilic highly−strained α–lactam 4.14 intermediate (in Scheme 
4.3). In the presence of a relatively more abundant nucleophile, ring−opening of the α–
lactam occurred in this case the ethanol group providing the ether product 4.12. 
Unfortunately, the heteroaryl primary amines of interest were found not to be sufficiently 
nucleophilic. It was furthermore found that performing the reactions in a non−polar solvent 
led to the recovery of compound 4.11. Table 4.1 demonstrates, the various conditions 
applied to resolve the unwanted formation of compound 4.12, unfortunately with mixed 
success. 
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Scheme 4.3. Reagents and conditions described by Lippa and co−workers: i) K2CO3, amines (a and b), EtOH 
under reflux. Lippa and co−workers proposed mechanistic pathway explaining the formation of the undesired 
ether product.128 
 
Table 4.1a. Reagents and conditions for the peptidyl linker synthesis. 
 
Entry Substrate Amine Product Yield (%) 
1 4.11 2−amino−4−methylthiazolea 4.13a 0 
2 4.11 2−amino−4−methylthiazoleb 4.13a 0 
3 4.11 2−amino−4−methylthiazolec 4.13a 0 
4 4.11 diethylaminea 4.13c 78 
5 4.11 N−methyl pyridin−3−aminea 4.13d 25 
Reaction conditions:(i) aheated at 80 C̊ in EtOH; bat RT in EtOH; cheated at 70 C̊ in THF. 
 
In an effort to obtain product, the following reaction conditions listed in Table 4.1 were 
attempted. As displayed by entries 1 – 3, despite the use of varied parameters such as the 
absence of base, variation of solvents and heat, failed to produce product, with starting 
material only being recovered, for entry 3. However, entries 4 and 5 proved to be successful 
with product being obtained in good to reasonable yields. In the second half of Table 4.1b, 
the chloroacetamides of amines a and b were treated under Schotten−Baumann conditions 
with the THIQ 4.10 scaffold. Shown by entry 1, success was obtained when using the 
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Table 4.1b. Reagents and conditions for the peptidyl linker synthesis with two thiazole 
analogues. 
 
Entry Substrate Amine Product Yield (%) 
1 4.15a THIQ 4.16 37 
2 4.15b THIQ 4.16 0 
Reaction conditions:(i) Heated at 115 C̊ in PhCH3. 
 
Not being able to successfully generate the peptidyl–linked compounds with our desired 
amines, further work on the peptidyl linker groups was abandoned, and our focus was shifted 
to other amide derivatized linker groups. Upon reviewing the literature, the urea group 
proved to show great promise considering its use, ranging from cosmetic, medicinal and 
industrial applications.129 This information led to the consideration of the urea group 
(essentially a modified amide), as the next sequence of linker groups. 
 
4.3 The synthesis of 1,2,3,4−tetrahydroisoquinolin−6−ol urea−linked analogues 
The urea motif occupies a prominent position in both pharmaceutical and industrial uses, 
demonstrated by its extensive applications.129 Substituted ureas have previously been 
employed agriculturally as plant growth regulators, pesticides and herbicides. In addition, 
their medicinal applications include being used as part of tranquilizing agents, 
anticonvulsants and for compounds used for the treatment of cardiac and respiratory 
diseases.129 They have further been incorporated in cosmetics to improve their value as 
dermatological applications for immune regulators, dyeing agents and in modified cellulose 
fibres.129 Lastly, industrial applications include their use as part of thermal stabilizers in the 
production of synthetic rubbers.129 The broad applications associated with the urea motif 
establishes its ability to participate in a number of interesting reactions and for the interest 
of this project, we aimed to take advantage of this versatile functional group at a molecular 
level. 
 
Synthesis of the carbamoyl moiety has been explored since 1848 as reported by Wϋrtz and 
many others.127,129,130 As a result, a number of efficient routes have been developed for the 
synthesis of this fascinating carbamoyl moiety.113 As illustrated in Scheme 4.4, carbamoyl 
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chlorides have been used in popular synthetic strategies for generating the urea moiety, 
which was the basis of interest to this work. However, a number of limitations have been 
associated with this protocol.113 Only a few carbamoyl chlorides are commercially available 
and their employment in a general synthetic strategy toward urea’s include the use of 
primary or secondary amines in the presence of hazardous reagents such as phosgene or 
bis(trichloromethyl)carbonate (BTC), thus limiting its general usage.113,131 In addition, 
carbamoyl chlorides are highly reactive species, illustrated by the number of side products 
generated with their use in the synthesis of ureas in Scheme 4.4. As described by 
Lemoucheux et al.,113 in this strategy THIQ 4.8 was treated under a range of conditions 
shown in the legend for Scheme 4.4. Apart from the dimerized product viz., 4.18 (conditions 
for ii), the carbamoyl chloride showed reactivity toward the amine base (conditions for iii), 
which resulted in the formation of compounds 4.17, 4.18, the unsymmetrical urea 4.19 and 
carbamoyl chloride 4.20. Carbamoyl chlorides are also prone to undergo hydrolysis, 
providing the corresponding carboxylic acids, which prevents long term storage and 
consequently requires careful handling under atmospheric conditions.131 In conclusion, the 
reactivity associated with the carbamoyl chlorides limit their application as a substrate for 
our intended strategy. The corresponding carboxylic acid could be formed by hydrolysis of 
the carbamoyl chloride 4.17. However, as previously mentioned, synthesis of 4.17 is 
associated with a few difficulties and was thus not considered as a suitable protocol for the 
synthesis of the urea linker groups. 
 
 
Scheme 4.4. Described by Lemoucheux et al., reagents and conditions for chloroacylation: (i) Excess COCl2, 
PhCH3, RT; (ii) [11C]OCl2, THF, −78 ̊C; (iii) COCl2 or BTC, Et3N, CH2Cl2.113 
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4.3.1 Coupling agents used for the synthesis of urea bonds 
Apart from the carbamoyl chloride synthon used in generating a urea motif, many coupling 
agents are available for application, under which activated carboxylic acids can easily 
undergo aminolysis for the formation of the urea moiety. These coupling agents are divided 
into classes depending on their structural architecture. The first developed coupling agents 
shown in Figure 4.8, viz., the carbodiimides, were used since 1955 for the coupling of 
carboxylic acids with amines.132  
 
 
Figure 4.8. Popular carbodiimide coupling reagents as reported in a review by Valeur and co−workers.132 
 
A major advantage when using carbodiimides as coupling agents includes mild reaction 
conditions resulting in enhanced peptide formation.127 However, a drawback associated with 
this class of coupling agent is that a portion of the carboxylic acid 4.29 is sacrificed by the 
formation of by−products viz., compound 4.32 and the symmetrical urea 4.34, with the 
remainder efficiently being converted into product 4.33 in Scheme 4.5.127,132-134 
 
Scheme 4.5. By−products generated from the carbodiimide coupling procedure. 
Stellenbosch University  https://scholar.sun.ac.za





The second class of coupling agents include those that incorporate the benzotriazole 
scaffold, as shown in Figure 4.9. The very effective Castro’s reagent, 
benzotriazolyl−N−oxytrisdimethyl amino phosphonium hexafluorophosphate (BOP, 4.35), 
was developed in the early 1970’s, but despite its efficiency its utilization was short−lived 
due to the hazardous hexamethyl phosphoric triamide (HMPA) intermediate generated 
during its synthetic pathway.127 For this reason, it was soon replaced by PyBOP 4.36, which 







Figure 4.9. Commonly used coupling agents as described in a review by Valeur and co−workers,132 
phosphonium salts (4.35 – 4.41) and uronium salts (4.42 – 4.45). 
 
4.3.2 Isocyanates as an intermediate towards the urea moiety 
The urea moiety may also be generated from an isocyanate intermediate. Isocyanates are 
easily prepared from a number of well−known rearrangement reactions (see Scheme 4.6), 
and thus with the desired isocyanate in hand, it could easily be reacted with the intended 
amine (i.e. a THIQ analogue) to deliver the corresponding urea moiety. 
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Scheme 4.6. Isocyanate synthesis by way of rearrangement reactions. 
 
As illustrated in Scheme 4.6, isocyanates can efficiently be provided from the Curtius 
rearrangement, which involves the degradation of acyl azides, usually catalyzed by 
photochemical or thermal stimuli. Secondly, starting from an amide substrate, the Hoffmann 
rearrangement proceeds by using strong alkaline conditions, in addition to bromine, thus 
providing the isocyanate. Lastly, an isocyanate can also be generated from an acetamide 
rearrangement under strong basic conditions, a procedure known as the Lossens 
rearrangement.130,135 Reactivity associated with isocyanate intermediates unfortunately limit 
their use. For example, the presence of moisture easily causes the isocyanate to revert to 
its corresponding amine with concomitant liberation of carbon dioxide.  
 
Batey and co−workers136 reported on the synthesis of a carbamoyl chloride equivalent, 
where the corresponding carbamoyl imidazole and carbamoyl imidazolium carbocation in 
Figure 4.10 of our intended substrates, could easily undergo nucleophilic substitution to 
provide the corresponding urea moiety. 
 
 
Figure 4.10. Least to most reactive carbamoyl chloride/equivalent species.131 
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The work reported by Batey136 was further elaborated on in research reported by Grzyb,131 
Padiya,137 Sumathi138 and co−workers and was thus the synthetic pathway chosen for the 
synthesis of the THIQ−urea linked analogues. 
 
4.3.3 Carbamoyl transfer agents for the synthesis of THIQ–urea analogues 
As illustrated in Figure 4.11, the scope of the intended library of urea linkers was limited to 
coupling of the THIQ scaffold with a number of primary and secondary amines. It was initially 
intended to incorporate heteroaryls such as triazole and tetrazole−type ring systems. 
However, due to numerous failed reactions on the model THIQ substrate, these were 
discarded as possibilities. An interesting and important feature associated with the urea 
linker previously reported by Benbrook and co−workers,139 which further prompted our 
interest, was the fact that the lone pair of electrons of the carbonyl group occurs in the same 
plane and forms angles of 120 ̊ with the carbon, thus providing a potentially improved 
hydrogen bond interaction with any biological receptor. Despite the ability for carbonyl 
groups to undergo hydrogen bond interactions at angles of between 115 ̊ and 180 ̊, the 
hydrogen bond interaction was shown to be greater when an angle of 120 ̊ was formed, an 
advantageous feature common to the urea moiety.55,139 The next sections will discuss the 
synthesis of compounds 4.46a – i. 
 
 
Figure 4.11. Targeted THIQ−urea−linked analogues. 
 
4.3.3.1 Synthesis of the THIQ–carbamoyl imidazolium iodide salt 
The library of THIQ analogues in Figure 4.11 were obtained after several optimization 
reactions, in which modelled reaction parameters were employed using THIQ 4.47, prior to 
following the reaction sequence described in Scheme 4.7. The more expensive, but 
essential precursor 4.48, was synthesized via a three−step protocol, previously discussed 
in Chapter 3. The value associated with compound 4.48 is essentially linked to its masked 
phenol, an important requirement for proton donor properties needed for mimicking the 
A−ring in E2. Potential competition between the reactivity of HN− and the HO− in the starting 
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material, 4.48, required that the phenol be masked as the aryl methyl ether throughout the 
synthetic protocol. 
 
The reagent 1,1ˈ−carbonyldiimidazole (CDI) is commonly used for coupling reactions 
between amines (and/or alcohols) with carboxylic acids.129,133,140 Grzyb and co−workers 
described and reported the use of CDI as an interesting carbamoyl transfer agent, and in 
our hands its use in the synthesis of compounds 4.49 and 4.50 gave excellent yields.131 The 
reaction was efficient in displacing one imidazole ring and displayed a great tolerance to an 
array of solvents viz., THF, CH2Cl2 and CH3CN. 
 
 
Scheme 4.7. Synthesis of the THIQ carbamoyl imidazolium iodide salts. Reagents and conditions: (i) CDI, 
K2CO3, CH3CN, RT, overnight; (ii) CH3I, CH3CN, RT, 6 h. 
 
Initially, compound 4.47 was employed to investigate the reaction parameters required for 
the optimized yield of 4.48. Compound 4.47 afforded 4.49 in excellent yields, and not 
surprisingly, reaction compound 4.48 with CDI afforded 4.50, also in reasonably good yield. 
Better yields for 4.50 were expected, since 4.48 was expected to be more nucleophilic due 
to the methyl ether electron−donating group on the aromatic ring. The THIQ carbamoyl 
imidazoles 4.49 and 4.50 were purified by way of column chromatography and their 
structures elucidated by 1H−NMR spectroscopy. The structural architecture of compound 
4.49 displayed a 6−proton complex multiplet at ẟ 7.21 – 7.01, in addition to a 1−proton 
aromatic doublet observed at ẟ 7.86. The successful synthesis of compound 4.50 was 
supported by among other signals, a few key signals such as the three 1−proton doublet 
signals at ẟ 7.86, ẟ 7.20 and ẟ 6.95 confirming the incorporation of the imidazole ring, and 
by a 5−proton multiplet of overlapping signals between ẟ 3.78 – 3.67 (OCH3 and CH2 groups) 
confirming the incorporation of the THIQ moiety. Additionally, 13C−NMR spectroscopy was 
employed for the identification of the carbonyl functional group, which in compound 4.49 
was found at ẟ 151.22 (C=O) and at ẟ 159.00 for compound 4.50. Unlike the corresponding 
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carbamoyl chloride, the carbamoyl imidazoles 4.49 and 4.50 were found to be a lot more 
stable under atmospheric conditions and could also be stored for extensive periods at low 
temperatures (refrigeration at −16 ̊C). 
 
Reacting compound 4.49 and 4.50 with a range of amines (a and c) proved to be unfruitful 
and gave no products, even under reflux, with only starting material and amine reagents 
being recovered. This illustrated the need for the imidazole ring to be activated, thus allowing 
for its easier displacement. Fortunately, this was easily achieved by methylation of the 
imidazole moiety of compounds 4.49 and 4.50, thereby transforming them into more 
effective leaving groups, and enabling substitution on the substrates 4.51 and 4.52. 
Synthesis of the THIQ carbamoyl imidazolium iodide salts 4.51 and 4.52 was affected by 
treatment of 4.49 and 4.50 with iodomethane. This activation of the imidazole ring was 
necessary for its efficient displacement by the varied selected primary and secondary 
amines as described in literature.131,140 Methylation of the imidazole ring occurred at a rapid 
rate with concomitant precipitation of the salt from the reaction mixture. No further 
purification was required and the salt, products 4.51 and 4.52, were obtained by the removal 
of solvent and excess MeI under reduced pressure. Structural confirmation of compounds 
4.51 and 4.52 was provided by the additional methyl signal observed in the 1H− and 
13C−NMR spectra. Apart from an increased reactivity, compounds 4.51 and 4.52 were still 
stable enough to be handled under atmospheric conditions and could be stored for long 
periods of time (months) in the refrigerator at −16 ̊C. 
 
4.3.3.2 Coupling of THIQ–carbamoyl imidazolium iodide salt with amines 
Optimization of reaction conditions were effected by employing the sacrificial compound 
4.51 prior to using 4.52. As previously mentioned, displacement of the imidazole ring had 
earlier failed, which necessitated use of the activated carbamoyl imidazolium iodide salts 
4.51 and 4.52. These were subsequently reacted with the primary amines 
(2−amino−4−methylthiazole, 2−amino−5−nitrothiazole, haloanilines and anisidine) and 
secondary amines (morpholine and piperazine), which unfortunately gave poor yields. 
However, Grzyb and co−workers overcame this problem by pre−treatment of the amines 
with base prior to the addition of salts 4.51 and 4.52, which further improved yields.131 When 
applying these conditions to the current substrates, improved yields were obtained as 
illustrated in Table 4.2. 
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Table 4.2. Results and conditions for the procedures followed in Scheme 4.4. 
 
Entry Substrate Nucleophile Product Yield (%) 
1 4.51 2−amino−4−methylthiazolea 
4.53a 
37 – 57 
2 4.52 2−amino−4−methylthiazolea 
4.54a 
92 
3 4.52 2−amino−5−nitrothiazoleb 
4.54b 
74 
4 4.52 4−anisidinec 
4.54c 
67 – 98 
5 4.52 3−chloroanilinec 
4.54d 
86 
6 4.52 3−fluoroanilinec 
4.54e 
70 
7 4.52 4−chloroanilinec 
4.54f 
44 
8 4.52 4−fluoroanilinec 
4.54g 
81 








Reagents and conditions described by Grzyb and co−workers:131 (i) THIQ salt (1.1 equiv), amine 
(1.0 equiv). aEt3N (2.0 equiv), CH3CN at RT, overnight; bCs2CO3 (3.0 equiv), CH3CN at RT, 
overnight; cnBuLi (3.0 equiv), THF at −78 C̊ – RT, overnight. 
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Displacement of the imidazolium salt 4.51 and 4.52 with 2−amino−4−methylthiazole was 
successful and the desired products were obtained in moderate to excellent yields, as 
illustrated in Table 4.2. Substrate 4.52 in entry 2, showed improved yield when compared to 
the displacement of the imidazolium moiety in comparison to 4.51. The structure of 4.53a 
and 4.54a were determined using 1H−NMR spectroscopy, the spectra of which contained a 
3−proton singlet upfield at ẟ 2.26 (for 4.53a) and ẟ 2.27 (4.54a) indicative of the methyl 
present on the thiazole ring. However, reaction of 4.52 with 4−anisidine and 
2−amino−5−nitrothiazole under similar conditions resulted in no product being formed. In an 
effort to improve on this, initial deprotonation with nBuLi was employed for these aromatic 
amines, which resulted in an improved yield for the amines (c – g). In contrast, treatment of 
4.52 with nBuLi to 2−amino−5−nitrothiazole resulted in multiple spots on TLC, indicating 
either the decomposition of the substrate or multiple by−product formation. Evaluation of a 
number of bases eventually led to the pre−treatment of 2−amino−5−nitrothiazole with either 
K2CO3 or Cs2CO3, which consequently provided products in good yield. As illustrated in 
entry 3, gentle heating (at 40 ̊C) was required for the delivery of product in good yield. In 
general, the unreacted amine and product displayed a slight difference in their Rf values, 
making column chromatography a rather challenging process. This was overcome by 
partitioning the reaction mixture between EtOAc and an aqueous 1 M HCl solution, which 
removed any excess amine as its water−soluble salt prior to purification by column 
chromatography. 
 
Upon comparison of the 1H−NMR spectra of 4.52 with 4.54b it was evident that the imidazole 
ring was absent. However, the 1H− and 13C−NMR spectra were insufficient for an 
unambiguous confirmation of the product 4.54b since the NMR spectrum displayed only an 
indistinctive signal for the thiazole aromatic proton. Heteronuclear single quantum 
correlation (HSQC) spectroscopy, as well as TOF MS, were consequently employed to 
support the assigned structure of product 4.54b. A 1−proton singlet observed downfield at 
ẟ 8.58 confirmed the presence of the thiazole proton, as well as the broad singlet observed 
at ẟ 12.17 which indicated the presence of an amine (NH). The assigned structure was 
further supported by four clearly assigned signals observed in the aromatic region of the 
13C−NMR spectrum at ẟ 165.54 (thiazole−ArCNO2), ẟ 157.90 (ArCOMe), ẟ 154.54 (C=O), 
and ẟ 142.10 (ArCNH), present in compound 4.54b, in addition to the expected carbons of 
the THIQ skeleton. 
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Entries 4 – 8, reflect the efficient substitution of the imidazolium iodide salt 4.52 by amines 
(c – g) affording 4.54c – g, which were successfully obtained after the use of the most 
efficient conditions, which included stirring at −60 ̊C for 3 hours prior to the addition of 4.52. 
The nucleophile used in entry 4, as expected, allowed good to excellent displacement of the 
imidazolium salt, with the product 4.54c being obtained in good yield. Inspection of the 
1H−NMR spectrum for the product 4.54c indicated a complex 2−proton multiplet between ẟ 
7.30 – 7.14, a 1−proton signal at ẟ 6.99, and a 4−proton multiplet at ẟ 6.84 – 6.60, illustrative 
of the presence of two substituted aromatic rings and a broad 1−proton singlet at ẟ 6.32 for 
the amine (NH). Key signals observed in the aliphatic region included an intense singlet at 
ẟ 4.52, a 6−proton signals at ẟ 3.73 indicative of the two methoxy−groups and two 2−proton 
triplets representing the methylene groups of the THIQ moiety. 
 
However, it was noted that those reactions involving the haloanilines (d – g) in entries 5 – 
8, required longer reaction times, in addition to increased amounts of nBuLi. On the other 
hand, the 3−haloanilines (entries 5 and 6) proved to be much more convenient to work with 
than the 4−haloanilines (entries 7 and 8), which required more extensive reaction times. The 
halogen−substituent on the aniline plays a role in deactivation of both ortho and para 
positions of the aryl ring by an inductive effect, thus making it a weaker nucleophile requiring 
more time for the successful displacement of the imidazolium iodide salt moiety (products 
were obtained in moderate to poor yields observed for entries 7 and 8). The 3−haloanilines 
proved to be sufficiently nucleophilic and product was obtained in good yields (entries 5 and 
6) in Table 4.2. Products 4.54d and 4.54e as expected, demonstrated similar 1H−NMR 
spectra profiles in the aromatic region with a 1−proton doublet of doublets at ẟ 7.47 (haloaryl 
moiety of the compound) for 4.54d and at ẟ 7.38 – 7.18 (haloaryl moiety of the compound) 
for 4.54e. Two 2−proton multiplets between ẟ 7.31 – 7.07 (haloaryl moiety of the compound) 
and ẟ 7.06 – 6.90 (haloaryl moiety of the compound) for 4.54d, while comparable signals 
between ẟ 7.09 – 7.03 (haloaryl moiety of the compound) were observed for 4.54e. Lastly, 
a 3−proton multiplet between ẟ 6.85 – 6.61 (for the THIQ−moiety) for 4.54d and ẟ 6.80 – 
6.70 (for the THIQ−moiety) for 4.54e confirmed the successful incorporation of the haloaryl 
substituents (d and e). However, in the 13C−NMR spectra, these two molecules were easily 
differentiated by a complex signal pattern in the aromatic region, as a result of the doubling 
of signals attributed to the C−F coupling observed for compound 4.54e. In addition, ESI+ 
TOF MS for the protonated molecular ion ([M+H]+; m/z) 317.1052 was found to correspond 
well to the calculated monoisotopic mass of 317.1057 of C17H17ClN2O2 for 4.54d, and of 
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301.1356 was calculated for C17H17FN2O2 and found to be 301.1356 for 4.54e, further 
supporting product formation. 
 
Similarly, compounds 4.54f and 4.54g displayed common features in both their 1H−NMR 
spectral profiles. Formation of compound 4.54f was confirmed by a 4−proton multiplet 
between ẟ 7.40 – 7.19, a 1−proton doublet at ẟ 7.06 and a 2−proton multiplet between ẟ 
6.88 – 6.65 ascribed to the aromatic protons for both the THIQ, as well as the haloaryl 
moiety. Additionally, a 1−proton broad singlet (NH, amine) at ẟ 6.45 confirmed product 4.54f 
formation. Compound 4.54g formation was substantiated by a 2−proton multiplet between 
ẟ 7.38 – 7.28, a 3−proton multiplet between ẟ 7.10 – 6.91, a 2−proton multiplet between ẟ 
6.83 – 6.68, accounting for the overlapping aromatic protons for both the THIQ and haloaryl 
moieties. Additionally, a 1−proton broad singlet at ẟ 6.43 provided evidence of the amine 
functional group.  
 
Entry 9 describes the reaction between morpholine and 4.52 under the alkaline conditions, 
whilst stirring at room temperature in CH2Cl2, to afford a quantitative yield for 4.54h. In this 
case, upon comparison of the spectral information obtained for the starting material 4.52, 
variation in the aliphatic region confirmed product formation. 1H−NMR spectroscopy 
depicted two new 4−proton multiplets at ẟ 3.74 – 3.53 and ẟ 3.29 – 3.13, indicative of the 
methylene groups on the morpholine moiety of compound 4.54h. It was disappointing 
however, to note that the reaction between piperazine and 4.52 gave no identifiable product 
(entry 10). 
 
4.4 The synthesis of 1,2,3,4−tetrahydroisoquinolin−6−ol thiourea−linked analogues 
The second linker introduced involved the thiocarbonyl system, for which a number of 
methods reported by Katritzky and co−workers was consulted.141 These methods included 
the use of thioacylating agents such as thiophosgene,141 carbon disulfide114,115,142-145 and 
1,1ˈ−thiocarbonyldiimidazole (TCDI),131 all being reported for the synthesis of thiourea and 
thioamide moieties.141 Apart from thioacylation, the alternatives to achieving the same 
objective included the use of thionating agents, in which conversion of carbonyls into their 
corresponding thiocarbonyls with the use of sulfur dihydride, phosphorous pentasulfide and 
Lawesson’s reagent among others, are important.141 However, since the results obtained in 
Table 4.2 illustrated that CDI was an effective carbamoyl transfer agent, the corresponding 
1,1ˈ−thiocarbonyldiimidazole (TCDI) was investigated for generating the intended 
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thiocarbonyl linker.131 For the purposes of comparison, it was considered that generating a 
library reflecting a variety of linker groups would empirically establish whether these groups 
could affect hydrogen bond interactions and/or affect the selectivity within the ER−binding 
pocket, especially since the thiocarbonyl motif has been quite pronounced in pharmaceutical 
applications.125,126 As with the carbonyl species, it was reported by Benbrook and 
co−workers146 that this feature could be attributed to the C−S bond containing a more 
pronounced lone pair forming a 105  ̊angle in molecules contain a thiocarbonyl functional 
group, viz., R2C=S, and being different to the angles between 130 ̊and 180̊ calculated for 
thiourea systems, which had proved less suitable for facilitating effective hydrogen 
bonding.139 
 
4.4.1 Synthesis of THIQ–thiocarbamoyl imidazolium iodide salt 
In Scheme 4.8 it is shown how the THIQ–thiocarbamoyl imidazoles 4.55 and 4.56 were 
prepared in reasonable yield, namely by treatment of compounds 4.51 and 4.52 with TCDI 
respectively. Surprisingly, treatment of 4.52 with TCDI gave in addition to product 4.56, the 
unexpected dimer 4.57, albeit in a low yield of 4%, not observed in the synthesis of 4.55. 
 
 
Scheme 4.8. Synthesis of the THIQ–thiocarbamoyl imidazolium iodide salts. Reagents and conditions: (i) 
TCDI, K2CO3, CH3CN, 5 ̊C, overnight; (ii) CH3I, CH3CN, RT, overnight. 
 
Dimerization resulting in the formation of 4.57 was not reported by Grzyb and co−workers,131 
but was easily avoided by the introduction of an excess of solvent and by conducting the 
reaction at lower temperatures (0 ̊C), while adding 4.52 portion−wise over 2 hour−periods. 
Confirmation of the structure of products 4.55 and 4.56 by 1H−NMR spectroscopy was as 
follows: two 1−proton multiplets at ẟ 7.92 – 7.83, ẟ 7.26 – 7.19, and a 1−proton doublet of 
doublets at ẟ 7.08 (J = 1.4 and 0.9 Hz) indicated the incorporation of the imidazole moiety. 
Furthermore, 13C−NMR spectroscopy confirmed the presence of the expected thiocarbonyl 
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(C=S) moiety signal observed at ẟ 178.24. Subsequent alkylation of THIQ–thiocarbamoyl 
imidazoles 4.55 and 4.56 was cleanly achieved upon treatment with iodomethane at room 
temperature. No precipitant was observed in this case. However, monitoring the progress of 
the reaction by TLC indicated the consumption of both 4.55 and 4.56 starting materials. The 
product 4.58 obtained was a brown foam upon removal of solvent under reduced pressure 
and the 1H−NMR spectrum for 4.58 displayed a 3−proton singlet at ẟ 3.77 indicating the 
presence of the newly incorporated methyl group. However, the analogue 4.59 proved to be 
too hygroscopic for isolation and characterization and consequently, a one−pot protocol was 
pursued for the subsequent reactions. It was noted that after storage of compound 4.59 at 
low temperatures and upon exposure to atmospheric conditions the foam−like material 
transformed into a sticky state which made its handling very onerous. 
 
4.4.2 Coupling of THIQ–thiocarbamoyl imidazolium iodide salt with amines 
With compounds 4.58 and 4.59 in hand, the initial displacement of the imidazolium moiety 
was optimized using the model compound 4.58. Once the best yields were obtained, 4.59 
reacted in the same way but gave quite variable yields of product, as described in Table 4.3. 
 
Table 4.3. Results and conditions for the procedures followed in Scheme 4.4. 
 
Entry Substrate Nucleophile Product Yield (%) 
1 4.58 2−amino−4−methylthiazolea 
4.60a 
40 
2 4.59 2−amino−4−methylthiazolea 
4.61a 
80 
3 4.59 2−amino−5−nitrothiazoleb 
4.61b 
7 
4 4.59 4−anisidinea-c 
4.61c 
17 
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6 4.59 morpholineb 
4.61h 
64 




Reagents and conditions described by Grzyb and co−workers: (i) THIQ salt (1.1 equiv), amine (1.0 equiv). 
aEt3N (2.0 equiv), CH3CN at RT, overnight; bCs2CO3 (3.0 equiv), CH3CN at RT, overnight; cnBuLi (3.0 equiv), 
THF at RT, overnight. 
 
Entry 2 demonstrates the successful displacement of the imidazolium moiety in 4.59 by 
2−amino−4−methylthiazole to yield 4.61a (80%). As previously observed in Table 4.2, the 
aryl methyl ether 4.59 resulted in better reactivity relative to 4.58, which resulted in a lower 
yield of 4.60a (40%). Progress of the reactions were monitored by TLC and despite longer 
reaction times and subsequent heating, no improvement on the 80% yield was observed for 
4.61a. An acidic work−up procedure was implemented for the removal of excess amine 
followed by purification with column chromatography, which afforded product as an oil in 
good yield. The 1H−NMR spectrum showed the presence of a 3−proton singlet at ẟ 2.16 and 
a 1−proton singlet at ẟ 6.30, both being characteristic of the methyl group and the heteroaryl 
hydrogen of the thiazole moiety on compound 4.61a, confirming product formation. Initially, 
no product was obtained (shown by entries 3 and 4) when similar conditions as for entries 
1 and 2 were applied to the 2−amino−5−nitrothiazole and 4−anisidine starting materials. To 
improve product formation, pre−treatment of amines (b and c) by evaluating a few bases 
such as nBuLi, NaH and K2CO3 were investigated, unfortunately without any real change in 
product formation. In contrast to the carbamoyl linker, working with the thiocarbamoyl moiety 
proved to be more challenging than expected. It was clear that the replacement of the 
oxygen atom (C=O) with the sulfur atom (C=S), significantly affected the electrophilic centre 
(ẟ+C=Sẟ−) resulting in a decreased electrophilicity thus requiring better nucleophiles to allow 
the displacement of the imidazolium iodide salt moiety reported by Grzyb and co−workers.131 
This was explained by the less efficient S3p−C2pπ−orbital overlap in the thiocarbonyl (C=S) 
bond relative to the O2p−C2pπ−bond and thus rendering a less polarized and more inert 
thiocarbonyl species.131 
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At the very best, only poor yields of product were obtained in Table 4.3 for entries 3 and 4. 
One obvious remedy for this conundrum would be the use of better nucleophiles. However, 
replacement of our current amines was not feasible since the synthesis of this library 
(containing varied linker groups) was to establish the influence of the substituent patterns 
on the potency and selectivity of these compounds provided by the varied linker groups 
within the receptors binding cavity. Achieving this, allowed only one variable viz., the linker 
group, and thus amines (a – g) had to remain constant. Further investigation into the 
generation of thiourea substituents was thus explored by further studies of current literature. 
 
4.4.3 Isothiocyanate to the rescue: Generating thiocarbamoyl analogues 
Perusal of the literature resulted in the consideration of using isothiocyanates as a precursor 
toward our synthetic target. Use of isothiocyanates upon treatment with amines to readily 
form thioureas has been reported by Grzyb and co−workers, as well as by Berglund et al.126 
130,133 Initial attempts by us at generating the isocyanate failed despite using a number of 
varied parameters.130,135 The problems associated with the synthesis of the isocyanates led 
to a degree of uncertainty as to whether the synthesis of isothiocyanates as an intermediate 
toward generating the thiourea bond should even be considered. Surprisingly, the 
isothiocyanate analogue proved to be much more stable and selective in comparison to the 
corresponding isocyanate. 
 
This observation was explained by the different phases in which the p−orbitals exist as 
illustrated in Figure 4.12 (frame a and frame b). In the isocyanate molecule (in Figure 4.12, 
frame a) all the LUMO p−orbitals are in phase, thus making electron transfer from the 
nitrogen to the carbon and oxygen viable and thus generating a good electrophile, easily 
attacked by a nucleophile. In contrast, for the isothiocyanate molecule (in Figure 4.12, frame 
b), the p−orbitals are out of phase making the electron transfer by the nitrogen to the sulfur 
less likely. In addition to the electron donation, resonance of the isothiocyanate further 
results in the carbon being less polarized and making the isothiocyanate less sensitive to 
moisture in contrast to that previously experienced with the isocyanate species. These 
findings necessitated further exploration into employing the isothiocyanate as a synthon in 
the synthesis of our thiourea linkers. 
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Figure 4.12. Frame a) Isocyanate, and frame b) Isothiocyanate. 
 
4.4.3.1 Synthesis of isothiocyanate analogues 
As previously mentioned, the isothiocyanate is another valuable reaction intermediate used 
for the synthesis of thiourea motifs. It was obtained upon treatment of the respective amines 
(b – g) with an excess of carbon disulfide under basic conditions (as shown in the Scheme 
associated with Table 4.4). 
 
Table 4.4. Results obtained, and reaction conditions employed. 
 







1 4.62b NaH, THF Boc2O, DMAP 36 Trace amounts 
2 4.62cˈ Et3N, EtOH Boc2O, DMAP 1.5 68 
3 4.62c” Et3N, EtOH Boc2O, DMAP 1.5 77 
4 4.62d NaH, THF TsCl 48 34 
5 4.62e NaH, THF TsCl 48 85 
6 4.62f NaH, THF TsCl 48 77 
7 4.62g NaH, THF TsCl 48 36 
Reaction conditions: (i) base (1.2 equiv), CS2 (5.0 equiv); (ii) desulfurating agents. 
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Compound 4.61a was successfully synthesized in respectable yields of 80% (see Table 4.3) 
using 4.59 and there was no need for synthesizing the corresponding isothiocyanate of 
2−amino−4−methylthiazole. In Table 4.4 (entry 1), no product was obtained for amine 4.62b. 
Despite changing parameters, viz., base and solvent, no product was isolated. Failure 
associated with amine 4.62b to react may be associated with its electron deficient amine 
due to resonance effects operating in the 2−amino−5−nitrothiazole (shown in Scheme 4.9a). 
The strong inductive and resonance effects associated with the nitro group would result in 
the lone pair of electrons of the 2−position amino moiety being less available for donation 
due to them being conjugated into the nitro group at the C5−position and thus not reactive 
enough toward the carbon disulfide. To improve the nucleophilicity of the amine functionality, 
reduction of the nitro−group would transform it into a better electron−donating group and 
thus improve the reactivity/nucleophilic character of the amine. However, upon 
consideration, the possibility that this procedure might lead to the formation of multiple 





Scheme 4.9. Proposed resonance structures for 2−amino−5−nitrothiazole 4.62b. 
 
Entries 2 and 3 from Table 4.4  illustrate a method described by Munch and co−workers,114 
where amines (4.62cˈ and 4.62c”) were dissolved in EtOH under basic conditions, and to 
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which an excess of carbon disulfide was then added. It was fortunate that the latter two 
phenols did not show any chemo selectivity issues in the reaction and thus saved a 
demethylation step which would have been required if anisole was used as the amine. The 
reaction was efficient, with short reaction times, and provided isocyanate product in 
moderate yields. Precipitation of the intermediate salt 4.63 occurred within 30 minutes, 
confirmed completion of the reaction. Formation of products 4.64cˈ and 4.63c” was 
achieved upon separate treatment of intermediates 4.63cˈ and 4.63cˈˈ with di−tert−butyl 
dicarbonate (Boc2O), catalyzed by the addition of 4−dimethyl aminopyridine (DMAP), which 
was required for accelerating the desulfurylation of the dithiocarbamate 4.63 intermediate to 
provide the isothiocyanate 4.64. 
 
Apart from the use of Boc2O, desulfurylation could additionally be effected by a) use of tosyl 
chloride as described in a method reported by Wong and Dolman,145 b) 
1,1ˈ−(ethane−1,2−diyl) dipyridinium bistribromide (EDPBT) as reported by Yella and 
co−workers,142 c) triphosgene as reported by Chaskar and co−workers144 or d) thiophosgene 
and 2,4,6−trichloro−1,3,5−triazine (TCT).114,115,142-145 However, these methods frequently 
result in the formation of many by−products, as well as require tedious work−up procedures 
for quenching the harsh reagents (viz., thiophosgene or phosgene) by acidification or 
basification (TCT), followed by purification with column chromatography which could be time 
consuming. The employment of Boc2O as the desulfurylation agent generated by−products 
such as carbonyl sulfide (COS) which could easily be eliminated as a gas, while the Et3N, 
tBuOH and EtOH were efficiently removed under reduced pressure with no further 
purification being needed (as illustrated in the scheme of Table 4.4). Unfortunately, this 
method was only successfully executed with the amines 4.62cˈ and 4.62cˈˈ containing 
electron−donating substituents. Unlike with 4.62cˈ and 4.62cˈˈ, much longer reaction times 
and stronger bases were required to obtain products 4.64d – g. For this reason, the method 
reported by Wong and Dolman145 was implemented which included the use of tosyl chloride. 
The use of tosyl chloride in entries 4 – 7 indicated good results, but were not very 
reproducible with variable yields being obtained.145 
 
For entries 4 – 7, the haloanilines (d – g) were treated with three equivalents of NaH in THF 
and left to stir at room temperature for 4 hours. During this time, multiple colour changes 
were observed with the chloroaniline species (4.62d and 4.62f) going from a black to a bright 
green coloured mixture and the fluoroaniline species (4.62e and 4.62g) from a white to a 
bright purple coloured mixture. Once the later colour change occurred the reaction mixture 
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remained this colour (indicating the complete deprotonation), and to which carbon disulfide 
(CS2) was added, affording an orange coloured mixture containing the dithiocarbamate salt 
4.63. Despite the addition of extra CS2 and NaH, and even with reaction times exceeding 
48 hours, no complete or improved conversion of starting material was observed. However, 
compound 4.64e, initially obtained in 35% yield, was the only case which showed an 
improved yield of product upon the addition of extra base and CS2, since after a further 
24−hour stirring period an 85% yield of 4.64e was obtained (entry 5, in Table 4.4). With the 
electron−rich amines (4.62cˈ and 4.62cˈˈ), use of Boc2O as a desulfurylating agent proved 
successful, but this was not the case when applied to the electron poor amines (4.62d – g), 
where the only products obtained after purification were the tert−butyl carbonate protected 
amines. Despite longer reaction times, for entries 4 – 7 the tosyl group was easily substituted 
by the more resonance stabilized intermediate system. The tosyl moiety thus provided an 
excellent leaving group, with products 4.64d – g obtained in poor to moderate yields after 
purification (as illustrated by entries 4 – 7 in Table 4.4). 
 
With the isothiocyanates 4.64 in hand, they were treated with the THIQ hydrochloride or 
hydrobromide salt 4.65 under basic conditions, to provide a small library of products 4.66, 
generally in moderate yields, as shown in Scheme 4.10. 
 
 
Scheme 4.10. Formation of the thiourea analogues. Reagents and conditions: (i) Et3N in CH3CN under reflux. 
 
The THIQ−based compounds 4.66 share significantly similar key signals in the aliphatic 
region for both 1H− and 13C−NMR spectral information of the THIQ moiety. For this reason, 
the NMR spectra described below will focus on the aromatic region for compounds 4.66c – 
g, in order to avoid too much repetition. Remarkable and interesting disparities were 
observed in the aromatic region of the 1H−NMR spectra of products 4.66c – g. The spectrum 
of the 4−hydroxy−analogue 4.66cˈ showed a 4−proton arrangement of doublets at ẟ 7.06 – 
7.94 for the 4−hydroxyphenyl moiety, in addition to a 3−proton multiplet observed at ẟ 6.64 
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– 6.59 for the THIQ aromatic moiety. On the other hand, the spectrum for the 
3−hydroxy−analogue 4.66cˈˈ displayed two 1−proton multiplets at ẟ 7.44 – 7.29 and ẟ 7.16 
– 7.02 (overlapping aromatic protons from both the THIQ moiety and the phenol moiety). In 
addition, a 2−proton complex multiplet between ẟ 7.16 – 7.00 and a 3−proton multiplet 
between ẟ 6.71 – 6.53, indicative of the THIQ moiety, made up the rest of the spectrum for 
compound 4.66cˈˈ. Upon comparison to the THIQ hydrochloride salt 4.65 precursor, the 
spectroscopic data obtained for compounds 4.66d and 4.66f contained an additional set of 
aromatic proton resonances. This was attributed to the successful incorporation of the 
isothiocyanatochlorobenzene portion of compound 4.66d. Three 2−proton multiplets were 
observed between ẟ 7.30 – 7.21 (6−protons), a 4−proton multiplet at ẟ 7.19 – 7.00 and a 
2−proton multiplet between ẟ 6.86 – 6.68, supporting the successful synthesis of 4.66d. The 
structural characterization of 4.66f was evident from a 2−proton multiplet at ẟ 7.25; a 
3−proton multiplet at ẟ 7.06, with an additional 2−proton multiplet between ẟ 6.86 – 6.70 
attributed to the overlapping aromatic protons of both the THIQ and chlorophenyl moiety. 
Apart from the 1H−NMR spectra, 13C−NMR spectroscopy was employed for the identification 
of the thiocarbonyl (C=S) group at ẟ 183.20 (for 4.66d) and ẟ 182.52 (for 4.66f), further 
confirming product formation. 
 
A similar NMR spectroscopic profile was also shared by compounds 4.66e and 4.66g in the 
aliphatic region, including a few key signals confirming the incorporation of the 
THIQ−moiety. However, compounds 4.66e and 4.66g could be differentiated by their 1H 
NMR spectroscopic J−values, and the aromatic profile in frame a and frame b in Figure 4.13. 
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Figure 4.13. Portions of the aromatic 1H−NMR spectra for compounds 4.66e and 4.66g. 
 
Figure 4.13 frame a, shows the overlapping aromatic signals for the THIQ and 
3−fluorophenyl moieties of compound 4.66e, two sets of multiplets between the regions δ 
7.31 – 7.26 and δ 7.14 – 6.75. Frame b, represents the overlapping signals associated with 
the THIQ and 4−fluorophenyl moiety of compound 4.66g. 
 
 
4.5 The synthesis of 1,2,3,4−tetrahydroisoquinolin−6−ol sulfonylurea–linked 
analogues 
4.5.1 Evaluation of protocols developed for the synthesis of the sulfonyl amide 
moiety 
One of the main goals of the current work was to generate varied linkers on the THIQ 
scaffold. To achieve this, an effective strategy for generating a library with a sulfonyl urea 
linker formed an essential part of the project. 
 
However, as previously described with the carbamoyl chloride analogues, only a limited 
number of sulfuryl chlorides are commercially available, and consequently a synthetic 
protocol for their preparation would be desired. However, as with the carbamoyl chlorides, 
the corresponding sulfonyl chlorides were found to be too reactive, placing a serious 
limitation on their synthesis. As illustrated by Scheme 4.11, employing conditions (i) for 
sulfonyl chlorination, resulted in several problems being encountered, the major one being 
the synthesis of the unwanted dimer 4.69. Attempts at varying the conditions, viz., order of 
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addition, concentration, as well as the rate of addition of amine 4.8 to sulfuryl chloride and 
temperature variation, yielded either very little or no product 4.68. Confirmation of the 
unwanted product 4.69 was provided by both ESI+ TOF MS, as well as 1H−NMR 
spectroscopy. Conditions used in method ii were employed to generate the sulfonic acid 
4.70 to avoid dimerization. However, treatment of 4.70 with a variety of chlorinating agents 




Scheme 4.11. Reagents and conditions for sulfonyl chlorination: (i) SO2Cl2, CH2Cl2, −78 ̊C; (ii) SO3HCl, 
CH2Cl2, 0 ̊C; (iii) SOCl2 or C(COCl)2 or POCl3, CH2Cl2, 0 ̊C. 
 
This result suggested that substrate 4.70 decomposed quite easily. This once again led to 
the use of a sulfonyl equivalent of the CDI transfer agent, prepared by means of the method 
described in Scheme 4.12. 
 
4.5.2 Synthesis of 1,1ˈ−sulfonylbis(1H−imidazolium) triflate salt 
Investigations into the literature suggested that, 1,1ˈ−sulfonylbis(1H−imidazolium) triflate 
salt chemistry associated with the imidazolium triflate salt 4.73 could offer alternative 
solutions to form CDI analogues.140 
 
 
Scheme 4.12. Reagents and conditions: (i) SO2Cl2, CH2Cl2, 0 ̊C, overnight; (ii) CH3OTf, CH2Cl2, 0 ̊C, 6 h. 
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Thus synthesis of compound 4.72 was efficiently undertaken, following a procedure 
previously described by Cívicos and co−workers,147 involving the slow addition of sulfuryl 
chloride to a solution of imidazole 4.71 in CH2Cl2 at low temperatures, as illustrated in 
Scheme 4.12. The low temperature (0 ̊C) was maintained for 5 hours during which formation 
of a dense white precipitant confirmed the complete consumption of imidazole. The white 
precipitant (salt) was filtered and the eluent partitioned between water and CH2Cl2, giving 
product 4.72 in good yields ranging from 60 – 97%. 
 
The structure of compound 4.72 was confirmed using 1H−NMR spectroscopy, which 
confirmed the presence of three 1−proton singlets at ẟ 8.02, ẟ 7.28 and ẟ 7.14, that 
corresponded well with the values reported in the literature.140 However, unlike CDI and 
TCDI, no substitution reactions were possible with 4.72 in our hands. Despite the 
pre−treatment regime of the THIQ amine 4.8 with base, or heating, no sulfonamide linker 
was obtained. Consequently, sulfone 4.72 was treated with methyl triflate at low 
temperatures, which generated the 1,1ˈ−sulfonylbis(1H−imidazolium) salt 4.73. The integrity 
of 4.73 was confirmed by 1H−NMR spectroscopy, in which an intense 3−proton singlet was 
observed upfield at ẟ 3.87, indicative of the successful methylation of the one imidazole 
moiety. Additionally, the chemical shifts observed in the aromatic region seemed more 
complex compared to the precursor, due to the asymmetric structure generated by the 
incorporation of the methyl group. Pleasingly, both 1H− and 13C−NMR spectra for 4.73 
corresponded well with the reported literature values described by Beaudoin and 
co−workers.140  
 
Preparation of the THIQ analogues 4.74 shown in Figure 4.14 were next undertaken, in 
which 4.73 upon treatment with the THIQ hydrochloride salt would provide the THIQ sulfonyl 
imidazole intermediate. The subsequent reactions included methylation of the THIQ sulfonyl 
imidazole moiety group, which would then be methylated providing the activated imidazolium 
triflate salt, for undergoing treatment with amines (a – h) to generate the sulfonyl analogues 
4.74 in Figure 4.14. 
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Figure 4.14. Intended structures for the sulfonyl urea linked library. 
 
4.5.3 Synthesis of 1−{[6−methoxy−3,4−dihydroisoquinolin−2(1H)−yl]sulfonyl}− 
3−methyl −1H−imidazol−3−ium triflate salt 
Neutralization by pre−treatment of the 6−methoxy−1,2,3,4−tetrahydroisoquinoline 
hydrochloride salt 4.51 with base, prior to addition of the sulfonyl imidazolium triflate salt 
4.73 was essential for improving on the homogeneity of the reaction (see Scheme 4.13). 
The reaction mixture was stirred at room temperature overnight to afford compound 4.75 in 
good yield. However, as previously observed in the TCDI reactions, caution had to be taken, 
since the dimer 4.78 was also obtained in minor amounts. 1H− and 13C−NMR spectroscopy 
was employed for confirmation of compound 4.75 and allowed characterization by the key 
identifiable structural features associated with the THIQ skeleton. Two 2−proton triplets 
(indicative of the methylene groups at C3 and C4) were found at ẟ 2.85 and ẟ 3.48, together 
with an intense 3−proton singlet at ẟ 3.74 (OCH3) and a 2−proton singlet at ẟ 4.33 (ArCH2N) 
which confirmed the presence of the THIQ moiety. Further signals observed were the three 
1−proton singlets at ẟ 7.91, ẟ 7.23 and ẟ 7.08 ascribed to the imidazole ring. The THIQ 
sulfonyl imidazole−analogue 4.75, was next converted into its corresponding imidazolium 
triflate salt 4.76 upon treatment with methyl triflate at low temperature, to give the final triflate 
salt 4.76 in quantitative yield as a white solid. 
 
Scheme 4.13. Synthesis of the THIQ–sulfonyl imidazolium triflate salt. Reagents and conditions: (i) 4.39, 
K2CO3, CH2Cl2, RT, overnight; (ii) CH3OTf, CH2Cl2, 0 ̊C, 6 h. 
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Compound 4.76 proved to be hygroscopic, which complicated its handling under 
atmospheric conditions. These findings resulted in the synthetic procedure described by 
Beaudoin and co−workers being modified to a one−pot procedure, in which the amine was 
directly added to 4.76 without prior isolation.140 Product 4.76 formation was elucidated from 
its 1H−NMR spectrum by the presence of an overlapping 5−proton multiplet between ẟ 3.86 
– 3.74 (CH3 and CH2 groups) indicating the presence of the THIQ moiety. Additionally, the 
aromatic protons of the imidazolium moiety appeared as 1−proton doublets (J = 3.0 Hz) at 
ẟ 9.59, ẟ 8.02 and ẟ 7.70 for all three protons. 
 
4.5.4 Coupling of the THIQ–sulfonyl imidazolium triflate salt 4.76 with amines 
The hygroscopic nature of the compound 4.76 made handling very challenging. Compound 
4.76 was thus generated, followed by solvent removal under reduced pressure to provide a 
residue. This residue was then placed under a vacuum followed by backfilling with nitrogen, 
and finally by addition of the respective amines (a – h) as illustrated in Table 4.5. 
 
Table 4.5. Reaction conditions applied in the synthesizing sulfonamide linked analogues.
 






No product but 4.78 
was obtained. 
Dimer 60 
2 4.76 4−anisidineb 
4.77c 
87 
3 4.76 3−chloroaniline 
4.77d 
40 
4 4.76 3−fluoroaniline 
4.77e 
46 
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5 4.76 4−chloroaniline 
4.77f 
54 
6 4.76 4−fluoroaniline 
4.77g 
94 
7 4.76 Morpholine 
4.77h 
70 
Reagents and conditions described by Beaudoin and co−workers:140 (i) 4.76 (1.1 equiv), amine (1.0 equiv). 
aEt3N (2.0 equiv), CH3CN at 80 ̊C, overnight; bK2CO3 (2.0 equiv), CH3CN at RT, overnight; cCs2CO3 (3.0 equiv), 
CH3CN at 80 ̊C, overnight. 
 
The synthesis of compounds 4.77c – h essentially followed a similar method to that 
employed for the urea analogues. It should be noted that there is a paucity of literature for 
the synthetic design of unsymmetrical sulfonyl urea analogues. Other popular methods for 
synthesis of the sulfonyl urea motif, includes oxidation of a sulfur−bridge to afford the desired 
sulfonamide (SO2NH) moiety. However, work described by Cívicos,147 Beaudoin140 and 
co−workers included the substitution of the imidazolium triflate salt with primary and 
secondary amines, thereby providing asymmetric sulfonyl ureas. The results reported in 
Table 4.5, were obtained by making use of a synthetic protocol similar to that described by 
Beaudoin and co−workers.140 However, it was necessary to modify the earlier developed 
parameters to achieve satisfactory results. 
 
Entry 1 in Table 4.5, demonstrated that the product obtained by treatment of the sulfonyl 
imidazolium triflate salt with the primary amine a (2−amino−4−methylthiazole), was the 
unwanted dimer 4.78. Considering the lability displayed by 4.76, the procedure was 
repeated at lower temperatures. It was found that at room temperature no reaction occurred 
with amine a, and 4.76 was recovered unchanged with no product formation. Optimization 
by investigating a variety of bases, solvents and temperatures, produced no product when 
trying to couple the 4.76 with the thiazole amine. The aminothiazole proved to be too weak 
a nucleophile, which caused the focus being shifted to coupling between amines (c – h) with 
compound 4.76. Entry 2 illustrates 4.77c being isolated in good yield (87%) when the 
reaction mixture was stirred at room temperature overnight. However, heating only led to 
formation of dimer 4.78 in a 70% yield. Furthermore, compound 4.77c was isolated as a 
brown oil and its structure confirmed by use of 1H−NMR spectroscopy. As observed with the 
former carbonyl and thiocarbonyl coupled compounds (4.54, 4.61 and 4.66), the 
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sulfonamide analogue displayed a similar 1H−NMR spectral profile. The presence of the 
THIQ moiety was confirmed by the two 2−proton triplets observed at ẟ 2.82 and ẟ 3.63 
indicative of the two methylene groups. Additionally, an intense 6−proton signal at ẟ 3.73 (2 
x OCH3), an intense 2−proton singlet at ẟ 4.52 (ArCH2N), two multiplets at ẟ 6.60 and ẟ 6.84, 
a 1−proton singlet at ẟ 6.99 and a 2−proton multiplet at ẟ 7.14 – 7.30 (2−protons) provided 
sufficient confirmation to the ascribed structure of the product 4.77c. HRMS ESI+ was further 
employed which provided a molar mass m/z [M+H]+ of 349.1207 that corresponded well with 
the calculated value 349.1177. 
 
Surprisingly, in order to obtain products 4.77d – g room temperature proved to be 
insufficient. Upon coupling the haloanilines with compounds 4.76, no strong base was 
necessary, but heating at 80 ̊C provided the products in moderate to good yields as shown 
in Table 4.5. When being stirred at room temperature all reagents were recovered 
unchanged. As previously described, product structures were confirmed by 1H− and 
13C−NMR spectroscopy. The THIQ moiety was easily confirmed by the general profile 
presented by the aliphatic region of the NMR spectral data. Use of ESI+ TOF MS was 
employed to further confirm product formation, in which the calculated monoisotopic masses 
of the compounds 4.77d – g corresponded well with the experimental values (see 
experimental section for more details). 
 
4.6 Deprotection of aryl methyl ethers 
The various linker groups displayed different stabilities toward demethylating protocols and 
reagents. A common problem associated with general compounds 4.79 was their solubility 
before and especially after deprotection of the aryl methyl ether functional group. Thus, a 
few methods were evaluated in Table 4.6 for obtaining demethylated products in good yield. 
A preferable method included one in which no water work−up would be required. In entries 
1, 2 and 5, the use of boron tribromide (BBr3) proved to be compatible with a range of 
functional groups. Despite its tolerance, the reagent had the tendency of coordinating to 
additional functional groups and was thus required in a large excess for effecting a 
successful demethylation of the aromatic methyl ether groups. Demethylation was efficient 
with the reaction being complete within 6 hours. Problems were however encountered during 
the aqueous work−up procedure. An aqueous work−up procedure was essential for 
hydrolysing the excess BBr3, as well as to promote the in situ HBr formation required for the 
protonation of the alkoxide to form the phenol group. Extraction of the phenolic products 
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4.46a, 4.46c and 4.80a from the aqueous layer proved to be a challenge and even after 
multiple ethyl acetate extractions only a limited amount of product was obtained. Despite 
TLC monitoring indicating 100% consumption of starting material the overall yield of product 
proved to be very low. 1H−NMR spectroscopy confirmed the structures of products 4.46a, 
4.46c and 4.80a. This was easily illustrated by the absence of the intense 3−proton singlet 
previously observed within the region of δ 4.00 – 3.50 for the methoxy group. This signal 
was replaced by a broad 1−proton singlet indicative of the hydroxyl moiety, which was not 
observed for all the products. 
 
Table 4.6. Reaction conditions for the demethylation of the aryl methyl ether. 
 
Entry Substrate X R Product Yield (%) 
1 4.54aa CO Me 
4.46a 
64 
2 4.61aa CS Me 
4.80a 
36 
3 4.54ba CO Me 
4.46b 
0 
4 4.61ba, b CS Me 
4.80b 
0 
5 4.54ca CO Me 
4.46c 
42 
6 4.77ca SO2 Me 
4.74c 
32 
7 4.54db CO Me 
4.46d 
50 
8 4.64da, b CS Me 
4.80d 
0 
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9 4.77da SO2 Me 
4.74d 
34 
10 4.54eb CO Me 
4.46e 
35 
11 4.64eb CS Me 
4.80e 
0 
12 4.77ea SO2 Me 
4.74e 
10 
13 4.54fb CO Me 
4.46f 
50 
14 4.64fa, b CS Me 
4.80f 
44 
15 4.77fa SO2 Me 
4.74f 
41 
16 4.54gb CO Me 
4.46g 
2 
17 4.64ga, b CS Me 
4.80g 
0 
18 4.77ga SO2 Me 
4.74g 
33 
19 4.54hc CO Bn 
4.46h 
79 
20 4.64hb CS Me 
4.80h 
20 
21 4.77hb SO2 Me 
4.74h 
25 
Reagents and conditions: (i) THIQ salt (1.1 equiv), amine (1.0 equiv). aBBr3 (10.0 equiv), CH2Cl2 at 0 ̊C, 24 – 
48 hours; bAlI3 (5.0 equiv), PhCH3/PhH at 40 – 110 ̊C, 24 – 48 hours; cPd/C, H2, EtOH at 40 ̊C, overnight. 
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It was found that despite the use of BBr3 or aluminium triiodide (AlI3), certain products were 
inaccessible (mostly C=S linked entries 3, 4, 8, 11 and 17). The reactions (entries 3 and 4), 
were monitored with TLC which indicated multiple spots and thus formation of a number of 
compounds or the decomposition of the product. Isolation of these compounds resulted in 
even more spots with yields too low for analytical evaluation. However, for entries 8, 11 and 
17, the TLC indicated the complete conversion of starting material to products 4.80d – g. 
Despite this, when purifying the crude residue through a small plug of silica gel, no product 
was obtained. TLC monitoring presented evidence of decomposition, where the initial single 
spot now presented multiple spots. Purification was attempted using a plug of activated 
aluminium oxide. However, this did not solve the problem and unfortunately no product was 
obtained. 
 
After a number of trial reactions, AlI3 proved to be the best demethylating protocol for the 
carbonyl ureas 4.54, as shown in entries 7, 10, 13, 16, 20 and 21. The AlI3 was prepared by 
treatment of suspended Al−filings with iodine, followed by heating under reflux for 2 hours 
in toluene.93 The reaction mixture was cooled, to which the ureas 4.54d – g, 4.64h and 
4.77h were then added. When left at room temperature no reaction occurred, but with 
heating at 60 ̊C for 24 – 48 hours, product in poor to moderate yields became obtainable. 
Strangely, while TLC monitoring of the reaction mixture indicated complete conversion, 
during purification products were only obtained in low yields. Apart from the sulfonyl urea 
4.77c (entry 6), the AlI3 reaction conditions proved to be too harsh. Even with mild heating 
at 40 C̊, no reaction proceeded when applied to sulfonyl ureas (4.77d – g). The products of 
entries 9, 12, 15 and 18 were then demethylated using BBr3 as the demethylating agent. 
Despite the poor yields obtained for compounds 4.74d – g enough product was obtained for 
characterization, as well as for the required biological testing. 
 
Unlike most of the reactions reported in Table 4.6, which were associated with solubility 
problems, as a precaution the hydroxyl group of the compound 4.54h was protected by 
conversion to a benzylic group using a benzyl chloride. The deprotection protocol required 
for substrate 4.54h has advantages since it eliminates (i) the aqueous work−up, (ii) filtration 
of the heterogeneous catalyst (10% Pd/C) gives less impurities and (iii) solubility would not 
be a problem since the reaction would be performed in a polar solvent (EtOH). For entry 19, 
good yields were obtained when compound 4.54h was dissolved in EtOH, to which the 10% 
Pd/C catalyst was added and stirred at 40 ̊C. Unfortunately, this method could not be applied 
to any of the sulfur containing compounds, since these have been well−known for poisoning 
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metal catalysts. Although the benzyl group proved to be the best protecting group 
experiencing very little challenge during the deprotection to generate the hydroxyl moiety, it 
was thus not a general method to be adopted. 
 
4.7 Summary and concluding remarks 
Three urea−linked THIQ molecules were synthesized using a general procedure, in which 
CDI−type equivalent reagents were used (in Figure 4.15). The imidazole behaved as an 
excellent leaving group, providing a near perfect transfer agent. However, removal of the 
second imidazole moiety was only achieved by initial methylation forming the imidazolium 
salts 4.82a – c, followed by displacement of the imidazolium portion with the THIQ 
hydrochloride salt (shown in Figure 4.15). 
 
Figure 4.15. General protocol for synthesis of the THIQ imidazolium salt 4.84. 
 
Compounds 4.83a and 4.83c were obtained in reasonable yields; however, the synthesis of 
compound 4.83b required much lower temperatures and the reaction mixture was diluted to 
avoid formation of the dimer 4.57. Treatment of compounds 4.83a and 4.83b with methyl 
iodide provided the imidazolium iodide salts 4.84a and b. Compound 4.83c was however 
treated with methyl triflate to yield the sulfomoyl imidazolium triflate salt 4.84c. Once 
compound 4.84 was in hand, it was treated with a few selected amines (a – g) under 
conditions previously described in earlier sections of the chapter to afford the pivotal, 
precursor 4.54, 4.61, 4.64 and 4.77 for target compounds 4.46, 4.74 and 4.80. However, in 
the case of 4.84b substitution with the haloanilines, using the nBuLi was not as successful 
and synthesis of the haloisothiocyanates were synthesized. 
 
The thiourea–linked THIQ analogues (4.66c – g) were synthesized in good yields, by 
heating the THIQ salt 4.65 with the isothiocyanate (4.64d – g) under alkaline conditions. 
One of the challenges associated with this method, was the poor reproducibility when 
synthesizing the isothiocyanate. Demethylation of the thiourea linked compounds 4.66d – g 
also proved to be quite challenging with either no or very poor yields of product being 
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obtained. Due to time restraints, no further attempts to demethylate compounds 4.66d – g 
were pursued. Despite the unsuccessful demethylation of the thiourea species, both the 
carbonyl and sulfonyl urea compounds were successfully demethylated in satisfactory yields 
and products are shown in Table 4.6. 
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Chapter 5 
Isochromanone: A surprisingly valuable intermediate 
 
The final library, library 3, in which the THIQ analogues do not contain the two−atom linkers 
previously discussed for library 2 (Chapter 4) is presented here. A broad range of synthetic 
approaches were trialled for this library of compounds which eventually led to a procedure 
including the condensation reaction between the isochromanone intermediate and a few 
selected primary amine aryls, which provided the desired target compounds. These 
compounds were specifically designed to compare their structure−activity relationship to that 
of the THIQ urea−linked analogues generated in library 2. 
4  
5.1 Introduction 
As mentioned in earlier chapters, THIQs are important synthetic targets because of their 
potent pharmacological properties.1,95,96,107 Members of this family displayed improved 
antagonistic/agonistic estrogen modulation upon comparison to a well−known SERM, 
lasofoxifene discussed in Chapter 3.1 This resulted in the designing of a library of 
compounds which contained the THIQ skeleton with varied linker groups having heteroaryl 
substituents intended for mimicking the estradiol D−ring interactions, within the ER binding 
pocket described for Library 1. A similar set of compounds designed by Redda et al. 
indicated that with a two−atom linker their compounds were able to demonstrate positive 
anti-proliferative results when tested against three different cancer cell lines.98 These 
encouragingly positive results indicated that despite our initial computational docking study 
predictions, such relatively large compounds were able to successfully enter the binding 
pocket of the ER and interact with targeted residues. Apart from Redda’s work, the docking 
studies generated some uncertainty in how compounds containing a linker group could 
behave within the binding pocket of the ER (Figure 5.1, frame a). To test this theory, 
modification in the THIQ series was included, whereby the linker unit was absent, to 
determine the structure−activity relationship between the compound in Figure 5.1 shown in 
frame a and frame b. Thus, an alternative approach was followed by eliminating the linker 
group, whilst maintaining the western and eastern sections of the compounds in this library 
(Figure 5.1, frame b). 
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Figure 5.1. a) Library 2, THIQ linker analogues, b) Library 3, THIQ analogues without linker groups. 
 
The envisaged new library was hoped to correspond quite well with E2 (the natural ligand), 
upon overlaying the desired analogues as illustrated in Figure 5.2 with the endogenous 
ligand in modelling. The docking studies indicated numerous promising binding interactions 
within the binding pocket and it was thus decided to proceed with the synthesis of a small 
library of THIQ analogues 5.1. 
 
 
Figure 5.2. Library of isoquinolines possessing no linker groups. 
 
Due to the structure−activity relationship studies for library 2 and library 3 the Ar−groups 
were to remain constant. The choice of aryl groups were determined by suggestions from 
Dowers,70 Bolton84 and co−workers, who proposed that the use of halogenated aromatic 
groups resulted in vivo in the generation of fewer metabolites, and less toxic DNA adducts. 
The toxic adducts were generated from aromatic methoxy and hydroxy functional groups 
during the analysis of their synthetic ligands for ERs, and therefore encouraged our use of 
haloaryl compounds for this study. 
 
5.2 Retrosynthetic analysis 1: Metal−mediated coupling protocol for synthesizing 
THIQ analogues 
In considering potential methods for construction of the target compounds (Figure 5.2), upon 
reviewing literature by Monnier and co−workers, a retrosynthetic analysis suggested that 
metal−mediated C−N bond formation could be employed as a good protocol for obtaining 
the various products depicted in the retrosynthetic Scheme 5.1.148 
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Scheme 5.1. Potential retrosynthetic route to the synthesis of the tetrahydroisoquinoline library. 
 
The starting material, viz. the aryl ethyl amine 5.3, has the required electron−donating group 
in the meta−position in order to promote a Pictet−Spengler reaction to form THIQ 5.2, which 
would then be treated with a metal catalyst and various halogenated aryl substrates to afford 
the intended target compounds 5.1 (Scheme 5.1). 
 
The development of protocols for C−C bond formation has seen some major innovative 
successes. Among these are well−known chemical procedures such as the Ullmann, 
Suzuki, Stille, and Negishi coupling reactions, described by Romero and co−workers in a 
review.149 Despite significant improvements in the scope of C–C cross coupling 
methodologies for aryl−heteroaryl ring couplings, the C−N bond formation scope has been 
fairly limited.150 These methods included the commonly used metal−mediated techniques 
such as the Buchwald−Hartwig,150-152 Chan−Lam153 and Ullmann condensation148,154,155–
type reactions depicted in Schemes 5.2 – 5.4. 
 
The Buchwald−Hartwig coupling reaction includes the use of palladium (Pd) catalysts with 
a broad range of ligands reviewed by Pujol and co−workers, which can be rather 
expensive.149 Upon consulting the literature it was noted that under these reaction conditions 
led to the successful coupling of N–based substrates with varied aryl groups. However, 
literature supporting our initially intended heteroaryls THIQ coupling could not be found  for 
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Scheme 5.2. A modified representation of the Buchwald−Hartwig coupling reaction as reported by Fischer and 
Koenig.156 
 
The Chan−Lam coupling is catalyzed by a copperII species by the oxidative coupling of 
boronic acid substrates with a heteroaryl substrate to afford products with the desired C−N 
bond.156 However, the Chan−Lam coupling reaction is limited to the use of boronic acids or 
boronic esters and is associated with long reaction times as reported by Rao et al.153 In 
addition, a relatively limited number of commercial boronic acids are available and they can 
be expensive. Upon reviewing literature, it was found that synthetic procedures used for the 
coupling of secondary amines with boronic acids could generate our heteroaryls. However, 
it was found that the use of substrates such as the amine (THIQ) with heteroaryls (a – 
2−bromothiazole, b – 4−bromothiazole and c – bromobenzene) were not that successful 
and were frequently associated with very low yields.148,149,153-155 As a result, this synthetic 




Scheme 5.3. A modified representation of the Chan−Lam coupling reaction as reported by Rao and Wu.153 
 
The Ullmann condensation reaction involves substitution reactions with a nucleophilic 
(heteroatoms such as NH, OH and SH groups) substrate with a haloaryl species where 
either a CuI or CuII species is employed as the catalyst.155 There are a few advantages 
associated with the application of the Ullmann condensation protocol viz., it is less toxic in 
terms of side products produced and utilizes less expensive reagents. However, like the 
Chan−Lam protocol, it is also associated with long reaction times and high temperatures, 
thus limiting its applications. A number of mechanistic pathways discussed in the literature 
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Scheme 5.4. A modified representation of the Ullmann condensation reaction as reported by Sambiagio et 
al.154 
 
An interesting review by de Vries and co−workers, describes the Ullmann−type reactions 
being composed of four possible steps demonstrated in Scheme 5.5. The first route is 
described by method A in the diagram and involves the oxidative addition of the aromatic 
halide by CuI, resulting in the formation of a CuIII intermediate formation. The CuIII 
intermediate was initially questioned, but further investigations led to the idea being 
supported by many other researchers.155 The second step, for method A, involves the 
coupled product and regeneration of the catalyst. Two possible protocols viz., single electron 
transfer (SET) or halide transfer of the aryl radical intermediate, were the described 
processes responsible for the product formation and catalyst regeneration. Metals and 
organometallics have been accepted as compounds able to facilitate electron transfers (for 
instance, unimolecular radical nucleophilic substitution reactions). Initially, the role of free 
radicals in recovery of the catalyst was proposed by Waters in 1937. Valuable experimental 
contributions by Russel, Kornblum, Bunnet and Kochi provided further support to this claim, 
as described in Sperotto’s review.155 The results provided evidence supporting the presence 
of aryl radical anions in the mechanistic cycle, with the unimolecular radical nucleophilic 
substitution being accepted. The CuI Nu thus behaves as the coupling agent and the Cu 
coordinates to the ArX via a 4−centred intermediate, orientated accordingly to the partial 
charges of the Cu (ẟ+) and halide (ẟ−) species. Polarization of the carbon−halide bond then 
generates a partial positive charge on the formed ipso−carbon and assists in the substitution 
of the nucleophile, providing the free Cu species, as demonstrated in Scheme 5.5. 
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Scheme 5.5. A schematic representation of the two proposed pathways for the Cu−catalyzed Ullmann 
arylation, as reported by de Vries and co−workers.155 
 
Step 3 in the proposed mechanism for method B, follows a σ−metathesis pathway, similar 
to the previously described step 2 for method A. Step 3 includes displacement of the halide 
by the nucleophile, forming the Cu−Nu species, and catalyzing the coupling reaction. The 
Cu coordinates to the ArX via a 4−centred intermediate, in which the coordination is again 
orientated by the partial charges on the Cu (ẟ+) and halide (ẟ−) species. Polarization of the 
carbon−halide bond generates a partial positive charge on the ipso−carbon promoting 
substitution of the nucleophile, providing the free Cu species in Scheme 5.4. The final step 
includes the π−complexation of CuI with the ArX. The ArX is activated through the CuI 
species with the π−electrons of the aryl system (cycle in step 4). The metal thus functions 
as an electron sink, assisting with the replacement of the halide for the nucleophile. Cu 
complexation to the aryl ring then leads to stabilization and forming the Wheland complex. 
The ArX undergoes polarization, further facilitating substitution of the X releasing the 
Cu−complex and product, thereby restoring the catalyst. Work by Ma and co−workers has 
shown that Ullmann−type reactions have also been accelerated by the introduction of 
ligands such as those shown in Figure 5.3.101,157 
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Figure 5.3. Ligands (L1 – L9) used in Ullmann–type reactions developed by Buchwald150 and Ma as reported 
in a review by Taillefer et al.148 
 
Research by Bethel described in Sperotto’s review, reported that the reaction rate was not 
just dependant on ligand inclusion, but also on the nature of the leaving group X (I>Br>Cl). 
This work further reported that N−deuteration produced a small kinetic isotopic effect, which 
did not affect product ratio, and that deuteration of the α−carbon of the amine gave an 
increase in formation of the aminated product.155 Work by both Ma,157 Taillefer148 and 
co−workers proved that the use of bidentate ligands, such as amino acids and diamines, 
enhanced product formation and gave higher yields at lower temperatures with shorter 
reaction times. The work by Taillefer et al.148 included the screening of a number of ligands 
containing an imine group, in addition to the oxygen or nitrogen sites enabling Cu 
coordination (Figure 5.3). 
 
The oxygen and nitrogen donor groups on the ligand are believed to promote the oxidative 
addition by the transfer of electrons to afford either the CuI species, or by stabilizing the CuIII 
intermediate species shown in Scheme 5.6. Ma and co−workers157 further focused on the 
use of amino acids as ligands, establishing (ʟ)−proline (L4) as a superior ligand for 
Ullmann−type reactions.148 Apart from these investigations, Buchwald and co−workers150-
152 reported that 1,2−diamines (L6 and L8) also proved to be highly efficient ligands for the 
coupling of aryl bromides with various nitrogen−based nucleophiles (Figure 5.3). Apart from 
the few ligands illustrated in Figure 5.3, many others have been screened. For the purpose 
of this work, the ligands L4 (ʟ−proline) and 1,2−diamine (ethylene diamine) were available. 
Since Buchwald and co−workers152 reported that L8 (with a saturated bond system) was 
able to efficiently couple compounds usually coupled under Pd−catalyzed conditions, 
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ethylene diamine (being available in the department) was employed to determine its 
efficiency in comparison to L4. Independent work by Surry et al.152 established that in a 
Cu−catalyzed arylation ethylene/cyclohexane diamine was an effective ligand (shown in 
Scheme 5.6). These researchers found that even the replacement of the methyl groups on 
L8 with hydrogen did not limit product formation. The presence of the methyl groups on L8 
gave improved reaction rates, while larger substituents slowed the rate of the coupling 
reaction. Apart from ligand introduction, the use of various bases viz., K2CO3, K3PO4, 
Cs2CO3 and NaOtBu,148,154,155,157 were shown to further improve the yield by improving the 
solubility of reagents. In addition, Ma and co−workers reported that additional coordination 




Scheme 5.6. A modified representation of bidentate ligands used in Ullmann reactions, and the proposed 
mechanisms, as described by de Vries et al.155 
 
5.2.1 Investigation toward the feasibility of Ullmann condensation for synthesizing 
N−aromatic THIQ analogues 
With the convenience of reagents such as CuI, ʟ−proline, 1,2−diamine, K2CO3 and K3PO4 
in hand, the synthetic procedure followed was similar to that described by Ma157 and 
Buchwald.150 The substrates utilized in Buchwald’s work included N−heterocycles and this 
offered a procedure promising for the reagents and substrates at hand for the synthesis of 
the intended target molecule 5.1. For the purposes of optimizing reaction conditions, a model 
substrate 5.4 was employed to be used with the readily available aryl bromides in Table 5.1. 
Interestingly, the thiazole chemistry described by Ganapathi and co−author reported that 
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thiazoles containing a halogen at the C2−position are able to undergo a nucleophilic 
substitution reaction.158 Entry 1, in Table 5.1 illustrates a substitution reaction protocol in the 
absence of the ligand and catalyst, in which a low yield of 5.5a was obtained. According to 
a protocol described by Klapars et al., addition of CuI was included; however, an insignificant 
improvement in the yield was obtained (5%), shown by entry 2. Despite a number of varied 
reaction conditions, which included different CuI loadings, ranging from catalytic to 
stoichiometric amounts, as well as elevated temperatures of up to 120 ̊C, no improvement 
in the yield of 5.5a was observed. Work described by Ganapathi and co−author suggests 
that  the chloride or bromide halogens present on the 5− and 4−position of the thiazole 
proved to be on the more unreactive position, thus better yields for entries 3, 4 and 5 were 
not expected.158 Entry 4 illustrates that with both ligand and catalyst, product was achieved, 
but only in poor yields. 
 
Table 5.1. Cu−mediated arylation of THIQ. 
 
Entry Substrate Ligand CuI (equiv) Base Product 
Yield 
(%) 
1 2−bromothiazolea / / Et3N 5.5a 18 
2 2−bromothiazolea LL1 10 mol% – 1 mol K3PO4 5.5a 23 
3 5−bromothiazolea / 10 mol% – 1 mol K2CO3 5.5b 0 
4 5−bromothiazolea LL1 10 mol% – 1 mol K3PO4 5.5b 9 
5 5−bromothiazolea LL2 10 mol% – 3 mol K3PO4 5.5b 0 
6 bromobenzeneb LL1 
10 mol% – 
0.5 mol 
K3PO4 5.5c 60 
Reagents and conditions described by Klapars et al.150: (i) Heteroaryl bromide (1.2 equiv), amine (1.0 equiv) 
and base (2.0 equiv). aDMF at 110 ̊C, overnight; bDMSO at 150 ̊C, 15 min. 
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In an effort to improve on the yield, the thiazole was treated with KI to affect a CuI−catalyzed 
aromatic Finkelstein−type halogen exchange reaction in situ described by Klapars et al.150 
Thus, treatment of the thiazole with an excess of CuI, KI and 1,2−diamine led to the 
formation of 5−iodothiazole (as per a procedure described by de Vries and co−workers).155 
It has been reported that the iodoaryl species performed optimally upon comparison to their 
corresponding bromo− and chloroaryl species148,154,155 and excess CuI and ethylene 
diamine was required to mediate the halogen exchange illustrated in Scheme 5.7. 
 
 
Scheme 5.7. Copper−catalyzed aromatic Finkelstein−type reaction a) in the absence of a ligand and b) aided 
by a ligand.150 
 
In contrast to results reported in literature, in our hands compound 5.5b was not formed. It 
was then decided to model the protocol on a known substrate (in entry 6). Similar conditions 
as applied to entries 2 and 4 were adopted in entry 6 in DMSO, which afforded product 5.5c 
in reasonable yields. These results suggested that the unsuccessful reactions were 
associated with the reactivity of the thiazole substrate and not the reaction protocol per se. 
Despite low yields, ʟ−proline (LL1) was the only ligand for which product was obtained. The 
low yields obtained in Table 5.1 resulted in the investigation taking on a different approach 
for the synthesis of THIQ analogues (as shown in Figure 5.2). 
 
5.3 Retrosynthetic analysis 2: Intramolecular cyclization as an approach to 
synthesizing THIQ analogues 
In this approach, the focus was to employ a SN2 substitution and/or implement reductive 
amination for generating the desired intermediates 5.6, which were required for the 
synthesis of the desired target molecule analogues as illustrated in Scheme 5.8. 
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Scheme 5.8. The Friedel−Crafts approach to the synthesis of THIQ analogues. 
 
Reductive amination between 5.8 with the aryl amine or a SN2 substitution reaction between 
the aryl amine with the substituted benzyl halide 5.9 would result in formation of compound 
5.7. Acylation of amine 5.7, followed by an intramolecular Friedel−Crafts (F−C) cyclization 
would then afford the target compound 5.1 after complete reduction of the keto group 
(Scheme 5.8). 
 
5.3.1 Reductive amination reactions 
The reductive amination protocol presented a “greener” approach with water being the major 
by−product, in addition to the absence of expensive ligands or metals required for this 
synthetic strategy. Reductive amination involves the initial formation of a Schiff base 
intermediate 5.13, shown in Scheme 5.9, by the condensation of an aldehyde with a primary 
amine and involves the proposed intermediates 5.10 – 5.12. 
 
 
Scheme 5.9. A general reaction mechanistic scheme proposed for the imine formation as described by Qin 
and co−workers.159 
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The classical approach described by Qin and co−workers included the azeotropic removal 
of water using a Dean−Stark apparatus.159 Elimination of water is essential, since 
conversion of the amine to the imine 5.13 is a reversible process. An interesting two reviews 
by da Silva,160 Qin159 and co−workers reported that the aid of acids (such as mineral, organic 
or Lewis acids) and dehydrating agents (like molecular sieves or MgSO4) greatly accelerated 
reactions, affording the desired imine 5.13 under milder conditions. By employing known 
chemistry and implementing a procedure described by Wei and co−workers,161 a model 
reaction was explored, in which benzaldehyde and aniline were condensed to optimize 
reaction conditions suitable for the intended substrate and subsequent reactions. One 
method tried included a mixture of benzaldehyde 5.14 and aniline which were heated at 
60 ̊C in EtOH with acetic acid catalyzing the removal of water, as illustrated in Scheme 5.10. 
 
 
Scheme 5.10. Reagents and conditions for reductive amination: (i) aniline, Mg(ClO4)3, MgSO4, CH3CHCl2 (1,2-
dichloroethane), 60 ̊C, 5 h; (ii) NaBH4, EtOH, RT, overnight. 
 
The reaction’s progress was monitored every hour using TLC for determining the complete 
consumption of reagents. However, despite overnight stirring, the reaction did not proceed 
to completion. Failing to obtain a high yield of product for this protocol, a method described 
by Kang et al.162 was explored, where triflic acid was introduced as an alternative catalyst, 
but still no improvement in the formation of 5.15 was observed. Failure to obtain complete 
conversion was explained by the grade of the EtOH used, as the presence of any additional 
water favoured the reverse reaction resulting in unreacted starting material being recovered. 
Thus, EtOH was replaced by benzene as solvent and triflic acid was used as the catalyst 
and the reaction mixture was heated to 60 ̊C. However, the yields obtained were still 
unsatisfactory with incomplete conversion. The incomplete conversion made purification 
very challenging since the product and reagents moved with similar Rf−values. Finally, 1,2-
dichloroethane was chosen as solvent in addition to the Lewis acid catalyst Mg(ClO4)3 and 
heating at 60 ̊C which afforded product 5.15 in a 53% yield. Furthermore, the stoichiometric 
addition of anhydrous MgSO4 to the reaction mixture gave product in quantitative yield within 
3 hours. As illustrated in Scheme 5.9, with the nature of the reaction being sensitive to water, 
no work−up procedures were implemented. The reaction mixture was thus concentrated to 
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dryness, followed by a general reduction commonly used in Schiff base chemistry.162-164 To 
this end, after treatment with NaBH4 in EtOH, the amine 5.16 was produced in a 70% yield 
and its structure and confirmed by 1H−NMR spectroscopy. A complex 7−proton multiplet in 
the aromatic region observed between ẟ 7.48 – 7.02, with an additional 3−proton multiplet 
between ẟ 6.79 – 6.55, were indicative of the two benzene rings. A broad 1−proton singlet 
observed in the aliphatic region at ẟ 4.03 (NH), with the benzylic methylene group observed 
at ẟ 4.34, further confirmed product formation. 
 
5.3.2 Nucleophilic substitution reactions 
In order to reduce the number of reaction steps, SN2 substitution was initially considered. 
This required the implementation of a protocol described by Kim and co−workers,165 where 
benzyl bromide 5.17 and amine 5.18 were allowed to react in the presence of Cs2CO3 and 
heated under reflux in DMF (parameters for condition i).164,165 The reaction mixture was 
stirred and heated for 24 hours and longer. However, in our hands the maximum yield 
obtained was only 34%. 
 
 
Scheme 5.11. Reagents and conditions for Ullmann reaction: (i) Cs2CO3, DMF, 80 ̊C, overnight; (ii) ւ −proline, 
CuI, Cs2CO3, DMF, 80 ̊C, overnight. 
 
Observations made from the Ullmann condensation−type chemistry previously discussed 
(in Table 5.1), indicated that a slight improvement in yield would be possible upon coupling 
the halogenated species with aryl amines and applying Cu as a catalyst. Subsequent 
addition of catalytic amounts of CuI and ʟ−proline to the reaction mixture resulted in a 
moderate improvement, with the yield increased to 47% for compound 5.19 (in Scheme 
5.11). 1H−NMR spectroscopy was employed for elucidating the structure of compound 5.19. 
What appeared to be rotamers were observed for the benzylic CH2 group of 5.19. The 
aromatic region showed a 5−proton complex multiplet between ẟ 7.54 – 6.89. In addition, a 
1−proton singlet at ẟ 6.42 was assigned to H5 of the thiazole ring. Upon close inspection, 
the methylene chemical shift, usually observed as an intense 2−proton singlet, was 
represented by two sets of multiplets at ẟ 5.29 and ẟ 5.16. In addition, the intense 3−proton 
singlet normally observed for the methyl group at ẟ 2.51 – 2.05 was in this case observed 
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as a 3−proton multiplet and not a singlet as expected. Furthermore, it was found that in ESI+ 
TOF MS, presented an experimental monoisotopic mass of 205.0793 for C11H12N2S being 
obtained, which corresponded well with the calculated mass of 205.0755. 
 
5.3.3 Acylation of secondary amines 
Addition of the alkyl group onto the side chain nitrogen of the side chain was essential for 
facilitation of the envisaged F−C ring closure. Due to the propensity of amines to undergo 
multiple alkylations providing the quarternized amine, α−chloroacetanilides 5.20 and 5.21 
were pursued (Scheme 5.12) circumventing quaternization. The shared electron density 
across the amide bond generates a resonance stabilized moiety preventing a second 
acylation. Thus, acylated compounds 5.20 and 5.21 would be subsequently reduced to 




Scheme 5.12. Reagents and conditions: (i) chloroacetyl chloride, DIPEA, CH2Cl2, RT, 6 – 18 h; (ii) LiAlH4/AlCl3 
(1:1), THF, 70 ̊C, 5 h. 
 
To this end, using a general procedure described by Velavan and co−workers,138 
compounds 5.16 and 5.19 in CH2Cl2, were subsequently separately cooled to 0 ̊C. DIPEA 
was added to render the reaction mixture basic and this was followed by the slow addition 
of the acylating agent. The reaction mixture was then stirred at room temperature for 6 hours 
to afford the acylated compounds 5.20 and 5.21. 1H−NMR spectroscopy confirmed product 
formation for structures 5.20 and 5.21, where an additional methylene signal observed at ẟ 
4.92 for 5.20 indicated the successful acylation. Compound 5.21 was confirmed by to the 
absence of rotamers previously observed for 5.19; additionally, the methylene signal 
represented by a singlet at ẟ 5.18 was observed for 5.21, further confirming product 
formation. Amides are considered to be rather stable, due to the presence of their 
delocalized electrons across the amide bond and they were thus reduced with a metal 
hydride affording the haloalkyl chain to accommodate the subsequent reactions. Reduction 
was effected by a procedure described by Nystrom,123 Davis124 and co−workers, which 
involved treatment of the acylated compounds 5.20 and 5.21 with the monochloroalane 
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generated in situ from a 1:1 mixture of AlCl3/LiAlH4. The reaction mixtures were heated 
under reflux for 4 hours, efficiently giving products 5.22 and 5.23 in reasonable yield after 
work−up. 
 
5.3.4 Intramolecular Friedel−Crafts cyclization reactions 
With the successful alkylated amines 5.22 and 5.23 in hand, subsequent reactions could 
resume for facilitating the intramolecular F−C cyclization to afford the THIQ analogues.166 
Work reported by Meyer and Turner,167 inspired the use of the intramolecular F−C cyclization 
protocol. Apart from the work implemented by Topsom,168 upon reviewing the literature 
several other publications prompted our further investigation into the use of the F−C 
intramolecular cyclization as a synthetic route toward our target compound 5.1.167-169 
 
The cyclization protocol described by Meyer and Turner, included the use of 
deuteriobenzylamine 5.24, which upon treatment with 2−bromoethanol in the presence of 
AlCl3, coordinated with the hydroxyl functionality and facilitated the cyclization that provided 
the deuteriotetrahydroisoquinoline 5.26 (seen in Scheme 5.13).167 
 
 
Scheme 5.13. Successful F−C intramolecular cyclization reported by the independent work of Topsom,168 
Meyers170 and co−workers. 
 
The work reported by Topsom and co−workers however, included the hydroxyl functionality 
being converted into an improved leaving group for further promotion of the electrophilic 
substitution.168 Surprisingly, the F−C intramolecular cyclization was able to occur in the 
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absence of an electron−rich aryl system, but unfortunately any yields were unreported. Upon 
comparison, compound 5.22 should provide similar reactive possibilities to the resulting b 
route intermediate in Scheme 5.13. This method allowed for the optimization of the protocol, 
using the tetrahydroisoquinoline model scaffold 5.22 (Scheme 5.14) prior to implementing 
the synthetic strategy on our valuable substrate containing the meta methoxy−substituent. 
 
 
Scheme 5.14. Reagents and conditions for the attempted intramolecular F−C cyclization: (i) AlCl3, CH2Cl2, 
RT, overnight; (ii) SnCl4, CH2Cl2, RT, overnight; (iii) SnCl4, PhNO2, RT – 150 ̊C, overnight. 
 
However, in our hands no product was isolated, despite the use of various metal chlorides 
commonly used for facilitating the F−C ring−closing reactions. Failure to obtain the cyclized 
product 5.30 with various acid catalysts was believed to result from the aromatic ring being 
too unreactive shown in Scheme 5.14. During the monitoring of the reaction’s progress with 
TLC, it appeared that a reaction had occurred; however, the difference in Rf values 
presented by the product and starting material could be clearly be differentiated by the 
complexation of the acid catalyst with substrates 5.22 and 5.23. 1H−NMR spectroscopy 
applied to the “products” yielded inconclusive results with no variation in chemical shifts to 
confirm product formation. The absence of product was confirmed using ESI+ TOF MS, in 
which the monoisotopic mass confirmed the presence of only the starting material being 
present. Apart from the advancements achieved by Meyers and Dickman, it was established 
that the cyclization was also Lewis acid−dependent and that even in the absence of an 
electron−donating group on the aryl ring, product could be obtained as illustrated in Scheme 
5.15 by the work reported by Charpentier−Morize and co−workers.171  
 
 
Scheme 5.15. The successful intramolecular F−C cyclization reported by Charpentier−Morize and 
co−workers.171 
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However, the acylium ion intermediate 5.28 and the electron−withdrawal caused by the 
terminal trifluoro carbonyl increases polarization of the C=O bond (δ+C−Oδ−), thereby 
lowering the HOMO−LUMO energy gap to favour cyclization. This work included the 
screening of several mineral acids and Lewis acids viz., ZnCl2, SnCl4, FeCl3, CF3CO2H, 
H2SO4, TiF4, SbF5, AlCl3 and TiCl4 with no product observed when ZnCl2 and SnCl4 were 
implemented.171 Cyclization of several compounds containing the general formula 5.27 
illustrated the successful cyclization depicted in Scheme 5.15. It was suggested that the 
successful ring closure could be attributed to the presence of the electrophilic terminal 
−COCF3 group (favouring the acylium ion formation), which mediated the ring−closure, 
aided by activation promoted by complexation of the Lewis acid. A general literature 
procedure, where two commonly used Lewis acids (AlCl3 and SnCl4) were employed, was 
attempted on compound 5.20, but failed (Scheme 5.16). Failure to obtain the desired product 
5.32 using the procedure described by Charpentier−Morize and co−workers on our 
substrates was frustrating since enough literature evidence was found to support this type 
of reaction.171 This led to making small protocol changes to redress this failure. 
 
 
Scheme 5.16. Reagents and conditions for intramolecular F−C cyclization: (i) AlCl3, CH2Cl2, overnight; (ii) 
SnCl4, CH2Cl2, overnight; (iii) SnCl4, PhNO2, RT – 150 ̊C, 48 h. The blue schematic is a representation of an 
alternate protocol, employed by Buchwald and co−workers,151 where yield could be obtained using a 
Pd−catalyzed reaction promoting cyclization of the α−chloroacetanilide. 
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Scheme 5.17. Reagents and conditions for intramolecular F−C cyclization: (i) AlCl3, CH2Cl2, 48 h; (ii) SnCl4, 
CH2Cl2, 48 h; (iii) SnCl4, PhNO2, RT – 150 ̊C, 48 h. 
 
Despite failure in our hands to successfully cyclize 5.20, a protocol employed by Shindikar 
and co−workers illustrated that at higher temperatures (180 ̊C) and with AlCl3 they were able 
to obtain product (in a reasonable yield of 58%) from the cyclization of 
2−chloro−N,N−diphenylacetamide illustrated in Scheme 5.17 b and c.169 A final attempt 
towards the desired cyclization thus involved the use of compound 5.33 (Scheme 5.17 a). 
The intention was to generate a more reactive species based on the work described by 
Shindikar and co−workers who reported higher yields being obtained upon comparison of 
the cyclization when using 2−(diphenylamino)−2−oxoacetyl chloride as it gave the 
corresponding product in 83% yield, to that of 58% yield on cyclization with 
2−chloro−N,N−diphenylacetamide in Scheme 5.17.169 However, it is important to note that 
this reaction worked well for generating the indole substrate, but unfortunately not for the 
isoquinoline scaffold when tried in our hands. The varied use of Lewis acids such as AlCl3 
and SnCl4 provided no positive results. In addition, temperature variations by the use of low 
boiling point solvent (CH2Cl2) and a high boiling point solvent such as nitrobenzene were 
employed. The synthetic problems experienced during this reaction procedure could 
perhaps have been overcome by the use of aryl substrates containing electron−donating 
groups compatible with the Lewis acids utilized in the synthetic procedure with much higher 
temperatures.41,151,169 Reports by Spangler and co−workers indicate that the presence of an 
electron−donating substituent on the aryl ring would further enhance the electron density 
required to improve the propensity for the intramolecular cyclization.172 
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5.4 Isochroman: A valuable intermediate for the synthesis of THIQ analogues 
With no successful results obtained from the F−C intramolecular cyclization, literature was 
again reviewed and focus was placed on the work reported by Ma and 
co−workers.173 This work introduced the concept where an isochroman 
motif would be used as a key intermediate in the synthesis of the THIQ 
skeleton. This prompted our interest in further exploring the isochroman as 
a valuable intermediate toward generating our target compounds with a general structure 
as 5.1. 
 
5.4.1 Synthesis of THIQ analogues from an isochroman 
In order to avoid the loss of the valuable aryl methyl ether substrate, it was not initially used 
and conditions for the isochroman work was primarily optimized starting from the 
commercially available 2−phenyl acetic acid as the model substrate. Generating the 
isochroman scaffolds required a number of reaction steps initiated from phenyl acetic acid. 
2−Phenyl acetic acid was first reduced by a well−known procedure described by Chapman 
and co−workers,174 whereby treatment of the 2−phenyl acetic acid with LiAlH4 in THF 
afforded the corresponding alcohol, 5.35 in good yield (Scheme 5.18). A 1H−NMR spectrum 
confirmed the successful reduction, as evident by the presence of two 2−proton triplets at ẟ 
3.81 and ẟ 2.85 in the aliphatic region, as expected for the CH2CH2 fragment and 
corresponding well with the reported literature values.173 
 
 
Scheme 5.18. Reagents and conditions: (i) LiAlH4, THF; (ii) CH2O, HCl, PCl3, 4 h; (iii) HI, reflux, overnight. 
 
A procedure described by Deady and co−workers was then implemented where cyclization 
of the alcohol 5.35 with paraformaldehyde under acidic conditions generated the isochroman 
5.36 in 96% yield.168 Furthermore, addition of PCl3 accelerated the elimination of water and 
provided isochroman 5.36 in good yields. Confirmation of the product was obtained by 
comparison of the 1H−NMR spectrum obtained experimentally, to that reported in the 
literature.168 Compound 5.36 displayed a 3−proton multiplet between ẟ 7.23 – 7.17 and a 
1−proton multiplet between ẟ 7.05 – 7.02, in addition to an intense 2−proton singlet at ẟ 4.83 
for the Ar−CH2−O protons. Synthesis of the 1−(2−iodoethyl)−2−(iodomethyl)benzene 5.37 
was performed by following a procedure described by Ma and co−workers,173 where heating 
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5.36 under reflux in excess HI for 3 hours in a darkened environment afforded the 
ring−opened diiodinated compound 5.37 as an oil in good yield. Furthermore, 1H−NMR 
spectroscopy identified this product. Iodination was evident by the different chemical shifts 
produced by the protons on the α− and β−carbons situated on the iodoethyl chain viz., a 
2−proton multiplet at ẟ 3.51 – 3.39 (α−CH2) and a 2−proton multiplet at ẟ 3.28 (β−CH2), 
confirming the successful ring opening and iodination of 5.36. The diiodinated substrate 5.37 
provided an interesting precursor for the synthesis for a number of different THIQ analogues 
by varying the added amines in the THIQ cyclization event (shown in Scheme 5.19). 
 
 
Scheme 5.19. Reagents and conditions for SN2 substitution reactions described by Ma and co−workers:173 (i) 
Primary amines (a – c), NaHCO3, H2O, SDS, reflux, 4 h. 
 
Amines (a – c) were chosen in accordance with the intended amines for generating the THIQ 
analogues 5.1, as well as to determine their compatibility under the reaction conditions 
applied. Thus, two THIQ analogues (5.38a – b) were successfully synthesized by the 
nucleophilic substitution of 5.37 with the various primary amines listed in Scheme 5.19. The 
reaction conditions included a procedure described by Ma and co−workers,173 using a weak 
base NaHCO3, which resulted in the formation of a number of inorganic by−products (such 
as NaI, H2O and CO2) thus decreasing the number of impurities. The amphiphile sodium 
N−dodecyl sulfate (SDS) was employed for homogenizing the reaction mixture to further 
increase the reaction rate. The reaction conditions could easily be optimized by longer 
reaction times or pre−treatment of the amines with stronger bases, prior to their addition to 
the halogenated species 5.37. The structure of product 5.38a was confirmed by 1H−NMR 
spectroscopy, illustrating the general THIQ skeleton. The key structural profile of the THIQ 
motif included a 4−proton multiplet between the ẟ 7.22 – 7.16, indicative of the aromatic 
protons H5 – H8. In addition, three 2−proton triplet signals were evident between ẟ 4.65 – 
4.31 (H1), ẟ 3.76 – 3.46 (H4) and at ẟ 3.00 (H3). The individual analogues were further 
differentiated according to the structure of their incorporated amines. The key identifying 
components for the structure of compound 5.38a was confirmed by the presence of a 
3−proton singlet at ẟ 2.30 (thiazole−CH3), in addition to a 1−proton singlet at ẟ 6.13 
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(thiazole−ArCH). The successful synthesis of 5.38b was confirmed by two 2−proton 
multiplets between ẟ 7.04 – 6.96 and ẟ 6.92 – 6.85, which were ascribed to the anisole 
portion of compound 5.38b. Furthermore, a 3−proton singlet observed at ẟ 3.79 was 
indicative of the presence of the aromatic methyl ether protons. Unfortunately, no expected 
product by reaction with 5−nitrothiazole was isolated. Subsequently, the successes 
achieved from the illustration in Scheme 5.19, prompted us to go ahead with synthesis of 
the isochroman 5.44 by using the 3−methoxyphenyl ethanol substrate. 
 
5.4.2 Synthesis of an isochroman analogue from 3−methoxyphenyl acetic acid 
3−Methoxyphenyl ethanol 5.40 was efficiently obtained in quantitative yield by the reduction 
of the corresponding 3−methoxyphenyl acetic acid upon treatment with LiAlH4 in THF, using 
a general procedure described by Chapman and co−workers.174 The structure of product 
5.40 was confirmed using 1H−NMR spectroscopy, which illustrated the presence of two 
overlapping signals integrating for 5−protons at ẟ 3.81 – 3.62 (OCH3 and CH2), in addition 
to a second methylene triplet at ẟ 2.72, providing evidence of the successful carbonyl 
reduction. The next step involved the crucial cyclization of compound 5.40 to form the 
isochroman 5.44, as illustrated in Scheme 5.20. An interesting review by Kaufman and 
Larghi,175 reported that this reaction has previously been classified as a variation of the F−C 
alkylation, the Prins cyclization, the Mukaiyama reaction, as well as the oxa−Pictet−Spengler 
reaction. The mechanism for the reaction is shown below in Scheme 5.20. 
 
 
Scheme 5.20. The proposed mechanism described by Kaufman and Larghi.175 Reagents and conditions for 
the oxa−Pictet−Spengler cyclization of 2−(3−methoxyphenyl)ethanol: (i) CH2O, HCl, PCl3, 4 h. 
Stellenbosch University  https://scholar.sun.ac.za




As described by Deady and co−workers,168 paraformaldehyde was treated with HCl and left 
to stir for 30 minutes allowing the formation of 5.39.168 Alcohol 5.40 was then added, 
generating the hemi acetal 5.41 in a process involving proton transfer. The reaction mixture 
was stirred for 2 hours after which PCl3 was added. Addition of PCl3 accelerated the removal 
of water by the in-situ formation of H3PO4 and HCl. The elimination of water was essential 
for generating two highly reactive intermediates viz., 5.42, which were required for the 
intramolecular electrophilic addition/cyclization to form the all−important substrate 5.44 via 
5.43. The reaction’s progress was carefully monitored with TLC, which indicated the 
presence of three different compounds. The major compound isolated was not the desired 
product 5.44, as demonstrated by 1H−NMR spectroscopic investigations. Rather compound 
5.45 (shown in Scheme 5.21) was obtained in an appreciable yield of 47% with the recovery 
of some starting material 5.40 (25%) and only trace amounts of product 5.44 (28%). 
 
 
Scheme 5.21. Proposed mechanism for the formation of compound 5.45. 
 
The chemical shifts observed in the 1H−NMR spectrum of 5.45 indicated that the ring closure 
was successful, namely the 2−proton triplets observed at ẟ 2.94 and ẟ 4.02, with an intense 
3−proton singlet at ẟ 3.83 and a 2−proton singlet at ẟ 4.83 (see Figure 5.4). These are 
chemical shifts common to the isochroman skeleton as discussed for compound 5.36. In 
addition to these signals, two further methylene signals at ẟ 4.62 and ẟ 4.56, together with 
a single 1−proton aromatic signal at ẟ 7.31 were observed. Based on this data, the structure 
assigned for the major compound was 5.45 in Figure 5.4. It can therefore be concluded that 
when using electron–rich aryl systems, they do not provide the predictable reactivity 
observed with the use of 2-phenylethanol (5.35). 
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Figure 5.4. 1H−NMR spectrum of undesired side product, compound 5.45. 
 
This result can be explained by the presence of the electron−donating methoxy group and 
its ability to activate both ortho− as well as para−positions, on the aryl ring. It is clear that 
the product 5.45 resulted from the excess paraformaldehyde added. However, even by 
adding only 1 mol of CH2O, formation of very little desired product 5.44 (35% yield) was 
obtained (for discussion of characterization see later). Since the isochroman 5.44 was a 
valuable intermediate required for generating a number of substrates, a different protocol 
for generating product in improved yields was needed. The second approach involved an 
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Scheme 5.22. Reagents and conditions for the cyclization described by Taber and Raciti:176 (i) 60% NaH, 
MOMCl, THF, overnight; (ii) TsOH, PhCH3, 80 ̊C, overnight. 
 
Taber and Raciti described a two−step procedure in which chloromethyl methyl ether and 
NaH were used to convert compound 5.40a into its corresponding MOM ether derivative.176 
Treatment of the intermediate 5.40b with tosic acid generated 5.46, a compound with an 
improved leaving group as illustrated in Scheme 5.22 and this intermediate underwent 
intramolecular cyclization to afford isochroman 5.44. Despite the rather low yield of 5.44 
(43%) obtained in our hands, 49% of the starting material 5.40a was recovered, which could 
fortunately be recycled in the protocol for the further synthesis of 5.44. Unfortunately, it 
should be noted that at higher temperatures (to try to improve the yield) multiple side 
products were formed. The structure of the major side product was confirmed using 1H−NMR 
spectroscopy and was found to be 5.44a. The only major differences in the spectra of 5.44 
and 5.44a were observed in the aromatic region, as illustrated in Figure 5.5. 
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Figure 5.5. 1H−NMR spectra of the aromatic regions for a) compound 5.44 and b) 5.44a. 
 
In compound 5.44 a doublet (3J = 8.4 Hz) at ẟ 6.89, a multiplet at ẟ 6.72, as well as a multiplet 
at ẟ 6.66 each integrating for 1−proton, supported the assigned structure illustrated in Figure 
5.5a. However, it is clear that the aromatic protons fit the classical 1,2,4 substitution pattern. 
In addition, the shielding effect resulted in the adjacent aromatic protons appearing 
marginally upfield. On the other hand, the ortho− and para−aromatic protons in compound 
5.44a appeared as a multiplet with overlapping signals between ẟ 6.75 – 6.67. A doublet of 
doublets, observed as a triplet, was observed for the meta−aromatic proton at ẟ 7.14 (3J = 
7.9 Hz). 
 
5.4.3 Ring−opening and halogenation of the 6−methoxyisochroman 
Ring−opening of the isochroman was considered as one of the crucial steps required for the 
synthesis of the THIQ analogues. However, ring−opening of 5.44 with the intent of 
generating a dihalogenated species was not successful, despite applying several varied 
procedures as described in Table 5.2. As a result, this led to the investigation of 
isochromanone 5.47, which upon treatment with LiAlH4 generated the diol species 5.48. To 
this end, the use of a procedure described by Spangler and co−workers172 was applied for 
the synthesis of isochromanone 5.47.172 This protocol involved the stirring of 
3−methoxyphenyl acetic acid and 37% formaldehyde in acetic acid at room temperature for 
5 days. It is important to note that the addition of excess formaldehyde, as well as 
introduction of heat, only led to the synthesis of several side products and thus the reaction 
was stirred at room temperature for an extensive time. After work−up, the product 5.47 was 
obtained as a white solid in moderate yields ranging between 45 – 70%. 1H−NMR 
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spectroscopy was employed to confirm the identity of compound 5.47. A 2−proton singlet at 
ẟ 5.26, a 2−proton singlet at ẟ 3.68, a 3−proton singlet (OCH3), as well as a singlet at ẟ 3.82 
supported product formation upon comparison to the literature values.176 Furthermore, 
treatment of 5.47 with LiAlH4 afforded the diol 5.48 as a white solid in a 98% yield, as 
confirmed by 1H−NMR spectroscopy. The unique chemical shifts observed for 5.48 were a 
2−proton triplet at ẟ 2.86, overlapping signals of the methoxy and methylene hydroxyl 
between ẟ 3.83 – 3.78, in addition to an intense 2−proton singlet at ẟ 4.52 for the benzylic 
methylene hydroxyl group, which accounted for all the aliphatic substituents. 
 
 
Scheme 5.23. Reagents and conditions: a) (i) LiAlH4, THF, 60 ̊C, 4 h; (ii) Refer to Table 5.2 and b) (i) Refer to 
Table 5.2. 
 
This next step entailed the double halogenation of diol 5.48 to generate the dihalogenated 
intermediate 5.49, as depicted in Scheme 5.23. The intention was next to substitute the 
halo−analogues 5.49 with a variety of amines to afford the intended products illustrated by 
the model reaction described in Scheme 5.19. Whilst the ring−opening worked very well in 
providing 5.48, formation of the desired products 5.49 remained elusive, despite the 
variation of a number of fine−tuned reaction parameters, such as halogenating agents and 
solvents, being attempted (see Tables 5.2). 
 
Table 5.2. Halogenation protocols of diol 5.48. 
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Table 5.2a.  
Entry Substrate Halogen source Conditions 
5.49 
Yield (%) 
1 5.44 BBr3, 3.0 equiv173 CH2Cl2 at RT 0 
2 5.44 HI, 10.0 equiv168 Neat under reflux 0 
 
As shown in Table 5.2, entries 1 and 2 indicated that no product was obtained when 
attempting to halogenate and open the aliphatic ether ring 5.44 by treatment with strong 
acids. It was however, expected that multiple product formation could occur giving rise to 
the formation of a few compounds (a – f), as illustrated in Figure 5.6. It was also surmised 
that upon treatment of 5.48 with halogenating agents a similar product profile would be 
formed. However, these compounds a – f, were still considered valuable for two reasons: (i) 
if a monohalogenation occurred, the substrate could be recycled for a second halogenation, 
and (ii) as demethylation of the aryl methyl ether is considered a final step in our reaction 
sequence, it could thus be avoided by using the demethylated products d – f. 
 
 
Figure 5.6. Possible mixture of products obtained upon halogenation. 
 
Table 5.2b. 




ZnCl2 cat.; SOCl2, 4.0 
equiv177,178 
Neat 0 








21 – 50 
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However, upon treatment of 5.48 under the conditions listed in Table 5.2b, only trace 
amounts of mixtures were isolated, all comprising a number of products (by TLC). Evaluation 
of the aliphatic region of the NMR spectroscopic results for the isolated products provided 
evidence of numerous triplets indicative of multiple methylene groups, thus demonstrating 
the possible formation of numerous products. Separation of these compounds seemed futile, 
especially because of the low overall yield associated with each formed product. 
 
The conditions employed for entry 2, were previously applied to the (3−methoxyphenyl) 
methanol scaffold for obtaining the monohalogenation providing product in quantitative yield, 
prior to dihalogenation of the diol 5.48. This prompted the procedure to be used in entry 2. 
However, entry 2 in Table 5.2, gave poor conversion, with entry 5 affording the most 
dihalogenated product in a moderate yield. For the latter experiment, a protocol described 
by Batey and co−workers was explored.136 Compound 5.48 was thus dissolved in 
CH3CHCl2, cooled to 0 C̊, to which SOCl2 was added followed by overnight heating and TLC 
monitoring. Product formation was confirmed by 1H−NMR spectroscopy, where two 
2−proton triplets were observed at ẟ 3.94 and ẟ 2.84 with the methyl ether at ẟ 3.79. In spite 
of product formation, the poor yield mitigated against the continuation of this protocol. A 
number of varied reaction conditions, halogenating agents and solvents were investigated 
(see Table 5.2b) without being able to satisfactorily optimize product formation. This failure 
led to an alternative approach being considered. 
 
Table 5.2c. 
Entry Substrate Halogen source Conditions 
5.49 
Yield (%) 
1 5.48 HCl, 10.0 equiv137 Neat under reflux 0 
 
 
5.5 Isochromanone as an intermediate toward the synthesis of THIQ analogues 
Since the halogenation of compounds 5.48 was not an efficient route towards the synthesis 
of our target compounds, a different synthetic approach, employing starting material 5.47, 
was explored. In this new approach, the use of amines (a – g) as reagents were used for 
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Table 5.3. Conditions employed for generating lactam analogues. 
 























Reagents and conditions for generating lactams 5.51: (i) nucleophiles, 150 ̊C; (ii) AlCl3, 150 ̊C, neat without 
solvent. 
 
Work by Chen and co−workers,180 demonstrated that the isochromanone 5.47 was able to 
undergo condensation reactions with high boiling point amines under specific reaction 
conditions, thereby providing the lactam analogue such as 5.51.180 Thus compound 5.47 
and the respective amines (nucleophiles) in Table 5.3 were heated together at 150 ̊C while 
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stirring for 48 hours, producing a melt.180 One would expect decomposition of the amine, 
especially with the extended time period of being exposed to such high temperatures. 
However, the use of conventional heat at 150 ̊C for 4 hours resulted in the recovery of 
reagents with no product formation, proving that longer reaction times were essential. The 
high temperatures were required to facilitate the ring opening, thereby generating the 
amido−alcohol intermediate 5.50. The melt was then cooled to room temperature, followed 
by the addition of AlCl3 in toluene for the facilitation of the ring−closing reaction leading to 
formation of the lactam analogue 5.51. Exposure to the high temperatures was important for 
the removal of water, which further promoted ring closure. In this manner, compounds 5.51a 
– c were obtained in low to moderate yields (15 – 40%). These reaction conditions could be 
improved by the use of excess amine, followed by shorter reaction times after the addition 
of AlCl3. 
 
Key structural features for compounds 5.51a – c were the signal profiles generated by the 
1H−NMR spectra from the substituted heteroaryl groups (a – c). However, the structural 
profile of the THIQ motif was generally identified by a 2−proton singlet for the methylene 
bridge (H1), which appeared in the region of ẟ 5.38 – 4.76, in addition to a 5−proton multiplet 
resulting from the overlapping signals of the methylene group at H4 and the methoxy protons 
observed between ẟ 3.92 – 3.80. The individual structural characteristics associated with 
the 5.51 analogues were differentiated and identified by the unique signals observed in the 
aromatic region for each of the individual heteroaryl moieties incorporated. Apart from the 
absence of a methylene at C3, the carbonyl motif at C3 was identified in the 13C−NMR 
spectra by a signal resonating at approximately ẟ 170.00, which was observed for all the 
5.51 analogues. 
 
Compound 5.51a was isolated as a white solid in 35% yield and its structure confirmed by 
1H−NMR spectroscopy. For example, an intense 3−proton singlet at ẟ 2.33 confirmed the 
presence of the thiazole’s methyl group. In comparison to the starting material 5.47, an 
additional aromatic proton singlet was observed at ẟ 6.58, indicative of the thiazole’s single 
aromatic proton. Compound 5.51b was isolated as a beige solid in 40% yield and its 
1H−NMR spectrum displayed a complex pattern in the aromatic region between ẟ 7.24 – 
6.77 integrating for 7−protons, which confirmed the incorporation of the anisidine 
substituent, further supported by an intense 6−proton singlet at ẟ 3.81 indicative of the two 
methoxy moieties. Product 5.51c was also confirmed by 1H−NMR spectroscopy and isolated 
as an orange solid in only 15% yield. The only variation upon comparison of 5.51c to 5.47 
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was the 1−proton singlet observed at ẟ 8.40 (thiazole−ArH). In addition to the 1H and 13C 
NMR spectroscopic data, ESI+ TOF MS data was implemented for all three products for final 
verification. An attempt to generate 5.51c from a two−step reaction process to improve the 
yield involved the heating of the substrate 5.47 under reflux in THF with amine (c) followed 
by removal of the solvent and providing a solid residue. This residue was then heated for 24 
hours under reflux in toluene with catalytic amounts of AlCl3 being added. However, no 
product was obtained with this approach. 
 
Entries 4, 5, 6 and 7 illustrate that products were formed in low to reasonable yields. The 
aniline nucleophiles used in these entries were liquid and thus added in excess, making TLC 
monitoring of the reaction’s progression easier since no hard melt was formed. The structure 
of compound 5.51d was elucidated by an 8−proton aromatic multiplet observed between ẟ 
7.56 – 6.97 including the NH signal observed in the 1H−NMR spectrum. Product formation 
of 5.51d was further validated by use of ESI+ TOF MS where the protonated molecular ion 
([M+H]+; m/z) was found to have a monoisotopic mass of 288.0785, which corresponded 
well to the calculated monoisotopic mass for C16H14ClNO2 being 288.0791 for 5.51d. 
Confirmation of compound 5.51e was established by use of 1H−NMR spectroscopy, in which 
a 1−proton multiplet between ẟ 7.46 – 7.21, a 3−proton multiplet between ẟ 7.20 – 6.90, in 
addition to a 3−proton multiplet found between ẟ 6.88 – 6.78 indicated the presence of two 
separate aromatic moieties. Additionally, the ESI+ TOF MS confirmed the monoisotopic 
mass as being 272.1086 compared to that calculated for C16H14FNO2, being 272.1087. 
Compounds 5.51f and 5.51g showed a similar aliphatic 1H−NMR spectroscopic profile to 
that observed for the compounds 5.51d and 5.51e. However, their aromatic profiles differed 
quite significantly, and they could be differentiated by their coupling constants. Compound 
5.51f was elucidated by 1H−NMR spectroscopy, in which a 4−proton multiplet between ẟ 
7.39 – 7.28, a 1−proton multiplet between ẟ 7.12 – 7.09 were found, in addition to a 2−proton 
multiplet found between ẟ 6.82 – 6.78 indicative of the presence of two separate aromatic 
moieties. Additionally, a 5−proton multiplet between ẟ 7.47 – 7.23, and a 2−proton multiplet 
between ẟ 7.00 – 6.95 for compound 5.51g indicated the presence of two separate aromatic 
moieties. Furthermore, all compounds therefore were verified by HRMS. 
 
5.5.1 Synthesis of THIQ analogues promoted through coupling reactions 
As shown in section 5.5, low yields were associated with the formation of most products 
(5.51) shown in Table 5.3. Despite the protocol described by Table 5.3, we would have 
preferred to reduce the carbonyl group. This method resulted in insufficient material for 
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generating the analogues 5.55 and a different method was required. This led to the notion 
of employing an alternate method, involving the use of the Pictet−Spengler protocol shown 
in Scheme 5.24, for generating the THIQ analogue precursor for compounds 5.1 in an 
improved yield. Using this approach, the successful synthesis of product was established 
upon examination of the 1H−NMR spectra, as well as mass spectrometry results. 
 
In an initial attempt, 3−methoxyphenyl acetic acid 5.52 was converted into the acid chloride 
5.53 upon treatment with thionyl chloride at 40 ̊C. Since the hydrolysis of this acyl chloride 
occurred quite readily, the reaction procedure was soon changed to take this into account 
by making use of coupling agents. As shown in Scheme 5.24, a method reported by Pelly 
and co–workers181 was employed where a cooled solution (0 ̊C) of amines (b and d – g) 
was dissolved in CH2Cl2, to which catalytic amounts of DMAP were added for activation of 
the coupling agent N,Nˈ−dicyclohexylcarbodimide (DCC), were added to carboxylic acid 
5.52. The resulting reaction mixture was stirred at room temperature for 5 hours to ensure 
complete conversion of the amine to afford amide 5.53, since they both possessed similar 
Rf values upon monitoring with TLC. 
 
Scheme 5.24. Reagents and conditions described by Kano and co−workers:182 (i) amines (b, d – g), DCC, 
cat. DMAP, CH2Cl2, RT, 5 h; (ii) LiAlH4/AlCl3, THF, overnight; (iii) CH2O, formic acid, 80 ̊C, overnight. 






THIQ analogue 5.55 
Yield (%) 
1 5.53b (16) 5.54b (no product) 5.55b (no product) 
2 5.53d (66) 5.54d (98) 5.55d (no product) 
3 5.53e (94) 5.54e (73) 5.55e (75) 
4 5.53f (87) 5.54f (88) 5.55f (83) 
5 5.53g (56) 5.54g (75) 5.55g (98) 
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Entry 1, suffered from a poor yield, which could be associated with the low solubility 
observed for amine b and poor nucleophilicity previously observed in earlier reactions. 
Despite the low yields associated with the generated amide 5.53b, the overall yield was 
improved upon comparison to entry 3, Table 5.4. As illustrated in Table 5.4, it is clear that 
the general coupling reaction proceeded successfully providing the products 5.53d – g in 
moderate to good yields. The general structural profile presented by products 5.53b and 
5.53d – g was confirmed using 1H−NMR spectroscopy which provided sufficient evidence 
of the amide, as well as the aromatic protons. The overlapping aromatic and amine signals 
were often observed as a multiplet and integrated for 9−protons between the region ẟ 7.51 
– 6.80 indicative of the incorporated aryl motifs. Additionally, the methylene signal was 
observed as a 2−proton singlet between ẟ 3.71 – 3.69. The amide carbonyl’s signal was 
confirmed and identified using 13C−NMR spectroscopy. This signal was found to resonate 
between ẟ 169.00 – 171.00. In addition, ESI+ TOF MS further confirmed product formation 
by an increase in the monoisotopic mass of the products. 
 
Reduction of the amides 5.53 was easily accomplished by gentle heating of the reaction 
mixture at 45 ̊C after treatment with monochloroalane in THF. Products 5.54d – g were 
obtained in reasonable yields as illustrated in Table 5.4. Their structures shared a general 
1H−NMR spectroscopy profile and were confirmed by the identification of two 2−proton 
triplets observed upfield between ẟ 3.35 – 2.50, indicating the presence of two methylene 
groups. Absence of the carbonyl amide signal previously observed in the 13C−NMR 
spectrum between ẟ 169.0 – 171.0, in addition to the new methylene signal resonating at 
approximately ẟ 35.0, further supported the structure of compounds 5.54. 
 
Work previously described by Kano and co−workers182 provided a procedure for the final 
step of the synthesis for cyclization of the amines 5.54d – g by condensation with a mixture 
of paraformaldehyde in formic acid at 80 ̊C overnight.182 The reaction mixture was then 
cooled to room temperature, followed by neutralization using a saturated sodium 
bicarbonate solution at 0 ̊C. The mixture was subsequently extracted with EtOAc to afford 
products 5.55d – g in good yield, with the added advantage being that no further purification 
required. The structures for products 5.55d – g, were confirmed using 1H−NMR 
spectroscopy, in which an intense 2−proton singlet observed between ẟ 4.00 – 4.50 
demonstrated the presence of the newly formed methylene signals. The chloroaryl 
substituted compounds 5.55d and 5.55f in Table 5.5 were found to lack stability and soon 
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decomposed. Decomposition of these compounds were confirmed by HRMS which showed 
the absence of their expected masses. Additional compounds such as 5.55a in Table 5.5 
(with an expected mass of 261.1062 and an experimental 261.1070), 5.55b (with an 
expected mass of 270.1494 and an experimental 270.1494), 5.55e (with an expected mass 
of 258.1294 and an experimental 258.1288) and 5.55g (with an expected mass of 258.1249 
and an experimental 258.1292) were however confirmed with HRMS. 
 
5.6 Demethylating routes toward obtaining 5.1 and 5.56 THIQ analogues 
The importance related to the demethylation of the aryl methyl ether moiety has previously 
been mentioned, since the hydroxyl group is essential for the intermolecular binding 
interactions within the binding pocket of the ER receptor. Successful demethylation of 
compounds 5.51 (a and c) and 5.55 (a and c) was achieved using BBr3 in a large excess 
for the efficient removal of the methyl group, thus generating the all−important phenol 
functionality. 
 





X Ar−Aryl group Product Yield (%) 
1 5.51aa C=O 
 
5.56a 45 
2 5.55aa CH2 
 
5.1a 45 
3 5.51ca C=O  
 
5.56c 78 
4 5.55ca CH2 
 
5.1c 38 
5 5.51db C=O  
 
5.55d  57 
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7 5.51eb C=O  
 
5.56e  89 
8 5.55eb CH2 
 
5.1e 48 







10 5.55fb CH2 
 
5.1f 58 
11 5.51gb C=O 
 
5.56g 24 
12 5.55gb CH2 
 
5.1g 55 
Reagents and conditions for demethylation of methyl ether aryls: (i) 5.51 or 5.55. aBBr3 (10.0 equiv), CH2Cl2, 
0 ̊C; bAlI3 (5.0 equiv), PhCH3/PhH 
 
Reasonable yields of products were obtained (see Table 5.5). Confirmation of the structural 
integrity of 5.56a and 5.56c was confirmed by the absence of the intense singlet previously 
observed at ẟ 3.00 – 3.98 (OCH3). Although not optimized, these experiments provided 
sufficient product for further modifications. Structural confirmation of products 5.56a, 5.56c 
– g, 5.1a and 5.1c – g was evident by 1H− and 13C−NMR spectroscopy and mass 
spectrometry. The series of compounds 5.56a and 5.56c – g, were easily identified by the 
lactam skeleton which had a 2−proton singlet in the region of δ 3.50 – 3.90 for H4, and a 
2−proton singlet at δ 5.00 indicative of the H1 methylene group, in addition to the aromatic 
signals. Apart from this, the structure of these products were confirmed by the absence of 
the methoxy previously observed in the ẟ 3.00 – 3.98 region. In addition, ESI+ TOF MS was 
employed, in which the monoisotopic mass was determined to further confirm product 
formation. Compounds 5.1a and 5.1c – g also presented a similar general spectral profile 
of 5.56 with two sets of 2−proton triplets found between δ 2.00 – 2.99 (H4) and δ 3.00 – 3.70 
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(H3). In addition, an intense 2−proton singlet at δ 4.00 – 5.00 (H1) and a complex aromatic 
region supported the formation of the desired product. Furthermore, absence of the methoxy 
signal, as well as the ESI+ TOF MS confirmed products 5.1a and 5.1c – g. Although not 
optimized, these experiments provided sufficient product for further biological screening. 
 
5.7 Summary and concluding remarks 
Synthesis of the THIQ analogues without linker groups proved quite challenging, despite the 
number of synthetic routes reported. The relevant synthetic routes to afford our target 
molecules included the use of Ullmann condensation reaction with our initial C−ring aryl 
groups (including heteroaryl systems). Coupling of the thiazoles (C−ring, heteroaryls) 
however failed. This issue was resolved by a method in which condensation between 
amines and aldehyde (5.14) formed a valuable Schiff base intermediate 5.15 shown in 
Scheme 5.25. This intermediate provided a substrate ready to undergo reduction, followed 
by an intramolecular F−C cyclization forming the THIQ analogue. 
 
 
Scheme 5.25. A subsequent F−C cyclization reaction with amine 5.16 would provide the desired product. 
 
It is unfortunate that none of these reactions were optimized using the 5.57 precursor (for 
synthesis of the Schiff base), since the presence of the electron−donating methyl ether 
group (see Figure 5.12) could have increased the electron density in the relative ortho− and 
para− positions, further improving reaction conditions for the F−C cyclization. However, 
cyclization could potentially occur at C4 or C2 of the aryl ring (depending on the specific 
functional groups on the aniline compound) providing a mixture of products. Thus, this 
approach was soon abandoned and synthesis of the isochroman molecule was pursued as 
an intermediate toward the THIQ analogue. 
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Scheme 5.26. m−Anisaldehyde 5.57, which could undergo F−C cyclization. 
 
Synthesis of the isochroman intermediate 5.36 and the subsequent reactions leading to the 
THIQ analogue 5.38 were optimised using the substrate without a methyl ether group. Once 
optimized the actual reaction was done on compound 5.40. However, it was found that the 
presence of the methyl ether moiety resulted in a number of unexpected products such as 
5.45 and 5.44a. Product 5.44 was eventually obtained in reasonable yield, but the 
subsequent reactions (ring opening and halogenation) provided multiple problems and 
product in very low yield. It was subsequently decided to generate the THIQ analogue by 
condensation between isochromanone 5.47 with a few selected amines (a – f). Products 
5.51 were obtained in low yield, but in sufficient amounts for subsequent reactions. 
Compounds 5.51 were comparatively easily demethylated, albeit in low yields as a mixture 
of starting material 5.51 and product 5.56. The THIQ analogues 5.1 were easily 
demethylated, but the final products were found to be relatively unstable and after storage 
gave spectra with additional 1H−NMR signals clearly indicating the slow decomposition of 
these compounds. 
 




Computational and Biological evaluation of the THIQ analogues 
 
The current study was aimed towards the generation of small compounds, with the potential 
to selectively bind with a greater affinity to the ERβ subtype. Computational docking 
simulations done by Dr Stephen Pelly were initially trialled, where ligand efficiency scores 
of the synthesized compounds were generated for both ERα and ERβ upon comparison to 
estradiol. Apart from computational analysis, with the successful synthesis, it was necessary 
to assess the bioactivity of the ability of the synthesized analogues of compounds 3.49b, 
3.49d and 4.46h (synthesis described in Chapters 3 – 5). For the biological assays, the EC50 
values were contributed by the valuable input of Prof Lech G. Milroy from the Technische 
Universiteit, Eindhoven, where the screening of some of these compounds 3.49 (discussed 
below) was carried out under the supervision of a PhD student in the Eindhoven group, Chan 
Vinh Lam. The remaining compounds (4.46d, 4.46f, 4.46g, 4.46h, 4.66cˈ, 4.66c”, 4.74h, 
5.1a, 5.1c, 5.1f, 5.1g, 5.56a, 5.56c, 5.56e and 5.56g) were screened by the Council for 
Scientific and Industrial Research (CSIR) investigator, Dr Alex Alexandre, to determine their 
cellular anti-proliferation values. 
 
6.1 Computational evaluation of the synthesized compounds 
Computational molecular docking simulations have been used as an important tool to 
understand the biochemical pharmacological interactions between receptors and their 
ligands. Ever since the early 1980s, this technique has become increasingly important in the 
world of medicinal drug discovery.183 The use of computational screening has permeated all 
aspects of drug discovery, frequently resulting in a more direct and rational medicinal 
chemical approach, with advantages such as low cost, time efficiency and effective 
screening of the designed compounds. Despite the value provided by virtual screening, 
reports by Carlson,184 Schultes,185 Friesner186 and co-workers further indicate the need for 
additional improvements in this approach to optimize its application. Essentially, the aim of 
the computational docking study utilized in our work was to provide a prediction of the ligand-
receptor complexed structures. This being a general method, it was employed for predicting 
the binding modes or ligand conformations required for designing a synthetic ligand with an 
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improved potency and selectivity for ERs. The virtual screening was targeted toward the 
design of an effective ligand, likely to bind with the ERs.183,186-188  
 
6.1.1 Ligand−ER efficiency docking results 
Ligand efficiency is a measure of the binding affinity (as measured by the Glide XP score), 
divided by the molecular weight of the ligand. There are many ways to calculate ligand 
efficiency but in general it is some measure of the ligand’s performance (be that docking 
score or, or binding energy), divided by its molecular weight). 
 
Docking studies were achieved by primarily sampling conformations of compounds (3.49, 
4.46, 4.66, 4.74, 4.80, 5.1 and 5.56) in the active site of the protein (ER), followed by ranking 
these conformations via a scoring function shown in Table 6.1. Ideally, sampling algorithms 
should be able to reproduce the experimental binding mode, in this case with estradiol, and 
the scoring function should also rank it highest among all generated conformations. From 
this, a brief overview of the basic docking results are provided, as demonstrated in the tables 
and graphs below.183,187,188 It is important to note that a lower or more negative ligand 
efficiency score, demonstrates a better ligand binding interaction. To facilitate comparisons 
between THIQs with specialized structural features the various entries in Table 6.1 have 
been grouped according to the ligand efficiency scores obtained by the aryl substituted 
groups on the THIQ amine. 
 
6.1.1.1 Computational results obtained for set 1 compounds 
The compounds of set 1 consisted of trifluoromethylsulfone–decorated THIQs and included 
compounds 3.3440, 3.49b, 3.49c and 3.49d. In terms of the molecular modelling, for ERα 
the reference 3.34 showed a ligand efficiency of -0.030 and -0.031 for ERβ. As mentioned 
before, the research reported by Brunsveld et al.,40 has shown that 3.34 had a 10–fold 
improved binding affinity for ERβ when compared to estradiol, although this did not seem 
reflected in the ligand efficiency scores which were very similar. It should thus be realized 
that the computational results were unable to distinguish this subtle difference in 3.34’s 
selectivity. Compounds 3.49b, 3.49c and 3.49d were generated to explore the effect of the 
varied R–groups in the 4–position of the THIQ scaffold. However, in terms of molecular 
modelling compounds 3.49b, 3.49c and 3.49d showed much lower ligand efficiency scores 
of -0.028 – -0.030 for ERα and -0.029 – -0.031 for ERβ, as shown in Table 6.1. It should 
also be noted that all three ligands docked much less efficiently when compared to the -
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0.042 values obtained for the natural ligand estradiol in ERα and ERβ). These results 
seemed to correlate well with the biological results discussed later in this chapter (6.2.1). 
 






















6.1.1.2 Computational results obtained for set 2 compounds 
The compounds described in Table 6.2 include the structures where the THIQ skeleton and 
the morpholine substituents were kept constant with varied linker groups between these 
moieties. Compound 4.46h had a carbonyl linker (resulting in an overall urea functional 
group), 4.80h had a thiocarbonyl linker (giving the thiourea functional group) and 4.74h had 
a sulfone linker. The amide–linked 4.46h and thioamide–linked 4.80h compounds of set 2 
showed the best efficiency scores with -0.036 for both ERα and ERβ and 4.80h showed an 
equal efficiency of -0.036 for both ERs. It should be noted that all of them were still quite far 
from the value of estradiol (-0.042). 






-0.042 (α)/-0.042 (β) 
1 3.49b 
 
-0.028 (α)/-0.029 (β) 
2 3.49c 
 
-0.028 (α)/-0.029 (β) 
3 3.49d 
 
-0.030 (α)/-0.029 (β) 
4 3.34 
 
-0.030 (α)/-0.031 (β) 
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Table 6.2. Ligand efficiency scores obtained for compounds from set 2. 
Entry Compound Structure 




-0.036 (α)/-0.035 (β) 
2 4.80h 
 
-0.036 (α)/-0.036 (β) 
3 4.74h 
 
-0.028 (α)/-0.028 (β) 
 
6.1.1.3 Computational results obtained for set 3 compounds 
The compounds in Table 6.3 from set 3, included a phenolic substituent with the THIQ 
skeleton remaining constant. Entries 1 – 4 contain varied linker groups, with compound 
4.46c possessing a carboamide linker (urea), compounds 4.66cˈ and 4.66c” the thioamide 
(thiourea) and 4.74c the sulfonamide linker. Of these three compounds 4.66c” showed the 
best score being -0.033 in the ERα and -0.032 for ERβ. Compounds 4.46c, 4.66cˈ and 4.74c 
showed similar scores within the range of -0.027 to -0.030 ligand efficiency toward both ERs. 
The remaining entries 5 and 6, for compounds 5.1c and 5.56c in set 3, with the phenol 
directly linked to the THIQ, showed improved ligand efficiency scores, with 5.1c having a 
value of -0.037 for ERα and -0.038 for ERβ. Of note was that compound 5.56c (entry 6) had 
the best ligand efficiency scores for both ERs upon comparison to estradiol (-0.041/-0.042 
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Table 6.3. Ligand efficiency scores obtained for compounds from set 3. 
Entry Compound Structure 




-0.027 (α)/-0.030 (β) 
2 4.66cˈ 
 
-0.029 (α)/-0.030 (β) 
3 4.66c” 
 
-0.033 (α)/-0.032 (β) 
4 4.74c 
 
-0.027 (α)/-0.028 (β) 
5 5.1c 
 
-0.037 (α)/-0.038 (β) 
6 5.56c 
 -0.041 (α)/-0.042 (β) 
 
 
6.1.1.4 Computational results obtained for set 4 compounds 
Compounds belonging to set 4 included the THIQ–skeleton with a thiazole substituent as 
invariables. The variable portion of set 4 compounds included different linker groups 
between the THIQ and thiazole moieties such as 4.46a (containing the carbamide linker to 
form a urea), 4.80a (the thioamide linker to form a thiourea), 5.1a (no linker group) and 5.56a 
where the linker group is absent and with a lactam group replacing the THIQ–skeleton in 
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Table 6.4. The linker–group compounds in entries 1 and 2 (Table 6.4) showed poor ligand 
efficiency scores, with the amide 4.46a proving to be the worst with a score of ~-0.020 for 
both ERs. Entry 2 (4.80a), showed a slightly better score with a value of -0.031 observed for 
both ERs. The directly–linked compounds, 5.1a and 5.56a in entries 3 – 4, showed 
reasonable ligand efficiency scores with 5.1a being -0.033 (for ERα), -0.034 (for ERβ). Lastly 
for this set, compound 5.56a showed an improved score of -0.035 for both ERs. 
 
Table 6.4. Ligand efficiency scores obtained for compounds from set 4. 
Entry Compound Structure 




-0.022 (α)/-0.023 (β) 
2 4.80a 
 
-0.031 (α)/-0.031 (β) 
3 5.1a 
 
-0.033 (α)/-0.034 (β) 
4 5.56a 
 
-0.035 (α)/-0.035 (β) 
 
6.1.1.5 Computational results obtained for set 5 compounds 
The compounds listed in Table 6.5 set 5, entries 1 – 3, contain the invariable fluoroaryl motif 
and the THIQ core. The compounds 4.46e, 4.46g and 4.74e showed relatively poor scores 
(as shown in Table 6.5) upon comparison to estradiol or the non–linker–containing 
compounds in entries 4 – 6. The γ–lactam (5.56e and 5.56g), in addition to the THIQ 5.1g, 
showed better ligand efficiency scores upon comparison to the amide– and sulfonamide–
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Table 6.5. Ligand efficiency scores obtained for compounds from set 5. 
Entry Compound Structure 




-0.027 (α)/-0.028 (β) 
2 4.46g 
 
-0.025 (α)/-0.029 (β) 
3 4.74e 
 
-0.031 (α)/-0.030 (β) 
4 5.56e 
 
-0.038 (α)/-0.036 (β) 
5 5.1g 
 
-0.037 (α)/-0.038 (β) 
6 5.56g 
 
-0.037 (α)/-0.038 (β) 
 
6.1.1.6 Computational results obtained for set 6 compounds 
The compounds shown in set 6 (Table 6.6) includes variations on the THIQ portion, and the 
chloroaryl substituent linker by way of a carboamide bridge. As seen in the previous sets 
(Tables 6.2 – 6.5), the compounds with linker groups showed a much lower efficiency score 
upon comparison to the γ–lactam and THIQ–based compounds (5.1 and 5.56). In Table 6.6, 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 6 | Biological evaluation of the THIQ analogues 
165 
 
entries 1 and 2 showed low scores of -0.022 (for ERα) and ~-0.026 (for ERβ), while entry 3 





Table 6.6. Ligand efficiency scores obtained for compounds from set 6. 
Entry Compound Structure 




-0.022 (α)/-0.027 (β) 
2 4.46f 
 
-0.022 (α)/-0.026 (β) 
3 5.1f 
 
-0.033 (α)/-0.035 (β) 
 
6.1.1.7 Overall results obtained for Table 6.1 to 6.6 
Compounds (3.49b – d, 4.46, 4.66, 4.74, 4.80, 5.1 and 5.56) shown in the Tables on the 
preceding pages in the active site of the receptor (ER), followed by their rankings via a ligand 
efficiency scoring function are summarized in the Tables 6.1 – 6.6 and depicted graphically 
in Figure 6.1. 
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Figure 6.1. a) ERα scoring and b) ERβ scoring of the virtual ligand efficiency scores.  
 
The results obtained from the virtual efficiency scores motivated further EC50 and anti-
proliferation evaluations of the compounds listed in Figure 6.1. The additional biological 
evaluations for some of the compounds are thus discussed below. 
 
6.2 EC50 results obtained for set 1 compounds 
The synthesis of compounds 3.49b and 3.49d was prompted by the continuation of the work 
reported by Brunsveld, L. et al., where compound 3.34 showed an enhanced 10−fold affinity 
for ERβ.40 However, for this study, unlike the reference compound 3.34, analogues 3.49 
included two R−groups at the 4−position of the THIQ skeleton as shown in Figure 6.2 below. 
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Figure 6.2. The reference compound 3.34 with the 4–substituted analogues 3.49. 
 
This variation was used to determine the effect the R−groups would have on the results with 
respect to compound 3.34. Particularly, with the impact of additional steric bulk in this section 
of the scaffold. It was hoped that this additional bulk would provide the ligands with an 
increased discretion for ERα or ERβ. The data measured for estradiol was analysed using 
a non−linear regression graph, with single−site binding and used to calculate the EC50 value 
of 86 nM (± 5 nM), which is in reasonable agreement with the value report for estradiol 
versus ERα in Brunsveld, L.et al., in previous work (EC50 value of 0.13 μM ± 0.04 μM) 
demonstrated in Figure 6.3.40 It should be noted that the value for estradiol were determined 
using the same experimental set–up. 
 
 
Figure 6.3. Representative ERβ–Fluorescein LXXLL peptide fluorescence polarization curves upon increasing 
ligand concentration. Estradiol and all tested ligands lead to an increase in fluorescence polarization (agonistic 
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effect). 4–Hydroxy tamoxifen, as an antagonistic reference, leads to a decrease in polarization. (Source: Taken 
from Brunsveld, L.et al., J. Med. Chem 2011, 54, 2005) 
 
Comparison between the reference compound 3.34, and its derivatives 3.49b and 3.49d, is 
shown in Figure 6.4. Compounds 3.49d, 3.49b and 4.46h, versus the use of estradiol as a 
positive control, were evaluated in a fluorescence polarization cofactor recruitment assay 
against SUMO−tagged ERα, using a protocol similar to the study described by Brunsveld, 
L.et al.40 In this bioevaluation, a 1 μM solution of SUM−ERα, 0.1 μM fluorescein-labelled 
SRC1−Box2 peptide and a dilution series of each compound from a 5 mM EtOH stock 
solution for estradiol was utilized. In addition, a 10 mM DMSO stock solution was prepared 
for each of the test compounds. The measurements were performed in triplicate in 
coregulator buffer E in black 384 round−bottomed well plates. It should be noted the error 
bars are included, but are obscured by the symbols, which means the data are highly 
reproducible within each set of triplicate measurements. The final DMSO content was a 
constant 10% in each well. 
 
 
Figure 6.4. Interpreted EC50 results obtained. Fluorescein LXXLL peptide fluorescence polarization curves 
upon increasing ligand concentration. Estradiol and tested compounds 3.49b, 3.49d and 4.46h which lead to 
a decrease in fluorescence polarization upon comparison to estradiol. 
 
As shown by Figure 6.4, compound 4.46h did not induce SRC1 Box2 peptide binding under 
these conditions up to the highest test concentration (100 μM), while 3.49d and 3.49b both 
appeared to induce a partial response (i.e. at a fraction of the maximum response induced 
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by estradiol) at concentrations above 1 μM. The activity of neither compounds plateaued at 
higher concentrations, which meant that determining an EC50 for both compounds was 
unfortunately not possible. 
 
6.3 Methodology used in screening of sets 2 – 6 against MCF7 
Despite the number of compounds submitted for EC50 analysis, only a few of the results 
were obtained for the compounds shown in Figure 6.2. It was decided to send the remaining 
compounds for proliferation analysis to the CSIR in Pretoria where whole cell testing was 
performed.189 The testing procedure included loading of the whole cell assays into sterile 
24−well tissue culture plates at 1.50 x 106 M of MCF7 (invasive ductal carcinoma) cell line, 
after which they were exposed to 2.50 mg/mL of compounds 4.46h, 4.66c”, 4.66cˈ, 4.46d, 
4.74h, 4.46f, 4.46g, 5.1a, 5.56a, 5.56c, 5.1c, 5.56e, 5.1f, 5.1g and 5.56e for 4 days. Post 
culturing, the array of plates were treated with immunofluorescence and imaged using a 
Cytation3 cell imaging Multi−Mode Reader, where three channels were used, as illustrated 
in Figure 6.5. 
 
 
Figure 6.5. MCF7 cell line on a mini compound array. The spots were imaged in the red channel 
(sulforhodamine b, 568 nm), the actin cytoskeleton in the green channel (phalloidin, 488 nm) and the DNA in 
the blue channel [4,6−diamidino−2−phenylindole, dihydrochloride (DAPI, 408 nm)]. 
 
The changes in fluorescent intensity were taken to be indicative of changes in MCF7 
apoptosis or cell proliferation. Individual experiments were subjected to Persomics analysis 
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software for the processing and analysis on images was performed using cell profiler and 
data quantification using Microsoft Excel. 
 
6.3.1 MCF7 cellular anti-proliferation results and discussion 
The structural characteristics of the compounds employed in determining the MCF7 anti-
proliferation results, included either the substitution of aryl groups (compounds 5.1a, 5.56a, 
5.56c, 5.1c, 5.56e, 5.1f, 5.1g and 5.56e) or the aryl–linked modified amido groups (4.46h, 
4.66c”, 4.66cˈ, 4.46d, 4.74h, 4.46f and 4.46g) via the nitrogen of the THIQ scaffold. These 
aryl rings, in addition to their heteroatoms, were intended to extend toward the His475 
residue within the receptors pocket.  
 
 
Figure 6.6. The best cellular anti-proliferation effects was shown by the compounds 4.46d and 5.56a 
(Proliferation percentage shown in brackets). 
 
The inhibition displayed by compound 4.46d was reasonable in terms of MCF7 anti-
proliferation), while 5.56a essentially did not affect the cellular growth (both structures shown 
in Figure 6.6). All other compounds showed poor inhibition (effectively the promotion of 

















































































Fulvestrant Zileuton 5.56a NFV 5.1a
4.74h 5.56g 5.1g 4.46h 5.1c
4.46f 5.1f 5.56c 5.56e 5.56e
4.46g 4.66c" 4.66c' 4.46d
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6.4 Summary and concluding remarks 
The compounds generated from Libraries 1, 2 and 3, were structurally designed to 
accommodate the receptors binding pocket and improve the potency and selectivity toward 
the ERβ protein. Upon reviewing the ligand efficiency scores obtained from the virtual 
screening process of compounds listed in Table 6.1 – 6.6, some reasonable results were 
obtained indicating the possibility that these compounds would be worthy of further 
biochemical studies. The virtual screening scores reflected good ligand efficiency for most 
of compounds. However, when doing whole cell testing only two compounds (4.46d and 
5.56a) showed potential activity with the rest showing quite poor activity. A common problem 
associated with the compounds listed in Table 6.1 was their sediment formation, when trying 
to solubilize the compounds for EC50 and cellular anti-proliferation analysis. This was 
commonly associated with the THIQ skeletons that included the 4–phenol (for example 
shown in Table 6.3; 4.46c, 4.66cˈ, 4.74c and 5.1c) which could be explained by Scheme 
6.1, as well as the 4–haloaryl substituents (demonstrated in Tables 6.5 and 6.6; 4.46g, 5.1g, 
4.46f and 5.1f). 
 
 
Scheme 6.1. Possible oxidation of the hydroxyl–functional group resulting in the quinone species. 
 
Not being able to completely dissolve the sample could result in the calculation of incorrect 
concentrations of the prepared samples with inaccurate results being expected. In addition, 
slow precipitation of the compounds could also result in the results being less reliable. 
 
Overall, it should be noted that due to rather poor results obtained from the admittedly limited 
bio-testing performed it is currently not possible to utilize these results for a reasonable SAR 
analysis. Further evaluations will therefore need to be planned to enable a better SAR 
evaluation on the THIQ compounds synthesized thus far (see Future work section). 






The purpose of this study was aimed toward generating sets of small compounds, to then 
test their ability to bind with ER, and for some of these new compounds to potentially bind 
with a greater affinity to the ERβ subtype. Three small libraries were generated (i) where the 
THIQ skeleton contained the trifluoromethylsulfonyl substituent as discussed in Chapter 3, 
(ii) in which the THIQ skeleton contained a number of variations of urea groups as elaborated 
upon in Chapter 4, and (iii) a lactam skeleton, in addition to the THIQ skeleton, with a number 
of aryl substituents as discussed in Chapter 5 (all general scaffolds depicted in Figure 7.1). 
 
 
Figure 7.1. General scaffolds upon which the varied sets of compounds synthesized in this project were 
designed. 
 
Once the compounds were successfully synthesised, based preliminary docking studies and 
previously published work,40 the use of virtual screening was employed to investigate 
computationally the potential binding and selectivity of the compounds generated 
(Compound structures shown in Table 6.1 – 6.6 for libraries 1 – 3 (in Chapter 6). The results 
obtained from the virtual screening indicated overall good to reasonable ligand binding 
efficiency scores when compared with estradiol as discussed in Chapter 6, although 
disappointingly little difference was found in terms of the potential to bind the ERβ subtype 
in preference to the  form. Finally, results obtained from the whole cell evaluation of these 
compounds in a number of bioassays were unfortunately inauspicious. The design of the 
compounds in libraries 1 – 3 were targeted to mimic the phenolic portion as well as the 
cyclopentanol portion of the estradiol structure, resulting in the requirement that for our final 
compounds the arylmethyl ether needed to be demethylated to expose the phenolic 
Stellenbosch University  https://scholar.sun.ac.za




functional group shown by other groups to be required for a significant portion of the binding 
affinity. In the biological assays the evaluation of the compounds turned out to be 
problematic with many of them not showing good activity. Compounding this matter was that 
a significant number of compounds demonstrated poor solubility in the media utilized for the 
bioactivity testing frequently resulting in time-dependant sedimentation and resulting in 
opaque solutions which posed problems during the actual biological evaluation. In addition, 
these problems often increased with the compounds in which the arylmethyl ether had been 
converted into the phenol group. 
 
It was frequently found that after demethylation a number of the compounds showed 
sensitivity toward environmental conditions and decomposed easily. This resulted in NMR 
spectra initially being good followed by gradual degradation of the samples was observed 
(for some compounds this degradation was already evident during purification by column 
chromatography or during NMR spectroscopy experiments. These significant problems 
need to be corrected or prevented by putting a number of strategies in place as will be 
discussed in some of the suggestions in this final chapter of the thesis. 
 
7.1 Addressing solubility problems 
Since a number of problems were discovered once the methoxy–compounds were 
demethylated, it would be interesting to evaluate the phenolic compounds biochemical 
interactions while maintaining the methoxy functional group. Despite the positive results 
obtained from computational docking studies, the compounds behaved poorly in aqueous 
media when tested. Thus, the methoxy–masked phenoxy groups could be evaluated by 
determining the inhibitory concentration and efficient concentration testing. The presence of 
the methoxy functional group would improve stability and prevent decomposition. However, 
it is expected that the loss of the phenoxy group would result in reduced interactions with 
amino acids Glu and His in the ER active site.40 Another possibility would be to replace the 
phenoxy group with a nitrogen-based functional group such as an aniline NH2 or NHMe so 
as to maintain the ability to hydrogen bond with the amino acids present in the binding site.  
 
7.2 Maintaining solubility while retaining the phenoxy functional group – a possible 
pro–drug strategy 
As seen from the design of most SERM’s, antiestrogens or estrogens, and supporting 
reports by Katzenellenbogen,60 Anstead,52 Komm,31 Dowers70 and co−workers, the phenol 
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functional group is a paramount structural feature. With that mentioned, the incorporation of 
cleavable protecting groups such as the sulfonate group a, as shown in Figure 7.2, could be 
considered.190 This type of functional group could easily undergo enzymatic hydrolysis, 
revealing the intended hydroxy group. The unmasked hydroxyl group would then be free for 




Figure 7.2. Minor modifications to the compounds from libraries 2 and 3. 
 
7.3 Modification to the synthesis of the thiourea linked compounds 4.66 




Scheme 7.1. Description of the protocol used in the preparation of the isothiocyanates 4.64. 
 
The isothiocyanates (4.64) were generated by synthesizing the dithiocarbamate salts 
followed by desulfurization; however, it was found that when using the halogenated anilines 
(4.62) the results were not reproducible when repeated. An interesting protocol recently 
described recently by Mandapati and co−workers191 describes the use of copper as a 
desulfurization agent for halogenated anilines and provides good yields in the examples 
investigated (up to 80%). Improved yield for the isothiocyanate intermediates 4.64 would 
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provide enough material for optimization of the sequential reactions. Nonetheless, the 
demethylation of compounds 4.66 resulted in the complete decomposition of the final 
compound 4.80. Methods to decrease the harsh nature of the demethylating procedures 
applied (resulting in the decomposition issues) could be overcome by use of the 
demethylated THIQ substrate, which proved to be successful in the synthesis of compounds 
4.66cˈ and 4.66c”. This would of course require reaction conditions that allowed for 




Scheme 7.2. Illustration of the thiourea groups discussed above. 
 
7.4 Boron–containing phenol-fused heterocycles to potentially mimic the 
tetrahydroisoquinoline scaffold 
Apart from our current approach in generating a scaffold able to selectively mediate 
estrogenic responses, the introduction of a heteroatom, such as boron presents numerous 
auspicious avenues in finding a suitable scaffold. Use of the element boron has rarely been 
observed in biological systems but with passing of the 20th century a plethora of research 
has contributed to boron’s coalescence within biologically active compounds.192,193 Despite 
the few mentioned, an immense amount of research reported by Endo et al.,108,194-197 has 
described boronic esters/clusters being employed as potential selective estrogen receptor 
modulators. In addition, the use of computational screening of the carboborane compounds 
listed below in Figure 7.3, does indicate their potential as estrogenic mediators. 
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Figure 7.3. Examples of possible major modifications to the THIQ skeleton. 
 
The general scaffold structure below entails a number of viable routes to easily generate 
compounds containing the organoborane skeleton 7.14. Method a) includes dehydration of 
the boronic acid, method b) includes displacement of the chlorine atoms, and lastly, method 
c) where the boronic ester would be generated from the Grignard reagent 7.12, followed by 
reaction with the diheteroatom-containing molecules 7.9 under reflux to produce analogues 
of compound 7.14 demonstrated in Scheme 7.3. 
 
 
Scheme 7.3. Synthetic routes to obtain the general skeleton of compound 7.14. 
 
Work on these scaffolds with the inclusion of the phenoxy–group by compounds such as 
compounds 7.6 – 7.8 shown in Figure 7.3 could lead to interesting biological results. 
 
7.5 Concluding remarks 
As reported throughout this dissertation, the THIQ – core compounds have displayed very 
good pharmacological activity and quite challenging in to work with in the laboratory. We 
hope to address these challenges by application of methodologies mentioned above. In 
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addition, the introduction of boron – based compounds could further expand our library and 
therapeutic targets.  
 




Experimental and Analytical results 
 
8.1 Glassware preparation 
For reactions performed under anhydrous conditions, all glassware and stirrer bars were 
prepared by rinsing with acetone followed with overnight drying in a 90˚C oven. Once 
removed, the glassware was placed under vacuum conditions for 10 minutes, followed by 
back filling of the reaction vessel with nitrogen unless stated otherwise in the experimental 
section. 
 
8.2 Reagent preparation 
Syntheses were carried out with commercially available chemicals purchased form Sigma 
Aldrich or Merck. Compounds that were impure were purified using methods from the 
purification of laboratory chemicals book.198 The solvents used for chromatography and 
experiments were redistilled prior to use. Generally used reaction solvents such as 
tetrahydrofuran, toluene, diethyl ether, methanol and ethanol were analytical grade and 
dried under standard anhydrous conditions prior to use.199 Drying agents for example sieves, 
were placed in a 300˚C oven for 48 hours cooled to 100˚C followed by storing under nitrogen, 
prior to its use. 
 
8.3 Temperature control 
Reactions being heated was monitored by use of a thermal couple attached to the heating 
plate in addition to the use of a thermometer as a reference. Cool reactions were monitored 
using a −100 ̊C alcohol thermometer. Low temperatures of −78 ̊C were maintained by use 
of a mixture of carbon dioxide/acetone. Temperatures of 0 to −5 ̊C were maintained with a 
mixture of a saturated brine solution/ice. 
 
8.4 Chromatography 
All crude residues/compounds were purified with column chromatography using silica gel 60 
(70 – 230 mesh used for gravity column chromatography and 230 – 400 mesh used for flash 
chromatography unless stated otherwise) purchased from Merck. Silica sensitive 
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compounds were purified using Aluminium oxide 90 active neutral 0.063 – 0.200 mm (70 – 
230 mesh ASTM) purchased Merck. Thin layer chromatography (TLC) analysis was carried 
out on aluminium plates precoated with silica gel 60 F254 (0.2 mm). Visualization of TLC 
spots were observed under a UV visible light at 254 nm or using agents such as potassium 
permanganate, ninhydrin, p-anisaldehyde, cerium ammonium molybdate, 2,4−dinitrophenyl 
hydrazine solution and silica coated iodine. 
 
8.5 Characterization 
All nuclear magnetic resonance (NMR) spectroscopic data was obtained using Varian 
Gemini−300 (1H NMR at 300 MHz and 13C NMR at 75 MHz) as well as a Varian VXR−400 
spectrometer (1H NMR at 400 MHz and 13C NMR at 101 MHz). Chemical shifts (ẟ) are 
denoted in units (ppm) relative to the respective deuterated solvents, where 1H NMR spectral 
signals at: ẟ 7.26 ppm for CDCl3, ẟ 2.50 ppm for DMSO-d6 and ẟ 3.30 ppm for CD3OD. 13C 
NMR spectral signals were observed at: ẟ 77.16 ppm for CDCl3, ẟ 39.52 ppm for DMSO-d6 
and ẟ 49.00 ppm for CD3OD. The following abbreviations are used to indicate the signal 
multiplicity’s and characteristics: b (broad), s (singlet), d (doublet), dd (double of doublet), t 
(triplet), q (quartet), and m (multiplet). In the following ArC is a representation of quaternary 
carbons and ArCH refers to the aryl protons. 
 
Positive electron spray impact (ESI+) high resolution mass spectrometry (HRMS) were 
recorded on a Unicam Automass mass spectrometer in conjunction with a gas 
chromatograph. Infrared spectra were obtained using a Nexus Thermo−Nicolet FT−IR 
instrument using thin film (NaCl plate) or using the ATR attachment or using an ATi Perkin 
Elmer Spectrum RX1 FTIR spectrometer using thin film (NaCl). Melting points were obtained 
using a Gallen lamp melting point apparatus and were uncorrected. However, not all 
compounds were submitted for HRMS which was generally employed for final compounds. 
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 General experimental methods  
 
8.6 Synthesis of 2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol 
3.34 
8.6.1 General procedure for the synthesis of bis[6−methoxy−3,4−dihydroiso 
quinoline − 2(1H)−yl]methane 3.36 
According to the general procedure described by 
Zhong and co−workers,119 a mixture of 
2−(3−methoxyphenyl) ethylamine 3.35 (0.500 mL, 
3.43 mmol), aqueous 1 N HCl solution (5.00 mL, 4.96 mmol) and 37% aqueous 
formaldehyde (1.00 mL, 13.0 mmol) were stirred at 60 ̊C for 4 h resulting in a yellow 
translucent solution. This solution was cooled to 0 ̊C after which a 50% aqueous NaOH 
solution (1.03 mL, 5.62 mmol) was added until the mixture was neutralized, forming a white 
sticky gum−like residue, which solidified with further stirring and was pulverized very 
carefully. 
Aminal dimer 3.36 was obtained in quantitative (1.16 g) yield as a white clay powder; mp = 
119 – 121 ̊C; Rf = 0.60 (60:40 EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 6.96 (d, 
J = 8.4 Hz, 2H, 2xArH), 6.76 – 6.61 (m, 4H, 4xArH), 3.78 (s, 6H, 2xOCH3), 3.68 (s, 4H, 
2xArCH2N), 3.26 (s, 2H, CH2−bridge), 2.90 – 2.86 (m, 8H, 2xCH2CH2). 13C NMR (101 MHz, 
CDCl3): δ (ppm) 29.73 (2xArCH2), 49.36 (2XCH2), 54.26 (2xArCH2N), 55.60 (2xOCH3), 
81.05 (CH2−bridge), 112.36 (2xArCH), 113.64 (2xArCH), 127.68 (2xArCH), 127.97 (2xArC), 
136.34 (2xArC), 158.22 (2xArCOMe). The experimental spectroscopic information 
corresponded well with the reported literature spectroscopic information.119 
 
8.6.2 General procedure for the synthesis of 6−methoxy−1,2,3,4−tetrahydroiso 
quinoline hydrochloride 3.37 
According to the general procedure described by Zhong and 
co−workers,119 the synthesis of 6−methoxy−1,2,3,4− 
tetrahydroisoquinoline hydrochloride was as follows. An aqueous 
11 M HCl solution (0.360 mL, 3.84 mmol) was slowly added to a suspension of the aminal 
dimer 3.36 (590 mg, 1.74 mmol) in isopropyl alcohol (IPA) (10 mL) providing a yellow 
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translucent mixture. The resulting solution was stirred at RT for 18 h, after which MTBE (1.00 
mL per mmol of dimer) was added. This was followed by additional stirring of 4 h and the 
resultant white solid was filtered, washed with IPA/MTBE (1:1) and air dried to yield the 
hydrochloride salt 3.37. 
Compound 3.37 was obtained in quantitative (348 mg) yield as a white amorphous powder; 
mp = 238 – 239 ̊C; Rf = 0.00 (100% EtOAc). 1H NMR (400 MHz, DMSO−d6): δ (ppm) 9.47 
(brs, 2H, NH), 7.13 (d, J = 8.4 Hz, 1H, ArH), 6.88 – 6.75 (m, 2H, 2xArH), 4.16 (s, 2H, 
ArCH2N), 3.74 (s, 3H, OCH3), 3.32 (t, J = 4.4 Hz, 2H, ArCH2CH2), 2.98 (t, J = 4.4 Hz, 2H, 
CH2). 13C NMR (101 MHz, DMSO−d6): δ (ppm) 24.90 (ArCH2), 40.28 (CH2), 42.92 (OCH3), 
55.15 (ArCH2N), 113.09 (ArCH), 113.11 (ArCH), 120.82 (ArCH), 127.88 (ArC), 133.39 (ArC), 
158.36 (ArCOMe). The experimental spectroscopic information, corresponded well with the 
reported literature spectroscopic information.119 
 
8.6.3 General procedure for the preparation of 6−methoxy−2−[(trifluoromethyl) 
sulfonyl] −1,2,3,4−tetrahydroisoquinoline 3.38 
According to the general procedure described by Brunsveld, L.et 
al,40 the hydrochloride salt 3.37 (200 mg, 1.00 mmol) was 
suspended in anhydrous CH2Cl2 (20 mL) and treated at −60 ̊C 
with Et3N (0.560 mL, 4.00 mmol). Trifluoromethanesulfonic anhydride (0.370 mL, 2.20 
mmol) was slowly added, followed by stirring at −20 ̊C for 2 h, and additional stirring at RT 
for 3 h. Once complete, the reaction mixture was partitioned between an aqueous saturated 
NaHCO3 solution and CH2Cl2 and extracted (25 mL x 3). The organic layers were separated, 
dried over MgSO4, filtered and concentrated under reduced pressure affording a brown 
residue which was purified by flash chromatography (5:95 EtOAc/Hexane). 
Compound 3.38 was obtained in 258 mg in 89% yield as a yellow/orange oil; Rf = 0.46 
(30:70, EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.01 (d, J = 8.5 Hz, 1H, ArH), 
6.80 (dd, J = 8.5, 2.6 Hz, 1H, ArH), 6.70 (d, J = 2.6 Hz, 1H, ArH), 4.61 (s, 2H, ArCH2N), 3.88 
– 3.65 (m, 5H, overlapping signals−OCH3 and CH2), 2.96 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CDCl3, no C−F coupling was clearly visible): δ (ppm) 29.41 (ArCH2CH2), 
44.59 (CH2), 47.46 (ArCH2N), 55.59 (OCH3), 113.47 (ArCH), 114.02 (ArCH), 122.56 (ArCH), 
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8.6.4 General procedure for the synthesis of 2−[(trifluoromethyl)sulfonyl]−1,2,3,4− 
tetrahydroisoquinolin−6−ol 3.34 
According to the general procedure described by McOmie and 
co−workers,121 a solution of the sulfonamide 3.38 (250 mg, 0.850 
mmol) in anhydrous CH2Cl2 (0.90 mL) was added at −78 ̊C to a 
solution of 1 M boron tribromide (BBr3) (0.730 mL, 7.75 mmol) in anhydrous CH2Cl2 (7.30 
mL). The reaction mixture was stirred at RT overnight and then quenched with water (15 
mL) at 0 ̊C hydrolysing excess BBr3 and boron complexes, and finally extracted with CH2Cl2 
(25 mL x 3). The organic layers were combined, dried over MgSO4, filtered and concentrated 
under reduced pressure yielding compound 3.34 in 80 – 95% yield as an orange−brown oil; 
Rf = 0.20 (100% EtOAc). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.02 – 6.84 (m, 1H, ArH), 6.79 
– 6.56 (m, 2H, 2xArH), 6.33 (s, 1H, ArH), 4.57 (brs, 1H, OH), 3.72 (s, 2H, ArCH2N), 3.00 (s, 
2H, ArCH2CH2), 2.95 – 2.86 (m, 2H, CH2). 13C NMR (101 MHz, CDCl3, C−F coupling was 
not clearly visible): δ (ppm) 29.15 (ArCH2), 44.55 (CH2CH2N), 47.47 (CH2), 114.67 (ArCH), 
115.66 (ArCH), 122.79 (ArCH), 127.48 (ArC), 134.34 (ArC), 155.30 (ArCOH). 
 
8.7 Synthesis of the C4 analogues of 
2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydro− isoquinolin−6−ol analogues 3.49 
8.7.1 General alkylation procedure for 2−(3−methoxyphenyl)acetonitrile 3.47a – d 
According to the general procedure described by Melvin and 
co−workers,122 a solution of 2−(3−methoxyphenyl) 
acetonitrile 3.46 (263 mg, 0.250 mL, 1.79 mmol) in 
anhydrous DMF (5.0 mL) was added to a cooled (3 ̊C) 60% 
suspension of NaH in mineral oil (180 mg, 7.50 mmol) in 
anhydrous DMF (5.0 mL). The resulting mixture was stirred for 30 min providing a red 
coloured mixture. The haloalkanes, viz., 1,2−dibromoethane (0.230 mL, 2.68 mmol), 
iodomethane (1.33 mL, 21.5 mmol), 1,3−bromoethane (1.33 mL, 21.5 mmol) and 
1,3−dibromopropane (0.230 mL, 2.68 mmol) were added, followed by stirring at RT for 16 
h. Once complete, the mixture was treated with an aqueous saturated NH4Cl solution (20 
mL) and further extracted with EtOAc (20 mL x 3). The organic layers were dried with 
MgSO4, filtered and concentrated under reduced pressure providing a residue. Purification 
of the residue was performed with flash chromatography (5:95 EtOAc/Hexane), yielding 
products 3.47a – d as oils, characterization of which are described below: 
 
Stellenbosch University  https://scholar.sun.ac.za




1−(3−Methoxyphenyl)cyclopropane carbonitrile 3.47a was obtained in 86% (273 mg) 
yield from 263 mg of starting material 3.46. Yellow oil; Rf = 0.30 (20:80 
EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.47 (d, J = 7.8 
Hz, 1H, ArH), 7.07 – 7.00 (m, 3H, ArH), 4.01 (s, 3H, OCH3), 1.93 – 1.88 (m, 2H, CH2), 1.62 
– 1.57 (m, 2H, CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 13.97 (C), 18.33 (2xCH2−spiro 
cyclopropyl), 55.45 (OCH3), 112.02 (ArCH), 113.00 (ArCH), 117.96 (CN), 122.65 (ArCH), 
130.09 (ArCH), 137.73 (ArC), 160.11 (ArCOMe). The experimental spectroscopic 
information, was similar to the literature spectroscopic information reported by O’Niel and 
co−workers.200 
 
2−(3−Methoxyphenyl)−2−methylpropane nitrile 3.47b was obtained in quantitative (125 
mg) yield from 263 mg of starting material 3.46. Colourless oil; Rf = 
0.60 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.33 
– 7.17 (m, 1H, ArH), 7.06 – 6.92 (m, 2H, 2xArH), 6.80 – 6.78 (m, 1H, 
ArH), 3.78 (s, 3H, OCH3), 1.67 (s, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.26 
(C), 37.31 (2xCH3), 55.47 (OCH3), 111.63 (ArCH), 112.86 (ArCH), 117.46 (ArCH), 126.61 
(CN), 130.12 (ArCH), 143.18 (ArC), 160.06 (ArCOMe). The experimental spectroscopic 
information, was similar to the literature spectroscopic information reported by Zacheis and 
co−workers.146 
 
2−Ethyl−2−(3−methoxyphenyl)butane nitrile 3.47c was obtained in 77% (212 mg) yield 
from 263 mg of starting material 3.46. Translucent oil; Rf = 0.57 (20:80 
CH2Cl2/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.29 – 7.22 (m, 
1H, ArH), 6.95 – 6.78 (m, 3H, 3xArH), 3.79 (s, 3H, OCH3), 2.03 – 1.82 
(m, 4H, 2xCH2), 0.880 (t, J = 7.50 Hz, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3, it is important 
to note one ArC not visible): δ (ppm) 10.02 (C), 34.14 (2xCH3), 50.18 (2xCH2), 55.59 (OCH3), 
112.84 (ArCH), 118.74 (ArCH), 122.58 (CN), 130.11 (ArCH), 140.06 (ArCH), 160.20 
(ArCOMe). 
 
1−(3−Methoxyphenyl)cyclobutene carbonitrile 3.47d was obtained in 81% (656 mg) yield 
from 263 mg of starting material 3.46. Yellow oil; Rf = 0.52 (100% 
Hexane). The crude compound was used in generating the 1H− and 
13C− NMR spectra. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.23 – 7.16 
(m, 1H, ArH), 6.93 – 6.80 (m, 2H, 2xArH), 6.78 – 6.69 (m, 1H, ArH), 3.73 (s, 3H, OCH3), 
2.77 – 2.61 (m, 2H, CH2), 2.58 – 2.40 (m, 2H, CH2), 2.30 – 2.07 (m, 2H, CH2). 13C NMR (75 
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MHz, CDCl3): δ (ppm) 17.16 (C), 29.81 (CH2), 34.67 (CH2), 40.26 (CH2), 55.38 (OCH3), 
111.81 (ArCH), 113.06 (ArCH), 117.86 (ArCH), 124.43 (CN), 130.10 (ArCH), 141.44 (ArC), 
160.10 (ArCOMe). 
 
8.7.2 General procedure for the reduction of nitriles 3.47a – d 
The general reduction procedure described by Nystrom, Davis and 
co−workers,123,124 was as follows. Lithium aluminium hydride (LiAlH4) 
(41.0 mg, 1.07 mmol) was suspended in anhydrous THF (30 mL) and 
cooled to −3 ̊C in an ice bath. Aluminium chloride (AlCl3) (140 mg, 
1.07 mmol) was then carefully added in small portions while 
maintaining the temperature at −3 ̊C. The resulting hydride (AlH2Cl) suspension was stirred 
at RT for 30 min, to which the nitrile derivatives 3.47a – d (0.713 mmol) in THF (4.0 mL) 
were added. The reaction mixture was stirred under reflux for 5 h, cooled to RT and carefully 
treated with water until no further effervescence occurred. The white solid (lithium aluminate) 
was separated by vacuum filtration and the filtrate extracted with EtOAc (20 mL x 2). The 
organic layers were combined, dried over MgSO4, filtered and concentrated under reduced 
pressure to give the corresponding amines 3.50a – d, as oils with no further purification 
required. The amine characteristics are described below: 
 
1−[(3−Methoxyphenyl)cyclopropyl]methanamine 3.50a was obtained in 93% (161 mg) 
yield from ~123 mg of starting material 3.47a. Yellow oil. 1H NMR 
(300MHz, CDCl3, no amine signal was visible): δ (ppm) 7.29 – 7.21 
(m, 1H, ArH), 6.98 – 6.88 (m, 2H, ArH), 6.78 (m, J = 8.2, 2.6, 1.0 Hz, 
1H, ArH), 3.82 (s, 3H, OCH3), 2.79 (s, 2H, CCH2NH2), 0.88 – 0.82 (m, 2H, CH2), 0.78 – 0.72 
(m, 2H, CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 11.95 (2xCH2), 29.67 (C), 52.22 (CCH2N), 
55.50 (OCH3), 111.84 (ArCH), 115.48 (ArCH), 121.93 (ArCH), 129.62 (ArCH), 145.45 (ArC), 
159.89 (ArCOMe). 
 
2−(3−Methoxyphenyl)−2−methylpropan−1−amine 3.50b was obtained in 81% (205 mg) 
yield from ~125 mg of starting material 3.47b. Yellow oil. 1H NMR 
(300MHz, CDCl3, no amine signal was visible): δ (ppm) 7.33 – 7.17 
(m, 1H, ArH), 6.98 – 6.75 (m, 3H, 3xArH), 3.81 (s, 3H, OCH3), 2.79 (s, 2H, CH2), 1.36 – 1.23 
(s, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3, not all quaternary carbon signals were visible): δ 
(ppm) 26.45 (2xCH3), 54.95 (CH2), 55.24 (OCH3), 110.43 (ArCH), 113.07 (ArCH), 118.77 
(ArCH), 129.33 (ArCH), 149.21 (ArC), 159.69 (ArCOMe). The experimental spectroscopic 
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information, was similar to the literature spectroscopic information reported by Johnson and 
co−workers.201 
 
2−[Ethyl−2−(3−methoxyphenyl)]butan−1−amine 3.50c was obtained in quantitative (140 
mg) yield from ~145 mg of starting material 3.47c. Yellow oil. 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.29 – 7.23 (m, 1H, ArH), 6.93 – 6.73 (m, 
3H, 3xArH), 3.82 (s, 3H, OCH3), 2.86 (s, 2H, CH2), 1.70 (q, J = 7.4 Hz, 
4H, 2xCH2), 0.95 (brs, 2H, NH2), 0.76 – 071 (m, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3): δ 
(ppm) 8.04 (2xCH3), 26.53 (2xCH2), 45.93 (C), 48.32 (CH2), 55.26 (OCH3), 110.18 (ArCH), 
113.99 (ArCH), 119.62 (ArCH), 129.17 (ArCH), 147.57 (ArC), 159.73 (ArCOMe). 
 
1−[(3−Methoxyphenyl)cyclobutyl]methanamine 3.50d was obtained in 54% (365 mg) 
yield from ~133 mg of starting material 3.47d. Yellow translucent oil. 
1H NMR (300 MHz, CDCl3, no amine signal was visible): δ (ppm) 7.20 
– 7.15 (m, 1H, ArH), 6.71 – 6.53 (m, 3H, 3xArH), 3.78 – 3.69 (s, 3H, 
OCH3), 2.85 (s, 2H, CH2), 2.34 – 2.16 (m, 2H, CH2), 2.13 – 1.91 (m, 4H, 2xCH2). 13C NMR 
(75 MHz, CDCl3, not all quaternary carbon signals were visible): δ (ppm) 15.87 (CH2), 30.52 
(CH2), 52.68 (CH2), 55.26 (OCH3), 110.68 (ArCH), 112.19 (ArCH), 118.50 (ArCH), 129.20 
(ArCH), 144.00 (ArC), 146.00 (ArC), 159.59 (ArCOMe). 
 
8.7.3 General procedure for the synthesis of 3.51a – d 
The general procedure described by Zhong and co−workers,119 was implemented for the 
synthesis of the aminal dimers 3.50a – d. A solution of 37% aqueous formaldehyde (1.00 
mL, 13.0 mmol) was added to a solution of 3.50a – d (0.500 mL, 3.31 mmol) in 1 N aqueous 
HCl solution (5.00 mL, 4.96 mmol). The mixture was heated and stirred at 60 ̊C for 4 h. This 
was followed by the mixture being cooled to 0 ̊C and neutralized by the slow addition of a 
50% aqueous NaOH solution (1.03 mL, 5.62 mmol). The resulting heavy suspension was 
extracted using EtOAc (20 mL x 2) providing compounds 3.51a – d, which were directly 
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8.7.4 General procedure for the synthesis of THIQ hydrochloride salts 3.52a – d 
The general procedure described by Zhong and 
co−workers,119 was implemented for the synthesis of 
3.52a – d. Aminal dimers 3.51a – d (2.00 mmol) were 
suspended in IPA (4.20 mL, 5.50 mmol), to which a 
concentrated aqueous 11 M HCl solution (0.420 mL, 
4.60 mmol) was slowly added with a slight exotherm being noted. Addition of the aqueous 
HCl solution resulted in a colour change, after which a solid precipitated. The resulting 
suspension was stirred at RT for 18 h. MTBE (1.00 mL per mmol of dimer) was added and 
the resulting mixture and left to stir for an additional 4 h. The solid was collected by vacuum 
filtration providing products 3.52a – d which were washed with a 1:1 ratio of IPA/MTBE and 
air dried to yield amorphous powders that are described below: 
 
6ˈ−Methoxy−2ˈ,3ˈ−dihydro−1ˈH−spiro(cyclopropane−1,4ˈ−isoquinoline) 
hydrochloride 3.52a was obtained in quantitative (170 mg) yield 
from 159 mg of starting material 3.51a. White solid; Rf = 0.00 
(100% EtOAc). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 9.78 (brs, 
2H, NH2), 7.12 (d, J = 8.5 Hz, 1H, ArH), 6.78 (dd, J = 8.5, 2.5 Hz, 1H, ArH), 6.34 (d, J = 2.5 
Hz, 1H, ArH), 4.25 (s, 2H, ArCH2N), 3.72 (s, 3H, OCH3), 3.17 (s, 2H, CH2), 1.11 – 1.07 (m, 
4H, CH2−CH2). 13C NMR (75 MHz, DMSO−d6): δ (ppm) 16.49 (CH2), 16.95 (CH2), 44.35 (C), 
48.82 (OCH3), 55.28 (ArCH2N), 106.89 (ArCH), 112.13 (ArCH), 121.25 (ArCH), 127.77 
(ArC), 138.91 (ArC), 159.27 (ArCOMe). HRMS ESI+: m/z [M−36.4609]+ calcd for C12H15NO, 
190.1232; found, 190.1243 (5.80 ppm). 
 
6−Methoxy−4,4−dimethyl−1,2,3,4−tetrahydroisoquinoline hydrochloride 3.52b was 
obtained in quantitative (457 mg) yield from 426 mg of starting 
material 3.51b. White solid; Rf = 0.00 (100% EtOAc). 1H NMR (300 
MHz, DMSO−d6): δ (ppm) 9.63 (brs, 2H, NH2), 7.12 (d, J = 8.6 Hz, 
1H, ArH), 6.97 (d, J = 2.5 Hz, 1H, ArH), 6.83 (dd, J = 8.6, 2.5 Hz, 1H, ArH), 4.15 (s, 2H, 
ArCH2N), 3.77 (s, 3H, OCH3), 3.14 (s, 2H, CH2), 1.35 (s, 6H, 2xCH3). 13C NMR (75 MHz, 
DMSO−d6): δ (ppm) 25.60 (2xCH3), 28.82 (C), 32.92 (CH2), 44.07 (OCH3), 55.32 (ArCH2N), 
111.26 (ArCH), 112.81 (ArCH), 119.47 (ArCH), 127.95 (ArC), 142.68 (ArC), 159.06 
(ArCOMe). HRMS ESI+: m/z [M−36.4609]+ calcd for C12H18NO, 192.1388; found, 192.1388 
(0.00 ppm). 
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4,4−Diethyl−6−methoxy−1,2,3,4−tetrahydroisoquinoline hydrochloride 3.52c was 
obtained in quantitative (400 mg) yield from 377 mg of starting 
material 3.51c. Brown powder; Rf = 0.00 (100% EtOAc). 1H NMR 
(300 MHz, DMSO−d6): δ (ppm) 9.62 (brs, 2H, NH2), 7.13 (d, J = 7.5 
Hz, 1H, ArH), 6.84 – 6.80 (m, 2H, 2xArH), 4.12 (s, 2H, ArCH2N), 3.75 (s, 3H, OCH3), 3.13 
(s, 2H, CH2), 1.89 – 1.84 (m, 2H, CH2), 1.68 – 1.60 (m, 2H, CH2), 0.74 (t, J = 7.4 Hz, 6H, 
2xCH3). 13C NMR (75 MHz, DMSO−d6): δ (ppm) 8.26 (2xCH3), 25.49 (CH2), 30.35 (C), 43.68 
(CH2), 45.34 (OCH3), 55.19 (ArCH2N), 111.80 (ArCH), 112.46 (ArCH), 120.74 (ArC), 127.98 
(ArCH), 140.15 (ArC), 158.67 (ArCOMe). HRMS ESI+: m/z [M−36.4609]+ calcd for 
C14H21NO, 220.1701; found, 220.1693 (3.60 ppm). 
 
6ˈ−Methoxy−2ˈ,3ˈ−dihydro−1ˈH−spiro(cyclobutane−1,4ˈ−isoquinoline)hydrochloride 
3.52d was obtained in quantitative (170 mg) yield from 159 mg of 
starting material 3.51d. Yellow oil; Rf = 0.00 (100% EtOAc). 1H NMR 
(300 MHz, DMSO−d6): δ (ppm) 9.73 (brs, 2H, NH2), 7.21 – 7.20 (m, 
2H, 2xArH), 6.85 (dd, J = 8.4, 2.5 Hz, 1H, ArH), 4.11 (s, 2H, CH2), 3.80 (s, 3H, OCH3), 3.43 
(brs, 2H, CH2), 2.40 – 2.36 (m, 2H, CH2), 2.19 – 2.16 (m, 4H, 2xCH2). 13C NMR (75 MHz, 
DMSO−d6): δ (ppm) 14.43 (CH2), 25.49 (CH2), 33.29 (CH2), 43.6 (C), 49.41 (CH2), 55.26 
(OCH3), 61.99 (ArCH2N), 111.10 (ArCH), 112.91 (ArCH), 119.91 (ArCH), 127.59 (ArC), 
141.31 (ArC), 159.16 (ArCOMe). HRMS ESI+: m/z [M−36.4609]+ calcd for C13H17NO, 
204.1344; found, 204.1384 (4.89 ppm). 
 
8.7.5 General procedure for the synthesis of trifluorosulfonamides 3.53a – d 
The general procedure described by Brunsveld40 Bailey120 and 
co−workers was implemented for sulfonation of 3.52a – d. A mixture 
of the analogues 3.52a – d (~0.878 mmol) and Et3N (0.490 mL, 3.50 
mmol) in anhydrous CH2Cl2 (20 mL) were stirred at RT for 30 min 
to ensure the complete solubilizing of the suspension. The resulting 
mixture was cooled to −40 ̊C, to which trifluoromethanesulfonic anhydride (0.160 mL, 0.966 
mmol) was slowly added. The mixture was stirred at −20 ̊C for an additional 2 h, followed by 
stirring at RT for 3 h with progress being monitored by TLC. After consumption of starting 
material, the reaction mixture was extracted with an aqueous 5 N HCl solution followed by 
CH2Cl2 (25 mL x 3). The organic layers were combined and further washed with an aqueous 
saturated NaHCO3 solution, followed by a final washing with a saturated brine solution. The 
organic layers were combined, dried with MgSO4 and concentrated under reduced pressure. 
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The residue was purified with flash chromatography (5:95 EtOAc/Hexane), yielding products 
as oils, which crystalized upon freezing with moderate yields. The characteristics of 
compounds 3.53a – d is described below: 
 
6ˈ−Methoxy−2ˈ−[(trifluoromethyl)sulfonyl]−2ˈ,3ˈ−dihydro−1ˈH−spirocyclopropane−1,
4ˈ−isoquinoline 3.53a was obtained in 69% (195 mg) yield from 
167 mg of starting material 3.52a. Brown oil; Rf = 0.62 (20:80 
EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.00 (d, J 
= 8.5 Hz, 1H, ArH), 6.74 (dd, J = 8.5, 2.5 Hz, 1H, ArH), 6.30 (d, J = 2.5 Hz, 1H, ArH), 4.70 
(brs, 2H, ArCH2N), 3.76 (s, 3H, OCH3), 3.51 (brs, 2H, CH2), 1.09 – 1.04 (m, 4H, 2xCH2). 13C 
NMR (101 MHz, CDCl3, C−F coupling was not clearly visible): δ (ppm) 20.18 (CH2−CH2), 
48.70 (CH2), 53.53 (CH2), 55.77 (OCH3), 108.22 (ArCH), 111.97 (ArCH), 123.85 (ArCH), 
127.28 (ArC), 139.79 (ArC), 159.77 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for 
C13H14F3NO3S, 322.0680; found, 290.2690 (101.54 ppm). The HRMS further confirmed the 
instability and decomposition of compound 5.53a and was not used in any further reactions. 
 
6−Methoxy−4,4−dimethyl−2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinoli
ne 3.53b was obtained in 86% (129 mg) yield from 89.2 mg of 
starting material 3.52b. Orange oil; Rf = 0.55 (20:80 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 6.98 (d, J = 
8.5 Hz, 1H, ArH), 6.88 (d, J = 2.6 Hz, 1H, ArH), 6.77 (d, J = 8.5 Hz, 2.6 Hz, 1H, ArH), 4.62 
(brs, 2H, ArCH2N), 3.81 (s, 3H, OCH3), 3.44 (brs, 2H, CH2), 1.35 (s, 6H, 2xCH3). 13C NMR 
(75 MHz, CDCl3, C−F coupling was not clearly visible): δ (ppm) 35.86 (2xCH3), 55.73 (CH2), 




3.53c was obtained in 70% (239 mg) yield from 214 mg of 
starting material 3.52c. Orange oil; Rf = 0.75 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 6.98 – 6.79 
(m, 1H, ArH), 6.77 – 6.60 (m, 2H, 2xArH), 4.49 (brs, 2H, 
ArCH2N), 3.71 (s, 3H, OCH3), 3.55 – 3.24 (m, 2H, CH2), 1.79 – 1.49 (m, 4H, 2xCH2), 0.820 
– 0.630 (m, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3, C−F coupling was not clearly visible): δ 
(ppm) 8.43 (CH3), 29.79 (CH2), 41.31 (CH2), 47.91 (C), 50.80 (CH2), 55.40 (OCH3), 112.74 
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(ArCH), 118.32 (ArCH), 122.73 (ArCH), 127.17 (ArC), 140.81 (ArC), 158.60 (ArCOMe). 
HRMS ESI+: m/z [M+H]+ calcd for C15H20F3NO3S, 350.1038; found, 350.1046 (2.30 ppm). 
 
6ˈ−Methoxy−2ˈ−[(trifluoromethyl)sulfonyl]−2ˈ,3ˈ−dihydro−1ˈH−spirocyclobutane−1,4ˈ
−isoquinoline 3.53d was obtained in 69% (194 mg) yield from 
171 mg of starting material 3.52d. Orange oil; Rf = 0.76 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.03 (d, J 
= 2.6 Hz, 1H, ArH), 6.87 (d, J = 8.5 Hz, 1H, ArH), 6.69 (dd, J = 
8.5, 2.6 Hz, 1H, ArH), 4.58 (brs, 2H, ArCH2N), 3.75 (s, 3H, OCH3), 2.38 – 2.07 (m, 6H, 
3xCH2). 13C NMR (75 MHz, CDCl3, C−F coupling was not clearly visible): δ (ppm) 15.12 
(CH2), 41.81 (CH2), 48.11 (CH2), 53.80 (CH2), 55.67 (OCH3), 111.87 (C), 112.55 (ArCH), 
120.75 (q, J = 322.5 Hz, CF3), 122.16 (ArCH), 127.16 (ArC), 142.41 (CF3), 159.60 
(ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C14H16F3NO3S, 336.0837; found, 336.1977 
(2.65 ppm). 
 
8.7.6 General procedure for the demethylation of aryl ethers 3.53a – d 
The general procedure described by McOmie and 
co−workers,121 was implemented for the demethylation of aryl 
methyl ethers 3.53a – d. Thus, a mixture of 1 M BBr3 (0.346 mL, 
3.65 mmol) in anhydrous CH2Cl2 (3.46 mL) was cooled to −40 ̊C, 
to which sulfonamide derivatives 3.53a – d (0.398 mmol) 
dissolved in anhydrous CH2Cl2 (0.90 mL), were slowly added and stirred at −40 ̊C for 2 h. 
The mixture was allowed to warm to RT and stirred for an additional 4 h. This was followed 
by quenching any excess BBr3 and boron complexes formed with water at 0 ̊C. Product was 
collected by extracting with CH2Cl2 (25 mL x 3), the organic solvent was dried over MgSO4, 
filtered and concentrated under reduced pressure. The spectroscopic details of compounds 
3.54b – d are described below: 
 
4,4−Dimethyl−2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol 3.49b 
was obtained in 85% (104 mg) yield from 127 mg of starting 
material 3.53b. Yellow oil; Rf = 0.43 (30:70 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 6.92 (d, J = 8.4 Hz, 1H, ArH), 6.83 
(d, J = 2.6 Hz, 1H, ArH), 6.70 (dd, J = 8.4, 2.6 Hz, 1H, ArH), 4.89 (brs, 1H, OH), 4.61 (s, 2H, 
ArCH2N), 3.44 (d, J = 6.6 Hz, 2H, CH2), 1.34 (s, 6H, 2xCH3). 13C NMR (75 MHz, CDCl3, no 
C−F coupling was clearly visible): δ (ppm) 35.43 (2xCH3), 48.21 (CH2), 56.09 (ArCH2N), 
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112.74 (ArCH), 114.45 (ArCH), 121.67 (C), 127.50 (ArCH), 144.10 (ArC), 155.16 (ArCOH). 
HRMS ESI+: m/z [M+H]+ calcd for C12H14F3NO3S, 310.0725; found, 310.0721 (1.3 ppm). 
 
4,4−Diethyl−2−[(trifluoromethyl)sulfonyl]−1,2,3,4−tetrahydroisoquinolin−6−ol 3.49c 
was obtained in 36% (83.9 mg) yield from 242 mg of starting material 
3.53c. Orange oil; Rf = 0.55 (30:70 EtOAc/Hexane). 1H NMR (300 
MHz, CDCl3): δ (ppm) 6.89 (d, J = 8.2 Hz, 1H, ArH), 6.71 (m, 2H, 
2xArH), 5.70 (brs, 1H, OH), 4.55 (brs, 2H, ArCH2N), 3.51 (brs, 2H, 
CH2), 1.86 – 1.78 (m, 2H, CH2), 1.66 – 1.59 (m, 2H, CH2), 0.740 (t, J = 7.5 Hz, 6H, 2xCH3). 
13C NMR (75 MHz, CDCl3, no C−F coupling was clearly visible): δ (ppm) 8.33 (2xCH3), 41.23 
(CH2), 47.96 (CH2), 50.75 (ArCH2N), 113.59 (ArCH), 114.09 (ArCH), 122.67 (ArCH), 127.36 
(ArC), 141.11 (ArC), 154.64 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C14H18F3NO3S, 
336.0881; found, 336.0881 (0.00 ppm). 
 
2ˈ−[(Trifluoromethyl)sulfonyl]−2ˈ,3ˈ−dihydro−1ˈH−spirocyclobutane−1,4ˈ−isoquinolin
−6ˈ−ol 3.49d was obtained in 65% (109 mg) yield from 175 mg of 
starting material 3.53d. Colourless oil; Rf = 0.53 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.00 (d, J = 
2.5 Hz, 1H, ArH), 6.83 (d, J = 8.3 Hz, 1H, ArH), 6.63 (dd, J = 8.3, 
2.5 Hz, 1H, ArH), 4.99 (brs, 1H, OH), 4.47 (brs, 2H, ArCH2N), 3.63 (s, 2H, CH2), 2.47 – 1.82 
[m, 6H, 3x(CH2)]. 13C NMR (75 MHz, CDCl3, no C−F coupling was clearly visible): δ (ppm) 
15.07 (CH2), 41.65 (CH2), 48.11 (CH2), 53.77 (ArCH2N), 112.86 (ArCH), 114.44 (ArCH), 
118.56 (q, J = 322.5 Hz, CF3), 122.24 (ArCH), 127.35 (ArC), 142.76 (ArC), 155.48 (ArCOH). 
HRMS ESI+: m/z [M+H]+ calcd for C13H14F3NO3S, 322.0646; found, 322.0706 (3.10 ppm). 
 
8.8 Synthesis of urea analogues 
8.8.1 General procedure for the synthesis of THIQ–carbamoyl imidazoles 
According to the general procedure described by 
Grzyb and co−workers,131 a cooled (0˚C) solution 
of 1,1ˈ−carbonyldiimidazole (350 mg, 2.20 mmol) 
in anhydrous CH3CN (25 mL) was treated with the 
THIQ (4.47 or 4.48) (2.00 mmol) and K2CO3 (4.00 
mmol). This was followed by overnight stirring at RT, which resulted in a yellow mixture. The 
mixture was concentrated under reduced pressure and the residue further purified with 
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column chromatography (100% EtOAc). The spectroscopic details of the compounds are 
described below: 
 
[3,4−Dihydroisoquinolin−2(1H)−yl](1H−imidazol−1−yl)methanone 4.49 was obtained in 
84% (307 mg) yield from 0.200 mL of starting material 4.47. Bright 
yellow solid; mp = 82 – 83 ̊C; Rf = 0.25 (100% EtOAc). 1H NMR (300 
MHz, CDCl3): δ (ppm) 7.86 (s, 1H, ArH), 7.25 – 6.97 (m, 6H, 6xArH), 
4.68 (s, 2H, ArCH2N), 3.75 (t, J = 6.0 Hz, 2H, CH2), 2.94 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CDCl3, not all aromatic signals were clearly visible): δ (ppm) 28.68 
(ArCH2CH2), 44.65 (CH2), 48.55 (ArCH2N), 117.99 (ArCH), 126.97 (ArCH), 127.43 (ArCH), 
129.00 (ArCH), 129.96 (ArC), 131.87 (ArCH), 133.80 (ArC), 136.93 (ArCH), 151.22 (C=O). 
HRMS ESI+: m/z [M+H]+ calcd for C13H13ON3, 228.1137; found, 228.1135 (0.90 ppm). The 
experimental spectroscopic information, was similar to that reported in the literature.131 
 
(1H−Imidazol−1−yl)[6−methoxy−3,4−dihydroisoquinolin−2(1H)−yl]methanone 4.50 
was obtained in 96% (449 mg) yield from 362 mg of starting 
material 4.48. Colourless oil; Rf = 0.31 (100% EtOAc). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.86 (d, J = 0.9 Hz, 1H, 
imidazole−ArH), 7.20 (d, J = 1.4 Hz, 1H, imidazole−ArH), 7.05 (d, J = 1.4 Hz, 1H, 
imidazole−ArH), 6.95 – 6.92 (m, J = 8.4 Hz, 1H, ArH), 6.71 – 6.64 (m, 2H, ArH), 4.61 (s, 2H, 
ArCH2N), 3.78 – 3.67 (m, 5H, overlapping signals−CH2 and OCH3), 2.90 (t, J = 6.0 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.11 (ArCH2CH2), 44.67 (CH2), 48.34 
(ArCH2N), 55.64 (OCH3), 113.32 (ArCH), 113.87 (ArCH), 118.17 (ArCH), 124.14 (ArC), 
127.59 (ArCH), 130.08 (ArCH), 135.29 (ArC), 137.11 (ArCH), 151.36 (C=O), 159.00 
(ArCOMe). 
 
8.8.2 General procedure for the synthesis of THIQ–carbamoyl imidazolium salts 
According to the general procedure 
described by Grzyb and co−workers,131 
iodomethane (MeI) (0.960 mL, 15.5 
mmol) was added to a suspension of 
the tetrahydroisoquinoline carbamoyl 
imidazole (4.49 and 4.50) (1.55 mmol) in anhydrous CH3CN (24 mL) and stirred overnight 
affording a precipitate. The solvent and excess MeI were removed under reduced pressure 
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to afford the product in quantitative yield as a solid iodium salt, with no further purification 
required. The spectroscopic details of the compounds are described below: 
 
1−[3,4 Dihydroisoquinolin−2(1H)−yl]carbonyl−3ˈ−methyl−1H−imidazol−3−ium iodide 
4.51 was obtained in quantitative (572 mg) yield from 353 mg of 
starting material 4.49. Bright yellow powder; mp = 166 – 168 ̊C; Rf 
= 0.00 (100% EtOAc). 1H NMR (400 MHz, DMSO−d6): δ (ppm) 8.79 
(s, 1H, imidazole−ArH), 7.27 (d, J = 1.8 Hz, 1H, ArH), 7.06 (d, J = 1.7 Hz, 1H, ArH), 6.41 (d, 
J = 6.6 Hz, 4H, 4xArH), 3.92 (s, 2H, ArCH2N), 3.11 (s, 3H, imidazole−CH3), 2.90 (s, 2H, 
CH2), 2.14 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (101 MHz, DMSO−d6, not all methylene 
signals were visible as two were hidden in the DMSO signal): δ (ppm) 36.46 (ArCH2CH2), 
121.07 (ArCH), 123.72 (ArCH), 126.50 (ArCH), 127.02 (ArCH), 128.45 (ArC), 131.86 
(ArCH), 134.19 (ArCH), 137.78 (ArC), 147.22 (C=O). HRMS ESI+: m/z [M−126.9045]+ calcd 
for C14H16IN3O, 242.1293; found, 242.1284 (3.7 ppm). 
 
1−(6−Methoxy−1,2,3,4−tetrahydroisoquinoline−2−carbonyl)−3ˈ−methyl−1H−imidazol
−3−ium 4.52 was obtained in quantitative (1.16 g) yield from 
748 mg of starting material 4.50. Off white solid; mp = 172 – 
173 ̊C; Rf = 0.00 (100% EtOAc). 1H NMR (300 MHz, 
DMSO−d6): δ (ppm) 9.62 (s, 1H, imidazole−ArH), 8.10 – 8.09 (m, 1H, imidazole−ArH), 7.89 
– 7.88 (m, 1H, ArH), 7.13 (brs, 1H, ArH), 6.84 – 6.81 (m, 2H, 2xArH), 4.67 (s, 2H, ArCH2N), 
3.94 (s, 3H, imidazole−CH3), 3.75 – 3.68 (m, 5H, overlapping signals−OCH3 and CH2), 2.95 
(t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, DMSO−d6, no methylene, methyl and one 
ArC signals were not visible): δ (ppm) 55.33 (OCH3), 112.85 (ArCH), 113.22 (ArCH), 121.14 
(ArC), 123.79 (ArCH), 127.59 (ArCH), 135.66 (ArC), 137.84 (ArCH), 147.26 (C=O), 158.33 
(ArCOMe). 
 
8.8.3 Coupling of THIQ – carbamoyl imidazolium salts with heteroaryls amines 
8.8.3.1 General procedure for the synthesis of compound 4.54 
According to the general 
procedure described by Grzyb and 
co−workers,131 a combined 
mixture of 2−amino−4−methyl 
thiazole (120 mg, 1.08 mmol), and 
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Et3N (0.150 mL, 1.08 mmol) in anhydrous CH3CN (15 mL) were stirred at RT for 30 min. 
Subsequently, the tetrahydroisoquinoline carbamoyl imidazolium salts (4.51 or 4.52) (0.542 
mmol) were then added. The work−up procedure included washing of the reaction mixture 
with an aqueous 1 N HCl solution (50 mL x 2) followed by an extraction with EtOAc (20 mL 
x 2). The organic layers were combined, dried over MgSO4, filtered and concentrated under 
reduced pressure providing oily residues. The residues were purified using column 
chromatography (50:50 EtOAc/Hexane). The spectroscopic details of the compounds are 
described below: 
 
N−(4ˈ−Methylthiazol−2−yl)−3,4−dihydroisoquinoline−2(1H)−carboxamide 4.53a was 
obtained in 44% (53.5 mg) yield from 164 mg of starting material 
4.51. Bright yellow foam/powder; Rf = 0.48 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.18 – 7.01 
(m, 4H, 4xArH), 6.38 (s, 1H, thiazole−ArH), 4.61 (s, 2H, ArCH2N), 3.70 (t, J = 5.9 Hz, 2H, 
CH2), 2.85 (t, J = 5.9 Hz, 2H, ArCH2CH2), 2.26 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, 
CDCl3, one ArC signal was not visible): δ (ppm) 16.69 (thiazole−CH3), 28.80 (ArCH2CH2), 
41.61 (CH2), 45.82 (ArCH2N), 106.98 (ArCH), 126.51 (ArCH), 126.93 (ArCH), 128.52 




4.54a was obtained in 80% (203 mg) yield from 334 mg of 
starting material 4.52. Orange oil; Rf = 0.39 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 6.95 (d, 
J = 8.4 Hz, 1H, ArH), 6.75 (dd, J = 8.4, 2.5 Hz, 1H, ArH), 6.66 
(d, J = 2.5 Hz, 1H, ArH), 6.39 (s, 1H, thiazole−ArH), 4.55 (s, 2H, ArCH2N), 3.78 (s, 3H, 
OCH3), 3.70 (t, J = 5.9 Hz, 2H, CH2), 2.84 (t, J = 5.9 Hz, 2H, ArCH2CH2), 2.27 (s, 3H, 
thiazole−CH3). 13C NMR (75 MHz, CDCl3, one ArC signal was not visible): δ (ppm) 16.81 
(thiazole−CH3), 29.14 (ArCH2CH2), 41.50 (CH2), 45.34 (ArCH2N), 55.41 (OCH3), 107.07 
(ArCH), 112.76 (ArCH), 113.40 (ArCH), 124.75 (ArC), 127.45 (ArCH), 135.87 (ArCNH), 
154.54 (C=O), 158.54 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C15H17N3O2S, 
304.1120; found, 304.1111 (3.00 ppm). 
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8.8.3.2 General procedure for the synthesis of compounds 4.54 
The general procedure described by Grzyb and co−workers131 was followed. A suspension 
of 2−amino−5−nitrothiazole (100 mg, 0.714 mmol), and Cs2CO3 (310 mg, 0.952 mmol) in 
anhydrous CH3CN (20 mL) was stirred at RT for 30 min, to which the tetrahydroisoquinoline 
imidazolium salt 4.52 (190 mg, 0.476 mmol) was added. The work−up procedure included 
rinsing of the reaction mixture with an aqueous 1 N HCl solution (15 mL x 2), followed by an 
EtOAc extraction (25 mL x 2). The organic layers were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure affording a solid residue. The residue was purified 
using column chromatography (30:70 EtOAc/Hexane). The spectroscopic details of the 
compounds are described below: 
 
6−Methoxy−N−(5ˈ−nitrothiazol−2−yl)−3,4−dihydroisoquinoline−2(1H)−carboxamide 
4.54b was obtained in 90% (90.0 mg) yield from 119 mg 
of starting material 4.52. Yellow powder; Rf = 0.50 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 
12.17 (s, 1H, NH), 8.58 (s, 1H, thiazole−ArH), 7.10 (d, J = 8.4 Hz, 1H, ArH), 6.89 – 6.67 (m, 
2H, 2xArH), 4.64 (s, 2H, ArCH2N), 3.89 – 3.62 (m, 5H, overlapping signals−OCH3 and CH2), 
2.84 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, DMSO−d6): δ (ppm) 28.31 
(ArCH2CH2), 41.53 (CH2), 44.95 (ArCH2N), 55.05 (OCH3), 112.50 (ArCH), 113.17 (ArCH), 
124.89 (ArCH), 127.23 (ArCH), 135.65 (ArC), 140.53 (ArCH), 142.10 (ArCNH), 153.84 
(C=O), 157.90 (ArCOMe), 165.54 (ArCNO2). HRMS ESI+: m/z [M+H]+ calcd for 
C14H14N4O4S, 335.0814; found, 335.0805 (2.7 ppm). 
 
6−[Benzyloxy−3,4−dihydroisoquinolin−2(1H)−yl(morpholino)]methanone 4.54h was 
obtained in 96% (260 mg) yield from 365 mg of starting 
material. White oil solidified at low temperatures; Rf = 0.48 
(100% EtOAc). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.39 
– 7.15 (m, 5H, 5xBnH), 6.93 (d, J = 8.4 Hz, 1H, ArH), 6.80 
– 6.62 (m, 2H, 2xArH), 4.96 (s, 2H, ArCH2O), 4.31 (s, 2H, ArCH2N), 3.74 – 3.53 (m, 4H, 
morpholine−2xOCH2), 3.42 (t, J = 5.8 Hz, 2H, CH2), 3.29 – 3.13 (m, 4H, 
morpholine−2xNCH2), 2.79 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ 
(ppm) 29.00 (ArCH2CH2), 44.49 (morpholine−2xNCH2), 47.41 (CH2), 48.44 (ArCH2N), 66.78 
(morpholine−2xCH2O), 70.15 (BnCH2O), 113.46 (ArCH), 114.71 (ArCH), 126.13 (ArC), 
127.42 (ArCH), 128.04 (ArCH), 128.68 (ArCH), 135.92 (ArC), 137.10 (BnC), 157.49 (C=O), 
Stellenbosch University  https://scholar.sun.ac.za




164.03 (ArCOBn). HRMS ESI+: m/z [M+H]+ calcd for C21H24N2O3, 353.1865; found, 
353.1866 (0.30 ppm). 
 
8.8.3.3 General procedure for the synthesis of compounds 4.54c – g 
The general procedure described by Grzyb and 
co−workers,131 was implemented as follows. A cooled (−78 ̊C) 
solution of the aniline analogues (c – g) (80.0 mg, 0.649 
mmol), 1.4 M nBuLi (0.690 mL, 0.974 mmol) in anhydrous THF 
(15 mL) was stirred for 1 h at −78 ̊C. The temperature was 
gradually allowed to increase to RT. Compound 4.52 (310 mg, 0.779 mmol) was then added 
and the reaction mixture was stirred at RT overnight. The work−up procedure involved a 
wash with an aqueous 1 N HCl solution (10 mL x 2), followed by an extraction with EtOAc 
(20 mL x 2). The organic layers were combined, dried over MgSO4, filtered and concentrated 
under reduced pressure affording a residue which was purified by column chromatography 
(50:50 EtOAc/Hexane). The spectroscopic details of the compounds are described below: 
 
N−[Benzo(d)thiazol−2−yl]−3,4−dihydroisoquinoline−2(1H)−carboxamide was obtained 
in 60% (102 mg) yield from 219 mg of starting material 4.51. 
White solid; mp = 180 – 182 ̊C; Rf = 0.56 (50:50 EtOAc/Hexane). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.77 (d, J = 7.7 Hz, 1H, 
benzothiazole−ArH), 7.62 (d, J = 7.7 Hz, 1H, 
benzothiazole−ArH), 7.37 (d, J = 7.7 Hz, 1H, benzothiazole−ArH), 7.31 – 7.09 (m, 2H, 
2xArH), 7.01 (s, 1H, ArH), 4.69 (s, 2H, ArCH2N), 3.78 (t, J = 5.9 Hz, 2H, CH2), 2.89 (t, J = 
5.9 Hz, 2H, ArCH2CH2). 13C NMR (101 MHz, CDCl3): δ (ppm) 29.02 (ArCH2CH2), 42.02 
(CH2), 45.87 (ArCH2N), 121.76 (benzothiazole−ArCH), 123.62 (benzothiazole−ArCH), 
126.38 (benzothiazole−ArCH), 126.61 (ArCH), 126.90 (ArCH), 127.23 (ArCH), 128.71 
(ArCH), 134.68 (ArCNH). HRMS ESI+: m/z [M+H]+ calcd for C14H14N4O4S, 310.0969; found, 
310.1017 (3.22 ppm). 
 
6−Methoxy−N−(4ˈ−methoxyphenyl)−3,4−dihydroisoquinoline−2(1H)−carboxamide 
4.54c was obtained in 98% (270 mg) yield from 352 mg 
of starting material 4.52. Brown oil; Rf = 0.50 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 
7.30 – 7.14 (m, 2H, 2xArH), 6.99 (d, J = 8.4 Hz, 1H, 
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ArH), 6.84 – 6.60 (m, 4H, 4xArH), 6.32 (s, 1H, NH), 4.52 (s, 2H, ArCH2N), 3.73 (s, 3H, 
OCH3), 3.74 (s, 3H, OCH3), 3.63 (t, J = 5.9 Hz, 2H, CH2), 2.82 (t, J = 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δ (ppm) 29.69 (ArCH2CH2), 41.68 (CH2), 45.58 (ArCH2N), 55.73 
(2xOCH3), 112.86 (ArCH), 113.59 (ArCH), 114.41 (ArCH), 122.85 (ArCH), 125.64 (ArCH), 




4.54d was obtained in 50% (70.0 mg) yield from 177 mg 
of starting material 4.52. Brown oil that solidified at low 
temperatures; Rf = 0.50 (50:50 EtOAc/Hexane). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.47 (dd, J = 1.9 Hz, 1H, ArH), 
7.31 – 7.07 (m, 2H, 2xArH), 7.06 – 6.90 (m, 2H, 2xArH), 6.85 – 6.61 (m, 3H, 2xArH and NH), 
4.55 (s, 2H, ArCH2N), 3.77 (s, 3H, OCH3), 3.65 (t, 6.0 Hz, 2H, CH2), 2.83 (t, J = 6.0 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.33 (ArCH2CH2), 41.60 (CH2), 45.39 
(ArCH2N), 55.42 (OCH3), 112.68 (ArCH), 113.38 (ArCH), 118.26 (ArCH), 120.27 (ArCH), 
123.09 (ArCH), 125.16 (ArCH), 127.40 (ArC), 129.83 (ArCH), 134.43 (ArC), 136.21 (ArCCl), 
140.52 (ArCNH), 154.90 (C=O), 158.52 (ArCOMe). HRMS ESI+ m/z [M+H]+ calcd for 
C17H17ClN2O2, 317.1057 (35Cl); found, 317.1052 (1.60 ppm) and 319.1027 (37Cl). 
 
N−(3ˈ−Fluorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−carboxamide 
4.54e was obtained in 98% (270 mg) yield from 366 mg of 
starting material 4.52. Brown oil that solidified at low 
temperatures; Rf = 0.50 (50:50 EtOAc/Hexane). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.38 – 7.18 (m, 1H, 1xArH), 
7.09 – 7.03 (m, 2H, 2xArH), 6.80 – 6.70 (m, 2H, 2xArH), 6.45 (s, 2H, NH), 4.62 (s, 2H, 
ArCH2N), 3.83 (s, 3H, OCH3), 3.70 (t, J = 5.8 Hz, 2H, CH2), 2.93 (t, J = 5.8 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3, some ArC signals were not observed): δ (ppm) 29.31 
(ArCH2CH2), 41.45 (CH2), 45.27 (ArCH2N), 55.33 (OCH3), 107.35 (ArCH), 109.52 (ArCH), 
112.64 (ArCH), 113.31 (ArCH), 114.86 (ArC), 127.33 (ArCH), 136.18 (ArCNH), 158.51 
(ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C17H17FN2O2, 301.1356 (18F); found, 301.1356 
(0.00 ppm) and 302.1383 (19F). 
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4.54f was obtained in 44% (53.0 mg) yield from 152 mg 
of starting material 4.52. Brown solid; mp = 105 – 107 ̊C; 
Rf = 0.50 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, 
CDCl3): δ (ppm) 7.40 – 7.19 (m, 4H, 4xArH), 7.06 (d, J = 8.4 Hz, 1H, ArH), 6.88 – 6.65 (m, 
2H, 2xArH), 6.45 (s, 1H, NH), 4.59 (s, 2H, ArCH2N), 3.80 (s, 3H, OCH3), 3.76 – 3.65 (m, 2H, 
CH2), 2.90 (t, J = 5.3 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, some ArC signals were 
not observed): δ (ppm) 29.68 (ArCH2CH2), 41.78 (CH2), 45.63 (ArCH2N), 55.69 (OCH3), 
112.99 (ArCH), 113.67 (ArCH), 121.53 (ArC), 125.14 (ArCH), 127.68 (ArCH), 129.21 (ArC), 
136.44 (ArCCl), 138.06 (ArCNH), 154.95 (ArCH), 155.21 (C=O), 158.38 (ArCOMe). HRMS 




4.46g was obtained in 81% (94.1 mg) yield from 154 mg 
of starting material 4.52. Brown solid; mp = 136 – 137 ̊C; 
Rf = 0.50 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, 
CDCl3): δ (ppm) 7.38 – 7.28 (m, 2H, 2xArH), 7.10 – 6.91 
(m, 3H, 3xArH), 6.83 – 6.68 (m, 2H, 2xArH), 6.43 (s, 1H, NH), 4.59 (s, 2H, ArCH2N), 3.80 
(s, 3H, OCH3), 3.70 (t, J = 5.9 Hz, 2H, CH2), 2.89 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR 
(75 MHz, CDCl3): δ (ppm) 29.70 (ArCH2CH2), 41.78 (CH2), 45.64 (ArCH2N), 55.71 (OCH3), 
112.98 (ArCH), 113.68 (ArCH), 115.81 (d, J = 22.5 Hz, ArCH−F), 122.48 (d, J = 7.7 Hz, 
ArCH−F), 125.49 (ArC), 127.70 (ArCH), 135.30 (ArC), 136.61 (ArCNH), 155.45 (C=O), 
157.56 (d, J = 67.5 Hz, ArC−F), 158.84 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for 
C17H17FN2O2, 302.1308 (18F); found, 302.1381 (3.30 ppm). 
 
8.9 Synthesis of thiourea analogues 
8.9.1 General procedure for the synthesis of [3,4−dihydroisoquinolin−2(1H)−yl] 
(1H−imidazol−1−yl)methanethione 
The general procedure described by Grzyb and 
co−workers131 was followed. Thus, a cooled 
(0 ̊C) diluted mixture of 
1,1ˈ−thiocarbonyldiimidazole (210 mg, 1.20 
mmol) in anhydrous CH3CN (100 mL) was 
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treated by the portion−wise addition of THIQ (4.47 or 4.48) (1.00 mmol) [in the case of the 
hydrochloric salt Et3N (0.420 mL, 3.00 mmol) was included] while maintaining a temperature 
of 0 ̊C for 2 h, followed by gradual heating to RT. Stirring was continued for 18 h. The 
reaction mixture was concentrated under reduced pressure to afford a residue which was 
purified with column chromatography (100% EtOAc), yielding product as an orange oil. It is 
important to note that in order to prevent the preferential formation of the dimer, the 
portion−wise addition of 4.47 or 4.48 was essential. The spectroscopic details of the 
compounds are described below: 
 
{[3,4−Dihydroisoquinolin−2(1H)−yl]1H−imidazol−1−yl}methanethione 4.55 was 
obtained in 86% (329 mg) yield from 213 mg of starting material 4.47. 
Yellow oil; Rf = 0.25 (100% EtOAc). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.88 – 7.79 (m, 1H, imidazole−ArH), 7.24 – 7.11 (m, 4H, 
4xArH), 7.07 – 6.96 (m, 2H, imidazole−2xArH), 4.88 (s, 2H, ArCH2N), 4.00 (t, J = 5.8 Hz, 
2H, CH2), 2.99 (t, J = 5.8 Hz, 2H, ArCH2CH2). No 13C NMR was reported since, the spectrum 
corresponded well with that described by Grzyb and co–workers.131 
 
(1H−Imidazol−1−yl)[6−methoxy−3,4−dihydroisoquinolin−2(1H)−yl]methanethione 
4.56 was obtained in quantitative (754 mg) yield from 550 mg 
of starting material 4.48. Yellow oil; Rf = 0.21 (100% EtOAc). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 7.92 – 7.83 (m, 1H, 
imidazole−ArH), 7.26 – 7.19 (m, 1H, imidazole−ArCH), 7.08 (dd, J = 1.4, 0.9 Hz, 1H, 
imidazole−ArH), 6.98 (s, 1H, ArH), 6.84 – 6.67 (m, 2H, 2xArH), 4.85 (s, 2H, ArCH2N), 4.00 
(d, J = 7.2 Hz, 2H, CH2), 3.78 (s, 3H, OCH3), 3.01 (t, J = 5.6 Hz, 2H, ArCH2CH2). 13C NMR 
(75 MHz, CDCl3, one of the methylene and ArC signals were not visible): δ (ppm) 49.95 
(ArCH2CH2), 53.25 (CH2), 55.42 (OCH3), 113.13 (ArCH), 113.35 (ArCH), 119.29 
(imidazole−ArCH), 123.52 (ArC), 127.40 (ArCH), 129.87 (ArC), 137.23 (imidazole−ArCH), 
159.01 (ArCOMe), 178.24 (C=S). 
 
8.9.2 General procedure for the synthesis of 1−[3,4 dihydroisoquinolin−2(1H)−yl]− 
3ˈ− methyl−1H−imidazole−3−ium iodide 
The general procedure described by Grzyb and co−worker131 was 
employed. Thus, a solution of 4.55 (110 mg, 0.400 mmol) in 
anhydrous CH3CN (24.0 mL) was treated with MeI (0.200 mL, 3.32 
mmol) and stirred at RT overnight. The reaction mixture was concentrated under reduced 
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pressure affording a brown froth in quantitative yields and was used as such without further 
purification. 
Compound 4.50 was obtained in 80% (139 mg) yield. Yellow froth; Rf = 0.00 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.87 (s, 1H, imidazole−ArH), 7.25 (dd, J = 10.5, 0.4 Hz, 
1H, imidazole−ArH), 7.08 (s, 1H, imidazole−ArH), 6.99 (s, 1H, ArH), 6.84 – 6.66 (m, 2H, 
2xArH), 4.85 (s, 2H, ArCH2N), 3.99 (d, 2H, CH2), 3.77 (s, 3H, imidazole−CH3), 3.01 (d, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3, one ArC signal was visible): δ (ppm) 28.65 
(imidazole−CH3), 49.73 (ArCH2CH2), 53.02 (CH2), 55.20 (ArCH2N), 113.01 
(imidazole−ArCH), 119.09 (ArCH), 123.31 (ArCH), 127.17 (ArCH), 129.62 (ArCH), 134.95 
(ArC), 137.04 (ArC), 158.76 (imidazole−NCHN), 177.93 (C=S). HRMS ESI+: m/z 
[M−126.9045]+ calcd for C14H16IN3S, 258.1060; found, 258.1068 (3.10 ppm). 
 
8.9.3 General procedure for the coupling of THIQ thiocarbamoyl imidazolium salts 
with heteroaryl amines 
The general procedure described 
by Grzyb and co−workers131 was 
adopted. Thus, a mixture of the 
heteroaryl amine derivatives (a, b, 
d, h) (0.578 mmol) and K2CO3 
(133 mg, 0.963 mmol) in anhydrous CH3CN (15 mL) was stirred for 30 min at RT, to which 
the tetrahydroisoquinoline imidazolium salt (4.58 or 4.59) (4.81 mmol) was added. The 
reaction mixture was stirred at RT (however, for 2−amino−5−nitrothiazole the reaction was 
stirred at 120 ̊C) for 24 – 48 h (and monitored with TLC). The work−up procedure included 
partitioning of the reaction mixture between an aqueous 1 N HCl solution (15 mL x 2) and 
EtOAc (20 mL x 2). The organic layers were combined, dried over MgSO4, filtered and 
concentrated under reduced pressure providing a residue, purified with column 




was obtained in 40% (80.0 mg) yield from 258 mg of starting 
material 4.58. Yellow oil; Rf = 0.73 (20:80 EtOAc/Hexane). 1H 
NMR (300 MHz, DMSO−d6): δ (ppm) 12.45 (brs, 1H, NH), 7.19 
(s, 4H, 4xArH), 6.32 (s, 1H, thiazole−ArH), 5.15 (s, 2H, ArCH2N), 4.22 (t, J = 5.9 Hz, 2H, 
CH2), 2.87 (t, J = 5.9 Hz, 2H, ArCH2CH2), 2.17 (s, 3H, thiazole−CH3). 
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ide 4.61a was obtained in 80% (184 mg) yield from 284 mg 
of starting material 4.59. Orange oil; Rf = 0.63 (40:60 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 12.42 
(s, 1H, NH), 7.08 (d, J = 7.3 Hz, 1H, ArH), 6.86 – 6.67 (m, 2H, 2xArH), 6.30 (s, 1H, 
thiazole−ArH), 5.05 (s, 2H, ArCH2N), 4.18 (t, J = 5.9 Hz, 2H, CH2), 3.72 (s, 3H, OCH3), 2.83 
(t, J = 5.9 Hz, 2H, ArCH2CH2), 2.16 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, CDCl3, two 
extra signals were visible in the aromatic region): δ (ppm) 29.20 (thiazole−CH3), 46.71 
(ArCH2CH2), 50.04 (CH2), 55.45 (ArCH2N), 55.49 (OCH3), 112.66 (ArCH), 113.06 (ArCH), 
114.10 (ArCH), 124.99 (ArC), 127.36 (ArCH), 127.56 (ArCH), 132.83 (ArCH), 136.42 (ArC), 
157.71 (thiazole−ArCNH), 158.75 (ArCOMe), 182.29 (C=S). HRMS ESI+: m/z [M+H]+ calcd 
for C15H17N3OS2, 320.0847; found, 320.0887 (3.13 ppm). 
 
N−(3ˈ−Chlorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.61d was obtained in 6% (14.0 mg) yield from 291 mg 
of starting material 4.59. White solid; mp = 184 – 186 ̊C; 
Rf = 0.20 (10:90 EtOAc/Hexane). 1H NMR (300 MHz, 
CDCl3): δ (ppm) 7.30 – 7.21 (m, 3H, 3xArH), 7.19 – 7.00 
(m, 4H, 4xArH), 6.86 – 6.68 (m, 2H, 2xArH), 4.86 (s, 2H, ArCH2N), 4.02 (t, J = 5.7 Hz, 2H, 
ArCH2N), 3.80 (s, 3H, OCH3), 2.96 (t, J = 5.7 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, 
one of the aromatic signals could not be detected): δ (ppm) 29.34 (ArCH2CH2), 47.45 (CH2), 
50.75 (ArCH2N), 55.73 (OCH3), 113.07 (ArCH), 113.44 (ArCH), 122.43 (ArC), 124.33 
(ArCH), 125.80 (ArCH), 127.81 (ArCH), 130.06 (ArCCl), 134.88 (ArCH), 136.42 (ArCH), 
141.46 (ArCNH), 158.98 (ArCOMe), 183.48 (C=S). HRMS ESI+: m/z [M+H]+ calcd for 
C17H17ClN2OS, 333.0828 (35Cl); found, 333.0821 (2.10 ppm) and 335.0786 (37Cl). 
 
[6−Methoxy−3,4−dihydroisoquinolin−2(1H)−yl](morpholino)methanethione 4.61h was 
obtained in 65% (220 mg) yield from 480 mg of starting material 
4.59. Yellow oil; Rf = 0.25 (30:70 EtOAc/Hexane). 1H NMR (300 
MHz, CDCl3): δ (ppm) 7.01 (d, J = 8.4 Hz, 1H, ArH), 6.84 – 6.63 
(m, 2H, 2xArH), 4.66 (s, 2H, ArCH2N), 3.91 – 3.82 (m, 4H, 
morpholine−2xCH2N), 3.81 – 3.64 (m, 7H, overlapping signals− morpholine−2xCH2 and 
OCH3), 3.62 – 3.50 (m, 4H, morpholine−overlapping signals−CH2), 2.98 (t, J = 5.8 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 28.62 (ArCH2CH2), 49.07 (CH2), 51.86 
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(morpholine−NCH2), 52.82 (ArCH2N), 55.13 (OCH3), 66.30 (morpholine−CH2O), 112.55 
(ArCH), 113.18 (ArCH), 124.94 (ArCH), 126.98 (ArC), 135.59 (ArC), 158.29 (ArCOMe), 
193.69 (C=S). HRMS ESI+: m/z [M+H]+ calcd for C15H20N2O2S, 293.1279; found, 293.1324 
(3.41 ppm). 
 
8.9.4 Method A: General procedure for the synthesis of isothiocyanates 4.64 from 
hydroxy anilines 
According to the general procedure described by 
Munch and co−workers,114 the corresponding 
aniline derivatives (cˈ or cˈˈ) (200 mg, ~1.83 mmol) 
were dissolved in analytical grade EtOH (20 mL), to 
which an excess of carbon disulphide (1.10 mL, 6.32 
mmol) and Et3N (0.260 mL, 1.83 mmol) were added at RT. Upon stirring for 30 min a 
precipitate became visible. Di−tert−butyl dicarbonate (Boc2O) (380 mg, 1.76 mmol) and 
4−dimethylaminopyridine (DMAP) (67.0 mg, 0.550 mmol, 10.0 mol%) was then added to the 
reaction mixture and stirred for 30 min (whilst monitored by TLC). Once complete, the 
reaction mixture was concentrated under reduced pressure to afford the product in moderate 
yields. No further purification was performed, and the compounds were used as is in the 
next reaction. 
 
8.9.5 Method B: General procedure for the synthesis of isothiocyanates 4.64 from 
haloanilines 
According to the general procedure described by Wong and co−workers,145 the 
corresponding haloanilines (d – g) (200 mg, 1.83 mmol) were dissolved in anhydrous THF 
(20 mL), to which a 60% suspension of NaH in mineral oil (0.260 mL, 1.83 mmol) was added 
at 0 ̊C. The suspension was stirred at RT for 2 h, after which an excess of carbon disulphide 
(1.10 mL, 6.32 mmol) was added and stirring was continued for 24 h at RT. A precipitant 
was noted and tosyl chloride (380 mg, 1.76 mmol) was added. The reaction mixture was 
stirred overnight (whilst monitored by TLC). Once complete, the reaction mixture was 
quenched with an aqueous 1 N HCl (5.0 mL) solution and extracted with CH2Cl2 (15 mL x 
3). The organic layers were concentrated under reduced pressure and purified with column 
chromatography (100% Hexane). The spectroscopic details of the compounds are 
described below: 
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1−Chloro−3−isothiocyanatobenzene 4.64d was obtained in 34% (52.2 mg) yield from 
98.0 mg of starting material d. Colourless oil; Rf = 0.85 (100% Hexane). 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.89 (s, 1H, ArH), 7.57 – 6.98 (m, 
3H, 3xArH). 13C NMR (75 MHz, CDCl3): δ (ppm) 123.24 (ArCH), 125.24 (ArCH), 127.36 
(ArCH), 130.59 (ArCH), 135.09 (ArCN),138.02 (ArCCl), 179.79 (C=S). 
 
1−Fluoro−3−isothiocyanatobenzene 4.64e was obtained in 85% (150 mg) yield from 128 
mg of starting material e. colourless oil; Rf = 0.90 (100% Hexane). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.53 – 6.79 (m, 4H, 4xArH). 13C NMR (75 MHz, 
CDCl3, no C=S signal was visible): δ (ppm) 113.09 (d, J = 25.5 Hz, ArCH−F), 114.62 (d, J = 
21.00 Hz, ArCH−F), 121.73 (ArCH), 130.68 (ArCH), 130.81 (ArCH). 
 
1−Chloro−4−isothiocyanatobenzene 4.64f was obtained in 77% (200 mg) yield from 166 
mg of starting material f. Yellow transparent oil; Rf = 0.85 (100% Hexane). 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.34 (dd, J = 8.5, 1.6 Hz, 2H, 2xArH), 
7.22 – 7.12 (m, 2H, 2xArH). 13C NMR (75 MHz, CDCl3, no C=S signal was visible): δ (ppm) 
126.99 (ArCH), 129.88 (ArCH). 
 
1−Fluoro−4−isothiocyanatobenzene 4.64g was obtained in 36% (90.0 mg) yield from 181 
mg of starting material g. Yellow oil; Rf = 0.85 (100% Hexane). 1H NMR 
(300 MHz, CDCl3, ArC signal was not clearly visible): δ (ppm) 7.28 – 7.13 
(m, 2H, 2xArH), 7.11 – 6.97 (m, 2H, 2xArH). 13C NMR (75 MHz, CDCl3, no C=S signal was 
visible): δ (ppm) 116.48 (d, J = 23.25 Hz, ArCH−F), 127.13 (ArCH), 127.24 (ArCH). 
 
8.9.6 General procedure for the coupling of isothiocyanates 4.64 with 4.65 
The general procedure described by 
Ganellin and co−workers202 was adopted. 
Thus, a mixture of amines 4.48 or 4.65 
(~0.782 mmol), isothiocyanates (4.64) 
(140 mg, ~0.939 mmol) and Et3N (0.330 mL, 2.35 mmol) in anhydrous MeCN (10 mL) were 
stirred overnight at 80 C̊. The mixture was cooled to RT, partitioned between an aqueous 
saturated brine solution (5.0 mL) and EtOAc (20 mL x 2). The organic layers were combined, 
dried over MgSO4, concentrated under reduced pressure and the residue further purified 
using column chromatography (50:50 EtOAc/Hexane). The spectroscopic details of the 
compounds are described below: 
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4.66cˈ was obtained in 41% (110 mg) yield from 178 mg of 
starting material 4.48. White solid; mp = 220 – 222 ̊C; Rf = 
0.43 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, 
DMSO−d6): δ (ppm) 9.31 (d, J = 5.6 Hz, 2H, NH), 9.04 (s, 
1H, OH), 7.06 – 6.94 (m, 2H, 2xArH), 6.72 – 6.58 (m, 3H, 3xArH), 4.88 (s, 2H, ArCH2N), 
3.98 (t, J = 6.0 Hz, 2H, CH2), 2.85 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, 
DMSO−d6, ArC was not clearly visible): δ (ppm) 28.65 (ArCH2CH2), 46.05 (CH2), 49.62 
(ArCH2N), 113.76 (ArCH), 114.75 (ArCH), 124.26 (ArCNH), 127.45 (ArC), 128.21 (ArCH), 
132.58 (ArCH), 136.62 (ArC), 155.02 (ArCOH), 156.30 (ArCOH), 181.30 (C=S). HRMS ESI+: 
m/z [M+H]+ calcd for C16H16N2O2S, 301.1011; found, 301.1017 (2.00 ppm). 
 
6−Hydroxy−N−(3ˈ−hydroxyphenyl)−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.66c” was obtained in 39% (92.5 mg) yield from 157 mg of 
starting material 4.48. White solid; mp = 174 – 176 ̊C; Rf = 0.68 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6): δ 
(ppm) 9.31 (s, 1H, NH), 8.32 (s, 1H, OH), 7.44 – 7.29 (m, 2H, 
2xArH), 7.16 – 7.02 (m, 4H, 4xArH), 6.66 – 6.61 (m, 2H, 2xArH), 
4.68 (s, 2H, ArCH2N), 3.83 (t, J = 6.0 Hz, 2H, CH2), 2.88 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, DMSO−d6): δ (ppm) 28.04 (ArCH2CH2), 43.12 (CH2), 46.64 (ArCH2N), 
109.19 (ArCH), 114.00 (ArCH), 115.13 (ArCH), 116.01 (ArCH), 120.65 (ArCH), 123.03 
(ArCH), 124.25 (ArC), 127.61 (ArCH), 135.43 (ArC), 143.37 (ArCNH), 148.67 (ArCOH), 
156.23 (ArCOH), 162.07 (C=S). HRMS ESI+: m/z [M+H]+ calcd for C16H16N2O2S, 301.1011; 
found, 301.1023 (2.00 ppm). 
 
N−(3ˈ−Chlorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.66d was obtained in 6% (14.0 mg) yield from 140 mg of 
starting material 4.48. White solid; mp = 184 – 186 ̊C; Rf 
= 0.20 (10:90 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): 
δ (ppm) 7.30 – 7.21 (m, 3H, 3xArH), 7.19 – 7.00 (m, 4H, 4xArH), 6.86 – 6.68 (m, 2H, 2xArH), 
4.86 (s, 2H, ArCH2N), 4.02 (t, J = 5.7 Hz, 2H, ArCH2N), 3.80 (s, 3H, OCH3), 2.96 (t, J = 5.7 
Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, one ArC signal was not able to be identified): 
δ (ppm) 29.34 (ArCH2CH2), 47.45 (CH2), 50.75 (ArCH2N), 55.73 (OCH3), 113.07 (ArCH), 
113.44 (ArCH), 122.43 (ArC), 124.33 (ArCH), 125.80 (ArCH), 127.81 (ArCH), 130.06 
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(ArCCl), 134.88 (ArCH), 136.42 (ArCH), 141.46 (ArCNH), 158.98 (ArCOMe), 183.48 (C=S). 
HRMS ESI+: m/z [M+H]+ calcd for C17H17ClN2OS, 333.0828 (35Cl); found, 333.0821 (2.10 
ppm) and 335.0786 (37Cl). 
 
N−(3ˈ−Fluorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.66e was obtained in 56% (146 mg) yield from 165 mg of 
starting material 4.48. White solid; mp = 184 – 186 ̊C; Rf 
= 0.53 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): 
δ (ppm) 7.31 – 7.28 (m, 2H, 2xArH overlapping with CDCl3), 7.14 – 6.75 (m, 6H, 5xArH and 
NH), 4.87 (s, 2H, ArCH2N), 4.03 (t, J = 5.9 Hz, 2H, CH2), 3.82 (s, 3H, OCH3), 2.98 (t, J = 5.9 
Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, not all ArC were visible): δ (ppm) 29.26 
(ArCH2CH2), 47.54 (CH2), 50.89 (ArCH2N), 55.66 (OCH3), 111.29 (d, J = 24.0 Hz, ArCH−F), 
112.36 (d, J = 17.25 Hz, ArCH−F), 113.18 (d, J = 28.5 Hz, ArCH−F), 119.33 (ArCH), 127.73 
(ArC), 130.47 (ArCH), 136.40 (ArC). 
 
N−(4ˈ−Chlorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.66f was obtained in 79% (150 mg) yield from 114 mg 
of starting material 4.48. White solid; mp = 170 – 171 ̊C; 
Rf = 0.33 (30:70 EtOAc/Hexane). 1H NMR (300 MHz, 
CDCl3, two extra ArH are attributed to overlapping of the 
CDCl3 signal and the NH signal in the aromatic region): δ (ppm) 7.32 – 7.17 (m, 2H, 2xArH), 
7.07 – 7.04 (m, 3H, 3xArH), 6.80 – 6.75 (m, 2H, 2xArH), 4.88 (s, 2H, ArCH2N), 4.02 (t, J = 
5.5 Hz, 2H, CH2), 3.81 (m, 2H, OCH3), 2.96 (t, J = 5.5 Hz, 2H, ArCH2CH2). 13C NMR (75 
MHz, CDCl3): δ (ppm) 29.35 (ArCH2CH2), 47.27 (CH2), 50.59 (OCH3), 55.68 (ArCH2N), 
113.01 (ArCH), 113.38 (ArCH), 124.66 (ArC), 126.12 (ArCH), 127.77 (ArCH), 129.38 
(ArCH), 131.07 (ArCCl), 137.85 (ArC), 138.78 (ArCNH), 159.13 (ArCOMe), 182.66 (C=S). 




4.66g was obtained in 62% (161 mg) yield from 164 mg of 
starting material 4.48. White solid; mp = 156 – 158 ̊C; Rf 
= 0.44 (30:70 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): 
δ (ppm) 7.27 – 7.20 (m, 2H, ArH and NH), 7.08 – 7.01 (m, 
4H, 4xArH), 6.81 – 6.75 (m, 2H, 2xArH), 4.89 (s, 2H, ArCH2N), 4.03 (t, J = 5.9 Hz, 2H, CH2), 
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3.81 (s, 3H, OCH3), 2.97 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 
29.16 (ArCH2CH2), 46.84 (CH2), 50.14 (OCH3), 55.44 (ArCH2N), 112.93 (d, J = 28.5 Hz, 
ArCH−F), 115.84 (d, J = 22.5 Hz, ArCH−F), 124.73 (ArCH), 127.09 (ArCH), 127.20 (ArC), 
135.52 (ArCNH), 136.33 (ArCH), 158.91 (ArCOMe), 182.52 (C=S). 
 
8.10 Synthesis of sulfonyl urea analogues 
8.10.1 General procedure for the synthesis of 1,1 – sulfonyl bisimidazole 4.72 
The general procedure described by Cívicos and co−workers147 for the 
synthesis of 1,1 – sulfonyl bisimidazole was adopted. Thus, sulfonyl 
chloride (0.740 mL, 9.19 mmol) was slowly added to a cooled (0˚C) 
solution of imidazole (2.00 g, 37.0 mmol) in anhydrous CH2Cl2 (50 mL). The reaction mixture 
was monitored by TLC and after starting material had been consumed, the reaction mixture 
was filtered, and the resulting filtrate partitioned between water (20 mL) and CH2Cl2. 
Extraction with CH2Cl2 (25 mL x 2) followed by removal of the organic layer under reduced 
pressure provided a white solid which was recrystallized from IPA to afford white crystals of 
product 4.72 (1.54 g) in 97% yield. White crystals; mp = 128 – 129 ̊C; Rf = 0.30 (100% 
EtOAc). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.04 (s, 1H, ArH), 7.31 (d, J = 1.3 Hz, 1H, ArH), 
7.17 (s, 1H, ArH). HRMS ESI+: m/z [M+H]+ calcd for C6H6N4O2S, 199.0245; found, 199.0294 
(5.01 ppm). The experimental spectroscopic data, corresponded with literature as reported 
by Cívicos and co−workers.147 
 
8.10.2 General procedure for the preparation of sulfamoyl imidazolium salts 4.73 
The general procedure described by Beaudoin and co−workers140 was adopted. Thus, 
methyl triflate (0.310 mL, 2.77 mmol) was slowly added to a cooled (0˚C) solutions of the 
different sulfomoyl imidazoles (4.72) (~2.52 mmol) in anhydrous CH2Cl2 (10 mL) and stirred 
for 4 h at 0˚C. The reaction mixtures were concentrated under reduced pressure, yielding 




sulfonate 4.73 was obtained in 83% (1.82 g) yield from 1.23 g of starting 
material 4.72. White powder; mp = 84 – 85 ̊C; Rf = 0.00 (100% EtOAc). 
Due to the hygroscopic nature of the triflate salt, the crude material was 
used as such in subsequent reactions and for NMR analysis. 1H NMR (400 MHz, CD3OD): 
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δ (ppm) 8.91 (s, 1H, ArH), 8.45 (s, 1H, ArH), 7.77 (d, J = 1.5 Hz, 1H, ArH), 7.62 – 7.51 (m, 
2H, 2xArH), 7.18 (d, J = 0.9 Hz, 1H, ArH), 3.98 (s, 3H, CH3). 13C NMR (101 MHz, CD3OD): 
δ (ppm) 23.12 (CH3), 73.50 (ArCH), 119.45 (ArCH), 120.32 (ArCH), 120.85 (ArCH), 124.31 
(ArCH), 132.46 (ArCH), 135.17 (ArCH), 136.82 (ArCH), 138.80 (ArCH). HRMS ESI+: m/z 
[M−149.0697]+ calcd for C7H9N4O2S+, 213.0441; found, 213.0428 (4.71 ppm). 
 
1−[6−Methoxy−3,4−dihydroisoquinolin−2(1H)−yl]sulfonyl−3ˈ−methyl−1H−imidazol−3
−ium trifluoromethane sulfonate 4.76 was obtained in 
87% (563 mg) yield from 416 mg of starting material 4.48. 
Beige semi–solid; mp = RT (hygroscopic and when handled 
at RT, it melted forming a brown oil); Rf = 0.00 (100% 
EtOAc). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 9.60 (m, 1H, imidazole−ArH), 8.04 (d, J = 
2.0 Hz, 1H, imidazole−ArH), 7.76 – 7.67 (m, 1H, imidazole−ArH), 7.11 (d, J = 8.5 Hz, 1H, 
ArH), 6.82 (dd, J = 8.5, 2.6 Hz, 1H, ArH), 6.75 (d, J = 2.6 Hz, 1H, ArH), 4.64 (s, 2H, ArCH2N), 
3.98 (s, 3H, OCH3), 3.86 – 3.74 (m, 5H, overlapping signals−CH2 and CH3), 2.99 (t, J = 6.2 
Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, DMSO−d6, one methylene signal was not visible): 
δ (ppm) 29.03 (imidazole−CH3), 37.43 (ArCH2CH2), 46.36 (ArCH2N), 55.90 (OCH3), 114.33 
(ArCH), 114.62 (ArCH), 121.95 (ArC), 123.32 (ArCH), 126.52 (ArC), 128.64 
(imidazole−ArCH), 135.32 (imidazole−ArCH), 139.18 (imidazole−ArCH), 160.60 (ArCOMe). 
 
8.10.3 General procedure for the synthesis of 
2−[(1H−Imidazol−1−yl)sulfonyl]−1,2,3,4− tetrahydroisoquinolines 4.64 and 4.75 
The general procedure described by Beaudoin 
and co−workers140 was implemented as follows. 
THIQ analogues (4.47 or 4.48) (1.00 mmol) were 
added to a cooled (0˚C) mixture of 4.64 (400 mg, 
1.10 mmol) in anhydrous CH2Cl2 (50 mL), which 
was gradually allowed to heat to RT and stirred for 18 h. Once complete, the reaction mixture 
was concentrated under reduced pressure and provided a residue, which was further 
purified by column chromatography (50:50 EtOAc/Hexane). Since the usual tendency is for 
the dimer to preferably form. It was necessary to dilute the solution and maintain low 
temperatures during the protocol. The spectroscopic details of the compounds are described 
below: 
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2−[(1H−Imidazol−1−yl)sulfonyl]−1,2,3,4−tetrahydroisoquinoline 4.64 was obtained in 
61% (179 mg) yield from 148 mg of starting material 4.47. Yellow oil; 
Rf = 0.48 (50:50 EtOAc/Hexane). 1H NMR (400 MHz, CDCl3, none of 
the imidazole–ArH signals were visible): δ (ppm) 7.94 (s, 1H, ArH), 
7.29 – 7.00 (m, 3H, 3xArH), 4.41 (s, 2H, ArCH2N), 3.52 (t, J = 6.0 Hz, 2H, CH2), 2.91 (t, J = 
6.0 Hz, 2H, ArCH2CH2). 13C NMR (101 MHz, CDCl3): δ (ppm) 28.13 (ArCH2CH2), 44.24 
(CH2), 47.68 (ArCH2N), 117.49 (imidazole−ArCH), 126.17 (ArCH), 126.81 (ArCH), 127.35 
(ArCH), 128.87 (ArCH), 129.92 (ArCH), 130.65 (imidazole−ArCH), 132.24 (ArC), 136.67 
(imidazole−NCHN). HRMS ESI+: m/z [M+H]+ calcd for C12H13N3O2S, 264.0762; found, 
264.0814 (19.7 ppm). 
 
2−[(1H−Imidazol−1−yl)sulfonyl]−6−methoxy−1,2,3,4−tetrahydroisoquinoline 4.75 was 
obtained in 70% (408 mg) yield from 396 mg of starting material 
4.48. Transparent oil; Rf = 0.58 (100% EtOAc). 1H NMR (300 
MHz, CDCl3): δ (ppm) 7.93 (d, J = 3.0 Hz, 1H, imidazole−ArH), 
7.31 (d, J = 3.0 Hz, 1H, imidazole−ArH), 7.15 (d, J = 3.0 Hz, 1H, 
imidazole−ArH), 6.96 (d, J = 8.5 Hz, 1H, ArH), 6.75 (dd, J = 8.5, 2.5 Hz, 1H, ArH), 6.61 (d, 
J = 2.5 Hz, 1H, ArH), 4.35 (s, 2H, ArCH2N), 3.76 (s, 3H, OCH3), 3.51 (t, J = 6.0 Hz, 2H, CH2), 
2.88 (t, J = 6.0 Hz, 2H, ArCH2CH2). HRMS ESI+: m/z [M+H]+ calcd for C13H15N3O3S, 
294.0914; found, 294.0908 (1.40 ppm). 
 
8.10.4 General procedure for the coupling of 4.76 with heteroaryl amines 
A modified procedure, based on the general procedure described by Beaudoin and 
co−workers140 was implemented as follows. Aniline analogues (c – g) (~0.739 mmol) were 
added to a solution of the sulfamoyl imidazolium salt 4.76 (~200 mg, 0.615 mmol) in 
anhydrous CH3CN (20 mL) and stirred at RT overnight yielding product. However, for the 
haloanilines (d – g) heating under reflux was required. The spectroscopic details of the 
compounds are described below: 
 
6−Methoxy−N−(4ˈ−methoxyphenyl)−3,4−dihydroisoquinoline−2(1H)−sulfonamide 
4.77c was obtained in 87% (122 mg) yield from 184 
mg of starting material 4.76 as a brown oil, which 
solidified at low temperatures; Rf = 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 
7.13 (dd, J = 8.9, 0.9 Hz, 2H, 2xArH), 6.99 – 6.86 (m, 2H, 2xArH), 6.83 – 6.67 (m, 3H, 
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3xArH), 6.60 (s, 1H, NH), 4.39 (s, 2H, ArCH2N), 3.86 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 
3.49 (t, J = 5.6 Hz, 2H, CH2), 2.76 (t, J = 5.6 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): 
δ (ppm) 29.25 (ArCH2CH2), 44.22 (CH2), 47.30 (ArCH2N), 55.49 (2xOCH3), 112.85 (ArCH), 
113.56 (ArCH), 114.58 (ArCH), 124.24 (ArCH), 124.56 (ArCH), 127.40 (ArC), 129.61 
(ArCNH), 134.73 (ArC), 157.64 (ArCOMe), 158.40 (ArCOMe). HRMS ESI+: m/z [M+H]+ 
calcd for C17H20N2O4S, 349.1177; found, 349.1207 (2.87 ppm). 
 
N−(3ˈ−Chlorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 
4.77d was obtained in 83% (130 mg) yield from 202 mg 
of starting material 4.76. Orange oil; Rf = 0.22 (15:85 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.37 
– 6.86 (m, 4H, 4xArH), 6.84 – 6.48 (m, 3H, 3xArH), 4.43 
(d, J = 3.9 Hz, 2H, ArCH2N), 3.68 (brm, 5H, overlapping signals−OCH3 and CH2), 3.00 – 
2.67 (m, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, one aromatic signal was not visible): δ 
(ppm) 28.99 (ArCH2CH2), 44.27 (CH2), 47.30 (ArCH2N), 55.41 (OCH3), 113.01 (ArCH), 
113.61 (ArCH), 118.02 (ArCH), 120.02 (ArCH), 123.84 (ArCH), 124.66 (ArC), 127.40 
(ArCH), 130.42 (ArC), 134.48 (ArCCl), 135.04 (ArCNH), 138.45 (ArCOMe). HRMS ESI+: m/z 
[M+H]+ calcd for C16H17ClN2O3S, 351.0570 (35Cl); found, 351.0551 (5.40 ppm). 
 
N−(3ˈ−Fluorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 4.77e 
was obtained in 46% (70.0 mg) yield from 207 mg of 
starting material 4.76. Colourless oil; Rf = 0.37 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.20 
(m, 2H, 2xArH), 6.99 – 6.67 (m, 4H, 4xArH), 6.60 (d, J = 
2.3 Hz, 1H, ArH), 4.42 (s, 2H, ArCH2N), 3.80 – 3.51 (m, 5H, overlapping signals−OCH3 and 
CH2), 2.81 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, no C−F coupling was 
visible): δ (ppm) 29.05 (ArCH2CH2), 44.25 (CH2), 47.29 (ArCH2N), 55.41 (OCH3), 107.04 
(ArCH), 107.38 (ArCH), 111.16 (ArCH), 111.44 (ArCH), 113.00 (ArCH), 113.60 (ArCH), 
115.28 (ArCH), 123.84 (ArCH), 127.41 (ArC), 130.64 (ArCH), 134.49 (ArC), 138.86 
(ArCNH), 158.52 (ArCOMe), 164.86 (ArCF). HRMS ESI+: m/z [M+H]+ calcd for 
C16H18N2O3FS, 337.1022 (18F); found, 337.1024 (0.60 ppm) and 338.1052 (19F). 
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was obtained in 54% (81.2 mg) yield from 194 mg of 
starting material 4.76. Brown translucent oil; Rf = 0.22 
(15:85 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.22 – 7.19 (m, 3H, 3xArH), 7.10 – 7.06 (m, 2H, 
2xArH), 6.94 – 6.91 (m, 1H, ArH), 6.73 – 6.70 (m, 1H, ArH), 6.60 (brs, 1H, NH), 4.48 (s, 2H, 
ArCH2N), 3.84 (s, 3H, OCH3), 3.61 (t, J = 5.9 Hz, 2H, CH2), 2.86 (t, J = 5.9 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.21 (ArCH2CH2), 44.44 (CH2), 47.49 
(ArCH2N), 55.60 (OCH3), 113.13 (ArCH), 113.81 (ArCH), 121.88 (ArCH), 124.05 (ArC), 
127.59 (ArCH), 129.65 (ArC), 130.29 (ArCH), 134.66 (ArCNH), 135.96 (ArCCl), 158.71 
(ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C16H17ClN2O3S, 353.0727 (35Cl); found, 
353.0723 (1.10 ppm) and 355.0706 (37Cl). 
 
N−(4ˈ−Fluorophenyl)−6−methoxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 4.77g 
was obtained in 94% (190 mg) yield from 274 mg of 
starting material 4.76. Colourless oil; Rf = 0.37 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.01 
– 6.95 (m, 2H, 2xArH), 6.78 – 6.77 (m, 3H, 3xArH), 6.74 – 
6.63 (m, 1H, ArH), 6.61 (m, 1H, ArH), 6.31 (brs, 1H, NH), 4.40 (s, 2H, ArCH2N), 3.77 (s, 3H, 
OCH3), 3.51 (t, J = 5.9 Hz, 2H, CH2), 2.78 (t, J = 5.9 Hz, 2H, ArCH2CH2). No 13C NMR was 
included, despite best efforts, the spectrum was not very clear and therefore not 
incorporated in the experimental section. HRMS ESI+: m/z [M+H]+ calcd for C16H18N2O3FS, 
337.1022 (18F); found, 337.1018 (1.80 ppm) and 338.1044 (19F). 
 
4−{[6−Methoxy−3,4−dihydroisoquinolin−2(1H)−yl]sulfonyl}morpholine 4.77h was 
obtained in 67% (120 mg) yield from 262 mg of starting material 
4.76. White amorphous solid; mp = 119 – 121 ̊C; Rf = 0.44 
(40:60 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 
6.99 (d, J = 8.4 Hz, 1H, ArH), 6.82 – 6.71 (m, 1H, ArH), 6.67 (s, 
1H, ArH), 4.39 (s, 2H, ArCH2N), 3.85 – 3.64 (m, 7H, overlapping signals−OCH3 and 
morpholine−2xOCH2), 3.54 (t, J = 5.9 Hz, 2H, CH2), 3.28 – 3.15 (m, 4H, 
morpholine−2xNCH2), 2.91 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ 
(ppm) 29.31 (ArCH2CH2), 44.12 (morpholine−2xNCH2), 46.55 (CH2), 47.60 (ArCH2N), 55.44 
(OCH3), 66.49 (morpholine−2xOCH2), 112.98 (ArCH), 113.71 (ArCH), 124.44 (ArCH), 
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127.43 (ArC), 134.63 (ArC), 158.53 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for 
C14H20N2O4S, 313.1222; found, 313.1218 (1.30 ppm). 
 
8.11 Deprotection of aryl methyl ethers 
8.11.1 General procedure for the demethylation using BBr3 
A general procedure described by McOmie and co−workers121 was adopted and performed 
as followed. Thus, a mixture of 1 M BBr3 (0.190 mL, 1.97 mmol) in anhydrous CH2Cl2 (1.90 
mL) was prepared using a Schlenk tube cooled to −78 ̊C, to which compounds 4.46, 4.80 
and 4.74 (0.659 mmol) in anhydrous CH2Cl2 (0.50 mL) were slowly added. The reaction 
mixture was stirred for 2 h at −60 ̊C followed by stirring for an additional 4 h (while being 
monitored by TLC) at RT. Ethanol was then slowly added until fuming ceased, after which 
the reaction mixture was poured into an aqueous saturated NaHCO3 solution (15 mL) and 
extracted with EtOAc (20 mL x 3). The organic layers were combined, dried over MgSO4, 
concentrated under reduced pressure and purified with column chromatography (40:60 
EtOAc/Hexane). The following compounds were synthesised in this manner. 
 
6−Hydroxy−N−(4ˈ−methylthiazol−2−yl)−3,4−dihydroisoquinoline−2(1H)−carboxamide 
4.46a was obtained in 64% (49.0 mg) yield from 0.80 mg of 
starting material 4.54a. Yellow solid; mp = 199 – 200 ̊C; Rf = 
0.22 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6) 
δ (ppm) 6.36 – 6.33 (s, 1H, ArH), 6.05 – 5.99 (m, 2H, 2xArH), 5.79 (s, 1H, thiazole-ArH), 
4.29 (brs, 2H, NH and OH), 3.98 (s, 2H, ArCH2N), 3.13 – 3.09 (m, 2H, NCH2), 2.19 (t, J = 
5.9 Hz, 2H, ArCH2CH2), 1.63 (d, J = 1.1 Hz, 3H, thiazole−CH3). 13C NMR (75 MHz, DMSO-
d6, no C=O signal was visible) δ 6.75 (thiazole-CH3), 20.56 (ArCH2CH2), 33.43 (CH2), 36.99 
(ArCH2N), 70.10 (thiazole−ArCH), 97.49 (ArCH), 105.44 (ArCH), 106.40 (ArC), 115.89 
(ArCH), 118.91 (ArC), 127.82 (thiazole−ArC), 134.47 (ArCNH), 147.77 (C=O), 148.56 




ide 4.80a was obtained in 36% (54.0 mg) yield from 157 mg 
of starting material 4.61a. Orange oil; Rf = 0.37 (40:60 
EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 
6.19 – 6.15 (m, 1H, ArH), 5.83 – 5.79 (m, 2H, 2xArH), 5.60 
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(s, 1H, thiazole−ArH), 3.79 (s, 2H, ArCH2N), 2.96 – 2.90 (m, 2H, NCH2), 2.02 – 1.98 (m, 2H, 
ArCH2CH2), 1.43 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, DMSO−d6, C=S and one ArC 
signal was not visible): δ (ppm) 6.65 (thiazole−CH3), 20.55 (ArCH2CH2), 33.45 (CH2), 36.98 
(ArCH2N), 97.39 (ArCH), 101.63 (ArCH), 105.40 (ArC), 106.36 (ArC), 115.93 (ArCH), 118.80 
(ArCH), 127.82 (ArCNH), 147.60 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C17H20N2O4S, 
306.0735; found, 306.0722 (4.20 ppm). 
 
N−(3ˈ−Chlorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 4.74d 
was obtained in 34% (41.0 mg) yield from 126 mg of starting 
material 4.77d. Colourless oil; Rf = 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.28 
– 7.24 (m, 1H, NH), 7.18 (d, J = 8.0 Hz, 1H, ArH), 7.13 – 
6.96 (m, 2H, 2xArH), 6.90 (d, J = 8.3 Hz, 1H, ArH), 6.71 – 6.51 (m, 2H, 2xArH), 4.71 (brs, 
1H, OH), 4.41 (s, 2H, ArCH2N), 3.55 (t, J = 6.0 Hz, 2H, NCH2), 2.77 (t, J = 6.0 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 28.98 (ArCH2CH2), 44.40 (CH2), 47.52 
(ArCH2N), 114.32 (ArCH), 115.47 (ArCH), 118.36 (ArCH), 120.38 (ArCH), 121.27 (ArC), 
124.14 (ArCH), 124.99 (ArCH), 127.78 (ArCH), 130.65 (ArCCl), 134.96 (ArC), 135.29 
(ArCNH), 154.63 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C15H15ClN2O3S, 339.0570 
(35Cl); found 339.0570 (0.00 ppm) and 341.0549 (37Cl). 
 
N−(3ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 4.74e 
was obtained in 10% (6.49 mg) yield from 643 mg of starting 
material 4.77e. Brown oil; Rf = 0.32 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.38 – 7.08 (m, 2H, ArH 
and NH), 7.01 – 6.44 (m, 6H, 6xArH), 4.87 (s, 1H, OH), 4.41 (d, J = 6.0 Hz, 2H, ArCH2N), 
3.54 (t, J = 6.0 Hz, 2H, NCH2), 2.77 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, 
CDCl3): δ (ppm) 29.04 (ArCH2CH2), 44.38 (CH2), 47.57 (ArCH2N), 107.55 (d, J = 25.5 Hz, 
ArCH−F), 111.65 (d, J = 30.75 Hz, ArCH−F), 114.29 (ArCH), 115.45 (ArCH), 115.57 (ArCH), 
115.61 (ArC), 124.14 (ArCH), 127.79 (ArCH), 130.81 (ArCH), 130.94 (ArC), 134.97 (ArCH), 
148.55 (ArCNH), 154.64 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C15H15FN2O3S, 
323.0821 (18F); found, 323.0854 (3.10 ppm). 
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was obtained in 41% (31.3 mg) yield from 79.0 mg of 
starting material 4.77f. Colourless oil; Rf = 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, no OH signal 
was visible): δ (ppm) 7.27 – 7.21 (m, 3H, 2xArH and NH), 7.09 – 7.06 (m, 2H, 2xArH), 6.90 
–6.56 (m, 3H, 3xArH), 4.39 (s, 2H, ArCH2N), 3.71 – 3.35 (m, 2H, NCH2), 2.76 (m, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3, not all ArCH signals were visible): δ (ppm) 29.03 
(ArCH2CH2), 44.35 (CH2), 47.51 (ArCH2N), 114.25 (ArCH), 115.43 (ArCH), 122.17 (ArC), 
127.75 (ArCH), 129.70 (ArCH), 130.44 (ArC), 134.80 (ArCCl), 135.75 (ArCNH), 154.60 
(ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C15H15ClN2O3S, 339.0571 (35Cl); found 
339.0556 (1.40 ppm) and 341.0534 (37Cl). 
 
N−(4ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−sulfonamide 4.74g 
was obtained in 33% (64.4 mg) yield from 204 mg of starting 
material 4.77g. Brown oil; Rf = 0.32 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3, no OH signal was visible): δ (ppm) 
7.12 – 7.06 (m, 2H, 2xArH), 7.96 – 6.83 (m, 6H, 5xArH and 
NH), 4.36 (d, J = 10.3 Hz, 2H, ArCH2N), 3.51 – 3.47 (m, 2H, NCH2), 2.71 (t, J = 6.0 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.78 (ArCH2CH2), 44.03 (CH2), 47.32 
(ArCH2N), 112.90 (ArCH), 114.19 (ArCH), 116.03 (ArC), 116.33 (ArCH), 123.49 (d, J = 8.2 
Hz, ArCH−F), 125.73 (ArC), 126.55 (ArCH), 133.50 (ArCNH), 151.31 (ArC−F), 161.77 
(ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C15H15FN2O3S, 323.0866 (18F); found, 323.0858 
(2.50 ppm). 
 
8.11.2 General procedure for the synthesis of demethylation using All3 
The general procedure described by Bhatt and co−workers93 was adopted. Thus, iodine (I2) 
(1.31 g, 10.0 mmol) was added to a cooled suspension of clean aluminium powder (180 mg, 
6.88 mmol) in anhydrous toluene (20 mL) followed by heating to 110 ̊C until the red colour 
dissipated. The reaction mixture was cooled to RT, to which the various methoxy substrates 
4.54, 4.66 and 4.77 (0.688 mmol) were added and stirred at 60 ̊C overnight. The reaction 
mixture was cooled to RT and the excess AlI3 was quenched by the slow addition of water 
(20 mL). The reaction mixture was extracted with EtOAc (20 mL x 3) and the organic layers 
combined and dried over MgSO4. The organic layer was concentrated under reduced 
pressure affording a brown residue, further purified by column chromatography (40:60 
EtOAc/Hexane) to afford compounds as described below: 
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4.46c was obtained in 42% (50.0 mg) yield from 110 mg of 
starting material 4.54c. White oil that solidified at low 
temperatures; Rf = 0.14 (50:50 EtOAc/Hexane). 1H and 13C 
NMR was not very clear and therefore not incorporated in 
the experimental section however, HRMS was further employed to confirm product 




4.46d was obtained in 50% (70.0 mg) yield from 146 mg of 
starting material 4.54d. Brown solid; mp = 188 – 190 ̊C; Rf 
= 0.50 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CD3OD, 
no OH or NH signals were visible): δ (ppm) 7.57 – 6.99 (m, 5H, 5xArH), 6.67 – 6.64 (m, 2H, 
2xArH), 4.59 (s, 2H, ArCH2N), 3.71 (t, J = 5.9 Hz, 2H, NCH2), 2.86 (t, J = 5.9 Hz, 2H, 
ArCH2CH2). 13C NMR (75 MHz, CD3OD): δ (ppm) 30.04 (ArCH2CH2), 42.93 (CH2), 46.49 
(ArCH2N), 114.78 (ArCH), 115.69 (ArCH), 119.94 (ArCH), 121.69 (ArC), 123.66 (ArCCl), 
125.38 (ArCH), 128.27 (ArCH), 130.75 (ArCH), 134.99 (ArC), 135.33 (ArCHCl), 137.34 
(ArCNH), 157.13 (C=O), 157.43 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C16H15ClN2O2, 
303.0900 (35Cl); found, 303.0910 (0.30 ppm) and 305.0875 (37Cl). 
 
N−(3ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−carboxamide 4.46e 
was obtained in 35% (40.0 mg) yield from 120 mg of starting 
material 4.54e. White solid; mp = 166 – 168 ̊C; Rf = 0.33 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6): δ 
(ppm) 9.25 (s, 1H, NH), 8.71 (brs, 1H, OH), 7.54 – 7.37 (m, 1H, ArH), 7.34 – 7.17 (m, 2H, 
2xArH), 6.96 (d, J = 8.2 Hz, 1H, ArH), 6.80 – 6.53 (m, 3H, 3xArH), 4.51 (s, 2H, ArCH2N), 
3.63 (t, J = 5.9 Hz, 2H, NCH2), 2.75 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, 
DMSO−d6, no C−F coupling was observable): δ (ppm) 28.72 (ArCH2CH2), 41.61 (CH2), 
45.40 (ArCH2N), 106.13 (ArCH), 106.48 (ArCH), 108.02 (ArCH), 108.30 (ArCH), 113.77 
(ArCH), 114.97 (ArCH), 115.33 (ArCH), 124.21 (ArC), [one extra signal 127.39 (ArCH)], 
130.00 (ArC), 136.05 (ArCNH), 142.86 (ArC−F), 154.92 (C=O), 156.01 (ArCOH). HRMS 
ESI+: m/z [M+H]+ calcd for C16H15FN2O2, 287.1196 (18F); found, 287.1198 (0.30 ppm) and 
288.1228 (19F). 
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was obtained in 50% (12.2 mg) yield from 26.0 mg of 
starting material 4.54f. Brown oil; Rf = 0.50 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CD3OD, both OH and 
NH signals were not visible): δ (ppm) 7.57 – 6.99 (m, 5H, 
5xArH), 6.67 – 6.64 (m, 2H, 2xArH), 4.59 (s, 2H, ArCH2N), 3.72 (t, J = 5.7 Hz, 2H, NCH2), 
2.86 (t, J = 5.7 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CD3OD, one ArC signal was not 
visible): δ (ppm) 28.62 (ArCH2CH2), 41.44 (CH2), 45.04 (ArCH2N), 113.35 (ArCH), 114.33 
(ArCH), 114.67 (ArC), 123.10 (ArCH), 123.57 (ArCH), 124.12 (ArCH), 126.85 (ArCNH), 
135.97 (ArCCl), 155.01 (ArCOH), 156.03 (C=O). HRMS ESI+: m/z [M+H]+ calcd for 
C16H15ClN2O2, 303.0793 (35Cl); found, 303.0899 (3.28 ppm). 
 
N−(4ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−carboxamide 4.46g 
was obtained in 2% (4.50 mg) yield from 236 mg of starting 
material 4.54g. White solid; mp = 225 – 226 ̊C; Rf = 0.33 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, CD3OD, both 
OH and NH signals were not visible): δ (ppm) 7.47 – 7.19 (m, 3H, 3xArH), 7.00 (d, J = 7.9 
Hz, 2H, 2xArH), 6.66 (d, J = 7.9 Hz, 2H, 2xArH), 4.58 (s, 2H, ArCH2N), 3.71 (t, J = 5.7 Hz, 
2H, CH2), 2.85 (t, J = 5.7 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CD3OD, no C−F coupling 
was not visible): δ (ppm) 30.02 (ArCH2CH2), 42.89 (CH2), 46.48 (ArCH2N), 114.77 (ArCH), 
115.71 (ArCH), 123.54 (ArC), 125.43 (ArC), 128.26 (ArCH), 128.96 (ArCH), 129.46 (ArCH), 
137.35 (ArCF), 139.87 (ArCNH), 157.19 (C=O), 157.69 (ArCOH). HRMS ESI+: m/z [M+H]+ 
calcd for C16H15FN2O2, 287.1196 (18F); found, 287.1204 (3.48 ppm). 
 
N−(3ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.80e was obtained in 2% (5.0 mg) yield from 146 mg of 
starting material 4.66e. Brown oil; Rf = 0.33 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.30 – 
7.16 (m, 2H, 2xArH), 7.13 (brs, 1H, NH), 7.08 – 6.94 (m, 3H, 
3xArH), 6.78 – 6.57 (m, 2H, 2xArH), 4.87 (s, 2H, ArCH2N), 4.00 (t, J = 5.8 Hz, 2H, NCH2), 
2.90 (t, J = 5.8 Hz, 2H, ArCH2CH2), 2.06 (brs, 1H, OH). 13C NMR (75 MHz, CDCl3): δ (ppm) 
28.99 (ArCH2CH2), 46.85 (CH2), 50.22 (ArCH2N), 114.15 (ArCH), 114.70 (ArCH), 115.73 
(ArCH), 116.03 (ArCH), 124.75 (ArC), 127.33 (d, J = 8.4 Hz, ArCH−F), [one extra ArCH 
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127.75 (ArCH)], 135.70 (ArC), 136.60 (ArCH), 155.04 (ArCOH), 159.11 (ArCNH), 162.34 (d, 
J = 18.0 Hz, ArCH−F), 166.26 (d, J = 67.5 Hz, ArC−F), 182.35 (C=S). 
 
N−(4ˈ−Chlorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.80f was obtained in 44% (61.5 mg) yield from 145 mg of 
starting material 4.66f. Yellow froth; Rf = 0.23 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, OH and NH 
signals were not visible): δ (ppm) 7.30 – 6.89 (m, 5H, 
5xArH), 6.77 – 6.63 (m, 2H, 2xArH), 4.86 (s, 2H, ArCH2N), 3.99 (t, J = 5.9 Hz, 2H, NCH2), 
2.90 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.17 (ArCH2CH2), 
47.04 (CH2), 50.41 (ArCH2N), 114.34 (ArCH), 114.89 (ArCH), 115.92 (ArCH), 124.94 
(ArCH), 127.51 (d, J = 8.4 Hz, ArCCl), 127.93 (ArC), 135.97 (ArCH), 136.78 (ArC), 155.22 
(ArCNH), 162.53 (ArCOH), 182.53 (C=S). 
 
N−(4ˈ−Fluorophenyl)−6−hydroxy−3,4−dihydroisoquinoline−2(1H)−carbothioamide 
4.80g was obtained in trace amounts from 161 mg of starting 
material 4.66g. Opaque oil that solidified at low 
temperatures; Rf = 0.23 (50:50 EtOAc/Hexane). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.30 – 7.16 (m, 2H, ArH and NH), 
7.13 (single signal, 1H, ArH), 7.08 – 6.94 (m, 3H, 3xArH), 6.78 – 6.57 (m, 2H, 2xArH), 4.87 
(s, 2H, ArCH2N), 4.00 (t, J = 5.9 Hz, 2H, NCH2), 2.90 (t, J = 5.9 Hz, 2H, ArCH2CH2), 2.06 
(brs, 1H, OH). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.17 (ArCH2CH2), 47.04 (CH2), 50.41 
(ArCH2N), 114.34 (ArCH), 114.89 (ArCH), 115.92 (ArC), 116.22 (ArCH), 124.94 (ArC), 
127.51 (d, J = 8.4 Hz, ArCHF), 135.97 (ArCH), 136.78 (ArCNH), 155.22 (ArCOH), 162.06 
(ArCF), 182.53 (C=S). 
 
[6−Hydroxy−3,4−dihydroisoquinolin−2(1H)−yl](morpholino)methanethione 4.80h was 
obtained in 20% (41.8 mg) yield from 219 mg of starting material 
4.61h with unreacted starting material being recovered. Brown oil; 
Rf = 0.32 (30:70 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 6.94 (d, J = 8.2 Hz, 1H, ArH), 6.76 – 6.53 (m, 2H, 2xArH), 4.64 (s, 2H, ArCH2N), 3.90 
– 3.71 (m, 4H, morpholine−2xOCH2), 3.64 – 3.44 (m, 6H, morpholine−2xNCH2 and NCH2), 
2.94 (t, J = 5.8 Hz, 2H, ArCH2CH2), 1.21 (brs, 1H, OH). 13C NMR (75 MHz, CDCl3): δ (ppm) 
28.89 (ArCH2CH2), 49.53 (CH2), 52.30 (ArCH2N), 53.34 (morpholine−2xCH2O), 66.82 
(morpholine−2xNCH2), 114.20 (ArCH), 115.30 (ArCH), 125.17 (ArC), 127.58 (ArCH), 136.24 
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(ArC), 155.00 (ArCOH), 193.98 (C=S). HRMS ESI+: m/z [M+H]+ calcd for C14H18N2O2S, 
279.1167; found, 279.1166 (0.40 ppm). 
 
6−Hydroxy−N−(4−hydroxyphenyl)−3,4−dihydroisoquinoline−2(1H)−sulfonamide 
4.74c was obtained in 32% (70.6 mg) yield from 240 mg of 
starting material 4.77c. White oil that solidified at low 
temperatures; Rf = 0.24 (50:50 EtOAc/Hexane). 1H NMR 
(300 MHz, CD3OD): δ (ppm) 7.09 – 6.97 (m, 2H, ArH and NH), 6.85 (d, J = 8.3 Hz, 1H, 
ArCH), 6.77 – 6.54 (m, 3H, 3xArH), 6.50 (d, J = 2.5 Hz, 2H, 2xArH), 4.59 (brs, 1H, OH), 4.26 
(s, 2H, ArCH2N), 3.38 (t, J = 5.9 Hz, 2H, NCH2), 2.65 (t, J = 5.9 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CD3OD): δ (ppm) 20.68 (ArCH2CH2), 36.10 (NCH2), 39.06 (ArCH2N), 105.56 
(ArCH), 106.68 (ArCH), 107.33 (ArC), 107.43 (ArCH), 115.22 (ArCH), 115.31 (ArCH), 
116.19 (ArCH), 119.01 (ArCH), 121.29 (ArCH), 121.54 (ArC), 126.77 (ArCNH), 146.83 
(ArCOH), 147.72 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C17H20N2O4S, 321.0864; 
found, 321.0912 (3.11 ppm). 
 
2−(Morpholinosulfonyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 4.74h was obtained in 
25*% (35.0 mg) yield from 147 mg of starting material 4.77h. 
White solid; mp = 168 – 170 ̊C; Rf = 0.53 (100% EtOAc). 1H 
NMR (300 MHz, DMSO−d6): δ (ppm) 6.94 (d, J = 8.2 Hz, 1H, 
ArH), 6.72 – 6.51 (m, 2H, 2xArH), 4.37 (s, 2H, ArCH2N), 3.69 
(single signal, 4H, morpholine−2xCH2O), 3.54 (t, J = 5.5 Hz, 2H, NCH2), 3.22 – 3.18 (m, 4H, 
morpholine−2xNCH2), 2.86 (t, J = 5.5 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, DMSO−d6): δ 
(ppm) 29.88 (ArCH2CH2), 45.32 (morpholine−2xNCH2), 47.70 (CH2), 48.56 (ArCH2N), 67.40 
(morpholine−2xCH2O), 114.90 (ArCH), 116.01 (ArCH), 124.56 (ArC), 128.25 (ArCH), 135.92 
(ArC), 157.11 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C13H18N2O4S, 299.1066; found, 
299.1061 (1.70 ppm). 
 
8.11.3 Debenzylation of 
6−[Benzyloxy−3,4−dihydroisoquinolin−2(1H)−yl](morpholino) methanone 
The general procedure described by Silverman and 
co−workers203 was adopted. Thus, a mixture of 4.54h (270 mg, 
0.766 mmol), Pd 10% on activated charcoal (81.0 mg, 0.766 
mmol), acetic acid (0.096 mL, 1.68 mmol) and anhydrous MeOH 
(6.00 mL) was stirred under a hydrogen atmosphere (balloon) at 40 C̊ for 48 h. The mixture 
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was filtered through celite and concentrated under reduced pressure. The residue was 
partitioned between EtOAc (30 mL) and washed with saturated aqueous NaHCO3 (10 mL x 
3). The organic layer was dried over MgSO4, followed by concentrating under reduced 
pressure. The residue was purified by column chromatography (100% EtOAc). 
[6−Hydroxy−3,4−dihydroisoquinolin−2(1H)−yl](morpholino)methanone 4.46h was 
obtained in 79% (89.0 mg) yield. White solid; mp = 188 – 190 ̊C; Rf = 0.21 (50:50 
EtOAc/Hexane). 1H NMR (400 MHz, DMSO−d6): δ (ppm) 9.02 (brs, 1H, OH), 6.90 (d, J = 
8.1 Hz, 1H, ArH), 6.67 (dd, J = 8.1 and 2.1 Hz, 1H, ArH), 6.55 – 6.46 (m, H, ArH), 3.58 – 
3.48 (m, 4H, morpholine−2xOCH2), 3.28 – 3.21 (m, 6H, morpholine−2xNCH2 and NCH2), 
3.13 (dd, J = 9.0, 3.8 Hz, 2H, CH2), 2.59 (dd, J = 9.0, 3.8 Hz, 2H, ArCH2CH2). 13C NMR (101 
MHz, DMSO−d6): δ (ppm) 18.60 (ArCH2CH2), 34.62 (morpholine−2xNCH2), 41.48 (CH2), 
44.45 (ArCH2N), 66.61 (morpholine−2xOCH2), 113.56 (ArCH), 116.68 (ArCH), 126.37 (ArC), 
131.36 (ArCH), 139.40 (ArC), 155.95 (ArCOH), 158.20 (C=O). 
 
8.12 Coupling protocols for the synthesis of THIQ analogues 
8.12.1 2ˈ−[3,4−Dihydroisoquinolin−2(1H)−yl]thiazole 5.5a 
The general procedure described by Klapars and co−workers150 was 
followed. Thus, a solution of THIQ 5.4 (0.200 mL, 1.66 mmol) and 
2−bromothiazole (0.100 mL, 1.11 mmol) in anhydrous DMF (2.0 mL) were 
stirred at RT for 1 h. The reaction mixture was treated with Et3N (0.340 mL, 2.44 mmol) and 
stirred for 18 h at 80 ̊C, after which the reaction mixture was poured into water (5.0 mL) and 
extracted with EtOAc (20 mL x 2). The organic layers were combined, dried over MgSO4 
and concentrated under reduced pressure providing a brown residue purified with column 
chromatography (30:70 EtOAc/Hexane). 
Compound 5.5a was obtained in 23% (44.0 mg) yield. Orange oil; Rf = 0.55 (50:50 
EtOAc/Hexane). 1H NMR (400 MHz, DMSO−d6, one ArH signal was not visible): δ (ppm) 
7.33 – 7.08 (m, 4H, 4xArH), 6.83 (d, J = 3.6 Hz, 1H, thiazole−ArH), 4.60 (s, 2H, ArCH2N), 
3.71 (t, J = 6.0 Hz, 2H, CH2), 2.93 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C NMR (101 MHz, 
DMSO−d6): δ (ppm) 27.80 (ArCH2CH2), 46.00 (CH2), 49.80 (ArCH2N), 107.73 
(thiazole−ArCH), 126.34 (ArCH), 126.62 (ArCH), 126.73 (ArCH), 128.69 (ArCH), 133.10 
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8.12.2 4ˈ−[3,4−Dihydroisoquinolin−2(1H)−yl]thiazole 5.5b 
The general procedure described by Klapars and co−workers150 was 
followed. Thus, ʟ−proline (17.0 mg, 0.149 mmol, 20.0 mol%), CuI (14.2 
mg, 74.6x10−3 mmol, 10.0 mol%) and K3PO4 (470 mg, 2.24 mmol) were 
mixed in DMF (1.0 mL) followed by addition of THIQ 5.4 (9.30x10−3 mL, 0.747 mmol) and 
4−bromothiazole (0.100 mL, 1.12 mmol) under anhydrous conditions. The reaction vessel 
was sealed and set to stir at 150 ̊C for 24 h, after which the reaction mixture was diluted with 
water (5.0 mL) and extracted with EtOAc (20.0 mL x 2). The organic layers were combined, 
dried over MgSO4 and concentrated under reduced pressure to afford a red/brown coloured 
residue, purified by column chromatography (30:70 EtOAc/Hexane). 
Compound 5.5b was obtained in 9.5% (15.2 mg) yield. Orange oil; Rf = 0.62 (50:50 
EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.75 (s, 1H, thiazole−SCHN), 7.39 – 
7.08 (m, 4H, 4xArH), 6.43 (s, 1H, thiazole−ArH), 4.65 (s, 2H, ArCH2N), 3.75 (t, J = 5.1 Hz, 
2H, CH2), 2.99 (t, J = 5.1 Hz, 2H, ArCH2CH2). 13C NMR was not very clear and therefore not 
reported. 
 
8.12.3 2−Phenyl−1,2,3,4−tetrahydroisoquinoline 5.5c 
ʟ−Proline (37.0 mg, 0.32 mmol, 20.0 mol%), K2CO3 (22.0 mg, 0.160 
mmol, 10.0 mol%) and CuI (80.0 mg, 0.160 mmol, 10.0 mol%) were 
combined, to which THIQ 5.4 (0.200 mL, 1.60 mmol) and bromobenzene 
(0.170 mL, 1.60 mmol) in anhydrous DMSO (1.50 mL) were added. The 
mixture was stirred for 30 seconds followed by heating in a Microwave oven at 150 ̊C for 15 
min at 24 – 37 W with a pressure of 1 bar forming a brown suspension. The suspension was 
diluted with water (5.0 mL) and extracted with EtOAc (20 mL x 3). The organic layers were 
combined, dried over MgSO4 and purified with column chromatography (40:60 
EtOAc/Hexane). 
Compound 5.5c was obtained in 60% yield. Yellow−brown oil, which solidified at low 
temperatures; Rf = 0.39 (90:10 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.25 – 
7.09 (m, 5H, 5xArH), 6.93 – 6.90 (m, 2H, 2xArH), 6.78 – 6.73 (m, 2H, 2xArH), 4.34 (s, 2H, 
ArCH2N), 3.49 (t, J = 5.8 Hz, 2H, NCH2), 2.92 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR (75 
MHz, CDCl3, one ArC was not visible): δ (ppm) 29.30 (ArCH2CH2), 46.70 (CH2), 50.90 
(ArCH2N), 115.27 (ArCH), 118.79 (ArCH), 126.16 (ArCH), 126.46 (ArCH), 126.57 (ArCH), 
128.65 (ArCH), 134.61 (ArC), 135.01 (ArC), 150.69 (ArCN). 
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8.13 Intramolecular Friedel−Crafts cyclization protocol toward synthesis of THIQ 
analogues 
8.13.1 Procedure for the synthesis of N−benzyl aniline 5.16 
The general procedure described by Romero and co−workers149 was 
adopted. Thus, benzaldehyde (0.200 mL, 1.96 mmol), aniline (0.200 mL, 
2.17 mmol), Mg(ClO4)3 (44.0 mg, 0.196 mmol) and MgSO4 (237 mg, 1.96 
mmol) were combined in anhydrous CH3CHCl2 (15 mL). The mixture was stirred at 60 ̊C for 
5 h then cooled to RT. The solid was filtered off and the eluent concentrated under reduced 
pressure to afford crude material which was dissolved in anhydrous EtOH (3.0 mL) and 
cooled to −3 ̊C. NaBH4 (50.0 mg, 1.30 mmol) was added and the mixture was stirred at RT 
overnight and solvent removed. Removal of the solvent under reduced pressure provided a 
residue, which was purified by column chromatography (20:80 EtOAc/Hexane). 
Compound 5.16 was obtained in quantitative (359 mg) yield. Colourless oil; Rf = 0.53 (20:80 
EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.48 – 7.02 (m, 7H, 7xArH), 6.79 – 
6.55 (m, 3H, 3xArH), 4.34 (s, 2H, ArCH2), 4.03 (brs, 1H, NH). 13C NMR (101 MHz, CDCl3, 
one ArCH was not visible): δ (ppm) 48.60 (CH2), 113.09 (ArCH), 117.82 (ArCH), 127.48 
(ArCH), 127.76 (ArCH), 128.88 (ArCH), 129.52 (BnC), 139.68 (ArCN). This data 
corresponded well with the literature as reported by Wang and co−workers.204 
 
8.13.2 SN2 substitution protocol for the synthesis of THIQ analogues 
8.13.2.1 Method A: General procedure for of N−benzyl−5−methylthiazol−2−amine 
5.19 
The general procedure described by Krishnaiah and co−workers165 was followed. Thus, a 
stirred suspension of 2−amino−4−methylthiazole (105 mg, 0.925 mmol), benzyl bromide 
(0.100 mL, 0.840 mmol) and Cs2CO3 (600 mg, 1.85 mmol) were combined in anhydrous 
DMF (5.0 mL). The mixture was stirred overnight at RT followed by addition of water (20 
mL). Extraction with EtOAc (10 mL x 3) afforded a brown residue which was purified with 
column chromatography (30:70 EtOAc/Hexane), yielding 34% of 5.19. 
 
8.13.2.2 Method B: General procedure for 5.19 using the Ullmann conditions 
The general procedure described by Klapars and co−workers150 was adopted. Thus, a 
suspension of 2−amino−4−methylthiazole (105 mg, 0.925 mmol), Cs2CO3 (600 mg, 1.85 
mmol), ʟ−proline (9.70 mg, 84.2x10−3 mmol, 5.00 mol%) and CuI (16.0 mg, 84.2x10−3 mmol, 
5.00 mol%) in anhydrous DMF (2.0 mL) were combined followed by the addition of benzyl 
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bromide (0.100 mL, 0.840 mmol). The reaction mixture was stirred overnight at RT followed 
by the addition of water (20 mL) and extraction with EtOAc (20 mL x 3) which afforded a 
brown residue purified by column chromatography (30:70 EtOAc/Hexane). 
Compound 5.19 was obtained in 48% (164 mg) yield. Yellow oil; Rf = 0.48 (50:50 
EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3, doubling of signals are attributed to 
rotamers): δ (ppm) 7.54 – 6.89 (m, 5H, rotamers 5xArH), 6.42 (s, 1H, 
thiazole−ArH), 5.50 – 5.01 (m, 2H, rotamers ArCH2), 4.40 (s, 1H, NH), 
2.23 (s, 3H, thiazole−CH3). HRMS ESI+: m/z [M+H]+ calcd for C11H12N2S, 205.0755; found, 
205.0793 (4.87 ppm). The experimental data, corresponded well with the literature as 
reported by Aoyama and co−workers.205 
 
8.13.3 General procedure for acylation of amines 
8.13.3.1 Chloroacetylation of amines (a and b) 
The protocol described by Velavan and co−workers138 was followed. Thus, chloroacetyl 
chloride (78.0x10−3 mL, 9.82 mmol) was slowly added to a stirred solution of 5.16 (150 mg, 
0.818 mmol) or 5.19 (164 mg, 0.800 mmol) and DIPEA (0.170 mL, 9.82 mmol) in anhydrous 
CH2Cl2 (20 mL) at −3 C̊. The solution was stirred for 6 – 18 h at RT, resulting in a yellow 
mixture, which changed to a red−brown colour. The reaction mixture was treated with water 
(10 mL) and extracted with EtOAc (20 mL x 2) to afford a brown residue, further purified by 
column chromatography (20:80 EtOAc/Hexane). The spectroscopic details of the 
compounds are described below: 
 
N−Benzyl−2−chloro−N−phenylacetamide 5.20 was obtained in 89% (203 mg) yield. 
Colourless oil; Rf = 0.19 (20:80 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): 
δ (ppm) 7.43 – 7.33 (m, 3H, 3xArH), 7.33 – 7.18 (m, 5H, 5xArH), 7.08 – 6.99 
(m, 2H, 2xArH), 4.92 (s, 2H, COCH2Cl), 3.87 (s, 2H, ArCH2). 13C NMR (75 
MHz, CDCl3): δ (ppm) 42.20 (ArCH2), 53.90 (CH2), 126.60 (ArCH), 127.80 
(ArCH), 128.40 (ArCH), 128.73 (ArCH), 128.87 (ArCH), 129.11 (ArCH), 129.97 (BnCCH2), 
136.69 (ArCN), 166.29 (C=O). Spectral data corresponded well with that reported by Flipo 
and co−workers.206 
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N−Benzyl−2−chloro−N−(5−methylthiazol−2−yl)acetamide 5.21 was obtained in 70% 
(158 mg) yield. Pale yellow crystal; mp = 68 – 70 ̊C; Rf = 0.23 (20:80 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.39 – 6.97 (m, 5H, 
5xArH), 6.43 (d, J = 1.0 Hz, 1H, thiazole−ArH), 5.31 (s, 2H, COCH2Cl), 
5.18 (s, 2H, ArCH2), 2.24 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, 
CDCl3): δ (ppm) 17.8 (single signal thiazole−CH3), 50.3 (ArCH2), 68.9 (CH2), 109.39 
(thiazole−ArCH), 127.58 (ArCH), 128.59 (ArCH), 128.73 (ArCH), 128.86 (ArCH), 135.40 
(thiazole−ArCN), 137.82 (BnC), 147.76 (C=O). 
 
8.13.3.2 2−[Benzyl(phenyl)amino]−2−oxoacetyl chloride 5.33 
The protocol described by Vekemans and co−worker207 was followed. Thus, 
oxalyl chloride (0.240 mL, 2.83 mmol) was slowly added to a stirred solution 
of 5.16 (413 mg, 2.36 mmol) in anhydrous CCl4 (20 mL) at 0 ̊C. The mixture 
was stirred for 6 – 18 h at RT. The resulting yellow mixture was treated with 
water (10 mL) and extracted with EtOAc (20 mL x 2) to afford a residue 
purified with column chromatography (20:80 EtOAc/Hexane). 
Compound 5.33 was obtained in 56% (272 mg) yield. Yellow oil; Rf = 0.32 (100% Hexane). 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.34 – 6.73 (m, 10H, 10xArH), 4.67 (s, 2H, ArCH2). 13C 
NMR (75 MHz, CDCl3, not all ArCH signals were visible): δ (ppm) 52.18 (ArCH2), 127.50 
(ArCH), 128.26 (ArCH), 128.91 (ArCH), 129.19 (ArCH), 136.54 (BnC), 139.64 (ArC), 164.73 
(C=O). HRMS ESI+: m/z [M+H]+ calcd for C15H11ClNO2, 275.0527; found, 274.1513 (6.92 
ppm). 
 
8.13.4 N−Benzyl−N−(2−chloroethyl)aniline 5.22 
The protocol described by Nystrom,123 Davis124 and co−workers was 
followed. Thus, to a suspension of LiAlH4 (88.9 mg, 2.34 mmol) in 
anhydrous THF (10.0 mL) at −3 ̊C, AlCl3 (312 mg, 2.34 mmol) was added 
in small portions maintaining the temperature at −3 ̊C. The resulting 
monochloroalane solution was then stirred for 30 min at RT, to which 5.20 
(203 mg, 0.780 mmol) in anhydrous THF (2.0 mL) was added. The reaction mixture was 
stirred under reflux for 5 h, cooled to RT and later to 0 ̊C. Water (15 mL) was slowly added 
till no further effervescence occurred. The lithium aluminate was separated by vacuum 
filtration and the eluent extracted with EtOAc (20 mL x 2) to afford an oily residue purified 
by column chromatography (10:90 CH2Cl2/Hexane). 
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Compound 5.22 was obtained in 59% (113 mg) yield. Orange oil; Rf = 0.45 (5:95 
CH2Cl2/Hexane). 1H NMR (400 MHz, CDCl3, doubling of signals is due to rotamers): δ (ppm) 
7.60 – 7.11 (m, 6H, rotamers 6xArH), 6.99 – 6.64 (m, 4H, 4xArH), 4.71 (s, 2H, ArCH2N), 
3.87 – 3.83 (m, 2H, CH2), 3.75 – 3.71 (m, 2H, CH2). 13C NMR (101 MHz, CDCl3): δ (ppm) 
40.5 (CH2), 53.20 (CH2Cl), 55.00 (ArCH2), 112.42 (ArCH), 117.38 (ArCH), 126.65 (ArCH), 
127.18 (ArCH), 128.83 (ArCH), 129.59 (ArCH), 138.51 (BnC), 147.74 (ArCN). 
 
8.14 Synthesis of isochromanone as a route to THIQ analogues 
8.14.1 Reduction of phenyl acetic acid to 2-phenylethanol 5.35 
The procedure described by Shindikar and co−workers169 was followed. The phenyl acetic 
acid (3.00 mmol) in anhydrous THF (9.0 mL) was slowly added to a mixture of LiAlH4 (460 
mg, 12.0 mmol) in anhydrous THF (18 mL) at RT and the resulting mixture was heated under 
reflux for 3 h whilst monitoring with TLC. the reaction mixture was cooled to 0°C, to which 
water was added until all effervescence ceased and water (10 mL) was added followed by 
extraction with EtOAc (20 mL x 3) which afforded a colourless oil in excellent yields with no 
further purification required. The spectroscopic details of the compounds are described 
below: 
 
2−Phenylethanol 5.35 was obtained in 91% (409 mg) yield from 501 mg of starting material 
phenyl acetic acid. Translucent liquid; Rf = 0.47 (50:50 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 7.38 – 7.16 (m, 5H, 5xArH), 3.81 (t, J = 
6.7 Hz, 2H, ArCH2CH2), 2.85 (t, J = 6.7 Hz, 2H, CH2CH2OH), 2.37 (brs, 1H, OH). 13C NMR 
(75 MHz, CDCl3): δ (ppm) 39.30 (ArCH2), 63.70 (CH2), 126.53 (ArCH), 128.66 (ArCH), 
129.18 (ArCH), 138.77 (ArC). The experimental data corresponded with that reported by 
Chapman and co−workers.174 
 
2−(3−Methoxyphenyl)ethanol 5.40 was obtained in 87% (411 mg) yield from 516 mg of 
starting material 3–methoxyphenyl acetic acid. Colourless oil; Rf = 
0.48 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 
7.13 (m, 1H, ArH), 6.76 – 6.61 (m, 3H, 3xArH), 3.81 – 3.62 (m, 5H, overlapping signals− 
OCH3, CH2OH), 2.72 (t, J = 6.5 Hz, 2H, ArCH2), 1.93 (brs, 1H, OH). 13C NMR (75 MHz, 
CDCl3): δ (ppm) 39.50 (ArCH2), 55.50 (OCH3), 63.80 (CH2OH), 112.03 (ArCH), 115.08 
(ArCH), 121.66 (ArCH), 129.82 (ArCH), 140.48 (ArC), 160.03 (ArCOMe). 
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8.14.2 Isochroman 5.36 
The procedure described by Deady and co−workers168 was followed. Thus, 
phosphorous trichloride (0.870 mL, 9.82 mmol) was added to a suspension of 
phenyl ethanol 5.35 (400 mg, 3.27 mmol), paraformaldehyde (60.0 mg, 1.64 
mmol) and aqueous 11 M HCl (0.100 mL, 0.900 mmol). The reaction mixture was stirred at 
40 ̊C for 4 h, cooled to RT neutralized to a pH7 with an aqueous 2 N NaOH and extracted 
with EtOAc (20 mL x 2), to give the product as an oil, which solidified at low temperatures. 
Compound 5.36 was obtained in 96% (420 mg) yield. Yellow oil; Rf = 0.70 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.23 – 7.17 (m, 3H, 3xArH), 7.05 – 
7.02 (m, 1H, ArH), 4.83 (s, 2H, ArCH2O), 4.03 (t, J = 5.7 Hz, 2H, ArCH2CH2), 2.92 (t, J = 5.7 
Hz, 2H, CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 28.40 (ArCH2CH2), 65.40 (CH2), 68.00 
(ArCH2O) 124.45 (ArCH), 126.03 (ArCH), 126.40 (ArCH), 128.96 (ArCH), 133.27 (ArC), 
134.99 (ArC). The spectroscopic data, corresponded with the literature.168 
 
8.14.3 1−(2−Iodoethyl)−2−(iodomethyl)benzene 5.37 
The protocol described by Ma and co−workers173 was adopted. Thus, 
isochroman 5.36 (173 mg, 1.29 mmol) was treated with aqueous 57% HI 
(0.680 mL, 9.00 mmol) and stirred overnight under reflux (130 ̊C) in a 
darkened environment. The reaction mixture was cooled to RT, diluted with water (5.0 mL) 
and extracted with ether (20 mL x 2) to afford the product. 
Compound 5.37 was obtained in 92% (444 mg) yield. Orange oil which crystallized upon 
being cooled to below zero; Rf = 0.28 (100% Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 
7.41 – 7.12 (m, 4H, 4xArH), 4.49 (s, 2H, ArCH2I), 3.51 – 3.39 (m, 2H, CH2CH2I), 3.28 (dd, J 
= 9.0, 9.0 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 3.24 (ArCH2I), 3.62 
(CH2CH2I), 36.85 (ArCH2CH2), 127.76 (ArCH), 128.79 (ArCH), 129.9 (ArCH), 130.43 
(ArCH), 136.82 (ArC), 138.87 (ArC). The spectroscopic data corresponds with reported 
literature.173 
 
8.14.4 General procedure for the THIQ formation from 5.37 
The protocol described by Ma and co−workers173 was adopted. Thus, a mixture of 5.37 (200 
mg, 0.538 mmol), amines (a – c) (0.538 mmol), NaHCO3 (90.0 mg, 1.07 mmol) and catalytic 
amounts of SDS (15.0 mg, 53.8x10−4 mmol) in distilled water (10 mL) were stirred under 
reflux for 4 h. The reaction mixture was cooled to RT, followed by an extraction with EtOAc 
(20 mL x 2) which afforded residues purified by column chromatography (20:80 
EtOAc/Hexane). The spectroscopic details of the compounds are described below: 
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2−[3,4−Dihydroisoquinolin−2(1H)−yl]4ˈ−methylthiazole 5.38a was obtained in 29% 
(34.8 mg) yield. Orange oil; Rf = 0.67 (50:50 EtOAc/Hexane). 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.21 – 7.16 (m, 4H, 4xArH), 6.13 (s, 1H, 
thiazole−ArH), 4.65 (s, 2H, ArCH2N), 3.76 (t, J = 5.9 Hz, 2H, NCH2), 
2.99 (t, J = 5.9 Hz, 2H, ArCH2CH2), 2.30 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, CDCl3, 
one of the aromatic signals were not visible): δ (ppm) 17.70 (thiazole−CH3), 28.70 
(ArCH2CH2), 45.90 (CH2), 49.60 (ArCH2N), 100.84 (thiazole−ArCH), 126.35 (ArCH), 126.39 
(ArCH), 126.60 (ArCH), 128.51 (ArCH), 132.84 (ArC), 134.39 (ArC), 149.58 
(thiazole−ArCN). 
 
2−(4ˈ−Methoxyphenyl)−1,2,3,4−tetrahydroisoquinoline 5.38b was obtained in 86% (80.9 
mg) yield. Beige oil; Rf = 0.57 (50:50 EtOAc/Hexane). 1H NMR (300 
MHz, CDCl3): δ (ppm) 7.22 – 7.10 (m, 4H, 4xArH), 7.04 – 6.96 (m, 
2H, 2xArH), 6.92 – 6.85 (m, 2H, 2xArH), 4.31 (s, 2H, ArCH2N), 3.79 
(s, 3H, OCH3), 3.46 (t, J = 5.8 Hz, 2H, NCH2), 3.00 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR 
(75 MHz, CDCl3): δ (ppm) 29.27 (ArCH2CH2), 48.59 (CH2), 52.82 (OCH3), 55.79 (ArCH2N), 
114.71 (ArCH), 118.16 (ArCH), 126.04 (ArCH), 126.52 (ArCH), 128.83 (ArCH), 134.69 
(ArCH), 145.51 (ArCN), 153.63 (ArCOCH3). HRMS ESI+: m/z [M+H]+ calcd for C15H15NO, 
226.1232 found, 226.1225 (3.09 ppm). 
 
8.14.5 6−Methoxyisochroman 5.44 
The protocol described by Taber and co−workers176 was followed. 
Thus, 3−methoxy phenyl ethanol 5.40 (0.200 mL, 1.41 mmol) in 
anhydrous THF (0.50 mL) was slowly added to a 60% suspension 
of NaH in mineral oil (47.0 mg, 1.98 mmol) in anhydrous THF (15 
mL) and stirred for 30 min at 0 ̊C. Chloromethyl methyl ether (0.110 mL, 1.50 mmol) was 
slowly added to the mixture and left to stir overnight at RT. The reaction was quenched 
aqueous saturated NH4Cl solution (10 mL), followed by extraction with ether (10 mL x 3) to 
afford an orange oil. The crude oil in anhydrous toluene (5.0 mL), containing p−toluene 
sulfonic acid (80.0 mg, 0.141 mmol) was stirred under reflux overnight. Water (15 mL) was 
added to the cooled reaction mixture which was extracted with EtOAc (20 mL x 2) to a brown 
oil, purified by column chromatography (2:98 EtOAc/Hexane) yielding compounds 5.44 and 
5.44a. 
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6−Methoxyisochroman 5.44 was obtained in 39% (244 mg) yield. Colourless oil; Rf = 0.41 
(20:80 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.27 (d, J = 
2.2 Hz, 1H, ArH), 6.92 (d, J = 8.4 Hz, 1H, ArH), 6.72 (dd, J = 8.4 and 2.2 
Hz, 1H, ArH), 4.75 (s, 2H, ArCH2O), 4.03 – 3.92 (m, 2H, NCH2), 3.79 (s, 3H, OCH3), 2.86 (t, 
J = 5.6 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 28.70 (ArCH2CH2), 55.30 
(OCH3), 65.30 (OCH2), 67.80 (ArCH2O), 112.36 (ArCH), 113.56 (ArCH), 125.43 (ArCH), 
127.08 (ArC), 134.41 (ArCCH2), 158.08 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for 
C10H12O2, 165.0871; found, 165.0910 (6.04 ppm). The experimental data, corresponded 
with the literature.176 
 
8−Methoxyisochroman 5.44a was obtained in 6% (42.7 mg) yield. Yellow oil; Rf = 0.52 
(20:80 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.17 – 7.12 (m, 
1H, ArH), 6.75 – 6.67 (m, 2H, 2xArH), 4.75 (s, 2H, ArCH2O), 3.93 (t, J = 5.6 
Hz, 2H, OCH2), 3.81 (s, 3H, OCH3), 2.83 (t, J = 5.6 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CDCl3): δ (ppm) 28.40 (ArCH2CH2), 55.20 (OCH3), 64.50 (CH2), 64.90 
(ArCH2O), 107.40 (ArCH), 121.21 (ArCH), 123.87 (ArCH), 127.02 (ArC), 134.93 (ArC), 
155.65 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C10H12O2, 165.0871; found, 165.0910 
(6.04 ppm). 
 
8.14.6 2−[2−(Hydroxymethyl)−5−methoxyphenyl]ethanol 5.48 
The protocol described by Shindikar and co−workers169 was 
followed. Thus, LiAlH4 (130 mg, 3.36 mmol) was added to a cooled 
mixture of 5.47 (300 mg, 4.68 mmol) in anhydrous THF (20 mL) 
followed by heating at 60 ̊C for 5 h. The reaction mixture was cooled to 0 ̊C and quenched 
by the slow addition of water (5.0 mL) followed by extracting with EtOAc (20 mL x 3) which 
afforded a residue, purified by column chromatography (50:50 EtOAc/Hexane). 
Compound 5.48 was obtained in 98% (299 mg) yield. White solid; mp = 79 – 81 ̊C; Rf = 0.33 
(75:25 EtOAc/Hexane). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.20 (d, J = 8.0 Hz, 1H, ArH), 
6.74 (d, J = 9.2 Hz, 2H, 2xArH), 4.52 (s, 2H, ArCH2OH), 3.89 – 3.71 (m, 5H, overlapping 
signals−OCH3 and CH2), 2.87 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR (101 MHz, CDCl3): δ 
(ppm) 35.60 (ArCH2CH2), 55.50 (OCH3), 62.80 (ArCH2O), 63.60 (ArCH2), 111.91 (ArCH), 
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8.14.7 General procedure for the halogenation of diol 5.48 
8.14.7.1 2−(2−Bromoethyl)−1−(bromomethyl)−4−methoxybenzene 5.49 
The protocol described by Taylor and co−workers179 was followed. 
Thus, phosphorous tribromide (1.17 mL, 12.5 mmol) was added to a 
cooled solution of 5.48 (900 mg, 4.94 mmol) in anhydrous toluene (10 
mL) and heated at 60 C̊ overnight. The reaction mixture was cooled to 0 ̊C, water (20 mL) 
was added and extracted with EtOAc (10 mL x 3) to afford a residue purified by column 
chromatography (100% Hexane). 
Compound 5.49 was obtained in 9% (105 mg) yield. Rf = 0.31 (20:80 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 7.25 – 7.12 (m, 1H, ArH), 6.77 – 6.63 (m, 2H, 2xArH), 4.52 
– 4.54 (m, 2H, CH2CH2Br), 4.46 (s, 2H, ArCH2Br), 3.71 (s, 3H, OCH3), 3.59 – 3.51 (m, 2H, 
ArCH2CH2), 3.18 (t, J = 7.7 Hz, 2H, CH2CH2Br). 13C NMR (75 MHz, CDCl3): δ (ppm) 31.80 
(CH2CH2Br), 32.20 (ArCH2Br), 36.20 (CH2), 55.60 (OCH3), 112.85 (ArCH), 115.97 (ArCH), 
128.13 (ArC), 132.26 (ArCH), 139.64 (ArC), 160.29 (ArCOMe). 
 
8.14.7.2 2−(2−Chloroethyl)−1−(chloromethyl)−4−methoxybenzene 5.49 
The protocol described by Batey and co−workers136 was followed. 
Thus, thionyl chloride (0.800 mL, 11.7 mmol) was added to a solution 
of 5.40 (200 mg, 1.10 mmol) in CH3CHCl2 (20 mL). The reaction mixture was stirred at 60 C̊ 
overnight. Excess thionyl chloride was removed under reduced pressure and the product 
purified by column chromatography (100% Hexane). 
Compound 5.49 was obtained in 50% (212 mg) yield. Yellow oil; Rf = 0.37 (20:80 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 6.90 (d, J = 8.4 H, 1H, ArH), 6.80 – 
6.5 (m, 2H, 2xArH), 4.73 (s, 2H, ArCH2Cl), 3.95 (t, J = 5.5 Hz, 2H, CH2CH2Cl), 3.79 (s, 3H, 
OCH3), 2.84 (t, J = 5.5 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 28.96 
(ArCH2CH2), 55.56 (CH2CH2Cl), 65.53 (ArCH2Cl), 68.00 (OCH3), 112.66 (ArCH), 113.86 
(ArCH), 125.73 (ArCH), 127.38 (ArC), 134.72 (ArC), 158.38 (ArCOMe). 
 
8.15 Synthesis of isochromanone as a route to THIQ analogues 
8.15.1 General procedure for the synthesis of 6−methoxyisochroman−3−one 5.47 
The protocol described by Spangler and co−workers172 was adopted. 
Thus, a mixture of 3−methoxyphenyl acetic acid (4.80 g, 28.8 mmol), 
34% aqueous formaldehyde solution (7.20 mL, 261 mmol) and 
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concentrated aqueous 11 M HCl (1.44 mL, 15.8 mmol) in glacial acetic acid (22.0 mL, 38.0 
mmol) was stirred under atmospheric conditions for 5 days. Heating resulted in the formation 
of multiple products. The reaction mixture was treated with an aqueous saturated NaHCO3 
solution (40 mL) and extracted with EtOAc (20 mL x 3) to afford a residue, purified using 
flash chromatography (20:80 EtOAc/Hexane). 
Compound 5.47 was obtained in a 50% (2.56 g) yield. White crystals; mp = 66 – 67 ̊C; Rf = 
0.45 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.16 (d, J = 8.3 Hz, 1H, 
ArH), 6.88 – 6.70 (m, 2H, 2xArH), 5.26 (s, 2H, ArCH2O), 3.82 (s, 3H, OCH3), 3.68 (s, 2H, 
ArCH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 36.67 (ArCH2C=O), 55.58 (OCH3), 69.93 
(ArCH2O), 112.70 (ArCH), 112.92 (ArCH), 123.80 (ArCH), 126.01 (ArC), 132.68 (ArC), 
160.20 (ArCOMe), 170.82 (C=O). HRMS ESI+: m/z [M+H]+ calcd for C10H10O3, 179.0708; 
found, 179.0702 (3.40 ppm). The experimental data, corresponded with literature.172 
 
8.15.2 General procedure for the lactamisation 5.47 
The protocol described by Chen and co−workers180 was followed. A mixture of 
6−methoxyisochroman−3−one 5.47 (300 mg, 1.68 mmol), aniline analogues (a – g) (2.52 
mmol) and 10 mol% of AlCl3 (45.0 mg, 0.340 mmol) were combined under anhydrous 
conditions in a sealed tube while being heated for 48 h at 150 ̊C. The reaction mixture was 
poured into aqueous 1 N HCl (5.0 mL) and extracted with EtOAc (20 mL x 2) providing a 
brown residue purified with column chromatography (30:70 EtOAc/Hexane). The 
spectroscopic details of the compounds are described below: 
 
6−Methoxy−2−(4ˈ−methylthiazol−2−yl)−1,2−dihydroisoquinolin−3(4H)−one 5.51a was 
obtained in 29% (136 mg) yield. Pale yellow powder; mp = ̊C; Rf 
= 0.76 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.27 – 7.25 (m, 1H, ArH), 6.84 – 6.75 (m, 2H, 2xArH), 6.58 
(s, 1H, thiazole−ArH), 5.29 (s, 2H, ArCH2N), 3.83 – 3.80 (m, 5H, 
overlapping signals−OCH3 and CH2), 2.33 (s, 3H, thiazole−CH3). 13C NMR (75 MHz, CDCl3): 
δ (ppm) 17.7 (thiazole−CH3), 39.10 (ArCH2), 49.70 (ArCH2N), 55.70 (OCH3), 109.98 
(thiazole−ArCH), 112.52 (ArCH), 113.33 (ArCH), 123.68 (ArCH), 127.37 (ArC), 132.78 
(ArC), 147.04 (thiazole−ArCMe), 158.71 (thiazole−ArCN), 159.75 (ArCOMe), 168.36 (C=O). 
HRMS ESI+: m/z [M+H]+ calcd for C14H14N2O2S, 275.0854; found, 275.0855 (0.40 ppm). 
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6−Methoxy−2−(4ˈ−methoxyphenyl)−1,2−dihydroisoquinolin−3(4H)−one 5.51b was 
obtained in 40% (117 mg) yield. Beige oily residue; Rf = 
0.17 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.26 – 7.19 (m, 2H, 2xArH), 7.09 – 7.07 (m, 1H, ArH), 
6.93 – 6.90 (m, 2H, 2xArH), 6.81 – 6.75 (m, 2H, 2xArH), 4.75 (s, 2H, ArCH2N), 3.81 – 3.73 
(m, 8H, overlapping signals−2xOCH3 and ArCH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 39.20 
(ArCH2), 54.30 (2xOCH3), 55.80 (ArCH2N), 112.56 (ArCH), 112.96 (ArCH), 114.49 (ArCH), 
124.50 (ArCH), 126.51 (ArCH), 127.25 (ArCH), 134.28 (ArC), 135.63 (ArC), 158.49 (ArCN), 
159.60 (ArCOMe), 169.45 (C=O). HRMS ESI+: m/z [M+H]+ calcd for C17H17NO3, 284.1287; 
found, 284.1292 (1.80 ppm). 
 
6−Methoxy−2−(5ˈ−nitro−3H−pyrrol−2−yl)−1,2−dihydroisoquinolin−3(4H)−one 5.51c 
was obtained in 15% (42.0 mg) yield. Orange solid; mp = ̊C; 
Rf = (20:80 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 8.39 (s, 1H, thiazole−ArH), 7.35 – 7.18 (m, 1H, ArH), 
6.97 – 6.69 (m, 2H, 2xArH), 5.37 (s, 2H, ArCH2N), 3.92 (s, 3H, OCH3), 3.84 (s, 2H, ArCH2). 
HRMS ESI+: m/z [M+H+ calcd for C13H11N3O4S, 306.0549; found, 306.0547 (0.70 ppm). 
 
2−(3ˈ−Chlorophenyl)−6−methoxy−1,2−dihydroisoquinolin−3(4H)−one 5.51d was 
obtained in 57% (80.0 mg) yield. White solid; mp = 87 – 88 ̊C; 
Rf = 0.36 (40:60 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): 
δ (ppm) 7.37 – 7.10 (m, 5H, 5xArH), 6.82 – 6.78 (m, 2H, 
2xArH), 4.80 (d, J = 6.0 Hz, 2H, ArCH2N), 3.85 – 3.75 (m, 5H, overlapping signals−OCH3 
and ArCH2). 13C NMR (75 MHz, CDCl3, not all ArCH and ArC were not visible): δ (ppm) 
39.12 (ArCH2), 53.38 (OCH3), 55.45 (ArCH2N), 112.35 (ArCH), 112.73 (ArCH), 123.81 
(ArCH), 125.79 (ArCH), 126.28 (ArCH), 126.81 (ArC), 129.99 (ArCCl), 132.74 (ArCH), 
134.84 (ArCN), 158.38 (ArCOMe), 160.26 (C=O). HRMS ESI+: m/z [M+H]+ calcd for 
C16H14ClNO2, 288.0791 (35Cl); found, 288.0785 (2.10 ppm) and 290.0757 (37Cl). 
 
2−(3ˈ−Fluorophenyl)−6−methoxy−1,2−dihydroisoquinolin−3(4H)−one 5.51e was 
obtained in 89% (150 mg) yield. White solid; mp = 108 – 110 ̊C; 
Rf = 0.41 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, 
the extra proton can be attributed to the overlapping of the 
CDCl3 signal): δ (ppm) 7.38 – 6.78 (m, 8H, 8xArH), 4.79 (s, 2H, ArCH2N), 4.01 – 3.55 (m, 
5H, overlapping signals−ArCH2 and OCH3). 13C NMR (75 MHz, CDCl3, one ArCH and two 
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ArC were not visible): δ (ppm) 39.31 (ArCH2), 53.49 (OCH3), 55.58 (ArCH2N), 112.67 (d, J 
= 28.50 Hz, ArCH−F), 113.70 (d, J = 21.00 Hz, ArCH−F), 120.99 (ArCH), 123.93 (ArCH), 
126.29 (ArCH), 130.16 (ArC), 133.72 (ArCH), 159.32 (ArCOMe), 169.80 (ArCF), 172.86 
(C=O). HRMS ESI+: m/z [M+H]+ calcd for C16H14FNO2, 272.1087 (18F); found, 272.1086 
(0.40 ppm). 
 
2−(4ˈ−Chlorophenyl)−6−methoxy−1,2−dihydroisoquinolin−3(4H)−one 5.51f was 
obtained in 35% (84.0 mg) yield. Yellow solid; mp = 123 – 
125 ̊C; Rf = 0.38 (40:60 EtOAc/Hexane). 1H NMR (300 MHz, 
CDCl3): δ (ppm) 7.39 – 7.28 (m, 4H, 4xArH), 7.12 – 7.09 (m, 
1H, ArH), 6.82 – 6.78 (m, 2H, 2xArH), 4.76 (s, 2H, ArCH2N), 3.92 – 3.63 (m, 5H, overlapping 
signals−ArCH2 and OCH3). 13C NMR (75 MHz, CDCl3, one ArC was not visible): δ (ppm) 
39.19 (ArCH2), 53.59 (ArCH2N), 55.59 (OCH3), 112.48 (ArCH), 112.88 (ArCH), 124.04 
(ArC), 126.41 (ArCH), 126.99 (ArCH), 129.37 (ArCH), 132.21 (ArCH), 133.91 (ArCH), 
140.67 (ArCCl), 157.21 (ArCN), 159.60 (ArCOMe), 169.25 (C=O). HRMS ESI+: m/z [M+H]+ 
calcd for C16H14ClNO2, 288.0684 (35Cl); found, 288.0782 (3.45 ppm). 
 
2−(4ˈ−Fluorophenyl)−6−methoxy−1,2−dihydroisoquinolin−3(4H)−one 5.51g was 
obtained in 29% (67.3 mg) yield as an oil; Rf = 0.38 (40:60 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.47 – 
7.23 (m, 5H, 5xArH), 7.00 – 6.95 (m, 2H, 2xArH), 4.93 (s, 2H, 
ArCH2N), 3.97 (m, 5H, overlapping signals−OCH3 and CH2). 13C NMR (75 MHz, CDCl3): δ 
(ppm) 39.23 (ArCH2CH2), 54.09 (ArCH2N), 55.76 (OCH3), 112.84 (d, J = 30.00 Hz, ArCH−F), 
116.17 (ArC), 116.47 (ArCH), 124.26 (ArC), 126.56 (ArCH), 127.74 (ArCH), 127.80 (ArCH), 
134.13 (ArCN), 159.72 (ArCF), 162.89 (ArCOMe), 169.50 (C=O). HRMS ESI+: m/z [M+H]+ 
calcd for C16H14FNO2, 272.1042 (18F); found, 272.1090 (3.67 ppm) and 273.1119 (19F). 
 
8.15.3 Synthesis of THIQ analogues via., amide formation 
8.15.3.1Coupling of amines with carboxylic acid 5.45 
The protocol described by Pelly and co−workers,181 was modified 
where N,Nˈ−dicyclohexylcarbodimide (220 mg, 1.08 mmol); f DMAP 
(11.1 mg, 9.03x10−5 mmol) and carboxylic acid 5.45 (150 mg, 0.903 
mmol) were combined at 0 ̊C. To this was added a mixture of amines 
(d – g) (0.903 mmol) in anhydrous CH2Cl2 (5.0 mL) and the resultant reaction mixture was 
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stirred at RT for 12 h. The suspension was filtered, and the eluent concentrated under 
reduced pressure to yield a solid residue purified by flash chromatography (15:85 
EtOAc/Hexane). The spectroscopic details of the compounds are described below: 
 
2−(3−Methoxyphenyl)−N−(5ˈ−nitrothiazol−2−yl)acetamide 5.53c was obtained in 16% 
(42.0 mg) yield. Orange solid; mp = 119 – 120 ̊C; Rf = 0.29 
(30:70 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 9.52 (brs, 1H, NH), 8.22 (s, 1H, thiazole−ArH), 7.29 
– 7.19 (m, 1H, ArH), 6.85 – 6.76 (m, 3H, 3xArH), 4.17 – 3.55 (m, 5H, overlapping 
signals−OCH3 and CH2). 13C NMR (75 MHz, CDCl3, one ArCH signal was not visible): δ 
(ppm) 43.42 (ArCH2), 55.56 (OCH3), 113.82 (thiazole−ArCH), 115.68 (ArCH), 121.79 
(ArCH), 130.99 (ArCH), 133.36 (ArC), 140.44 (thiazole−ArC), 160.66 (thiazole−ArCN), 
161.17 (ArCOMe), 169.54 (C=O). HRMS ESI+: m/z [M+H]+ calcd for C12H11N3O4S, 
294.0549; found, 294.0547 (0.70 ppm). 
 
N−(3ˈ−Chlorophenyl)−2−(3−methoxyphenyl)acetamide 5.53d was obtained in 66% (330 
mg) yield. White oil which solidified at low temperatures; Rf 
= 0.66 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.51 (d, J = 1.8 Hz, 1H, ArH), 7.38 – 7.14 (m, 3H, 
3xArH), 7.11 – 7.00 (m, 1H, ArH), 6.95 – 6.80 (m, 3H, 3xArH), 3.83 (s, 3H, OCH3), 3.71 (s, 
2H, ArCH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 45.06 (ArCH2), 55.43 (OCH3), 113.38 
(ArCH), 115.31 (ArCH), 117.89 (ArCH), 120.00 (ArCH), 121.80 (ArCH), 124.61 (ArCH), 
130.04 (ArCH), 130.54 (ArCH), 134.71 (ArCCl), 135.65 (ArCCH2), 138.86 (ArCN), 160.21 
(ArCOMe), 169.04 (C=O). HRMS ESI+: m/z [M+H]+ calcd for C15H15NO2Cl, 276.0684 (35Cl); 
found, 276.0792 (3.60 ppm) and 278.0765 (37Cl). 
 
N−(3ˈ−Fluorophenyl)−2−(3−methoxyphenyl)acetamide 5.53e was obtained in 94% (220 
mg) yield. White solid; mp = 57 – 58 ̊C; Rf = 0.46 (20:80 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, no NH signal 
was detected): δ (ppm) 7.45 – 7.11 (m, 3H, 3xArH), 7.06 – 6.69 (m, 5H, 5xArH), 3.80 (s, 3H, 
OCH3), 3.69 (s, 2H, ArCH2). 13C NMR (75 MHz, CDCl3, two of the aromatic signals were not 
visible): δ (ppm) 44.85 (ArCH2), 55.49 (OCH3), 107.77 (d, J = 26.25 Hz, ArCH−F), 111.38 
(d, J = 21.00 Hz, ArCH−F), 113.27 (ArCH), [too many ArCHF 115.53 (d, J = 12.75 Hz, 
ArCH−F)], 121.93 (ArCH), 130.32 (m, J = 9.00 Hz, ArCH−F), 136.03 (ArCN), 139.63 (d, J = 
10.50 Hz, ArCH−F), 161.55 (ArCOMe), 164.79 (ArCF), 170.01 (C=O). HRMS ESI+: m/z 
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[M+H]+ calcd for C15H15NO2F, 260.1087 (18F); found, 260.1083 (1.50 ppm) and 261.1115 
(19F). 
 
N−(4ˈ−Chlorophenyl)−2−(3−methoxyphenyl)acetamide 5.53f was obtained in 87% (210 
mg) yield. White oil which solidified at low temperatures; Rf 
= 0.41 (30:70 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, 
no NH signal was observed): δ (ppm) 7.51 – 7.50 (m, 5H, 
5xArH), 7.11 – 6.80 (m, 3H, 3xArH), 3.83 (s, 3H, OCH3), 3.71 (s, 2H, ArCH2). 13C NMR (75 
MHz, CDCl3, no C=O was not visible): δ (ppm) 45.06 (ArCH2), 55.43 (OCH3), 113.40 (ArCH), 
115.33 (ArCH), 117.85 (ArCH), 119.96 (ArCH), 121.82 (ArCH), 124.61 (ArCH), 130.06 
(ArCCl), 130.75 (ArCH), 130.36 (ArC), 135.74 (ArCNH), 135.53 (ArCOMe). HRMS ESI+: m/z 
[M+H]+ calcd for C15H15NO2Cl, 276.0791 (35Cl); found, 276.0780 (4.0 ppm) and 278.0752 
(37Cl). 
 
N−(4ˈ−Fluorophenyl)−2−(3−methoxyphenyl)acetamide 5.53g was obtained in 56% (130 
mg) yield. White solid; mp = 70 – 72 ̊C; Rf = 0.46 (30:70 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.45 – 
7.11 (m, 3H, 3xArH), 7.06 – 6.69 (m, 5H, 5xArH), 3.80 (s, 
3H, OCH3), 3.69 (s, 2H, ArCH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 44.70 (ArCH2), 55.27 
(OCH3), 113.12 (ArCH), 115.20 (ArCH), 115.55 (d, J = 22.5 Hz, ArCH−F), 121.76 (m, J = 
7.50 Hz, ArCH−F), 130.33 (ArCH), 133.45 (ArCH), 135.78 (ArCN), 157.89 (ArCCH2), 160.20 
(ArCOMe), 161.06 (ArCF), 169.00 (C=O). HRMS ESI+: m/z [M+H]+ calcd for C15H15NO2F, 
260.1042 (18F); found, 260.1083 (3.14 ppm). 
 
8.15.3.2 General procedure for the reduction of the carbonyl function 
This protocol described by Nystrom, Davis and co−workers123,124 was adopted. Thus, LiAlH4 
(41.0 mg, 1.07 mmol) was suspended in anhydrous THF (30 mL) and cooled to −3 ̊C in an 
ice bath AlCl3 (140 mg, 1.07 mmol) was added in small portions maintaining the temperature 
at −3 ̊C. The resulting hydride suspension (AlH2Cl) was stirred at RT for 30 min, to which 
the amides 5.53d – g (0.713 mmol) in THF (4.0 mL) were added. The reaction mixture was 
stirred under reflux for 5 h, cooled to RT and carefully treated with water until no further 
effervescence occurred. The white solid (lithium aluminate) was separated by vacuum 
filtration and the filtrate extracted with EtOAc (20 mL x 2) to give the corresponding amines 
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5.54 as oils with no further purification required. The spectroscopic details of the compounds 
are described below: 
 
3ˈ−Chloro−N−(3−methoxyphenethyl)aniline 5.54d was obtained in 98% (100 mg) yield 
from 114 mg of starting material 5.53d. Yellow oil solidified 
at low temperatures; Rf = 0.82 (50:50 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3, no clean spectra was recorded, 
therefore no spectral information was recorded). 13C NMR (75 MHz, CDCl3): δ (ppm) 35.66 
(ArCH2), 45.01 (CH2), 55.52 (OCH3), 111.63 (ArCH), 112.14 (ArCH), 112.85 (ArCH), 114.93 
(ArCH), 117.56 (ArCH), 121.43 (ArCH), 130.02 (ArCH), 130.55 (ArCH), 135.58 (ArCCl), 
140.92 (ArCNH), 149.48 (ArC), 160.20 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for 
C15H15NO2Cl, 262.0999 (35Cl); found, 262.0988 (4.20 ppm) and 264.0961 (37Cl). 
 
3ˈ−Fluoro−N−(3−methoxyphenethyl)aniline 5.54e was obtained in 73% (153 mg) yield 
from 235 mg of starting material 5.53e. White oil; Rf = 0.63 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, no NH 
signal was visible): δ (ppm) 7.77 – 7.29 (m, 5H, 5xArH), 6.42 
– 6.28 (m, 3H, 3xArH), 3.80 (s, 3H, OCH3), 3.38 (t, J = 6.9 Hz, 2H, ArCH2CH2), 2.89 (t, J = 
6.9 Hz, 2H, CH2CH2NH). 13C NMR (75 MHz, CDCl3): δ (ppm) 35.33 (ArCH2CH2), 44.75 
(CH2CH2NH), 55.18 (OCH3), 99.55 (d, J = 26.25 Hz, ArCH−F), 103.91 (d, J = 9.00 Hz, 
ArCH−F), 108.84 (ArCH), 111.76 (ArCH), 114.58 (ArCH), 121.08 (ArCH), 129.95 (ArCH), 
130.20 (ArCH), 130.37 (ArC), 140.82 (ArCNH), 150.00 (ArCOMe). HRMS ESI+: m/z [M+H]+ 
calcd for C15H15NO2F, 246.1294 (18F); found, 246.1290 (1.6 ppm) and 247.1321 (19F). 
 
4ˈ−Chloro−N−(3−methoxyphenethyl)aniline 5.54f was obtained in 88% (176 mg) yield 
from 198 mg of starting material 5.53f. Yellow oil which 
solidified at low temperatures; Rf = 0.80 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 7.30 – 
7.18 (m, 1H, ArH), 7.17 – 7.08 (m, 2H, 2xArH), 6.87 – 6.67 (m, 3H, 3xArH), 6.58 – 6.47 (m, 
2H, 2xArH), 3.80 (s, 3H, OCH3), 3.68 (brs, 1H, NH), 3.37 (t, J = 6.8 Hz, 2H, ArCH2CH2), 2.88 
(t, J = 6.8 Hz, 2H, CH2CH2NH). 13C NMR (75 MHz, CDCl3, one of the ArCH was not visible): 
δ (ppm) 35.55 (ArCH2CH2), 45.28 (CH2CH2NH), 55.50 (OCH3), 112.03 (ArCH), 114.34 
(ArCH), 114.91 (ArCH), 121.39 (ArCH), 122.48 (ArCCl), 129.39 (ArCH), 129.96 (ArC), 
141.62 (ArCNH), 159.79 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C15H15NO2Cl, 
262.0891 (35Cl); found, 262.0988 (3.79 ppm). 
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4ˈ−Fluoro−N−(3−methoxyphenethyl)aniline 5.54g was obtained in 96% (120 mg) yield 
from 140 mg of starting material 5.53g. Translucent oil; Rf = 
0.71 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, no 
NH signal was observed): δ (ppm) 7.29 – 7.23 (s, 1H, ArH), 
6.78 – 6.03 (m, 5H, 5xArH), 6.58 – 6.54 (m, 2H, 2xArH), 3.90 (s, 3H, OCH3), 3.38 (t, J = 6.0 
Hz, 2H, CH2CH2NH), 2.90 (t, J = 6.0 Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 
35.49 (ArCH2CH2), 45.58 (CH2CH2NH), 55.20 (OCH3), 111.71 (ArCH), 113.85 (d, J = 7.50 
Hz, ArCH−F), 114.62 (ArCH), 115.69 (d, J = 21.75 Hz, ArCH−F), 121.12 (ArCH), 129.65 
(ArCH), 141.05 (ArC), 144.06 (ArCNH), 156.77 (ArCF), 159.90 (ArCOMe). HRMS ESI+: m/z 
[M+H]+ calcd for C15H15NO2F, 246.1249 (18F); found, 246.1290 (4.06 ppm). 
 
8.15.3.3 General procedure for the Pictet−Spengler cyclization of amines 5.54 
The protocol described by Kano and co−workers182 was adopted. Thus, the amine 
substrates 5.54 (1.05 mmol) and paraformaldehyde (1.15 mmol) were heated in formic acid 
(5.0 mL) at 80 ̊C overnight. The reaction mixture was diluted with water (20 mL) and to the 
pH adjusted to 5 with NaHCO3 solution, followed by extraction with EtOAc (20 mL x 2). The 
organic layers afforded crude material which was purified by chromatography in (20:80 
EtOAc/Hexane). The spectroscopic details of the compounds are described below: 
 
2−(3ˈ−Fluorophenyl)−6−methoxy−1,2,3,4−tetrahydroisoquinoline 5.55e was obtained 
in 75% (120 mg) yield from 153 mg of starting material 5.54e. 
Orange oil; Rf = 0.00 (40:60 EtOAc/Hexane). 1H NMR (300 
MHz, CDCl3, one ArH was not visible): δ (ppm) 7.28 – 7.00 (m, 
2H, 2xArH), 6.87 – 6.37 (m, 4H, 4xArH), 4.36 (s, 2H, ArCH2N), 
3.80 (s, 3H, OCH3), 3.55 (t, J = 5.8 Hz, 2H, CH2), 2.96 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CDCl3, one ArC signal was not visible): δ (ppm) 29.28 (ArCH2CH2), 45.80 
(CH2), 49.55 (ArCH2N), 55.30 (OCH3), 101.30 (d, J = 25.5 Hz, ArCH−F), 104.44 (d, J = 21.75 
Hz, ArCH−F), 109.85 (ArCH), 112.41 (ArCH), 113.15 (ArCH), 126.18 (ArCH), 127.48 
(ArCH), 130.14 (ArC), 136.03 (ArCN), 157.18 (ArCOMe), 159.29 (ArCF). HRMS ESI+: m/z 
[M+H]+ calcd for C16H16FNO 258.1294 (18F); found, 258.1288 (2.30 ppm) and 259.1317 
(19F). 
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2−(4ˈ−Fluorophenyl)−6−methoxy−1,2,3,4−tetrahydroisoquinoline 5.55g was obtained 
in 98% (120 mg) yield from 117 mg of starting material 5.54g. 
Brown solid; mp = 75 – 78 ̊C; Rf = 0.00 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.12 – 6.87 (m, 5H, 5xArH), 
6.82 – 6.66 (m, 2H, 2xArH), 4.28 (s, 2H, ArCH2N), 3.81 (s, 3H, 
OCH3), 3.48 (t, J = 5.8 Hz, 2H, NCH2), 2.97 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR (75 
MHz, CDCl3): δ (ppm) 29.61 (ArCH2CH2), 48.05 (CH2), 51.69 (ArCH2N), 55.60 (OCH3), 
112.70 (ArCH), 113.56 (ArCH), 115.86 (d, J = 22.50 Hz, ArCH−F), 117.46 (d, J = 7.50 Hz, 
ArCH−F), 126.77 (ArCH), 127.78 (ArC), 136.02 (ArC), 147.50 (ArCN), 155.17 (ArCF), 
158.41 (ArCOMe). HRMS ESI+: m/z [M+H]+ calcd. C16H16FNO, 258.1249 (18F); found, 
258.1292 (3.87 ppm) and 259.1319 (19F). 
 
8.15.4 General procedure for the reduction of Isochromanones 5.43 
The protocol described by Nystrom, Davis and co−workers123,124 was followed. Thus, LiAlH4 
(99.0 mg, 2.62 mmol) in anhydrous THF (50 mL) was cooled to 0 ̊C, to which AlCl3 (350 mg, 
2.62 mmol) was added portion−wise. The mixture was stirred at RT providing AlH2Cl, to 
which 5.43a and b (0.873 mmol) were added and the mixture stirred at RT for 5 h. Water 
(15 mL) was added and the resulting solution extracted with EtOAc (20 mL x 3) affording 
products 5.55a and b as oils after chromatographic purification (20:80 EtOAc/Hexane). The 
spectroscopic details of the compounds are described below: 
 
2−[6−Methoxy−3,4−dihydroisoquinolin−2(1H)−yl]−4ˈ−methylthiazole 5.55a was 
obtained in 82% (189 mg) yield from 243 mg of starting material 
5.43a. Yellow oil that solidified after exposure to low temperatures; 
Rf = 0.33 (20:80 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.09 (d, J = 8.4 Hz, 1H, ArH), 6.83 – 6.65 (m, 2H, 2xArH), 
6.12 (single signal, 1H, thiazole−ArH), 4.58 (s, 2H, ArCH2N), 3.87 – 3.65 (m, 5H, overlapping 
signals−OCH3 and CH2), 2.95 (t, J = 5.8 Hz, 2H, ArCH2CH2), 2.28 (d, J = 1.1 Hz, 3H, 
thiazole−CH3). 13C NMR (75 MHz, CDCl3): δ (ppm) 21.40 (thiazole−CH3), 29.40 
(ArCH2CH2), 46.10 (CH2), 49.60 (ArCH2N), 55.60 (OCH3), 101.16 (ArCH), 112.94 (ArCH), 
113.61 (ArCH), 125.31 (ArC), 127.74 (ArC), 136.00 (ArC), 149.83 (ArC), 158.58 (ArCOMe), 
170.82 (ArCN). HRMS ESI+: m/z [M+H]+ calcd for C14H16N2OS, 261.1062; found, 261.1070 
(3.10 ppm). 
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6−Methoxy−2−(4ˈ−methoxyphenyl)−1,2,3,4−tetrahydroisoquinoline 5.55b was 
obtained in 67% (107 mg) yield from 168 mg of starting 
material 5.43b. Off white solid, mp = 116 – 118 ̊C; Rf = 0.73 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 7.12 – 7.11 (m, 1H, ArH), 6.93 – 6.90 (m, 2H, 2xArH), 
6.78 – 6.69 (m, 3H, 3xArH), 6.58 (s, 1H, ArH), 4.38 (s, 2H, ArCH2N), 3.80 and 3.82 (each 
as a s, 6H, 2xOCH3), 3.47 (t, J = 5.7 Hz, 2H, CH2), 2.75 (t, J = 5.7 Hz, 2H, ArCH2CH2). 13C 
NMR (75 MHz, CDCl3): δ (ppm) 29.40 (ArCH2CH2), 44.40 (CH2), 47.50 (ArCH2N), 55.60 
(OCH3), 55.70 (OCH3), 113.04 (ArCH), 113.75 (ArCH), 114.77 (ArCH), 124.43 (ArCH), 
124.75 (ArCH), 127.60 (ArC), 129.80 (ArC), 134.92 (ArCN), 157.83 (ArCOMe), 158.59 
(ArCOMe). HRMS ESI+: m/z [M+H]+ calcd for C17H19NO2, 270.1494; found, 270.1494 (0.00 
ppm). 
 
8.16 Demethylation protocols for 6−hydroxy THIQ analogues 
8.16.1 Method A: Using BBr3 
The protocol described by McOmie and co−workers121 was followed. Thus, a mixture of 1 M 
BBr3 (0.670 ml, 6.68 mL) in anhydrous CH2Cl2 (6.7 mL) was prepared in a Schlenk tube 
cooled to −78 ̊C. Compounds 5.51 and 5.55 (0.729 mmol) in anhydrous CH2Cl2 (0.5 mL) 
were slowly added, and stirred for 2 h while maintaining the temperature at −60 ̊C. The 
mixture was stirred for an additional 4 h and then warmed to RT. Water (15 mL) was slowly 
added to the cooled (0 ̊C) solution until effervescence ceased. Extraction with CH2Cl2 (15 
mL x 3) yielded an orange−brown oil in low to moderate yields after chromatographic 
purification (40:60 EtOAc/Hexane). The spectroscopic details of the compounds are 
described below: 
 
6−Hydroxy−2−(4ˈ−methylthiazol−2−yl)−1,2−dihydroisoquinolin−3(4H)−one 5.56a was 
obtained in 45% (52.6 mg) yield from 123 mg of starting material 
5.51a. Yellow solid; mp = 204 – 206 C̊; Rf = 0.79 (5:95 
MeOH/CH2Cl2). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 9.58 (brs, 
1H, OH), 7.25 (d, J = 8.1 Hz, 1H, ArH), 6.86 (sharp m, 1H, 
thiazole−ArH), 6.69 – 6.66 (m, 2H, 2xArH), 5.23 (s, 2H, ArCH2N), 3.83 (s, 2H, ArCH2CH2), 
2.32 (d, J = 1.0 Hz, 3H, thiazole−CH3). 13C NMR (75 MHz, DMSO−d6): δ (ppm) 17.03 
(thiazole−CH3), 38.13 (ArCH2O), 48.69 (ArCH2N), 109.57 (thiazole−ArCH), 113.36 (ArCH), 
113.61 (ArCH), 121.74 (ArCH), 126.88 (ArC), 132.86 (ArC), 145.89 (thiazole−ArC), 156.93 
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(ArCOH), 158.37 (thiazole−ArCN), 168.46 (C=O). HRMS ESI+: m/z [M+H]+ calcd for 
C13H12N2O2S, 261.0653; found, 261.0701 (3.83 ppm). 
 
2−(4ˈ−Methylthiazol−2−yl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1a was obtained in 
45% (52.6 mg) yield from 149 mg of starting material 5.55a. Yellow 
solid; mp = 120 – 122 C̊; Rf = 0.24 (40:60 EtOAc/Hexane). 1H NMR 
(300 MHz, DMSO−d6): δ (ppm) 6.34 (d, J = 8.2 Hz, 1H, ArH), 6.10 – 
5.94 (m, 2H, 2xArH), 5.78 (sharp m, 1H, thiazole−ArH), 4.29 (brs, 
1H, OH), 3.97 (s, 2H, ArCH2N), 3.10 (t, J = 6.0 Hz, 2H, CH2), 2.18 (t, J = 6.0 Hz, 2H, 
ArCH2CH2), 1.63 (d, J = 1.1 Hz, 3H, thiazole−CH3). 13C NMR (75 MHz, DMSO−d6): δ (ppm) 
20.24 (thiazole−CH3), 33.11 (ArCH2CH2), 36.67 (CH2), 69.79 (ArCH2N), 97.17 
(thiazole−ArCH), 105.12 (ArCH), 106.09 (ArCH), 115.57 (ArCH), 118.59 (ArC), 127.50 
(ArC), 134.15 (thiazole−ArC), 147.45 (ArCOH), 148.24 (thiazole−ArCN). HRMS ESI+: m/z 
[M+H]+ calcd for C13H14N2OS, 247.0860; found, 247.0910 (4.04 ppm). 
 
6−Hydroxy−2−(4ˈ−hydroxyphenyl)−1,2−dihydroisoquinolin−3(4H)−one 5.56b was 
obtained in a 78% (110 mg) yield from 156 mg of starting 
material 5.51b. Beige solid; decomposition temperature = 230 – 
240 ̊C; Rf = 0.21 (40:60 EtOAc/Hexane). 1H NMR (300 MHz, 
DMSO−d6): δ (ppm) 9.45 (brs, 2H, 2xOH), 7.09 – 7.06 (m, 3H, 3xArH), 6.75 (d, J = 8.6 Hz, 
2H, 2xArH), 6.63 (d, J = 8.6 Hz, 2H, 2xArH), 4.65 (s, 2H, ArCH2N), 3.57 (s, 2H, ArCH2CH2). 
13C NMR (75 MHz, DMSO−d6, two ArCH signals were not visible): δ (ppm) 38.50 
(ArCH2CH2), 53.06 (ArCH2N), 113.33 (ArCH), 115.21 (ArCH), 123.27 (ArCH), 126.32 (ArC), 
126.82 (ArC), 134.15 (ArCN), 155.50 (ArCOH), 156.70 (ArCOH), 168.49 (C=O). HRMS 
ESI+: m/z [M+H]+ calcd for C15H13NO3, 256.0929; found, x. 
 
2−(4ˈ−Hydroxyphenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1c was obtained in a 38% 
(17.7 mg) yield from 52.0 mg of starting material 5.55c. Yellow 
solid; mp = 178 – 180 C̊. 1H NMR (300 MHz, CD3OD): δ (ppm) 
7.05 – 6.89 (m, 3H, 3xArH), 6.83 – 6.69 (m, 2H, 2xArH), 6.67 – 
6.53 (m, 2H, 2xArH), 4.12 (s, 2H, ArCH2N), 2.92 (t, J = 5.8 Hz, 2H, ArCH2CH2). 13C NMR 
(75 MHz, CD3OD, the methylene signals were hidden behind the CD3OD signal and the 
ArCOH signals were not visible): δ (ppm) 29.98 (ArCH2CH2), 51.05 (CH2), 54.60 (ArCH2N), 
114.52 (ArCH), 115.69 (ArCH), 116.71 (ArC), 120.73 (ArCH), 126.13 (ArC), 126.84 (ArCH), 
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135.79 (ArCH), 136.74 (ArCH). HRMS ESI+: m/z [M+H]+ calcd for C15H15NO2, 242.1181; 
found, 242.1185 (1.65 ppm). 
 
8.16.2 Method B: Using AlI3 
The protocol described by Bhatt and co−workers93 was adopted. Thus, I2 (990 mg, 7.80 
mmol) was added to a cooled suspension of Al powder (160 mg, 6.00 mmol) in anhydrous 
toluene (20 mL) stirred under reflux for 6 h (red colour dissipates). The mixture was cooled 
to RT, to which the methoxy substrates 5.55d – g (0.600 mmol) were added and stirred 
overnight at 60 ̊C. The reaction was cooled to RT and excess AlI3 was quenched by the slow 
addition of water (15 mL). The suspension was extracted with EtOAc (20 mL x 3) to yield a 
brown residue purified by column chromatography (50:50 EtOAc/Hexane). The 
spectroscopic details of the compounds are described below: 
 
2−(3ˈ−Chlorophenyl)−6−hydroxy−1,2−dihydroisoquinolin−3(4H)−one 5.56d was 
obtained in 57% (80.0 mg) yield from 146 mg of starting material 
5.51d. Translucent oil which solidified to a white solid at low 
temperatures; Rf = 0.36 (40:60 EtOAc/Hexane). 1H NMR and 13C 
NMR spectra were not clear enough and not recorded, therefore 
no spectral information was recorded. HRMS ESI+: m/z [M+H]+ calcd for C15H12ClNO2, 
275.0527 (35Cl); found, 275.0527 (3.65 ppm). 
 
2−(3ˈ−Chlorophenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1d was obtained in 57% 
(80.0 mg) yield from 148 mg of starting material 5.55d. White 
crystal; mp = 128 – 130 ̊C; Rf = 0.36 (40:60 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 7.27 – 7.06 (m, 1H, ArH), 6.99 
(d, J = 8.0 Hz, 1H, ArH), 6.87 (d, J = 1.9 Hz, 1H, ArH), 6.82 – 6.51 (m, 4H, 4xArH), 4.30 (s, 
2H, ArCH2N), 3.49 (t, J = 5.3 Hz, 2H, CH2), 2.87 (t, J = 5.3 Hz, 2H, ArCH2CH2). 13C NMR 
(75 MHz, CDCl3): δ (ppm) 29.44 (ArCH2CH2), 46.25 (CH2), 49.99 (ArCH2N), 113.02 (ArCH), 
114.05 (ArCH), 114.77 (ArCH), 115.23 (ArCH), 118.35 (ArCH), 126.34 (ArCH), 128.03 
(ArC), 130.47 (ArCH), 135.42 (ArC), 136.60 (ArCCl), 151.76 (ArCN), 154.77 (ArCOH). 
HRMS ESI+: m/z [M+H]+ calcd for C15H14ClNO, 261.0842 (35Cl); found, 261.0833 (3.50 ppm) 
and 262.0807 (37Cl). 
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2−(3ˈ−Fluorophenyl)−6−hydroxy−1,2−dihydroisoquinolin−3(4H)−one 5.56e was 
obtained in 89% (150 mg) yield from 177 mg of starting material 
5.51e. White solid; mp = 118 – 200 ̊C; Rf = 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CD3OD, no OH signal was 
detected): δ (ppm) 7.56 – 7.33 (m, 1H, ArH), 7.23 – 6.96 (m, 4H, 4xArH), 6.84 – 6.58 (m, 
2H, 2xArH), 4.81 (s, 2H, ArCH2N), 3.70 (s, 2H, ArCH2). 13C NMR (75 MHz, CD3OD): δ (ppm) 
37.27 (ArCH2CH2), 52.35 (ArCH2N), 114.14 (d, J = 21.75 Hz, ArCH−F), 114.47 (d, J = 24.00 
Hz, ArCH−F), 122.42 (ArCH), 122.38 (ArCH), 123.98 (ArC), 127.25 (ArCH), 131.22 (ArCH), 
131.34 (ArCH), 145.05 (ArC), 158.24 (ArCOH), 162.47 (ArCN), 165.86 (ArCF), 170.05 
(C=O). HRMS ESI+: m/z [M+H]+ calcd for C15H12FNO2, 258.0930 (18F); found, 258.0919 
(4.30 ppm). 
 
2−(3ˈ−Fluorophenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1e was obtained in 48% 
(63.8 mg) yield from 140 mg of starting material 5.55e. Yellow 
solid; mp = ̊C; Rf = 0.41 (50:50, EtOAc/Hexane). 1H NMR and 13C 
NMR spectra were not clear enough and not recorded, therefore 
no spectral information was recorded. HRMS ESI+: m/z [M+H]+ calcd for C15H14FNO, 
244.1093 (18F); found, 244.1140 (4.09 ppm). 
 
2−(4ˈ−Chlorophenyl)−6−hydroxy−1,2−dihydroisoquinolin−3(4H)−one 5.56f was 
obtained in trace amounts 9% (7 mg) yield from 84.0 mg of 
starting material 5.51f. White solid; mp = 156 – 158 ̊C; Rf = 0.41 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, CD3OD): δ (ppm) 7.49 
– 7.40 (m, 1H, ArH), 7.39 – 7.30 (m, 2H, 2xArH), 7.11 (d, J = 6.6 Hz, 2H, 2xArH), 6.71 (d, J 
= 6.6 Hz, 2H, 2xArH), 4.80 (s, 2H, ArCH2N), 4.59 (brs, 1H, OH), 3.70 (s, 2H, ArCH2). 
Unfortunately, not enough product was obtained for a good 13C NMR. HRMS ESI+: m/z 
[M+H]+ calcd for C15H12ClNO2, 275.0527 (35Cl); found, 274.0634 (3.60 ppm) and 276.0611 
(37Cl). 
 
2−(4ˈ−Chlorophenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1f was obtained in 58% 
(81.7 mg) yield from 133 mg of starting material 5.55f. Brown 
solid; mp = 116 – 117 ̊C; Rf = 0.41 (50:50 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3, no OH signal was visible): δ (ppm) 7.27 
– 7.15 (m, 2H, 2xArH), 7.00 (d, J = 8.2 Hz, 1H, ArH), 6.90 – 6.81 (m, 2H, 2xArH), 6.71 – 
6.58 (m, 2H, 2xArH), 4.28 (s, 2H, ArCH2N), 3.48 (t, J = 5.9 Hz, 2H, CH2), 2.89 (t, J = 5.9 Hz, 
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2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) 29.11 (ArCH2CH2), 46.63 (CH2), 50.32 
(ArCH2N), 113.68 (ArCH), 114.97 (ArCH), 116.36 (ArCH), 123.15 (ArCH), 123.95 (ArCH), 
126.46 (ArC), 127.82 (ArCCl), 129.13 (ArCH), 136.29 (ArCH), 149.13 (ArC), 149.60 (ArCN), 
154.18 (ArCOH). HRMS ESI+: m/z [M+H]+ calcd for C15H14ClNO, 261.0842 (35Cl); found, 
260.0833 (3.50 ppm) and 262.0803 (37Cl). 
 
2−(4ˈ−Fluorophenyl)−6−hydroxy−1,2−dihydroisoquinolin−3(4H)−one 5.56g was 
obtained in 24% (5.50 mg) yield from 24.2 mg of starting material 
5.51g. Brown solid; mp = 115 – 117 ̊C; Rf = 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, DMSO−d6): δ (ppm) 6.53 (m, 
2H, 2xArH), 6.42 – 6.22 (m, 3H, 3xArH), 5.88 (d, J = 6.1 Hz, 2H, 2xArH), 3.97 (d, J = 3.2 Hz, 
2H, ArCH2N), 3.77 (brs, 1H, OH), 2.88 (s, 2H, ArCH2). 13C NMR (75 MHz, DMSO−d6, no 
ArC and C=O signals were visible): δ (ppm) 29.97 (ArCH2CH2), 45.69 (ArCH2N), 105.41 (d, 
J = 31.5 Hz, ArCH−F), 107.57 (d, J = 23.0 Hz, ArCH−F), 118.10 (ArCH), 119.82 (ArCH), 
125.43 (ArCH). HRMS ESI+: m/z [M+H]+ calcd for C15H12FNO2, 258.0886 (18F); found, 
258.0934 (3.87 ppm). 
 
2−(4ˈ−Fluorophenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol 5.1g was obtained in 55% 
(60.8 mg) yield from 116 mg of starting material 5.55g. Orange 
solid; mp = 105 – 107 ̊C; Rf = 0.53 (50:50 EtOAc/Hexane). 1H 
NMR (300 MHz, CDCl3): δ (ppm) 7.06 – 6.88 (m, 5H, 5xArH), 6.74 
– 6.59 (m, 2H, 2xArH), 4.26 (s, 2H, ArCH2N), 3.46 (t, J = 5.7 Hz, 2H, NCH2), 2.92 (t, J = 5.7 
Hz, 2H, ArCH2CH2). 13C NMR (75 MHz, CDCl3, no C−F coupling was visible): δ (ppm) 29.41 
(ArCH2CH2), 48.16 (CH2), 51.87 (ArCH2N), 113.87 (ArCH), 115.27 (ArCH), 115.80 (ArCH), 
116.09 (ArCH), 117.68 (ArCH), 126.05 (ArCH), 126.80 (ArCH), 128.04 (ArC), 136.35 (ArC), 
154.38 (ArCN), 157.79 (ArCOH), 159.89 (ArCF). HRMS ESI+: m/z [M+H]+ calcd for 
C15H14FNO, 244.1038 (18F); found, 244.1140 (0.80 ppm) and 245.1168 (19F). 
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